Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof

ABSTRACT

The present application provides immune cells (such as T cells) comprising a chimeric antibody-T cell receptor (TCR) construct (caTCR) and a chimeric signaling receptor (CSR) construct. The caTCR comprises an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule, and the CSR comprises a ligand-binding domain that specifically binds to a target ligand and a co-stimulatory signaling domain capable of providing a stimulatory signal to the immune cell. Also provided are methods of making and using these cells.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. Provisional Application No.62/490,576, filed on Apr. 26, 2017, U.S. Provisional Application No.62/490,578, filed on Apr. 26, 2017, and U.S. Provisional Application No.62/490,580, filed on Apr. 26, 2017, the contents of which are herebyincorporated by reference in their entireties.

SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

The content of the following submission on ASCII text file isincorporated herein by reference in its entirety: a computer readableform (CRF) of the Sequence Listing (file name: 750042001040SEQLIST.txt,date recorded: Apr. 24, 2018, size: 107 KB).

FIELD OF THE INVENTION

The invention relates to immune cells (such as T cells) comprising achimeric antibody-T cell receptor (TCR) construct (caTCR) and a chimericsignaling receptor (CSR) construct. The caTCR comprises anantigen-binding module that specifically binds to a target antigen and aT cell receptor module (TCRM) capable of recruiting at least oneTCR-associated signaling molecule, and the CSR comprises aligand-binding domain that specifically binds to a target ligand and aco-stimulatory signaling domain capable of providing a stimulatorysignal to the immune cell.

BACKGROUND OF THE INVENTION

T-cell mediated immunity is an adaptive process of developing antigen(Ag)-specific T lymphocytes to eliminate viruses, bacterial, parasiticinfections or malignant cells. It can also involve aberrant recognitionof self-antigen, leading to autoimmune inflammatory diseases. The Agspecificity of T lymphocytes is based on recognition through the T CellReceptor (TCR) of unique antigenic peptides presented by MajorHistocompatibility Complex (MIIC) molecules on Ag-presenting cells (APC)(Broere, et al., Principles of Immunopharmacology, 2011). Each Tlymphocyte expresses a unique TCR on the cell surface as the result ofdevelopmental selection upon maturation in the thymus. The TCR occurs intwo forms as either an αβ heterodimer or as a γδ heterodimer. T cellsexpress either the αβ form or the γδ form TCR on the cell surface. Thefour chains, α/β/γ/δ, all have a characteristic extracellular structureconsisting of a highly polymorphic “immunoglobulin variable region”-likeN-terminal domain and an “immunoglobulin constant region”-like seconddomain. Each of these domains has a characteristic intra-domaindisulfide bridge. The constant region is proximal to the cell membrane,followed by a connecting peptide, a transmembrane region and a shortcytoplasmic tail. The covalent linkage between the 2 chains of theheterodimeric TCR is formed by the cysteine residue located within theshort connecting peptide sequence bridging the extracellular constantdomain and the transmembrane region which forms a disulfide bond withthe paired TCR chain cysteine residue at the corresponding position (TheT cell Receptor Factsbook, 2001).

The αβ and γδ TCRs are associated with the non-polymorphicmembrane-bound CD3 proteins to form the functional octameric TCR-CD3complex, consisting of the TCR heterodimer and three dimeric signalingmolecules, CD3δ/ε, CD3γ/ε and CD3ζ/ζ or ζ/η. Ionizable residues in thetransmembrane domain of each subunit form a polar network ofinteractions that hold the complex together. For T cell activation, theTCR N-terminal variable regions recognize the peptide/MHC complexpresented on the surface of target cell, whereas the CD3 proteinsparticipate in signal transduction (Call et al., Cell. 111(7):967-79,2002; The T cell Receptor Factsbook, 2001).

αβ TCR, also called conventional TCR, is expressed on most lymphocytesand consists of the glycosylated polymorphic α and β chains. Different aTCRs can discriminate among different peptides embedded in the surfacesof MHC II (mostly expressed on APC cell surfaces) and MHC I (expressedon all nucleated cells) molecules, whose dimensions and shapes arerelatively constant. The γδ TCR, though structurally similar to the αβTCR, recognizes carbohydrate-, nucleotide-, or phosphor-carryingantigens in a fashion independent of MHC presentation (The T cellReceptor Factsbook, 2001; Girardi et al., J. Invest. Dermatol.126(1):25-31, 2006; Hayes et al., Immunity. 16(6):827-38, 2002).

In the past two decades, fundamental advances in immunology and tumorbiology, combined with the identification of a large number of tumorantigens, have led to significant progress in the field of cell-basedimmunotherapy. T cell therapy occupies a large space in the field ofcell-based immunotherapy, with the goal of treating cancer bytransferring autologous and ex vivo expanded T cells to patients, andhas resulted in some notable antitumor responses (Blattman et al.,Science. 305(5681):200-5, 2004). For example, the administration ofnaturally occurring tumor infiltrating lymphocytes (TILs) expanded exvivo mediated an objective response rate ranging from 50-70% in melanomapatients, including bulky invasive tumors at multiple sites involvingliver, lung, soft tissue and brain (Rosenberg et al., Nat. Rev. Cancer.8(4):299-308, 2008; Dudley M E et al., J. Clin. Oncol. 23(10):2346-57,2005).

A major limitation to the widespread application of TIL therapy is thedifficulty in generating human T cells with antitumor potential. As analternative approach, exogenous high-affinity TCRs can be introducedinto normal autologous T cells of the patients through T cellengineering. The adoptive transfer of these cells into lympho-depletedpatients has been shown to mediate cancer regression in cancers such asmelanoma, colorectal carcinoma, and synovial sarcoma (Kunert R et al.,Front. Immunol. 4:363, 2013). A recent phase I clinical trial using antiNY-ESO-1 TCRs against synovial sarcoma reported an overall response rateof 66% and complete response was achieved in one of the patientsreceiving the T cell therapy (Robbins P F et al., Clin. Cancer Res.21(5):1019-27, 2015).

One of the advantages of TCR-engineered T cell therapy is that it cantarget the entire array of potential intracellular tumor-specificproteins, which are processed and delivered to the cell surface throughMHC presentation. Furthermore, the TCR is highly sensitive and can beactivated by just a few antigenic peptide/MHC molecules, which in turncan trigger a cytolytic T cell response, including cytokine secretion, Tcell proliferation and cytolysis of defined target cells. Therefore,compared with antibody or small molecule therapies, TCR-engineered Tcells are particularly valuable for their ability to kill target cellswith very few copies of target intracellular antigens (Kunert R et al.,Front. Immunol. 4:363, 2013).

However, unlike therapeutic antibodies, which are mostly discoveredthrough hybridoma or display technologies, identification oftarget-specific TCRs requires the establishment of target peptide/MHCspecific TCR clones from patient T cells and screening for the right α-βchain combination that has the optimal target antigen-binding affinity.Very often, phage/yeast display is employed after cloning of the TCRfrom patient T cells to further enhance the target binding affinity ofthe TCR. The whole process requires expertise in many areas and istime-consuming (Kobayashi E et al., Oncoimmunology. 3(1):e27258, 2014).The difficulties in the TCR discovery process have largely impeded thewidespread application of TCR-engineered T cell therapy. It has alsobeen hampered by treatment-related toxicity, in particularly with TCRsagainst antigens that are over-expressed on tumor cells but alsoexpressed on healthy cells, or with TCRs recognizing off-targetpeptide/MHC complexes (Rosenberg S A et al., Science. 348(6230):62-8,2015).

A different approach has been developed in recent years to engage Tcells for targeted cancer immunotherapy. This new approach is calledChimeric Antigen Receptor T cell Therapy (CAR-T). It merges theexquisite targeting specificity of monoclonal antibodies with the potentcytotoxicity and long-term persistence provided by cytotoxic T cells. ACAR is composed of an extracellular domain that recognizes a cellsurface antigen, a transmembrane region, and an intracellular signalingdomain. The extracellular domain consists of the antigen-bindingvariable regions from the heavy and light chains of a monoclonalantibody that are fused into a single-chain variable fragment (scFv).The intracellular signaling domain contains an immunoreceptortyrosine-based activation motif (ITAM), such as those from CD3ζ or FcRγ,and one or more co-stimulatory signaling domains, such as those fromCD28, 4-1BB or OX40 (Barrett D M et al., Annu. Rev. Med. 65:333-47,2014; Davila M L et al., Oncoimmunology. 1(9):1577-1583, 2012). Bindingof target antigens by CARs grafted onto a T cell surface can trigger Tcell effector functions independent of TCR-peptide/MHC complexinteraction. Thus, T cells equipped with CARs can be redirected toattack a broad variety of cells, including those that do not match theMIIC type of the TCRs on the T cells but express the target cell-surfaceantigens. This approach overcomes the constraints of MIC-restricted TCRrecognition and avoids tumor escape through impairments in antigenpresentation or MIIC molecule expression. Clinical trials have shownclinically significant antitumor activity of CAR-T therapy inneuroblastoma (Louis C U et al., Blood. 118(23):6050-6056, 2011), B-ALL(Maude, S L, et al., New England Journal of Medicine 371:16:1507-1517,2014), CLL (Brentjens, R J, et al. Blood 118:18:4817-4828, 2011), and Bcell lymphoma (Kochenderfer, I N, et al. Blood 116:20:4099-4102, 2010).In one study, a 90% complete remission rate in 30 patients with B-ALLtreated with CD19-CAR T therapy was reported (Maude, S L, et al.,supra).

All CARs studied so far have been directed to tumor antigens with highcell surface expression. To target low-copy number cell-surface tumorantigens and intracellular tumor antigens, which represent 95% of allknown tumor-specific antigens, there is a need to develop more potentand effective engineered cell therapies (Cheever, et al., Clin. CancerRes. 15(17):5323-37, 2009).

Several attempts have been made to engineer chimeric receptor moleculeshaving antibody specificity with T cell receptor effector functions.See, for example, Kuwana, Y, et al., Biochem. Biophys. Res. Commun.149(3):960-968, 1987; Gross, G, et al., Proc. Nat. Acad. Sci. USA.86:10024-10028, 1989; Gross, G & Eshhar, Z, FASEB J. 6(15):3370-3378,1992; and U.S. Pat. No. 7,741,465. To this date, none of these chimericreceptors have been adopted for clinical use, and novel designs forantibody-TCR chimeric receptors with improved expression andfunctionality in human T cells are needed.

The disclosures of all publications, patents, patent applications andpublished patent applications referred to herein are hereby incorporatedherein by reference in their entirety. PCT Application NumberPCT/US2016/058305 is hereby incorporated herein by reference in itsentirety.

BRIEF SUMMARY OF THE INVENTION

The present application in one aspect provides immune cells (such as Tcells) comprising a chimeric antibody-T cell receptor (TCR) construct(caTCR) and a chimeric signaling receptor (CSR) construct. The caTCRcomprises an antigen-binding module that specifically binds to a targetantigen and a T cell receptor module (TCRM) capable of recruiting atleast one TCR-associated signaling molecule, and the CSR comprises aligand-binding domain that specifically binds to a target ligand and aco-stimulatory signaling domain capable of providing a stimulatorysignal to the immune cell.

In some embodiments, there is provided an immune cell comprising: a) achimeric antibody-T cell receptor (TCR) construct (caTCR) comprising: i)an antigen binding module that specifically binds to a target antigen;and ii) a T cell receptor module (TCRM) comprising a first TCR domain(TCRD) comprising a first TCR transmembrane domain (TCR-TM) and a secondTCRD comprising a second TCR-TM, wherein the TCRM facilitatesrecruitment of at least one TCR-associated signaling molecule; and b) achimeric signaling receptor (CSR) comprising: i) a ligand-binding modulethat is capable of binding or interacting with a target ligand; ii) atransmembrane module; and iii) a co-stimulatory immune cell signalingmodule that is capable of providing a co-stimulatory signal to theimmune cell, wherein the ligand-binding module and the co-stimulatoryimmune cell signaling module are not derived from the same molecule, andwherein the CSR lacks a functional primary immune cell signaling domain.

In some embodiments, there is provided one or more nucleic acidsencoding a caTCR and CSR as described here, wherein the caTCR and CSReach consist of one or more polypeptide chains encoded by the one ormore nucleic acids.

In some embodiments, there is provided one or more nucleic acidsencoding: a) a chimeric antibody-T cell receptor (TCR) construct (caTCR)comprising: i) an antigen binding module that specifically binds to atarget antigen; and ii) a T cell receptor module (TCRM) comprising afirst TCR domain (TCRD) comprising a first TCR transmembrane domain(TCR-TM) and a second TCRD comprising a second TCR-TM, wherein the TCRMfacilitates recruitment of at least one TCR-associated signalingmolecule, and wherein the caTCR consists of one or more polypeptidechains; and b) a chimeric signaling receptor (CSR) comprising: i) aligand-binding module that is capable of binding or interacting with atarget ligand; ii) a transmembrane module; and iii) a co-stimulatoryimmune cell signaling module that is capable of providing aco-stimulatory signal to the immune cell, wherein the ligand-bindingmodule and the co-stimulatory immune cell signaling module are notderived from the same molecule, wherein the CSR lacks a functionalprimary immune cell signaling domain, and wherein the CSR consists ofone or more polypeptide chains.

In some embodiments, there is provided one or more vectors comprisingone or more nucleic acids as described herein.

In some embodiments, there is provided a composition comprising one ormore nucleic acids or one or more vectors as described herein.

In some embodiments, there is provided an immune cell comprising one ormore nucleic acids or one or more vectors as described herein.

In some embodiments, there is provided a pharmaceutical compositioncomprising an immune cell as described herein, and a pharmaceuticallyacceptable carrier.

In some embodiments, there is provided a method of killing a target cellpresenting a target antigen, comprising contacting the target cell withan immune cell as described herein.

In some embodiments, there is provided a method of treating a targetantigen-associated disease in an individual in need thereof, comprisingadministering to the individual an effective amount of a pharmaceuticalcomposition as described herein.

In some embodiments, there is provided a method of providing aco-stimulatory signal to an immune cell comprising a caTCR or transducedwith a nucleic acid encoding a caTCR, comprising introducing into saidcell one or more nucleic acids or one or more vectors as describedherein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a schematic representation of several caTCR moleculeshaving different antigen-binding modules.

FIG. 2 shows percent specific lysis from the killing of cancer cell lineNALM6 (CD19+), mediated by T cells transduced with anti-CD19 caTCR-1-0alone, anti-CD19 CSR alone, or anti-CD19 caTCR (1-0 and 1-TM5)+anti-CD19CSR.

FIG. 3 shows the concentration of cytokines (IL-2, GM-CSF, IFN-γ, andTNF-α) found in the supernatant after in vitro killing of cancer cellline NALM6, mediated by T cells transduced with anti-CD19 caTCR-1-0alone, anti-CD19 CSR alone, or anti-CD19 caTCR (1-0 and 1-TM5)+anti-CD19CSR.

FIG. 4 shows the degranulation activity (as determined by CD107aexpression) in T cells transduced with anti-CD19 caTCR-1-0 alone,anti-CD19 CSR alone, or anti-CD19 caTCR (1-0 and 1-TM5)+anti-CD19 CSRfollowing stimulation with cancer cell line NALM6.

FIG. 5 shows the proliferation (as determined by CFSE dye dilution) of Tcells transduced with anti-CD19 caTCR-1-0 alone or anti-CD19 caTCR (1-0and 1-TM5)+anti-CD19 CSR following stimulation with cancer cell linesBV173 or NALM6.

FIG. 6 shows percent specific lysis from the killing of cancer celllines HepG2 (AFP⁺/GPC3⁺) and HepG2-GPC3.ko (AFP⁺/GPC3⁻), mediated by Tcells transduced with anti-AFP158/HLA-A*2:01 caTCR-1-0 alone, anti-GPC3CSR alone, or anti-AFP158/HLA-A*2:01 caTCR (1-0 and 1-TM5)+anti-GPC3CSR.

FIG. 7 shows the concentration of cytokines (IL-2, GM-CSF, IFN-γ, andTNF-α) found in the supernatant after in vitro killing of cancer celllines HepG2 and HepG2-GPC3.ko, mediated by T cells transduced withanti-AFP158/HLA-A*2:01 caTCR-1-0 alone, anti-GPC3 CSR alone, oranti-AFP158/HLA-A*2:01 caTCR (1-0 and 1-TM5)+anti-GPC3 CSR.

FIG. 8 shows the degranulation activity (as determined by CD107aexpression) in T cells transduced with anti-AFP158/HLA-A*2:01 caTCR-1-0alone, anti-GPC3 CSR alone, or anti-AFP158/HLA-A*2:01 caTCR (1-0 and1-TM5)+anti-GPC3 CSR following stimulation with cancer cell line HepG2.

FIG. 9 shows the proliferation (as determined by CFSE dye dilution) of Tcells transduced with anti-AFP158/HLLA-A*2:01 caTCR-1-0 alone, anti-GPC3CSR alone, or anti-AFP158/HLLA-A*2:01 caTCR (1-0 and 1-TM5)+anti-GPC3CSR following stimulation with cancer cell line HepG2.

FIG. 10 shows percent specific lysis from the killing of cancer celllines Raji, BV173, NALM6, and Jeko-1 (each CD19⁺/CD20⁺), mediated by Tcells transduced with anti-CD19 caTCR (1-0 and 1-TM5)+anti-CD20 CSR.

FIG. 11 shows the concentration of cytokines (IL-2, GM-CSF, IFN-γ, andTNF-α) found in the supernatant after in vitro killing of cancer cellline Raji, mediated by T cells transduced with anti-CD19 caTCR-1-0 aloneor anti-CD19 caTCR (1-0 and 1-TM5)+anti-CD20 CSR.

FIG. 12 shows the degranulation activity (as determined by CD107aexpression) in T cells transduced with anti-CD19 caTCR-1-0 alone,anti-CD20 CSR alone, or anti-CD19 caTCR (1-0 and 1-TM5)+anti-CD20 CSRfollowing stimulation with cancer cell line Raji.

FIGS. 13A-13E show schematic structures of exemplary bispecific caTCRmolecules.

FIGS. 14-15 show the proliferation (as determined by CFSE dye dilution)of T cells expressing anti-CD19 caTCR-1-0 and anti-CD19 CSR followingstimulation with cancer cell line NALM6.

FIG. 16 shows the tumor growth in a subcutaneous mouse model of NALM6with mock treatment or with a single intratumoral injection of T cellsexpressing an anti-CD19 caTCR-1, or an anti-CD19 caTCR-1 in combinationwith anti-CD19 CSR-1.

FIG. 17 shows the serum cytokine levels in mice treated with T cellsexpressing an anti-CD19 CAR or T cells expressing both anti-CD19 caTCR-1and anti-CD19 CSR-1. The student t-test is used to analyze statisticalsignificance of the serum cytokine levels in the two groups (**P<0.01;***P<0.001; ****P<0.0001).

FIG. 18 shows the tumor growth in a subcutaneous mouse model of HepG2with mock treatment or with a single intratumoral injection of T cellsexpressing an anti-AFP CAR, or an anti-AFP CAR in combination with ananti-GPC3 CSR.

DETAILED DESCRIPTION OF THE INVENTION

The present application provides immune cells (such as T cells)comprising a chimeric antibody-T cell receptor (TCR) construct (caTCR)and a chimeric signaling receptor (CSR) construct. The caTCR comprisesan antigen-binding module that specifically binds to a target antigenand a T cell receptor module (TCRM) capable of recruiting at least oneTCR-associated signaling molecule. The CSR comprises a ligand-bindingdomain that specifically binds to a target ligand and a co-stimulatoryimmune cell signaling domain capable of providing a stimulatory signalto the immune cell, and does not comprise a functional primary immunecell signaling sequence. The target antigen and target ligand can beproteins expressed on the cell surface or complexes comprising a peptideand an MHC protein (referred to herein as a “pMHC complex,” or “pMHC”),such as an MHC-presented disease-associated antigen peptide on thesurface of a diseased cell. caTCRs are regulated by the naturallyoccurring machinery that controls T cell receptor activation, andsignaling through the CSR is capable of potentiating the immune responsemediated by the caTCR.

We have developed a series of novel T cells comprising caTCR and CSRconstructs. They exhibited potent cytotoxicity against target-bearingtumor cells, with increased cytokine expression in response to targetcell engagement as compared to cells expressing only the caTCR in theabsence of the CSR. Inclusion of the CSR in these cells further enhanceddegranulation, proliferation, and viability as compared to cellsexpressing only the caTCR.

The present application thus provides immune cells comprising a caTCRspecific for a target antigen and a CSR specific for a target ligand,wherein the caTCR comprises an antigen-binding module that specificallybinds to the target antigen and a T cell receptor module (TCRM) capableof recruiting at least one TCR-associated signaling molecule, andwherein the CSR a) comprises a ligand-binding domain that specificallybinds to the target ligand and a co-stimulatory immune cell signalingdomain capable of providing a stimulatory signal to the immune cell andb) does not comprise a functional primary immune cell signalingsequence. The caTCR can take any of a number of formats with variationsin the antigen-binding module and/or TCRM. For example, the caTCR canhave an antigen-binding module comprising a moiety selected from thegroup consisting of a Fab, a Fab′, a (Fab′)₂, an Fv, and an scFv, and aTCRM comprising one or more sequences derived from an α/β or γ/δ TCR,including variants in one or more of the transmembrane domain,connecting peptide, and intracellular domain. See FIG. 1. In someembodiments, the antigen-binding module is multispecific (such asbispecific). The CSR can similarly have a ligand-binding modulecomprising a moiety selected from the group consisting of a Fab, a Fab′,a (Fab′)₂, an Fv, and an scFv. In some embodiments, the target antigenand the target ligand are the same. In some embodiments, theantigen-binding module of the caTCR and the ligand-binding module of theCSR are the same, or comprise the same sequences conferring antigenspecificity, such as CDRs or variable domains. In some embodiments, thetarget antigen and the target ligand are different.

In yet other aspects, there are provided a) one or more nucleic acidsencoding a caTCR and a CSR, b) immune cells comprising one or morenucleic acids encoding a caTCR and a CSR, and c) compositions comprisingimmune cells comprising i) a caTCR and a CSR, or ii) one or more nucleicacids encoding the caTCR and the CSR. The compositions can bepharmaceutical compositions.

Also provided are methods of making and using immune cells comprising acaTCR and a CSR for treatment purposes, as well as kits and articles ofmanufacture useful for such methods. Further provided are methods oftreating a disease using immune cells comprising a caTCR and a CSR.

Definitions

The term “antibody” or “antibody moiety” includes full-length antibodiesand antigen-binding fragments thereof. A full-length antibody comprisestwo heavy chains and two light chains. The variable regions of the lightand heavy chains are responsible for antigen-binding. The variablesregion in both chains generally contain three highly variable loopscalled the complementarity determining regions (CDRs) (light chain (LC)CDRs including LC-CDR1, LC-CDR2, and LC-CDR3, heavy chain (HC) CDRsincluding HC-CDR1, HC-CDR2, and HC-CDR3). CDR boundaries for theantibodies and antigen-binding fragments disclosed herein may be definedor identified by the conventions of Kabat, Chothia, or Al-Lazikani(Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987;Kabat 1991). The three CDRs of the heavy or light chains are interposedbetween flanking stretches known as framework regions (FRs), which aremore highly conserved than the CDRs and form a scaffold to support thehypervariable loops. The constant regions of the heavy and light chainsare not involved in antigen-binding, but exhibit various effectorfunctions. Antibodies are assigned to classes based on the amino acidsequence of the constant region of their heavy chain. The five majorclasses or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, whichare characterized by the presence of α, δ, ε, γ, and μ heavy chains,respectively. Several of the major antibody classes are divided intosubclasses such as lgG1 (γ1 heavy chain), lgG2 (γ2 heavy chain), lgG3(γ3 heavy chain), lgG4 (γ4 heavy chain), lgA1 (α1 heavy chain), or lgA2(α2 heavy chain).

The term “antigen-binding fragment” as used herein refers to an antibodyfragment including, for example, a diabody, a Fab, a Fab′, a F(ab′)2, anFv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, abispecific dsFv (dsFv-dsFv′), a disulfide stabilized diabody (dsdiabody), a single-chain antibody molecule (scFv), an scFv dimer(bivalent diabody), a multispecific antibody formed from a portion of anantibody comprising one or more CDRs, a camelized single domainantibody, a nanobody, a domain antibody, a bivalent domain antibody, orany other antibody fragment that binds to an antigen but does notcomprise a complete antibody structure. An antigen-binding fragment iscapable of binding to the same antigen to which the parent antibody or aparent antibody fragment (e.g., a parent scFv) binds. In someembodiments, an antigen-binding fragment may comprise one or more CDRsfrom a particular human antibody grafted to a framework region from oneor more different human antibodies.

As used herein, a first antibody moiety “competes” for binding to atarget antigen with a second antibody moiety when the first antibodymoiety inhibits target antigen-binding of the second antibody moiety byat least about 50% (such as at least about any of 55%, 60%, 65%, 70%,75%, 80%, 85%, 90%, 95%, 98% or 99%) in the presence of an equimolarconcentration of the first antibody moiety, or vice versa. A highthroughput process for “binning” antibodies based upon theircross-competition is described in PCT Publication No. WO 03/48731.

As use herein, the term “specifically binds” or “is specific for” refersto measurable and reproducible interactions, such as binding between atarget and an antibody or antibody moiety that is determinative of thepresence of the target in the presence of a heterogeneous population ofmolecules, including biological molecules. For example, an antibodymoiety that specifically binds to a target (which can be an epitope) isan antibody moiety that binds the target with greater affinity, avidity,more readily, and/or with greater duration than its bindings to othertargets. In some embodiments, an antibody moiety that specifically bindsto an antigen reacts with one or more antigenic determinants of theantigen (for example a cell surface antigen or a peptide/MHC proteincomplex) with a binding affinity that is at least about 10 times itsbinding affinity for other targets.

The term “T cell receptor,” or “TCR,” refers to a heterodimeric receptorcomposed of αβ or γδ chains that pair on the surface of a T cell. Eachα, β, γ, and δ chain is composed of two Ig-like domains: a variabledomain (V) that confers antigen recognition through the complementaritydetermining regions (CDR), followed by a constant domain (C) that isanchored to cell membrane by a connecting peptide and a transmembrane(TM) region. The TM region associates with the invariant subunits of theCD3 signaling apparatus. Each of the V domains has three CDRs. TheseCDRs interact with a complex between an antigenic peptide bound to aprotein encoded by the major histocompatibility complex (pMHC) (Davisand Bjorkman (1988) Nature, 334, 395-402; Davis et al. (1998) Annu RevImmunol, 16, 523-544; Murphy (2012), xix, 868 p.).

The term “TCR-associated signaling molecule” refers to a molecule havinga cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM) thatis part of the TCR-CD3 complex. TCR-associated signaling moleculesinclude CD3γε, CD3δε, and ζζ (also known as CD3ζ or CD3ζζ).

“Activation”, as used herein in relation to a cell expressing CD3,refers to the state of the cell that has been sufficiently stimulated toinduce a detectable increase in downstream effector functions of the CD3signaling pathway, including, without limitation, cellular proliferationand cytokine production.

The term “module” when referring to a portion of a protein is meant toinclude structurally and/or functionally related portions of one or morepolypeptides which make up the protein. For example, a transmembranemodule of a dimeric receptor may refer to the portions of eachpolypeptide chain of the receptor that span the membrane. A module mayalso refer to related portions of a single polypeptide chain. Forexample, a transmembrane module of a monomeric receptor may refer toportions of the single polypeptide chain of the receptor that span themembrane. A module may also include only a single portion of apolypeptide.

The term “isolated nucleic acid” as used herein is intended to mean anucleic acid of genomic, cDNA, or synthetic origin or some combinationthereof, which by virtue of its origin the “isolated nucleic acid” (1)is not associated with all or a portion of a polynucleotide in which the“isolated nucleic acid” is found in nature, (2) is operably linked to apolynucleotide which it is not linked to in nature, or (3) does notoccur in nature as part of a larger sequence.

As used herein, the term “CDR” or “complementarity determining region”is intended to mean the non-contiguous antigen combining sites foundwithin the variable region of both heavy and light chain polypeptides.These particular regions have been described by Kabat et al., J. Biol.Chem. 252:6609-6616 (1977); Kabat et al., U.S. Dept. of Health and HumanServices, “Sequences of proteins of immunological interest” (1991);Chothia et al., J. Mol. Biol. 196:901-917 (1987); Al-Lazikani B. et al.,J. Mol. Biol., 273: 927-948 (1997); MacCallum et al., J. Mol. Biol.262:732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45: 3832-3839(2008); Lefranc M. P. et al., Dev. Comp. Immunol., 27: 55-77 (2003); andHonegger and Plückthun, J. Mol. Biol., 309:657-670 (2001), where thedefinitions include overlapping or subsets of amino acid residues whencompared against each other. Nevertheless, application of eitherdefinition to refer to a CDR of an antibody or grafted antibodies orvariants thereof is intended to be within the scope of the term asdefined and used herein. The amino acid residues which encompass theCDRs as defined by each of the above cited references are set forthbelow in Table 1 as a comparison. CDR prediction algorithms andinterfaces are known in the art, including, for example, Abhinandan andMartin, Mol. Immunol., 45: 3832-3839 (2008); Ehrenmann F. et al.,Nucleic Acids Res., 38: D301-D307 (2010); and Adolf-Bryfogle J. et al.,Nucleic Acids Res., 43: D432-D438 (2015). The contents of the referencescited in this paragraph are incorporated herein by reference in theirentireties for use in the present invention and for possible inclusionin one or more claims herein.

TABLE 1 CDR DEFINITIONS Kabat¹ Chothia² MacCallum³ IMGT⁴ AHo⁵ V_(H) CDR131-35 26-32 30-35 27-38 25-40 V_(H) CDR2 50-65 53-55 47-58 56-65 58-77V_(H) CDR3  95-102  96-101  93-101 105-117 109-137 V_(L) CDR1 24-3426-32 30-36 27-38 25-40 V_(L) CDR2 50-56 50-52 46-55 56-65 58-77 V_(L)CDR3 89-97 91-96 89-96 105-117 109-137 ¹Residue numbering follows thenomenclature of Kabat et al., supra ²Residue numbering follows thenomenclature of Chothia et al., supra ³Residue numbering follows thenomenclature of MacCallum et al., supra ⁴Residue numbering follows thenomenclature of Lefranc et al., supra ⁵Residue numbering follows thenomenclature of Honegger and Phückthun, supra

The term “chimeric antibodies” refer to antibodies in which a portion ofthe heavy and/or light chain is identical with or homologous tocorresponding sequences in antibodies derived from a particular speciesor belonging to a particular antibody class or subclass, while theremainder of the chain(s) is identical with or homologous tocorresponding sequences in antibodies derived from another species orbelonging to another antibody class or subclass, as well as fragments ofsuch antibodies, so long as they exhibit a biological activity of thisinvention (see U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl.Acad. Sci. USA, 81:6851-6855 (1984)).

The term “semi-synthetic” in reference to an antibody or antibody moietymeans that the antibody or antibody moiety has one or more naturallyoccurring sequences and one or more non-naturally occurring (i.e.,synthetic) sequences.

The term “fully synthetic” in reference to an antibody or antibodymoiety means that the antibody or antibody moiety has fixed naturallyoccurring V_(H)/V_(L) framework pairings, but non-naturally occurring(i.e., synthetic) sequences of all 6 CDRs of both heavy and lightchains.

“Humanized” forms of non-human (e.g., rodent) antibodies are chimericantibodies that contain minimal sequence derived from the non-humanantibody. For the most part, humanized antibodies are humanimmunoglobulins (recipient antibody) in which residues from ahypervariable region (HVR) of the recipient are replaced by residuesfrom a hypervariable region of a non-human species (donor antibody) suchas mouse, rat, rabbit or non-human primate having the desired antibodyspecificity, affinity, and capability. In some instances, frameworkregion (FR) residues of the human immunoglobulin are replaced bycorresponding non-human residues. Furthermore, humanized antibodies cancomprise residues that are not found in the recipient antibody or in thedonor antibody. These modifications are made to further refine antibodyperformance. In general, the humanized antibody will comprisesubstantially all of at least one, and typically two, variable domains,in which all or substantially all of the hypervariable loops correspondto those of a non-human immunoglobulin and all or substantially all ofthe FRs are those of a human immunoglobulin sequence. The humanizedantibody optionally also will comprise at least a portion of animmunoglobulin constant region (Fc), typically that of a humanimmunoglobulin. For further details, see Jones et al., Nature321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); andPresta, Curr. Op. Struct. Biol. 2:593-596 (1992).

“Homology” refers to the sequence similarity or sequence identitybetween two polypeptides or between two nucleic acid molecules. When aposition in both of the two compared sequences is occupied by the samebase or amino acid monomer subunit, e.g., if a position in each of twoDNA molecules is occupied by adenine, then the molecules are“homologous” at that position. The “percent of homology” or “percentsequence identity” between two sequences is a function of the number ofmatching or homologous positions shared by the two sequences divided bythe number of positions compared times 100, considering any conservativesubstitutions as part of the sequence identity. For example, if 6 of 10of the positions in two sequences are matched or homologous then the twosequences are 60% homologous. By way of example, the DNA sequencesATTGCC and TATGGC share 50% homology. Generally, a comparison is madewhen two sequences are aligned to give maximum homology. Alignment forpurposes of determining percent amino acid sequence identity can beachieved in various ways that are within the skill in the art, forinstance, using publicly available computer software such as BLAST,BLAST-2, ALIGN, Megalign (DNASTAR), or MUSCLE software. Those skilled inthe art can determine appropriate parameters for measuring alignment,including any algorithms needed to achieve maximal alignment over thefull-length of the sequences being compared. For purposes herein,however, % amino acid sequence identity values are generated using thesequence comparison computer program MUSCLE (Edgar, R. C., Nucleic AcidsResearch 32(5):1792-1797, 2004; Edgar, R. C., BMC Bioinformatics5(1):113, 2004).

The “C_(H)1 domain” of a human IgG Fc region (also referred to as “C1”of “H1” domain) usually extends from about amino acid 118 to about aminoacid 215 (EU numbering system).

Unless otherwise specified, a “nucleotide sequence encoding an aminoacid sequence” includes all nucleotide sequences that are degenerateversions of each other and that encode the same amino acid sequence. Thephrase nucleotide sequence that encodes a protein or an RNA may alsoinclude introns to the extent that the nucleotide sequence encoding theprotein may in some version contain an intron(s).

The term “operably linked” refers to functional linkage between aregulatory sequence and a heterologous nucleic acid sequence resultingin expression of the latter. For example, a first nucleic acid sequenceis operably linked with a second nucleic acid sequence when the firstnucleic acid sequence is placed in a functional relationship with thesecond nucleic acid sequence. For instance, a promoter is operablylinked to a coding sequence if the promoter affects the transcription orexpression of the coding sequence. Generally, operably linked DNAsequences are contiguous and, where necessary to join two protein codingregions, in the same reading frame.

The term “inducible promoter” refers to a promoter whose activity can beregulated by adding or removing one or more specific signals. Forexample, an inducible promoter may activate transcription of an operablylinked nucleic acid under a specific set of conditions, e.g., in thepresence of an inducing agent or conditions that activates the promoterand/or relieves repression of the promoter.

As used herein, “treatment” or “treating” is an approach for obtainingbeneficial or desired results, including clinical results. For purposesof this invention, beneficial or desired clinical results include, butare not limited to, one or more of the following: alleviating one ormore symptoms resulting from the disease, diminishing the extent of thedisease, stabilizing the disease (e.g., preventing or delaying theworsening of the disease), preventing or delaying the spread (e.g.,metastasis) of the disease, preventing or delaying the recurrence of thedisease, delay or slowing the progression of the disease, amelioratingthe disease state, providing a remission (partial or total) of thedisease, decreasing the dose of one or more other medications requiredto treat the disease, delaying the progression of the disease,increasing or improving the quality of life, increasing weight gain,and/or prolonging survival. Also encompassed by “treatment” is areduction of pathological consequence of the disease (such as, forexample, tumor volume in cancer). The methods of the inventioncontemplate any one or more of these aspects of treatment.

The terms “recurrence,” “relapse” or “relapsed” refers to the return ofa cancer or disease after clinical assessment of the disappearance ofdisease. A diagnosis of distant metastasis or local recurrence can beconsidered a relapse.

The term “refractory” or “resistant” refers to a cancer or disease thathas not responded to treatment.

An “effective amount” of a caTCR or composition comprising a caTCR asdisclosed herein is an amount sufficient to carry out a specificallystated purpose. An “effective amount” can be determined empirically andby known methods relating to the stated purpose.

The term “therapeutically effective amount” refers to an amount of acaTCR or composition comprising a caTCR as disclosed herein, effectiveto “treat” a disease or disorder in an individual. In the case ofcancer, the therapeutically effective amount of a caTCR or compositioncomprising a caTCR as disclosed herein can reduce the number of cancercells; reduce the tumor size or weight; inhibit (i.e., slow to someextent and preferably stop) cancer cell infiltration into peripheralorgans; inhibit (i.e., slow to some extent and preferably stop) tumormetastasis; inhibit, to some extent, tumor growth; and/or relieve tosome extent one or more of the symptoms associated with the cancer. Tothe extent a caTCR or composition comprising a caTCR as disclosed hereincan prevent growth and/or kill existing cancer cells, it can becytostatic and/or cytotoxic. In some embodiments, the therapeuticallyeffective amount is a growth inhibitory amount. In some embodiments, thetherapeutically effective amount is an amount that improves progressionfree survival of a patient. In the case of infectious disease, such asviral infection, the therapeutically effective amount of a caTCR orcomposition comprising a caTCR as disclosed herein can reduce the numberof cells infected by the pathogen; reduce the production or release ofpathogen-derived antigens; inhibit (i.e., slow to some extent andpreferably stop) spread of the pathogen to uninfected cells; and/orrelieve to some extent one or more symptoms associated with theinfection. In some embodiments, the therapeutically effective amount isan amount that extends the survival of a patient.

As used herein, by “pharmaceutically acceptable” or “pharmacologicallycompatible” is meant a material that is not biologically or otherwiseundesirable, e.g., the material may be incorporated into apharmaceutical composition administered to a patient without causing anysignificant undesirable biological effects or interacting in adeleterious manner with any of the other components of the compositionin which it is contained. Pharmaceutically acceptable carriers orexcipients have preferably met the required standards of toxicologicaland manufacturing testing and/or are included on the Inactive IngredientGuide prepared by the U.S. Food and Drug administration.

It is understood that embodiments of the invention described hereininclude “consisting” and/or “consisting essentially of” embodiments.

Reference to “about” a value or parameter herein includes (anddescribes) variations that are directed to that value or parameter perse. For example, description referring to “about X” includes descriptionof “X”.

As used herein, reference to “not” a value or parameter generally meansand describes “other than” a value or parameter. For example, the methodis not used to treat cancer of type X means the method is used to treatcancer of types other than X.

As used herein and in the appended claims, the singular forms “a,” “or,”and “the” include plural referents unless the context clearly dictatesotherwise.

caTCR Plus CSR Immune Cells

The present invention provides an immune cell (such as a T cell)presenting on its surface a caTCR and a CSR according to any of thecaTCRs and CSRs described herein (such an immune cell is also referredto herein as a “caTCR plus CSR immune cell”). In some embodiments, theimmune cell comprises nucleic acid encoding the caTCR and CSR, whereinthe caTCR and CSR are expressed from the nucleic acid and localized tothe immune cell surface. In some embodiments, the immune cell is a Tcell. In some embodiments, the immune cell is selected from the groupconsisting of a cytotoxic T cell, a helper T cell, a natural killer Tcell, and a suppressor T cell. In some embodiments, the immune cell doesnot express the TCR subunits from which the TCR-TMs of the caTCR arederived. For example, in some embodiments, the immune cell is an αβ Tcell and the TCR-TMs of the introduced caTCR comprise sequences derivedfrom TCR δ and γ chains, or the T cell is a γδ T cell and the TCR-TMs ofthe introduced caTCR comprise sequences derived from TCR α and β chains.In some embodiments, the immune cell is modified to block or decreasethe expression of one or both of the endogenous TCR subunits of theimmune cell. For example, in some embodiments, the immune cell is an αβT cell modified to block or decrease the expression of the TCR α and/orβ chains or the immune cell is a γδ T cell modified to block or decreasethe expression of the TCR γ and/or δ chains. Modifications of cells todisrupt gene expression include any such techniques known in the art,including for example RNA interference (e.g., siRNA, shRNA, miRNA), geneediting (e.g., CRISPR- or TALEN-based gene knockout), and the like.

For example, in some embodiments, there is provided an immune cell (suchas a T cell) comprising nucleic acid encoding a caTCR according to anyof the caTCRs described herein and a CSR according to any of the CSRsdescribed herein, wherein the caTCR and CSR are expressed from thenucleic acid and localized to the immune cell surface. In someembodiments, the nucleic acid comprises a first caTCR nucleic acidsequence encoding a first caTCR polypeptide chain of the caTCR, a secondcaTCR nucleic acid sequence encoding a second caTCR polypeptide chain ofthe caTCR, and a CSR nucleic acid sequence encoding a CSR polypeptidechain of the CSR. In some embodiments, the first and second caTCRnucleic acid sequences and CSR nucleic acid sequence are each containedin different vectors. In some embodiments, some or all of the nucleicacid sequences are contained in the same vector. Vectors may beselected, for example, from the group consisting of mammalian expressionvectors and viral vectors (such as those derived from retroviruses,adenoviruses, adeno-associated viruses, herpes viruses, andlentiviruses). In some embodiments, one or more of the vectors isintegrated into the host genome of the immune cell. In some embodiments,the first and second caTCR nucleic acid sequences and CSR nucleic acidsequence are each under the control of different promoters. In someembodiments, some or all of the promoters have the same sequence. Insome embodiments, some or all of the promoters have different sequences.In some embodiments, some or all of the nucleic acid sequences are underthe control of a single promoter. In some embodiments, some or all ofthe promoters are inducible. In some embodiments, the immune cell isselected from the group consisting of a cytotoxic T cell, a helper Tcell, a natural killer T cell, and a suppressor T cell.

Thus, in some embodiments, there is provided a caTCR plus CSR immunecell (such as a T cell) expressing on its surface a caTCR according toany of the caTCRs described herein and a CSR according to any of theCSRs described herein, wherein the caTCR plus CSR immune cell comprisesa) a first caTCR nucleic acid sequence encoding a first caTCRpolypeptide chain of the caTCR; b) a second caTCR nucleic acid sequenceencoding a second caTCR polypeptide chain of the caTCR; and c) a CSRnucleic acid sequence encoding a CSR polypeptide chain of the CSR,wherein the first and second caTCR polypeptide chains are expressed fromthe first and second caTCR nucleic acid sequences to form the caTCR,wherein the CSR polypeptide chain is expressed from the CSR nucleic acidto form the CSR, and wherein the caTCR and CSR localize to the surfaceof the immune cell. In some embodiments, the first caTCR nucleic acidsequence is contained in a first vector (such as a lentiviral vector),the second caTCR nucleic acid sequence is contained in a second vector(such as a lentiviral vector), and the CSR nucleic acid sequence iscontained in a third vector (such as a lentiviral vector). In someembodiments, some or all of the first and second caTCR nucleic acidsequences and CSR nucleic acid sequence are contained in the same vector(such as a lentiviral vector). In some embodiments, each of the firstand second caTCR nucleic acid sequences and CSR nucleic acid sequenceare, individually, operably linked to a promoter. In some embodiments,some or all of the nucleic acid sequences are under the control of asingle promoter. In some embodiments, some or all of the promoters havethe same sequence. In some embodiments, some or all of the promotershave different sequences. In some embodiments, some or all of thepromoters are inducible. In some embodiments, some or all of the vectorsare viral vectors (such as lentiviral vectors). In some embodiments, theimmune cell does not express the TCR subunits from which the TCR-TMs ofthe caTCR are derived. For example, in some embodiments, the immune cellis an αβ T cell and the TCR-TMs of the introduced caTCR comprisesequences derived from TCR δ and γ chains, or the immune cell is a γδ Tcell and the TCR-TMs of the introduced caTCR comprise sequences derivedfrom TCR α and β chains. In some embodiments, the immune cell ismodified to block or decrease the expression of one or both of itsendogenous TCR subunits. For example, in some embodiments, the immunecell is an αβ T cell modified to block or decrease the expression of theTCR α and/or β chains, or the immune cell is a γδ T cell modified toblock or decrease the expression of the TCR γ and/or δ chains. In someembodiments, the immune cell is selected from the group consisting of acytotoxic T cell, a helper T cell, a natural killer T cell, and asuppressor T cell. In some embodiments, some or all of the vectors areviral vectors (such as lentiviral vectors) integrated into the hostgenome of the immune cell.

In some embodiments, there is provided a caTCR plus CSR immune cell(such as a T cell) expressing on its surface a caTCR according to any ofthe caTCRs described herein and a CSR according to any of the CSRsdescribed herein, wherein the caTCR plus CSR immune cell comprises a) afirst vector comprising a first promoter operably linked to a firstcaTCR nucleic acid sequence encoding a first caTCR polypeptide chain ofthe caTCR; b) a second vector comprising a second promoter operablylinked to a second caTCR nucleic acid sequence encoding a second caTCRpolypeptide chain of the caTCR; and c) a third vector comprising a thirdpromoter operably linked to a CSR nucleic acid sequence encoding a CSRpolypeptide chain of the CSR, wherein the first and second caTCRpolypeptide chains are expressed from the first and second caTCR nucleicacid sequences to form the caTCR and the CSR polypeptide chain isexpressed from the CSR nucleic acid sequence to form the CSR, andwherein the caTCR and CSR localize to the surface of the immune cell. Insome embodiments, some or all of the promoters have the same sequence.In some embodiments, some or all of the promoters have differentsequences. In some embodiments, some or all of the promoters areinducible. In some embodiments, the immune cell does not express the TCRsubunits from which the TCR-TMs of the caTCR are derived. For example,in some embodiments, the immune cell is an αβ T cell and the TCR-TMs ofthe introduced caTCR comprise sequences derived from TCR δ and γ chains,or the immune cell is a γδ T cell and the TCR-TMs of the introducedcaTCR comprise sequences derived from TCR α and β chains. In someembodiments, the immune cell is modified to block or decrease theexpression of one or both of its endogenous TCR subunits. For example,in some embodiments, the immune cell is an αβ T cell modified to blockor decrease the expression of the TCR α and/or β chains, or the immunecell is a γδ T cell modified to block or decrease the expression of theTCR γ and/or δ chains. In some embodiments, the immune cell is selectedfrom the group consisting of a cytotoxic T cell, a helper T cell, anatural killer T cell, and a suppressor T cell. In some embodiments, thefirst and second vectors are viral vectors (such as lentiviral vectors)integrated into the host genome of the immune cell.

In some embodiments, there is provided a caTCR plus CSR immune cell(such as a T cell) expressing on its surface a caTCR according to any ofthe caTCRs described herein and a CSR according to any of the CSRsdescribed herein, wherein the caTCR plus CSR immune cell comprises a) afirst vector comprising i) a first promoter operably linked to a firstcaTCR nucleic acid sequence encoding a first caTCR polypeptide chain ofthe caTCR and ii) a second promoter operably linked to a second caTCRnucleic acid sequence encoding a second caTCR polypeptide chain of thecaTCR; and b) a second vector comprising a third promoter operablylinked to a CSR nucleic acid sequence encoding a CSR polypeptide chainof the CSR, wherein the first and second caTCR polypeptide chains areexpressed from the first and second caTCR nucleic acid sequences to formthe caTCR and the CSR polypeptide chain is expressed from the CSRnucleic acid sequence to form the CSR, and wherein the caTCR localizesto the surface of the immune cell. In some embodiments, some or all ofthe promoters have the same sequence. In some embodiments, some or allof the promoters have different sequences. In some embodiments, some orall of the promoters are inducible. In some embodiments, the immune celldoes not express the TCR subunits from which the TCR-TMs of the caTCRare derived. For example, in some embodiments, the immune cell is an αβT cell and the TCR-TMs of the introduced caTCR comprise sequencesderived from TCR δ and γ chains, or the immune cell is a γδ T cell andthe TCR-TMs of the introduced caTCR comprise sequences derived from TCRα and β chains. In some embodiments, the immune cell is modified toblock or decrease the expression of one or both of its endogenous TCRsubunits. For example, in some embodiments, the immune cell is an αβ Tcell modified to block or decrease the expression of the TCR α and/or βchains, or the immune cell is a γδ T cell modified to block or decreasethe expression of the TCR γ and/or δ chains. In some embodiments, theimmune cell is selected from the group consisting of a cytotoxic T cell,a helper T cell, a natural killer T cell, and a suppressor T cell. Insome embodiments, the first and second vectors are viral vectors (suchas lentiviral vectors) integrated into the host genome of the immunecell. It is to be appreciated that embodiments where any of the nucleicacid sequences are swapped are also contemplated, such as where thefirst or second caTCR nucleic acid sequence is swapped with the CSRnucleic acid sequence.

In some embodiments, there is provided a caTCR plus CSR immune cell(such as a T cell) expressing on its surface a caTCR according to any ofthe caTCRs described herein and a CSR according to any of the CSRsdescribed herein, wherein the caTCR plus CSR immune cell comprises a) afirst vector comprising i) a first caTCR nucleic acid sequence encodinga first caTCR polypeptide chain of the caTCR and ii) a second caTCRnucleic acid sequence encoding a second caTCR polypeptide chain of thecaTCR, wherein the first and second caTCR nucleic acid sequences areunder the control of a first promoter; and b) a second vector comprisinga second promoter operably linked to a CSR nucleic acid sequenceencoding a CSR polypeptide chain of the CSR, wherein the first andsecond caTCR polypeptide chains are expressed from the first and secondcaTCR nucleic acid sequences to form the caTCR and the CSR polypeptidechain is expressed from the CSR nucleic acid sequence to form the CSR,and wherein the caTCR and CSR localize to the surface of the immunecell. In some embodiments, the first promoter is operably linked to the5′ end of the first caTCR nucleic acid sequence, and there is nucleicacid linker selected from the group consisting of an internal ribosomalentry site (IRES) and a nucleic acid encoding a self-cleaving 2A peptide(such as P2A, T2A, E2A, or F2A) linking the 3′ end of first caTCRnucleic acid sequence to the 5′ end of the second caTCR nucleic acidsequence, wherein the first caTCR nucleic acid sequence and the secondcaTCR nucleic acid sequence are transcribed as a single RNA under thecontrol of the promoter. In some embodiments, the first promoter isoperably linked to the 5′ end of the second caTCR nucleic acid sequence,and there is nucleic acid linker selected from the group consisting ofan internal ribosomal entry site (IRES) and a nucleic acid encoding aself-cleaving 2A peptide (such as P2A, T2A, E2A, or F2A) linking the 3′end of second caTCR nucleic acid sequence to the 5′ end of the firstcaTCR nucleic acid sequence, wherein the first caTCR nucleic acidsequence and the second caTCR nucleic acid sequence are transcribed as asingle RNA under the control of the promoter. In some embodiments, thefirst and/or second promoters have the same sequence. In someembodiments, the first and/or second promoters have different sequences.In some embodiments, the first and/or second promoters are inducible. Insome embodiments, the immune cell does not express the TCR subunits fromwhich the TCR-TMs of the caTCR are derived. For example, in someembodiments, the immune cell is an αβ T cell and the TCR-TMs of theintroduced caTCR comprise sequences derived from TCR δ and γ chains, orthe immune cell is a γδ T cell and the TCR-TMs of the introduced caTCRcomprise sequences derived from TCR α and β chains. In some embodiments,the immune cell is modified to block or decrease the expression of oneor both of its endogenous TCR subunits. For example, in someembodiments, the immune cell is an αβ T cell modified to block ordecrease the expression of the TCR α and/or β chains, or the immune cellis a γδ T cell modified to block or decrease the expression of the TCR γand/or δ chains. In some embodiments, the immune cell is selected fromthe group consisting of a cytotoxic T cell, a helper T cell, a naturalkiller T cell, and a suppressor T cell. In some embodiments, the vectoris a viral vector (such as a lentiviral vector) integrated into the hostgenome of the immune cell. It is to be appreciated that embodimentswhere any of the nucleic acid sequences are swapped are alsocontemplated, such as where the first or second caTCR nucleic acidsequence is swapped with the CSR nucleic acid sequence.

In some embodiments, there is provided a caTCR plus CSR immune cell(such as a T cell) expressing on its surface a caTCR according to any ofthe caTCRs described herein and a CSR according to any of the CSRsdescribed herein, wherein the caTCR plus CSR immune cell comprises avector comprising a) a first caTCR nucleic acid sequence encoding afirst caTCR polypeptide chain of the caTCR; b) a second caTCR nucleicacid sequence encoding a second caTCR polypeptide chain of the caTCR;and c) a CSR nucleic acid sequence encoding a CSR polypeptide chain ofthe CSR, wherein the first and second caTCR nucleic acid sequences andthe CSR nucleic acid sequence are under the control of a singlepromoter; wherein the first and second caTCR polypeptide chains areexpressed from the first and second caTCR nucleic acid sequences to formthe caTCR and the CSR polypeptide chain is expressed from the CSRnucleic acid sequence to form the CSR, and wherein the caTCR and CSRlocalize to the surface of the immune cell. In some embodiments, thepromoter is operably linked to one of the nucleic acid sequences, whichis linked to the other nucleic acid sequences by nucleic acid linkersselected, individually, from the group consisting of an internalribosomal entry site (IRES) and a nucleic acid encoding a self-cleaving2A peptide (such as P2A, T2A, E2A, or F2A), such that the first andsecond caTCR nucleic acid sequences and the CSR nucleic acid sequenceare transcribed as a single RNA under the control of the promoter. Insome embodiments, the promoter is inducible. In some embodiments, theimmune cell does not express the TCR subunits from which the TCR-TMs ofthe caTCR are derived. For example, in some embodiments, the immune cellis an αβ T cell and the TCR-TMs of the introduced caTCR comprisesequences derived from TCR δ and γ chains, or the immune cell is a γδ Tcell and the TCR-TMs of the introduced caTCR comprise sequences derivedfrom TCR α and β chains. In some embodiments, the immune cell ismodified to block or decrease the expression of one or both of itsendogenous TCR subunits. For example, in some embodiments, the immunecell is an αβ T cell modified to block or decrease the expression of theTCR α and/or β chains, or the immune cell is a γδ T cell modified toblock or decrease the expression of the TCR γ and/or δ chains. In someembodiments, the immune cell is selected from the group consisting of acytotoxic T cell, a helper T cell, a natural killer T cell, and asuppressor T cell. In some embodiments, the vector is a viral vector(such as a lentiviral vector) integrated into the host genome of theimmune cell.

Chimeric Antibody/T Cell Receptor (caTCR) Constructs

In one aspect, the target antigen-specific chimeric antibody/T cellreceptor (caTCR) described herein specifically binds to a target antigen(such as a cell surface antigen or a peptide/MHC complex) and is capableof recruiting at least one TCR-associated signaling molecule (such asCD3δε, CD3γε, and/or ζζ). In some embodiments, the caTCR comprisesnaturally occurring TCR domains. In some embodiments, the caTCRcomprises at least one non-naturally occurring TCR domain. The caTCRcomprises an antigen-binding module that provides the antigenspecificity and a T cell receptor module (TCRM) that allows for CD3recruitment and signaling. The antigen-binding module is not a naturallyoccurring T cell receptor antigen-binding moiety. In some embodiments,the antigen-binding module is linked to the amino terminus of apolypeptide chain in the TCRM. In some embodiments, the antigen-bindingmodule is an antibody moiety. In some embodiments, the antibody moietyis a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv (scFv). In someembodiments, the antigen-binding module is multispecific (such asbispecific). The TCRM comprises a transmembrane module derived from thetransmembrane domains of one or more TCRs (TCR-TMs), such as an αβand/or γδ TCR, and optionally further comprises one or both of theconnecting peptides or fragments thereof of a TCR and/or one or more TCRintracellular domains or fragments thereof. In some embodiments, theTCRM comprises two polypeptide chains, each polypeptide chaincomprising, from amino terminus to carboxy terminus, a connectingpeptide, a transmembrane domain, and optionally a TCR intracellulardomain. In some embodiments, the TCRM comprises one or morenon-naturally occurring TCR domains. For example, in some embodiments,the TCRM comprises one or two non-naturally occurring TCR transmembranedomains. A non-naturally occurring TCR domain may be a correspondingdomain of a naturally occurring TCR modified by substitution of one ormore amino acids, and/or by replacement of a portion of thecorresponding domain with a portion of an analogous domain from anotherTCR. The caTCR may comprise a first polypeptide chain and a secondpolypeptide chain, wherein the first and second polypeptide chainstogether form the antigen-binding module and the TCRM. In someembodiments, the first and second polypeptide chains are separatepolypeptide chains, and the caTCR is a multimer, such as a dimer. Insome embodiments, the first and second polypeptide chains are covalentlylinked, such as by a peptide linkage, or by another chemical linkage,such as a disulfide linkage. In some embodiments, the first polypeptidechain and the second polypeptide chain are linked by at least onedisulfide bond. In some embodiments, the caTCR further comprises one ormore T cell co-stimulatory signaling sequences. The one or moreco-stimulatory signaling sequences can be, individually, all or aportion of the intracellular domain of a co-stimulatory moleculeincluding, for example, CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40,ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT,NKG2C, B7-H3, a ligand that specifically binds with CD83, and the like.In some embodiments, the one or more co-stimulatory signaling sequencesare between the first TCR-TM and the first TCR intracellular domainand/or between the second TCR-TM and the second TCR intracellulardomain. In some embodiments, the one or more co-stimulatory signalingsequences are carboxy-terminal to the first TCRD and/or the second TCRD.In some embodiments, the caTCR lacks a T cell co-stimulatory signalingsequence. In some embodiments, the caTCR further comprises astabilization module comprising a first stabilization domain and asecond stabilization domain, wherein the first and second stabilizationdomains have a binding affinity for each other that stabilizes thecaTCR. In some embodiments, the stabilization module is located betweenthe antigen-binding module and the TCRM. In some embodiments, the caTCRfurther comprises a spacer module between any two caTCR modules ordomains. In some embodiments, the spacer module comprises one or morepeptide linkers connecting two caTCR modules or domains.

The caTCRs described herein may have one or more features described inthis section. It is intended that any of the features for each componentof the caTCR (e.g., antigen-binding module, TCRD, TCR-TM, spacer module,stabilization module, T cell co-stimulation sequences, and variouslinkers etc.) described herein can be combined with each other, with anyof the features of the CSR, and with any of the features of the SSE asif each and every combination is individually described.

In some embodiments, the antigen-binding module (such as an antibodymoiety) specifically binds to a target antigen with a) an affinity thatis at least about 10 (including for example at least about any of 10,20, 30, 40, 50, 75, 100, 200, 300, 400, 500, 750, 1000 or more) timesits binding affinity for other molecules; or b) a K_(d) no more thanabout 1/10 (such as no more than about any of 1/10, 1/20, 1/30, 1/40,1/50, 1/75, 1/100, 1/200, 1/300, 1/400, 1/500, 1/750, 1/1000 or less)times its K_(d) for binding to other molecules. Binding affinity can bedetermined by methods known in the art, such as ELISA, fluorescenceactivated cell sorting (FACS) analysis, or radioimmunoprecipitationassay (RIA). K_(d) can be determined by methods known in the art, suchas surface plasmon resonance (SPR) assay utilizing, for example, Biacoreinstruments, or kinetic exclusion assay (KinExA) utilizing, for example,Sapidyne instruments.

Examples of stabilization domains include an Fc region; a hinge region;a C_(H)3 domain; a C_(H)4 domain; a C_(H)1 or C_(L) domain; a leucinezipper domain (e.g., a jun/fos leucine zipper domain, see, e.g.,Kostelney et al, J. Immunol, 148: 1547-1553, 1992; or a yeast GCN4leucine zipper domain); an isoleucine zipper domain; a dimerizing regionof a dimerizing cell-surface receptor (e.g., interleukin-8 receptor(IL-8R); or an integrin heterodimer such as LFA-1 or GPIIIb/IIIa); adimerizing region of a secreted, dimerizing ligand (e.g., nerve growthfactor (NGF), neurotrophin-3 (NT-3), interleukin-8 (IL-8), vascularendothelial growth factor (VEGF), or brain-derived neurotrophic factor(BDNF); see, e.g., Arakawa et al, J. Biol. Chem. 269:27833-27839, 1994,and Radziejewski et al, Biochem. 32: 1350, 1993); a coiled coildimerization domain (see, for example, WO2014152878; Fletcher et al, ACSSynth. Biol. 1:240-250, 2012; and Thomas et al., J. Am. Chem. Soc.135(13):5161-5166, 2013); and a polypeptide comprising at least onecysteine residue (e.g., from about one, two, or three to about tencysteine residues) such that disulfide bond(s) can form between thepolypeptide and a second polypeptide comprising at least one cysteineresidue.

In some embodiments, the TCRM described herein comprises a) a first Tcell receptor domain (TCRD) comprising a first TCR transmembrane domain(TCR-TM) and b) a second TCRD comprising a second TCR-TM, wherein theTCRM facilitates recruitment of at least one TCR-associated signalingmolecule. In some embodiments, both of the TCR-TMs are naturallyoccurring. In some embodiments, at least one of the TCR-TMs isnon-naturally occurring. In some embodiments, both of the TCR-TMs arenon-naturally occurring. In some embodiments, the first TCR-TM isderived from one of the transmembrane domains of a T cell receptor (suchas an αβ TCR or a γδ TCR) and the second TCR-TM is derived from theother transmembrane domain of the T cell receptor. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising thetransmembrane domains of the T cell receptor. Recruitment ofTCR-associated signaling molecules can be determined by methods known inthe art, such as FACS analysis for TCR-CD3 complex surface expression orco-immunoprecipitation of CD3 subunits with the caTCR.

For example, in some embodiments, the first TCR-TM of a TCRM describedherein comprises, consists essentially of, or consists of thetransmembrane domain of the TCR α chain (e.g., GenBank Accession No:CCI73895) or a variant thereof and the second TCR-TM of the TCRMcomprises, consists essentially of, or consists of the transmembranedomain of the TCR R chain (e.g., GenBank Accession No: CCI73893) or avariant thereof. In some embodiments, the first TCR-TM comprises,consists essentially of, or consists of the transmembrane domain of theTCR δ chain (e.g., GenBank Accession No: AAQ57272) or a variant thereofand the second TCR-TM comprises, consists essentially of, or consists ofthe transmembrane domain of the TCR γ chain (e.g., GenBank Accession No:AGE91788) or a variant thereof. In some embodiments, the first andsecond TCR-TMs of a TCRM described herein comprise, consist essentiallyof, or consist of the transmembrane domain of a TCR α chain constantdomain (e.g., SEQ ID NO: 1) or a variant thereof and the transmembranedomain of a TCR β chain constant domain (e.g., SEQ ID NO: 2) or avariant thereof, respectively. In some embodiments, the first and secondTCR-TMs comprise, consist essentially of, or consist of thetransmembrane domain of a TCR δ chain constant domain (e.g., SEQ ID NO:3) or a variant thereof and the transmembrane domain of a TCR γ chainconstant domain (e.g., SEQ ID NO: 4) or a variant thereof, respectively.In some embodiments, the first and second TCR-TMs comprise, consistessentially of, or consist of the amino acid sequences of SEQ ID NOs: 5and 6, or variants thereof, respectively. In some embodiments, the firstand second TCR-TMs comprise, consist essentially of, or consist of theamino acid sequences of SEQ ID NOs: 7 and 8, or variants thereof,respectively. Variants of the transmembrane domains include, withoutlimitation, transmembrane domains with one or more amino acidsubstitutions compared to the reference sequence. In some embodiments, avariant transmembrane domain comprises no more than 5 amino acidsubstitutions compared to the reference sequence. In some embodiments,the first TCRD further comprises a first connecting peptideamino-terminal to the transmembrane domain and/or the second TCRDfurther comprises a second connecting peptide amino-terminal to thetransmembrane domain. In some embodiments, the first connecting peptidecomprises all or a portion of the connecting peptide of the TCR subunitfrom which the first TCR-TM is derived, or a variant thereof, and/or thesecond connecting peptide comprises all or a portion of the connectingpeptide of the TCR subunit from which the second TCR-TM is derived, or avariant thereof. In some embodiments, the first and/or second connectingpeptides comprise, consist essentially of, or consist of all or aportion of the connecting peptide of a TCR α chain constant domain(e.g., SEQ ID NO: 1) or a variant thereof and all or a portion of theconnecting peptide of a TCR β chain constant domain (e.g., SEQ ID NO: 2)or a variant thereof, respectively. In some embodiments, the firstand/or second connecting peptides comprise, consist essentially of, orconsist of all or a portion of the connecting peptide of SEQ ID NO: 27or 28, or a variant thereof, and all or a portion of the connectingpeptide of SEQ ID NO: 29 or 30, or a variant thereof, respectively. Insome embodiments, the first and/or second connecting peptides comprise,consist essentially of, or consist of all or a portion of the connectingpeptide of a TCR δ chain constant domain (e.g., SEQ ID NO: 3) or avariant thereof and all or a portion of the connecting peptide of a TCRγ chain constant domain (e.g., SEQ ID NO: 4) or a variant thereof,respectively. In some embodiments, the first and/or second connectingpeptides comprise, consist essentially of, or consist of all or aportion of the connecting peptide of SEQ ID NO: 31 or 32, or a variantthereof, and all or a portion of the connecting peptide of SEQ ID NO: 33or 34, or a variant thereof, respectively. In some embodiments, thefirst TCRD further comprises a first TCR intracellular domaincarboxy-terminal to the first TCR-TM and/or the second TCRD furthercomprises a second TCR intracellular domain carboxy-terminal to thesecond TCR-TM. In some embodiments, the first TCR intracellular domaincomprises all or a portion of the intracellular domain of the TCRsubunit from which the first TCR-TM is derived, or a variant thereof,and/or the second TCR intracellular domain comprises all or a portion ofthe intracellular domain of the TCR subunit from which the second TCR-TMis derived, or a variant thereof. In some embodiments, the second TCRintracellular domains comprise any one of the amino acid sequences ofSEQ ID NOs: 35-36, or variants thereof. In some embodiments, the firstTCRD is a fragment of one chain of a naturally occurring TCR, or avariant thereof, and/or the second TCRD is a fragment of the other chainof the naturally occurring TCR, or a variant thereof. In someembodiments, at least one of the TCRDs is non-naturally occurring. Insome embodiments, the first and second TCRDs are linked by a disulfidebond. In some embodiments, the first and second TCRDs are linked by adisulfide bond between a residue in the first connecting peptide and aresidue in the second connecting peptide. In some embodiments, the TCRMis capable of recruiting at least one TCR-associated signaling moleculeselected from the group consisting of CD3δε, CD3γε, and ζζ. In someembodiments, the TCRM is capable of recruiting each of CD3δε, CD3γε, andζζ to form a caTCR-CD3 complex (i.e., promotes caTCR-CD3 complexformation).

Contemplated caTCR constructs include, for example, caTCRs thatspecifically bind to cell surface antigens, caTCRs that specificallybind to cell surface-presented peptide/MHC complexes, and caTCRs thatspecifically bind to both cell surface antigens and cellsurface-presented peptide/MHC complexes.

In some embodiments, the antigen-binding module is an antibody moietyselected from the group consisting of a Fab, a Fab′, a (Fab′)2, an Fv,or a single chain Fv (scFv). In some embodiments, the antibody moiety ismonospecific. In some embodiments, the antibody moiety ismulti-specific. In some embodiments, the antibody moiety is bispecific.In some embodiments, the antibody moiety is a tandem scFv, a diabody(Db), a single chain diabody (scDb), a dual-affinity retargeting (DART)antibody, a dual variable domain (DVD) antibody, a chemicallycross-linked antibody, a heteromultimeric antibody, or a heteroconjugateantibody. In some embodiments, the antibody moiety is a tandem scFvcomprising two scFvs linked by a peptide linker. In some embodiments,the antibody moiety is two scFvs that are not directly linked. In someembodiments, the antibody moiety is fully human, semi-synthetic withhuman antibody framework regions, or humanized.

In some embodiments, the antigen-binding module comprises a firstantigen-binding domain comprising a V_(H) antibody domain and a secondantigen-binding domain comprising a V_(L) antibody domain. In someembodiments, the V_(H) antibody domain and V_(L) antibody domain CDRsare derived from the same antibody moiety. In some embodiments, some ofthe V_(H) antibody domain and V_(L) antibody domain CDRs are derivedfrom different antibody moieties. In some embodiments, the V_(H)antibody domain and/or V_(L) antibody domain are human, humanized,chimeric, semi-synthetic, or fully synthetic.

In some embodiments, the antigen-binding module is an antibody moietythat is semi-synthetic, comprising fully human sequences and one or moresynthetic regions. In some embodiments, the antigen-binding module is asemi-synthetic antibody moiety, comprising a fully human V_(L) and asemi-synthetic V_(H) comprising fully human FR1, HC-CDR1, FR2, HC-CDR2,FR3, and FR4 regions and a synthetic HC-CDR3. In some embodiments, thesemi-synthetic V_(H) comprises a fully synthetic HC-CDR3 having asequence from about 5 to about 25 (such as about any of 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) aminoacids in length. In some embodiments, the semi-synthetic V_(H) or thesynthetic HC-CDR3 is obtained from a semi-synthetic library (such as asemi-synthetic human library) comprising fully synthetic HC-CDR3 regionshaving a sequence from about 5 to about 25 (such as about any of 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or25) amino acids in length, wherein each amino acid in the sequence is,independently from one another, randomly selected from the standardhuman amino acids, minus cysteine. In some embodiments, the syntheticHC-CDR3 is from about 10 to about 19 (such as about any of 10, 11, 12,13, 14, 15, 16, 17, 18 or 19) amino acids in length. In someembodiments, the antigen-binding module is a semi-synthetic antibodymoiety, comprising a semi-synthetic V_(L) and a semi-synthetic V_(H). Insome embodiments, the antigen-binding module is a fully-syntheticantibody moiety, comprising fixed human V_(H)/V_(L) framework pairings,but randomized and synthetic sequences for all 6 CDRs of both heavy andlight chains.

The antigen-binding module in some embodiments is an antibody moietycomprising specific CDR sequences derived from one or more antibodymoieties (such as a monoclonal antibody) or certain variants of suchsequences comprising one or more amino acid substitutions. In someembodiments, the amino acid substitutions in the variant sequences donot substantially reduce the ability of the antigen-binding module tobind the target antigen. Alterations that substantially improve targetantigen binding affinity or affect some other property, such asspecificity and/or cross-reactivity with related variants of the targetantigen, are also contemplated.

In some embodiments, the stabilization module is derived from anantibody moiety. For example, in some embodiments, the stabilizationmodule comprises a first stabilization domain comprising a C_(H)1antibody domain or variant thereof and a second stabilization domaincomprising a C_(L) antibody domain or variant thereof. In anotherembodiment, the stabilization module comprises a first stabilizationdomain comprising a C_(H)3 antibody domain or variant thereof and asecond stabilization domain comprising a C_(H)3 antibody domain or avariant thereof. In some embodiments, antibody heavy chain constantdomains (e.g., C_(H)1 or C_(H)3) contained in the stabilization moduleare derived from an IgG (e.g., IgG1, IgG2, IgG3, or IgG4), IgA (e.g.,IgA1 or IgA2), IgD, IgM, or IgE heavy chain, optionally human. In someembodiments, an antibody heavy chain constant domain (e.g., C_(H)1 orC_(H)3) contained in the stabilization module is a variant comprisingone or more modifications (e.g., amino acid substitutions, insertions,and/or deletions) compared to the sequence from which it is derived. Insome embodiments, antibody light chain constant domains (C_(L))contained in the stabilization module are derived from a kappa or lambdalight chain, optionally human. In some embodiments, an antibody lightchain constant domain (C_(L)) contained in the stabilization module is avariant comprising one or more modifications (e.g., amino acidsubstitutions, insertions, and/or deletions) compared to the sequencefrom which it is derived. In some embodiments, the first and/or secondstabilization domains comprise one or more modifications that do notsubstantially alter their binding affinity for each other. In someembodiments, the first and/or second stabilization domains comprise oneor more modifications that increase their binding affinity for eachother and/or introduce a non-naturally occurring disulfide bond. In someembodiments, the stabilization module comprises a knob-into-holemodification (see, for example, Carter P. J Immunol Methods. 248:7-15,2001). For example, in some embodiments, the stabilization modulecomprises antibody constant domain regions (e.g., C_(H)3 domains)comprising a knob-into-hole modification. In some embodiments, thestabilization module comprises antibody constant domain regions (e.g.,C_(H)3 domains) modified by electrostatic steering to enhance theirassociation (see, for example, WO2006106905 and Gunasekaran K, et al. JBiol Chem. 285:19637-46, 2010). In some embodiments, the first andsecond stabilization domains are linked by a disulfide bond.

In some embodiments, the caTCR comprises an antigen-binding moduledescribed herein linked to a TCRM described herein, optionally includinga stabilization module. For example, in the some embodiments, the caTCRcomprises the antigen-binding module linked to the N-terminus of one orboth of the TCRDs. In some embodiments, the caTCR comprises astabilization module between a TCRM and an antigen-binding module. Insome embodiments, the caTCR further comprises a spacer module betweenany two caTCR modules or domains. In some embodiments, the spacer modulecomprises one or more peptide linkers between about 5 to about 70 (suchas about any of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, or70, including any ranges between these values) amino acids in length. Insome embodiments, the caTCR further comprises one or more accessoryintracellular domains. In some embodiments, the one or more accessoryintracellular domains are carboxy-terminal to the first and/or secondTCRD. In some embodiments, the one or more accessory intracellulardomains are between the first TCR-TM and the first TCR intracellulardomain and/or between the second TCR-TM and the second TCR intracellulardomain. In some embodiments, the one or more accessory intracellulardomains comprise, individually, a TCR co-stimulatory domain. In someembodiments, the TCR co-stimulatory domain comprises all or a portion ofthe intracellular domain of an immune co-stimulatory molecule (such asCD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, ICOS, lymphocytefunction-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, aligand that specifically binds with CD83, and the like). In someembodiments, the TCR co-stimulatory domain comprises all or a portion ofthe amino acid sequence of any one of SEQ ID NOs: 51-56, or a variantthereof.

In some embodiments, the antigen-binding module specifically binds acell surface antigen. In some embodiments, the cell surface antigen isselected from the group consisting of a protein, a carbohydrate, and alipid. In some embodiments, the cell surface antigen is adisease-associated antigen expressed in a diseased cell. In someembodiments, the antigen-binding module specifically binds a complexcomprising a peptide and an MHC protein. Peptide/MHC complexes include,for example, a surface-presented complex comprising a peptide derivedfrom a disease-associated antigen expressed in a diseased cell and anMHC protein. In some embodiments, the full-length disease-associatedantigen is not normally expressed on the surface of the diseased cell(e.g., the disease-associated antigen is an intracellular or secretedprotein). In some embodiments, the disease is cancer and thedisease-associated antigen is a tumor-associated antigen expressed in acancer cell. In some embodiments, the tumor-associated antigen is anoncoprotein. In some embodiments, the oncoprotein is the result of amutation in a proto-oncogene, and the oncoprotein comprises a neoepitopecomprising the mutation. For example, in some embodiments, theantigen-binding module specifically binds a cell surfacetumor-associated antigen (e.g., an oncoprotein comprising a neoepitope).In some embodiments, the antigen-binding module specifically binds acomplex comprising a peptide derived from a tumor-associated antigen(e.g., an oncoprotein comprising a neoepitope) not normally expressed onthe surface of a cancer cell (e.g., an intracellular or secretedtumor-associated antigen) and an MHC protein. In some embodiments, thedisease is viral infection and the disease-associated antigen is avirus-associated antigen expressed in an infected cell. For example, insome embodiments, the antigen-binding module specifically binds a cellsurface virus-associated antigen. In some embodiments, theantigen-binding module specifically binds a complex comprising a peptidederived from a virus-associated antigen not normally expressed on thesurface of a virus-infected cell (e.g., an intracellular or secretedvirus-associated antigen) and an MHC protein. In some embodiments, thecaTCR construct binds the target antigen with a K_(d) between about 0.1pM to about 500 nM (such as about any of 0.1 pM, 1.0 pM, 10 pM, 50 pM,100 pM, 500 pM, 1 nM, 10 nM, 50 nM, 100 nM, or 500 nM, including anyranges between these values).

In some embodiments, the caTCR comprises an antigen-binding module thatspecifically binds to a cell surface antigen, wherein the cell surfaceantigen is CD19, CD20, CD22, CD47, GPC-3, ROR1, ROR2, BCMA, GPRC5D, orFCRL5, including variants or mutants thereof. Specific binding to a fullantigen, e.g., a cell surface antigen, is sometimes referred to as“non-MHC-restricted binding”.

In some embodiments, the caTCR comprises an antigen-binding module thatspecifically binds to a complex comprising a peptide and an MHC protein,wherein the peptide is derived from a protein selected from the groupconsisting of WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, HIV-1,KRAS, Histone H3.3, and PSA, including variants or mutants thereof.Specific binding to a complex comprising a peptide and an MHC protein issometimes referred to as “MHC-restricted binding”.

In some embodiments, the caTCR comprises an antigen-binding module thatspecifically binds to a complex comprising a peptide derived from adisease-associated antigen (such as a tumor-associated orvirally-encoded antigen) and an MHC class I protein, wherein the MHCclass I protein is HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, or HLA-G. In someembodiments, the MHC class I protein is HLA-A, HLA-B, or HLA-C. In someembodiments, the MHC class I protein is HLA-A. In some embodiments, theMHC class I protein is HLA-B. In some embodiments, the MHC class Iprotein is HLA-C. In some embodiments, the MHC class I protein isHLA-A01, HLA-A02, HLA-A03, HLA-A09, HLA-A10, HLA-A11, HLA-A19, HLA-A23,HLA-A24, HLA-A25, HLA-A26, HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-A32,HLA-A33, HLA-A34, HLA-A36, HLA-A43, HLA-A66, HLA-A68, HLA-A69, HLA-A74,or HLA-A80. In some embodiments, the MHC class I protein is HLA-A02. Insome embodiments, the MHC class I protein is any one of HLA-A*02:01-555,such as HLA-A*02:01, HLA-A*02:02, HLA-A*02:03, HLA-A*02:04, HLA-A*02:05,HLA-A*02:06, HLA-A*02:07, HLA-A*02:08, HLA-A*02:09, HLA-A*02:10,HLA-A*02:11, HLA-A*02:12, HLA-A*02:13, HLA-A*02:14, HLA-A*02:15,HLA-A*02:16, HLA-A*02:17, HLA-A*02:18, HLA-A*02:19, HLA-A*02:20,HLA-A*02:21, HLA-A*02:22, or HLA-A*02:24. In some embodiments, the MHCclass I protein is HLA-A*02:01.

In some embodiments, the caTCR comprises an antigen-binding module thatspecifically binds to a complex comprising a peptide derived from adisease-associated antigen (such as a tumor-associated orvirally-encoded antigen) and an MHC class II protein, wherein the MHCclass II protein is HLA-DP, HLA-DQ, or HLA-DR. In some embodiments, theMHC class II protein is HLA-DP. In some embodiments, the MHC class IIprotein is HLA-DQ. In some embodiments, the MHC class II protein isHLA-DR.

In some embodiments, the caTCR described herein comprises a) anantigen-binding module that specifically binds to a target antigen, andb) a TCRM comprising first and second TCR-TMs derived from thetransmembrane domains of a TCR (such as an αβTCR or a γδTCR), whereinthe TCRM is capable of recruiting at least one TCR-associated signalingmolecule. In some embodiments, the antigen-binding module is linked tothe amino-terminus of one or more polypeptide chains in the TCRM. Forexample, in some embodiments, the TCRM comprises two polypeptide chains,and the antigen-binding module is linked to the amino-terminus of one orboth of the TCRM polypeptide chains. In some embodiments, the first andsecond TCR-TMs are naturally occurring. In some embodiments, at leastone of the TCR-TMs is non-naturally occurring. In some embodiments, thefirst and second TCR-TMs are non-naturally occurring. In someembodiments, the TCRM further comprises at least one connecting peptideor fragment thereof of the TCR amino-terminal to a TCR-TM. In someembodiments, the TCRM further comprises at least one TCR intracellulardomain comprising a sequence from an intracellular domain of the TCRcarboxy-terminal to a TCR-TM. In some embodiments, the TCRM comprisesTCRDs derived from fragments of the TCR chains. In some embodiments, atleast one of the TCRDs is non-naturally occurring. In some embodiments,the caTCR further comprises at least one accessory intracellular domaincomprising a T cell co-stimulatory signaling sequence (such as fromCD27, CD28, 4-1BB (CD137), OX40, CD30, or CD40) carboxy-terminal to aTCR-TM. In some embodiments, the caTCR lacks a co-stimulatory signalingsequence. In some embodiments, the antigen-binding module is an antibodymoiety. In some embodiments, the antibody moiety comprises a V_(H)antibody domain and a V_(L) antibody domain. In some embodiments, theantibody moiety is human, humanized, chimeric, semi-synthetic, or fullysynthetic. In some embodiments, the caTCR further comprises astabilization module comprising a first stabilization domain and asecond stabilization domain, wherein the first and second stabilizationdomains have a binding affinity for each other that stabilizes thecaTCR. In some embodiments, the stabilization module comprises at leastone disulfide bond linking the stabilization domains. In someembodiments, the first and second stabilization domains compriseantibody domains, such as C_(H)1 and C_(L) antibody domains, or variantsthereof. In some embodiments, the TCRM is capable of recruiting at leastone TCR-associated signaling molecule selected from the group consistingof CD3δε, CD3γε, and ζζ. In some embodiments, the TCRM allows forenhanced recruitment of the at least one TCR-associated signalingmolecule as compared to a TCRM comprising the T cell receptortransmembrane domains. In some embodiments, the TCRM promotes caTCR-CD3complex formation. In some embodiments, there is a spacer module betweenany two caTCR modules or domains. In some embodiments, the caTCR is aheteromultimer, such as a heterodimer. For example, in some embodiments,the caTCR is a heterodimer comprising a first polypeptide chaincomprising the first TCRD and a second polypeptide chain comprising thesecond TCRD, wherein the antigen-binding module is linked to the firstand/or second polypeptide chains. In some embodiments, theantigen-binding module is multispecific (such as bispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the transmembrane domains of a TCR and a second TCRDcomprising a second TCR-TM derived from the other transmembrane domainof the TCR, wherein the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule;and b) an antigen-binding module that specifically binds to the targetantigen, wherein the antigen-binding module is linked to the firstand/or second TCRDs. In some embodiments, both of the TCR-TMs arenaturally occurring. In some embodiments, at least one of the TCR-TMs isnon-naturally occurring. In some embodiments, the TCR is an αβ TCR andthe first and second TCR-TMs are derived from TCR α and β subunittransmembrane domains. In some embodiments, the TCR is a γδ TCR and thefirst and second TCR-TMs are derived from TCR γ and δ subunittransmembrane domains. In some embodiments, the first TCRD furthercomprises a first TCR connecting peptide or a fragment thereof and/orthe second TCRD further comprises a second TCR connecting peptide or afragment thereof. In some embodiments, the first connecting peptidecomprises all or a portion of the connecting peptide of the TCR subunitfrom which the first TCR-TM is derived, or a variant thereof, and/or thesecond connecting peptide comprises all or a portion of the connectingpeptide of the TCR subunit from which the second TCR-TM is derived, or avariant thereof. In some embodiments, the first and second connectingpeptides are linked by a disulfide bond. In some embodiments, the firstTCRD further comprises a first TCR intracellular domain and/or thesecond TCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain comprises a sequencefrom the intracellular domain of the TCR subunit from which the firstTCR-TM is derived and/or the second TCR intracellular domain comprises asequence from the intracellular domain of the TCR subunit from which thesecond TCR-TM is derived. In some embodiments, the first TCRD is afragment of the TCR subunit from which the first TCR-TM is derivedand/or the second TCRD is a fragment of the TCR subunit from which thesecond TCR-TM is derived. In some embodiments, the caTCR furthercomprises at least one accessory intracellular domain comprising a Tcell co-stimulatory signaling sequence (such as from CD27, CD28, 4-1BB(CD137), OX40, CD30, or CD40). In some embodiments, the caTCR furthercomprises a stabilization module comprising a first stabilization domainand a second stabilization domain, wherein the first and secondstabilization domains have a binding affinity for each other thatstabilizes the caTCR. In some embodiments, the first and secondstabilization domains are linked by a disulfide bond. In someembodiments, the first and second stabilization domains compriseantibody domains, such as C_(H)1 and C_(L) antibody domains, or variantsthereof. In some embodiments, the TCRM is capable of recruiting at leastone TCR-associated signaling molecule selected from the group consistingof CD3δε, CD3γε, and ζζ. In some embodiments, the TCRM allows forenhanced recruitment of the at least one TCR-associated signalingmolecule as compared to a TCRM comprising the T cell receptortransmembrane domains. In some embodiments, the TCRM promotes caTCR-CD3complex formation. In some embodiments, there is a spacer module betweenany two caTCR modules or domains. In some embodiments, theantigen-binding module is an antibody moiety. In some embodiments, theantibody moiety is a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv(scFv). In some embodiments, the antigen-binding module is multispecific(such as bispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the transmembrane domains of a naturally occurring aTCR and a second TCRD comprising a second TCR-TM derived from the othertransmembrane domain of the naturally occurring a TCR, wherein the firstand second TCRDs form a TCRM that is capable of recruiting at least oneTCR-associated signaling molecule; and b) an antigen-binding module thatspecifically binds to the target antigen, wherein the antigen-bindingmodule is linked to the first and/or second TCRDs. In some embodiments,both of the TCR-TMs are naturally occurring. In some embodiments, atleast one of the TCR-TMs is non-naturally occurring. In someembodiments, the first TCRD further comprises a first TCR connectingpeptide or a fragment thereof and/or the second TCRD further comprises asecond TCR connecting peptide or a fragment thereof. In someembodiments, the first connecting peptide comprises all or a portion ofthe connecting peptide of the TCR subunit from which the first TCR-TM isderived, or a variant thereof, and/or the second connecting peptidecomprises all or a portion of the connecting peptide of the TCR subunitfrom which the second TCR-TM is derived, or a variant thereof. In someembodiments, the first and second connecting peptides are linked by adisulfide bond. In some embodiments, the first TCRD further comprises afirst TCR intracellular domain and/or the second TCRD further comprisesa second TCR intracellular domain. In some embodiments, the first TCRintracellular domain comprises a sequence from the intracellular domainof the TCR subunit from which the first TCR-TM is derived and/or thesecond TCR intracellular domain comprises a sequence from theintracellular domain of the TCR subunit from which the second TCR-TM isderived. In some embodiments, the first TCRD is a fragment of the TCRsubunit from which the first TCR-TM is derived and/or the second TCRD isa fragment of the TCR subunit from which the second TCR-TM is derived.In some embodiments, the caTCR further comprises at least one accessoryintracellular domain comprising a T cell co-stimulatory signalingsequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30, or CD40).In some embodiments, the caTCR further comprises a stabilization modulecomprising a first stabilization domain and a second stabilizationdomain, wherein the first and second stabilization domains have abinding affinity for each other that stabilizes the caTCR. In someembodiments, the first and second stabilization domains are linked by adisulfide bond. In some embodiments, the first and second stabilizationdomains comprise antibody domains, such as C_(H)1 and C_(L) antibodydomains, or variants thereof. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD3δε, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising thenaturally occurring a T cell receptor transmembrane domains. In someembodiments, the TCRM promotes caTCR-CD3 complex formation. In someembodiments, there is a spacer module between any two caTCR modules ordomains. In some embodiments, the antigen-binding module is an antibodymoiety. In some embodiments, the antibody moiety is a Fab, a Fab′, a(Fab′)2, an Fv, or a single chain Fv (scFv). In some embodiments, theantigen-binding module is multispecific (such as bispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the transmembrane domains of a naturally occurringγδ TCR and a second TCRD comprising a second TCR-TM derived from theother transmembrane domain of the naturally occurring γδ TCR, whereinthe first and second TCRDs form a TCRM that is capable of recruiting atleast one TCR-associated signaling molecule; and b) an antigen-bindingmodule that specifically binds to the target antigen, wherein theantigen-binding module is linked to the first and/or second TCRDs. Insome embodiments, both of the TCR-TMs are naturally occurring. In someembodiments, at least one of the TCR-TMs is non-naturally occurring. Insome embodiments, the first TCRD further comprises a first TCRconnecting peptide or a fragment thereof and/or the second TCRD furthercomprises a second TCR connecting peptide or a fragment thereof. In someembodiments, the first connecting peptide comprises all or a portion ofthe connecting peptide of the TCR subunit from which the first TCR-TM isderived, or a variant thereof, and/or the second connecting peptidecomprises all or a portion of the connecting peptide of the TCR subunitfrom which the second TCR-TM is derived, or a variant thereof. In someembodiments, the first and second connecting peptides are linked by adisulfide bond. In some embodiments, the first TCRD further comprises afirst TCR intracellular domain and/or the second TCRD further comprisesa second TCR intracellular domain. In some embodiments, the first TCRintracellular domain comprises a sequence from the intracellular domainof the TCR subunit from which the first TCR-TM is derived and/or thesecond TCR intracellular domain comprises a sequence from theintracellular domain of the TCR subunit from which the second TCR-TM isderived. In some embodiments, the first TCRD is a fragment of the TCRsubunit from which the first TCR-TM is derived and/or the second TCRD isa fragment of the TCR subunit from which the second TCR-TM is derived.In some embodiments, the caTCR further comprises at least one accessoryintracellular domain comprising a T cell co-stimulatory signalingsequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30, or CD40).In some embodiments, the caTCR further comprises a stabilization modulecomprising a first stabilization domain and a second stabilizationdomain, wherein the first and second stabilization domains have abinding affinity for each other that stabilizes the caTCR. In someembodiments, the first and second stabilization domains are linked by adisulfide bond. In some embodiments, the first and second stabilizationdomains comprise antibody domains, such as C_(H)1 and C_(L) antibodydomains, or variants thereof. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD3δε, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising thenaturally occurring γδ T cell receptor transmembrane domains. In someembodiments, the TCRM promotes caTCR-CD3 complex formation. In someembodiments, there is a spacer module between any two caTCR modules ordomains. In some embodiments, the antigen-binding module is an antibodymoiety. In some embodiments, the antibody moiety is a Fab, a Fab′, a(Fab′)2, an Fv, or a single chain Fv (scFv). In some embodiments, theantigen-binding module is multispecific (such as bispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from a transmembrane domain contained in one of the amino acidsequences of SEQ ID NO: 1 and SEQ ID NO: 2 and a second TCRD comprisinga second TCR-TM derived from a transmembrane domain contained in theother amino acid sequence, wherein the first and second TCRDs form aTCRM that is capable of recruiting at least one TCR-associated signalingmolecule; and b) an antigen-binding module that specifically binds tothe target antigen, wherein the antigen-binding module is linked to thefirst and/or second TCRDs. In some embodiments, both of the TCR-TMs arenaturally occurring. In some embodiments, at least one of the TCR-TMs isnon-naturally occurring. In some embodiments, the first TCRD furthercomprises a first TCR connecting peptide or a fragment thereof and/orthe second TCRD further comprises a second TCR connecting peptide or afragment thereof. In some embodiments, the first connecting peptide andthe second connecting peptide each comprise, independently from oneanother, the amino acid sequence of a connecting peptide contained inany one of the amino acid sequences of SEQ ID NOs: 1-4, or a variantthereof. In some embodiments, the first connecting peptide and thesecond connecting peptide each comprise, independently from one another,the amino acid sequence of any one of SEQ ID NOs: 27-34, or a variantthereof. In some embodiments, the first and second connecting peptidesare linked by a disulfide bond. In some embodiments, the first TCRDfurther comprises a first TCR intracellular domain and/or the secondTCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain and the second TCRintracellular domain each comprise, independently from one another, theamino acid sequence of an intracellular domain contained in any one ofSEQ ID NOs: 1-4, or a variant thereof. In some embodiments, the firstTCR intracellular domain and the second TCR intracellular domain eachcomprise, independently from one another, the amino acid sequence of SEQID NO: 35 or 36, or a variant thereof. In some embodiments, the caTCRfurther comprises at least one accessory intracellular domain comprisinga T cell co-stimulatory signaling sequence (such as from CD27, CD28,4-1BB (CD137), OX40, CD30, or CD40). In some embodiments, the caTCRfurther comprises a stabilization module comprising a firststabilization domain and a second stabilization domain, wherein thefirst and second stabilization domains have a binding affinity for eachother that stabilizes the caTCR. In some embodiments, the first andsecond stabilization domains are linked by a disulfide bond. In someembodiments, the first and second stabilization domains compriseantibody domains, such as C_(H)1 and C_(L) antibody domains, or variantsthereof. In some embodiments, the TCRM is capable of recruiting at leastone TCR-associated signaling molecule selected from the group consistingof CD3δε, CD3γε, and ζζ. In some embodiments, the TCRM allows forenhanced recruitment of the at least one TCR-associated signalingmolecule as compared to a TCRM comprising T cell receptor transmembranedomains having the sequences of the transmembrane domains contained inSEQ ID NOs: 1 and 2. In some embodiments, the TCRM promotes caTCR-CD3complex formation. In some embodiments, there is a spacer module betweenany two caTCR modules or domains. In some embodiments, theantigen-binding module is an antibody moiety. In some embodiments, theantibody moiety is a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv(scFv). In some embodiments, the antigen-binding module is multispecific(such as bispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from a transmembrane domain contained in one of the amino acidsequences of SEQ ID NO: 1 and SEQ ID NO: 2 and a second TCRD comprisinga second TCR-TM derived from a transmembrane domain contained in theother amino acid sequence, wherein at least one of the TCR-TMs comprisesone or more (such as 2, 3, 4, 5, or more) amino acid substitutionscompared to the amino acid sequence from which it is derived, and thefirst and second TCRDs form a TCRM that is capable of recruiting atleast one TCR-associated signaling molecule; and b) an antigen-bindingmodule that specifically binds to the target antigen, wherein theantigen-binding module is linked to the first and/or second TCRDs. Insome embodiments, each of the TCR-TMs comprises, independently from oneanother, one or more (such as 2, 3, 4, 5, or more) amino acidsubstitutions compared to the amino acid sequence from which it isderived. In some embodiments, the first TCR-TM and/or the second TCR-TMeach comprise, independently from one another, no more than 5 amino acidsubstitutions compared to the amino acid sequences from which they arederived. In some embodiments, at least one of the TCR-TMs comprises asingle amino acid substitution compared to the amino acid sequence fromwhich it is derived. In some embodiments, each of the TCR-TMs comprisesa single amino acid substitution compared to the amino acid sequencefrom which it is derived. In some embodiments, at least one of thesubstituted amino acids in the first TCR-TM is positioned such that inthe caTCR it can interact with at least one of the substituted aminoacids in the second TCR-TM. In some embodiments, the first TCRD furthercomprises a first TCR connecting peptide or a fragment thereof and/orthe second TCRD further comprises a second TCR connecting peptide or afragment thereof. In some embodiments, the first connecting peptide andthe second connecting peptide each comprise, independently from oneanother, the amino acid sequence of a connecting peptide contained inany one of the amino acid sequences of SEQ ID NOs: 1-4, or a variantthereof. In some embodiments, the first connecting peptide and thesecond connecting peptide each comprise, independently from one another,the amino acid sequence of any one of SEQ ID NOs: 27-34, or a variantthereof. In some embodiments, the first and second connecting peptidesare linked by a disulfide bond. In some embodiments, the first TCRDfurther comprises a first TCR intracellular domain and/or the secondTCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain and the second TCRintracellular domain each comprise, independently from one another, theamino acid sequence of an intracellular domain contained in any one ofSEQ ID NOs: 1-4, or a variant thereof. In some embodiments, the firstTCR intracellular domain and the second TCR intracellular domain eachcomprise, independently from one another, the amino acid sequence of SEQID NO: 35 or 36, or a variant thereof. In some embodiments, the caTCRfurther comprises at least one accessory intracellular domain comprisinga T cell co-stimulatory signaling sequence (such as from CD27, CD28,4-1BB (CD137), OX40, CD30, or CD40). In some embodiments, the caTCRfurther comprises a stabilization module comprising a firststabilization domain and a second stabilization domain, wherein thefirst and second stabilization domains have a binding affinity for eachother that stabilizes the caTCR. In some embodiments, the first andsecond stabilization domains are linked by a disulfide bond. In someembodiments, the first and second stabilization domains compriseantibody domains, such as C_(H)1 and C_(L) antibody domains, or variantsthereof. In some embodiments, the TCRM is capable of recruiting at leastone TCR-associated signaling molecule selected from the group consistingof CD3δε, CD3γε, and ζζ. In some embodiments, the TCRM allows forenhanced recruitment of the at least one TCR-associated signalingmolecule as compared to a TCRM comprising T cell receptor transmembranedomains having the sequences of the transmembrane domains contained inSEQ ID NOs: 1 and 2. In some embodiments, the TCRM promotes caTCR-CD3complex formation. In some embodiments, there is a spacer module betweenany two caTCR modules or domains. In some embodiments, theantigen-binding module is an antibody moiety. In some embodiments, theantibody moiety is a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv(scFv). In some embodiments, the antigen-binding module is multispecific(such as bispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from a transmembrane domain contained in one of the amino acidsequences of SEQ ID NO: 1 and SEQ ID NO: 2 and a second TCRD comprisinga second TCR-TM derived from a transmembrane domain contained in theother amino acid sequence, wherein at least one of the TCR-TMs comprisesa chimeric sequence comprising a portion of consecutive amino acids froma transmembrane domain contained in SEQ ID NO: 3 or 4, and the first andsecond TCRDs form a TCRM that is capable of recruiting at least oneTCR-associated signaling molecule; and b) an antigen-binding module thatspecifically binds to the target antigen, wherein the antigen-bindingmodule is linked to the first and/or second TCRDs. In some embodiments,each of the TCR-TMs comprises, independently from one another, achimeric sequence comprising a portion of consecutive amino acids from atransmembrane domain contained in SEQ ID NO: 3 or 4. In someembodiments, the first TCR-TM and/or the second TCR-TM each comprise,independently from one another, a chimeric sequence comprising a portionof no more than about 10 (such as no more than about 9, 8, 7, 6, 5, orfewer) consecutive amino acids from a transmembrane domain contained inSEQ ID NO: 3 or 4. In some embodiments, the chimeric sequence in thefirst or second TCR-TM is from a transmembrane domain contained in SEQID NO: 3 and the chimeric sequence in the other TCR-TM is from atransmembrane domain contained in SEQ ID NO: 4. In some embodiments, thechimeric sequence in the first TCR-TM is positioned such that it caninteract with the chimeric sequence in the second TCR-TM. In someembodiments, the first TCRD further comprises a first TCR connectingpeptide or a fragment thereof and/or the second TCRD further comprises asecond TCR connecting peptide or a fragment thereof. In someembodiments, the first connecting peptide and the second connectingpeptide each comprise, independently from one another, the amino acidsequence of a connecting peptide contained in any one of the amino acidsequences of SEQ ID NOs: 1-4, or a variant thereof. In some embodiments,the first connecting peptide and the second connecting peptide eachcomprise, independently from one another, the amino acid sequence of anyone of SEQ ID NOs: 27-34, or a variant thereof. In some embodiments, thefirst and second connecting peptides are linked by a disulfide bond. Insome embodiments, the first TCRD further comprises a first TCRintracellular domain and/or the second TCRD further comprises a secondTCR intracellular domain. In some embodiments, the first TCRintracellular domain and the second TCR intracellular domain eachcomprise, independently from one another, the amino acid sequence of anintracellular domain contained in any one of SEQ ID NOs: 1-4, or avariant thereof. In some embodiments, the first TCR intracellular domainand the second TCR intracellular domain each comprise, independentlyfrom one another, the amino acid sequence of SEQ ID NO: 35 or 36, or avariant thereof. In some embodiments, the caTCR further comprises atleast one accessory intracellular domain comprising a T cellco-stimulatory signaling sequence (such as from CD27, CD28, 4-1BB(CD137), OX40, CD30, or CD40). In some embodiments, the caTCR furthercomprises a stabilization module comprising a first stabilization domainand a second stabilization domain, wherein the first and secondstabilization domains have a binding affinity for each other thatstabilizes the caTCR. In some embodiments, the first and secondstabilization domains are linked by a disulfide bond. In someembodiments, the first and second stabilization domains compriseantibody domains, such as C_(H)1 and C_(L) antibody domains, or variantsthereof. In some embodiments, the TCRM is capable of recruiting at leastone TCR-associated signaling molecule selected from the group consistingof CD3δε, CD3γε, and ζζ. In some embodiments, the TCRM allows forenhanced recruitment of the at least one TCR-associated signalingmolecule as compared to a TCRM comprising T cell receptor transmembranedomains having the sequences of the transmembrane domains contained inSEQ ID NOs: 1 and 2. In some embodiments, the TCRM promotes caTCR-CD3complex formation. In some embodiments, there is a spacer module betweenany two caTCR modules or domains. In some embodiments, theantigen-binding module is an antibody moiety. In some embodiments, theantibody moiety is a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv(scFv). In some embodiments, the antigen-binding module is multispecific(such as bispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from a transmembrane domain contained in one of the amino acidsequences of SEQ ID NO: 3 and SEQ ID NO: 4 and a second TCRD comprisinga second TCR-TM derived from a transmembrane domain contained in theother amino acid sequence, wherein the first and second TCRDs form aTCRM that is capable of recruiting at least one TCR-associated signalingmolecule; and b) an antigen-binding module that specifically binds tothe target antigen, wherein the antigen-binding module is linked to thefirst and/or second TCRDs. In some embodiments, both of the TCR-TMs arenaturally occurring. In some embodiments, at least one of the TCR-TMs isnon-naturally occurring. In some embodiments, the first TCRD furthercomprises a first TCR connecting peptide or a fragment thereof and/orthe second TCRD further comprises a second TCR connecting peptide or afragment thereof. In some embodiments, the first connecting peptide andthe second connecting peptide each comprise, independently from oneanother, the amino acid sequence of a connecting peptide contained inany one of the amino acid sequences of SEQ ID NOs: 1-4, or a variantthereof. In some embodiments, the first connecting peptide and thesecond connecting peptide each comprise, independently from one another,the amino acid sequence of any one of SEQ ID NOs: 27-34, or a variantthereof. In some embodiments, the first and second connecting peptidesare linked by a disulfide bond. In some embodiments, the first TCRDfurther comprises a first TCR intracellular domain and/or the secondTCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain and the second TCRintracellular domain each comprise, independently from one another, theamino acid sequence of an intracellular domain contained in any one ofSEQ ID NOs: 1-4, or a variant thereof. In some embodiments, the firstTCR intracellular domain and the second TCR intracellular domain eachcomprise, independently from one another, the amino acid sequence of SEQID NO: 35 or 36, or a variant thereof. In some embodiments, the caTCRfurther comprises at least one accessory intracellular domain comprisinga T cell co-stimulatory signaling sequence (such as from CD27, CD28,4-1BB (CD137), OX40, CD30, or CD40). In some embodiments, the caTCRfurther comprises a stabilization module comprising a firststabilization domain and a second stabilization domain, wherein thefirst and second stabilization domains have a binding affinity for eachother that stabilizes the caTCR. In some embodiments, the first andsecond stabilization domains are linked by a disulfide bond. In someembodiments, the first and second stabilization domains compriseantibody domains, such as C_(H)1 and C_(L) antibody domains, or variantsthereof. In some embodiments, the TCRM is capable of recruiting at leastone TCR-associated signaling molecule selected from the group consistingof CD36, CD3γε, and ζζ. In some embodiments, the TCRM allows forenhanced recruitment of the at least one TCR-associated signalingmolecule as compared to a TCRM comprising T cell receptor transmembranedomains having the sequences of the transmembrane domains contained inSEQ ID NOs: 3 and 4. In some embodiments, the TCRM promotes caTCR-CD3complex formation. In some embodiments, there is a spacer module betweenany two caTCR modules or domains. In some embodiments, theantigen-binding module is an antibody moiety. In some embodiments, theantibody moiety is a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv(scFv). In some embodiments, the antigen-binding module is multispecific(such as bispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from a transmembrane domain contained in one of the amino acidsequences of SEQ ID NO: 3 and SEQ ID NO: 4 and a second TCRD comprisinga second TCR-TM derived from a transmembrane domain contained in theother amino acid sequence, wherein at least one of the TCR-TMs comprisesone or more (such as 2, 3, 4, 5, or more) amino acid substitutionscompared to the amino acid sequence from which it is derived, and thefirst and second TCRDs form a TCRM that is capable of recruiting atleast one TCR-associated signaling molecule; and b) an antigen-bindingmodule that specifically binds to the target antigen, wherein theantigen-binding module is linked to the first and/or second TCRDs. Insome embodiments, each of the TCR-TMs comprises, independently from oneanother, one or more (such as 2, 3, 4, 5, or more) amino acidsubstitutions compared to the amino acid sequence from which it isderived. In some embodiments, the first TCR-TM and/or the second TCR-TMeach comprise, independently from one another, no more than 5 amino acidsubstitutions compared to the amino acid sequences from which they arederived. In some embodiments, at least one of the TCR-TMs comprises asingle amino acid substitution compared to the amino acid sequence fromwhich it is derived. In some embodiments, each of the TCR-TMs comprisesa single amino acid substitution compared to the amino acid sequencefrom which it is derived. In some embodiments, at least one of thesubstituted amino acids in the first TCR-TM is positioned such that inthe caTCR it can interact with at least one of the substituted aminoacids in the second TCR-TM. In some embodiments, the first TCRD furthercomprises a first TCR connecting peptide or a fragment thereof and/orthe second TCRD further comprises a second TCR connecting peptide or afragment thereof. In some embodiments, the first connecting peptide andthe second connecting peptide each comprise, independently from oneanother, the amino acid sequence of a connecting peptide contained inany one of the amino acid sequences of SEQ ID NOs: 1-4, or a variantthereof. In some embodiments, the first connecting peptide and thesecond connecting peptide each comprise, independently from one another,the amino acid sequence of any one of SEQ ID NOs: 27-34, or a variantthereof. In some embodiments, the first and second connecting peptidesare linked by a disulfide bond. In some embodiments, the first TCRDfurther comprises a first TCR intracellular domain and/or the secondTCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain and the second TCRintracellular domain each comprise, independently from one another, theamino acid sequence of an intracellular domain contained in any one ofSEQ ID NOs: 1-4, or a variant thereof. In some embodiments, the firstTCR intracellular domain and the second TCR intracellular domain eachcomprise, independently from one another, the amino acid sequence of SEQID NO: 35 or 36, or a variant thereof. In some embodiments, the caTCRfurther comprises at least one accessory intracellular domain comprisinga T cell co-stimulatory signaling sequence (such as from CD27, CD28,4-1BB (CD137), OX40, CD30, or CD40). In some embodiments, the caTCRfurther comprises a stabilization module comprising a firststabilization domain and a second stabilization domain, wherein thefirst and second stabilization domains have a binding affinity for eachother that stabilizes the caTCR. In some embodiments, the first andsecond stabilization domains are linked by a disulfide bond. In someembodiments, the first and second stabilization domains compriseantibody domains, such as C_(H)1 and C_(L) antibody domains, or variantsthereof. In some embodiments, the TCRM is capable of recruiting at leastone TCR-associated signaling molecule selected from the group consistingof CD3δε, CD3γε, and ζζ. In some embodiments, the TCRM allows forenhanced recruitment of the at least one TCR-associated signalingmolecule as compared to a TCRM comprising T cell receptor transmembranedomains having the sequences of the transmembrane domains contained inSEQ ID NOs: 3 and 4. In some embodiments, the TCRM promotes caTCR-CD3complex formation. In some embodiments, there is a spacer module betweenany two caTCR modules or domains. In some embodiments, theantigen-binding module is an antibody moiety. In some embodiments, theantibody moiety is a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv(scFv). In some embodiments, the antigen-binding module is multispecific(such as bispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from a transmembrane domain contained in one of the amino acidsequences of SEQ ID NO: 3 and SEQ ID NO: 4 and a second TCRD comprisinga second TCR-TM derived from a transmembrane domain contained in theother amino acid sequence, wherein at least one of the TCR-TMs comprisesa chimeric sequence comprising a portion of consecutive amino acids froma transmembrane domain contained in SEQ ID NO: 1 or 2, and the first andsecond TCRDs form a TCRM that is capable of recruiting at least oneTCR-associated signaling molecule; and b) an antigen-binding module thatspecifically binds to the target antigen, wherein the antigen-bindingmodule is linked to the first and/or second TCRDs. In some embodiments,each of the TCR-TMs comprises, independently from one another, achimeric sequence comprising a portion of consecutive amino acids from atransmembrane domain contained in SEQ ID NO: 1 or 2. In someembodiments, the first TCR-TM and/or the second TCR-TM each comprise,independently from one another, a chimeric sequence comprising a portionof no more than about 10 (such as no more than about 9, 8, 7, 6, 5, orfewer) consecutive amino acids from a transmembrane domain contained inSEQ ID NO: 1 or 2. In some embodiments, the chimeric sequence in thefirst or second TCR-TM is from a transmembrane domain contained in SEQID NO: 1 and the chimeric sequence in the other TCR-TM is from atransmembrane domain contained in SEQ ID NO: 2. In some embodiments, thechimeric sequence in the first TCR-TM is positioned such that it caninteract with the chimeric sequence in the second TCR-TM. In someembodiments, the first TCRD further comprises a first TCR connectingpeptide or a fragment thereof and/or the second TCRD further comprises asecond TCR connecting peptide or a fragment thereof. In someembodiments, the first connecting peptide and the second connectingpeptide each comprise, independently from one another, the amino acidsequence of a connecting peptide contained in any one of the amino acidsequences of SEQ ID NOs: 1-4, or a variant thereof. In some embodiments,the first connecting peptide and the second connecting peptide eachcomprise, independently from one another, the amino acid sequence of anyone of SEQ ID NOs: 27-34, or a variant thereof. In some embodiments, thefirst and second connecting peptides are linked by a disulfide bond. Insome embodiments, the first TCRD further comprises a first TCRintracellular domain and/or the second TCRD further comprises a secondTCR intracellular domain. In some embodiments, the first TCRintracellular domain and the second TCR intracellular domain eachcomprise, independently from one another, the amino acid sequence of anintracellular domain contained in any one of SEQ ID NOs: 1-4, or avariant thereof. In some embodiments, the first TCR intracellular domainand the second TCR intracellular domain each comprise, independentlyfrom one another, the amino acid sequence of SEQ ID NO: 35 or 36, or avariant thereof. In some embodiments, the caTCR further comprises atleast one accessory intracellular domain comprising a T cellco-stimulatory signaling sequence (such as from CD27, CD28, 4-1BB(CD137), OX40, CD30, or CD40). In some embodiments, the caTCR furthercomprises a stabilization module comprising a first stabilization domainand a second stabilization domain, wherein the first and secondstabilization domains have a binding affinity for each other thatstabilizes the caTCR. In some embodiments, the first and secondstabilization domains are linked by a disulfide bond. In someembodiments, the first and second stabilization domains compriseantibody domains, such as C_(H)1 and C_(L) antibody domains, or variantsthereof. In some embodiments, the TCRM is capable of recruiting at leastone TCR-associated signaling molecule selected from the group consistingof CD3δε, CD3γε, and ζζ. In some embodiments, the TCRM allows forenhanced recruitment of the at least one TCR-associated signalingmolecule as compared to a TCRM comprising T cell receptor transmembranedomains having the sequences of the transmembrane domains contained inSEQ ID NOs: 3 and 4. In some embodiments, the TCRM promotes caTCR-CD3complex formation. In some embodiments, there is a spacer module betweenany two caTCR modules or domains. In some embodiments, theantigen-binding module is an antibody moiety. In some embodiments, theantibody moiety is a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv(scFv). In some embodiments, the antigen-binding module is multispecific(such as bispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the amino acid sequences of SEQ ID NO: 5 and SEQ IDNO: 6 and a second TCRD comprising a second TCR-TM derived from theother amino acid sequence, wherein the first and second TCRDs form aTCRM that is capable of recruiting at least one TCR-associated signalingmolecule; and b) an antigen-binding module that specifically binds tothe target antigen, wherein the antigen-binding module is linked to thefirst and/or second TCRDs. In some embodiments, both of the TCR-TMs arenaturally occurring. In some embodiments, at least one of the TCR-TMs isnon-naturally occurring. In some embodiments, the first TCRD furthercomprises a first TCR connecting peptide or a fragment thereof and/orthe second TCRD further comprises a second TCR connecting peptide or afragment thereof. In some embodiments, the first connecting peptide andthe second connecting peptide each comprise, independently from oneanother, the amino acid sequence of any one of SEQ ID NOs: 27-34, or avariant thereof. In some embodiments, the first and second connectingpeptides are linked by a disulfide bond. In some embodiments, the firstTCRD further comprises a first TCR intracellular domain and/or thesecond TCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain and the second TCRintracellular domain each comprise, independently from one another, theamino acid sequence of SEQ ID NO: 35 or 36, or a variant thereof. Insome embodiments, the caTCR further comprises at least one accessoryintracellular domain comprising a T cell co-stimulatory signalingsequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30, or CD40).In some embodiments, the caTCR further comprises a stabilization modulecomprising a first stabilization domain and a second stabilizationdomain, wherein the first and second stabilization domains have abinding affinity for each other that stabilizes the caTCR. In someembodiments, the first and second stabilization domains are linked by adisulfide bond. In some embodiments, the first and second stabilizationdomains comprise antibody domains, such as C_(H)1 and C_(L) antibodydomains, or variants thereof. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD3δε, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising Tcell receptor transmembrane domains having the sequences of SEQ ID NOs:5 and 6. In some embodiments, the TCRM promotes caTCR-CD3 complexformation. In some embodiments, there is a spacer module between any twocaTCR modules or domains. In some embodiments, the antigen-bindingmodule is an antibody moiety. In some embodiments, the antibody moietyis a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv (scFv). In someembodiments, the antigen-binding module is multispecific (such asbispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the amino acid sequences of SEQ ID NO: 5 and SEQ IDNO: 6 and a second TCRD comprising a second TCR-TM derived from theother amino acid sequence, wherein at least one of the TCR-TMs comprisesone or more (such as 2, 3, 4, 5, or more) amino acid substitutionscompared to the amino acid sequence from which it is derived, and thefirst and second TCRDs form a TCRM that is capable of recruiting atleast one TCR-associated signaling molecule; and b) an antigen-bindingmodule that specifically binds to the target antigen, wherein theantigen-binding module is linked to the first and/or second TCRDs. Insome embodiments, each of the TCR-TMs comprises, independently from oneanother, one or more (such as 2, 3, 4, 5, or more) amino acidsubstitutions compared to the amino acid sequence from which it isderived. In some embodiments, the first TCR-TM and/or the second TCR-TMeach comprise, independently from one another, no more than 5 amino acidsubstitutions compared to the amino acid sequences from which they arederived. In some embodiments, at least one of the TCR-TMs comprises asingle amino acid substitution compared to the amino acid sequence fromwhich it is derived. In some embodiments, each of the TCR-TMs comprisesa single amino acid substitution compared to the amino acid sequencefrom which it is derived. In some embodiments, at least one of thesubstituted amino acids in the first TCR-TM is positioned such that inthe caTCR it can interact with at least one of the substituted aminoacids in the second TCR-TM. In some embodiments, the first TCRD furthercomprises a first TCR connecting peptide or a fragment thereof and/orthe second TCRD further comprises a second TCR connecting peptide or afragment thereof. In some embodiments, the first connecting peptide andthe second connecting peptide each comprise, independently from oneanother, the amino acid sequence of any one of SEQ ID NOs: 27-34, or avariant thereof. In some embodiments, the first and second connectingpeptides are linked by a disulfide bond. In some embodiments, the firstTCRD further comprises a first TCR intracellular domain and/or thesecond TCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain and the second TCRintracellular domain each comprise, independently from one another, theamino acid sequence of SEQ ID NO: 35 or 36, or a variant thereof. Insome embodiments, the caTCR further comprises at least one accessoryintracellular domain comprising a T cell co-stimulatory signalingsequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30, or CD40).In some embodiments, the caTCR further comprises a stabilization modulecomprising a first stabilization domain and a second stabilizationdomain, wherein the first and second stabilization domains have abinding affinity for each other that stabilizes the caTCR. In someembodiments, the first and second stabilization domains are linked by adisulfide bond. In some embodiments, the first and second stabilizationdomains comprise antibody domains, such as C_(H)1 and C_(L) antibodydomains, or variants thereof. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD36, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising Tcell receptor transmembrane domains having the sequences of SEQ ID NOs:5 and 6. In some embodiments, the TCRM promotes caTCR-CD3 complexformation. In some embodiments, there is a spacer module between any twocaTCR modules or domains. In some embodiments, the antigen-bindingmodule is an antibody moiety. In some embodiments, the antibody moietyis a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv (scFv). In someembodiments, the antigen-binding module is multispecific (such asbispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the amino acid sequences of SEQ ID NO: 5 and SEQ IDNO: 6 and a second TCRD comprising a second TCR-TM derived from theother amino acid sequence, wherein at least one of the TCR-TMs comprisesa chimeric sequence comprising a portion of consecutive amino acids fromSEQ ID NO: 7 or 8, and the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule;and b) an antigen-binding module that specifically binds to the targetantigen, wherein the antigen-binding module is linked to the firstand/or second TCRDs. In some embodiments, each of the TCR-TMs comprises,independently from one another, a chimeric sequence comprising a portionof consecutive amino acids from SEQ ID NO: 7 or 8. In some embodiments,the first TCR-TM and/or the second TCR-TM each comprise, independentlyfrom one another, a chimeric sequence comprising a portion of no morethan about 10 (such as no more than about 9, 8, 7, 6, 5, or fewer)consecutive amino acids from SEQ ID NO: 7 or 8. In some embodiments, thechimeric sequence in the first or second TCR-TM is from SEQ ID NO: 7 andthe chimeric sequence in the other TCR-TM is from SEQ ID NO: 8. In someembodiments, the chimeric sequence in the first TCR-TM is positionedsuch that it can interact with the chimeric sequence in the secondTCR-TM. In some embodiments, the first TCRD further comprises a firstTCR connecting peptide or a fragment thereof and/or the second TCRDfurther comprises a second TCR connecting peptide or a fragment thereof.In some embodiments, the first connecting peptide and the secondconnecting peptide each comprise, independently from one another, theamino acid sequence of any one of SEQ ID NOs: 27-34, or a variantthereof. In some embodiments, the first and second connecting peptidesare linked by a disulfide bond. In some embodiments, the first TCRDfurther comprises a first TCR intracellular domain and/or the secondTCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain and the second TCRintracellular domain each comprise, independently from one another, theamino acid sequence of SEQ ID NO: 35 or 36, or a variant thereof. Insome embodiments, the caTCR further comprises at least one accessoryintracellular domain comprising a T cell co-stimulatory signalingsequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30, or CD40).In some embodiments, the caTCR further comprises a stabilization modulecomprising a first stabilization domain and a second stabilizationdomain, wherein the first and second stabilization domains have abinding affinity for each other that stabilizes the caTCR. In someembodiments, the first and second stabilization domains are linked by adisulfide bond. In some embodiments, the first and second stabilizationdomains comprise antibody domains, such as C_(H)1 and C_(L) antibodydomains, or variants thereof. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD3δε, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising Tcell receptor transmembrane domains having the sequences of SEQ ID NOs:5 and 6. In some embodiments, the TCRM promotes caTCR-CD3 complexformation. In some embodiments, there is a spacer module between any twocaTCR modules or domains. In some embodiments, the antigen-bindingmodule is an antibody moiety. In some embodiments, the antibody moietyis a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv (scFv). In someembodiments, the antigen-binding module is multispecific (such asbispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the amino acid sequences of SEQ ID NO: 7 and SEQ IDNO: 8 and a second TCRD comprising a second TCR-TM derived from theother amino acid sequence, wherein the first and second TCRDs form aTCRM that is capable of recruiting at least one TCR-associated signalingmolecule; and b) an antigen-binding module that specifically binds tothe target antigen, wherein the antigen-binding module is linked to thefirst and/or second TCRDs. In some embodiments, both of the TCR-TMs arenaturally occurring. In some embodiments, at least one of the TCR-TMs isnon-naturally occurring. In some embodiments, the first TCRD furthercomprises a first TCR connecting peptide or a fragment thereof and/orthe second TCRD further comprises a second TCR connecting peptide or afragment thereof. In some embodiments, the first connecting peptide andthe second connecting peptide each comprise, independently from oneanother, the amino acid sequence of any one of SEQ ID NOs: 27-34, or avariant thereof. In some embodiments, the first and second connectingpeptides are linked by a disulfide bond. In some embodiments, the firstTCRD further comprises a first TCR intracellular domain and/or thesecond TCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain and the second TCRintracellular domain each comprise, independently from one another, theamino acid sequence of SEQ ID NO: 35 or 36, or a variant thereof. Insome embodiments, the caTCR further comprises at least one accessoryintracellular domain comprising a T cell co-stimulatory signalingsequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30, or CD40).In some embodiments, the caTCR further comprises a stabilization modulecomprising a first stabilization domain and a second stabilizationdomain, wherein the first and second stabilization domains have abinding affinity for each other that stabilizes the caTCR. In someembodiments, the first and second stabilization domains are linked by adisulfide bond. In some embodiments, the first and second stabilizationdomains comprise antibody domains, such as C_(H)1 and C_(L) antibodydomains, or variants thereof. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD3δε, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising Tcell receptor transmembrane domains having the sequences of SEQ ID NOs:7 and 8. In some embodiments, the TCRM promotes caTCR-CD3 complexformation. In some embodiments, there is a spacer module between any twocaTCR modules or domains. In some embodiments, the antigen-bindingmodule is an antibody moiety. In some embodiments, the antibody moietyis a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv (scFv). In someembodiments, the antigen-binding module is multispecific (such asbispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the amino acid sequences of SEQ ID NO: 7 and SEQ IDNO: 8 and a second TCRD comprising a second TCR-TM derived from theother amino acid sequence, wherein at least one of the TCR-TMs comprisesone or more (such as 2, 3, 4, 5, or more) amino acid substitutionscompared to the amino acid sequence from which it is derived, and thefirst and second TCRDs form a TCRM that is capable of recruiting atleast one TCR-associated signaling molecule; and b) an antigen-bindingmodule that specifically binds to the target antigen, wherein theantigen-binding module is linked to the first and/or second TCRDs. Insome embodiments, each of the TCR-TMs comprises, independently from oneanother, one or more (such as 2, 3, 4, 5, or more) amino acidsubstitutions compared to the amino acid sequence from which it isderived. In some embodiments, the first TCR-TM and/or the second TCR-TMeach comprise, independently from one another, no more than 5 amino acidsubstitutions compared to the amino acid sequences from which they arederived. In some embodiments, at least one of the TCR-TMs comprises asingle amino acid substitution compared to the amino acid sequence fromwhich it is derived. In some embodiments, each of the TCR-TMs comprisesa single amino acid substitution compared to the amino acid sequencefrom which it is derived. In some embodiments, at least one of thesubstituted amino acids in the first TCR-TM is positioned such that inthe caTCR it can interact with at least one of the substituted aminoacids in the second TCR-TM. In some embodiments, the first TCRD furthercomprises a first TCR connecting peptide or a fragment thereof and/orthe second TCRD further comprises a second TCR connecting peptide or afragment thereof. In some embodiments, the first connecting peptide andthe second connecting peptide each comprise, independently from oneanother, the amino acid sequence of any one of SEQ ID NOs: 27-34, or avariant thereof. In some embodiments, the first and second connectingpeptides are linked by a disulfide bond. In some embodiments, the firstTCRD further comprises a first TCR intracellular domain and/or thesecond TCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain and the second TCRintracellular domain each comprise, independently from one another, theamino acid sequence of SEQ ID NO: 35 or 36, or a variant thereof. Insome embodiments, the caTCR further comprises at least one accessoryintracellular domain comprising a T cell co-stimulatory signalingsequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30, or CD40).In some embodiments, the caTCR further comprises a stabilization modulecomprising a first stabilization domain and a second stabilizationdomain, wherein the first and second stabilization domains have abinding affinity for each other that stabilizes the caTCR. In someembodiments, the first and second stabilization domains are linked by adisulfide bond. In some embodiments, the first and second stabilizationdomains comprise antibody domains, such as C_(H)1 and C_(L) antibodydomains, or variants thereof. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD36, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising Tcell receptor transmembrane domains having the sequences of SEQ ID NOs:7 and 8. In some embodiments, the TCRM promotes caTCR-CD3 complexformation. In some embodiments, there is a spacer module between any twocaTCR modules or domains. In some embodiments, the antigen-bindingmodule is an antibody moiety. In some embodiments, the antibody moietyis a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv (scFv). In someembodiments, the antigen-binding module is multispecific (such asbispecific).

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the amino acid sequences of SEQ ID NO: 7 and SEQ IDNO: 8 and a second TCRD comprising a second TCR-TM derived from theother amino acid sequence, wherein at least one of the TCR-TMs comprisesa chimeric sequence comprising a portion of consecutive amino acids fromSEQ ID NO: 5 or 6, and the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule;and b) an antigen-binding module that specifically binds to the targetantigen, wherein the antigen-binding module is linked to the firstand/or second TCRDs. In some embodiments, each of the TCR-TMs comprises,independently from one another, a chimeric sequence comprising a portionof consecutive amino acids from SEQ ID NO: 5 or 6. In some embodiments,the first TCR-TM and/or the second TCR-TM each comprise, independentlyfrom one another, a chimeric sequence comprising a portion of no morethan about 10 (such as no more than about 9, 8, 7, 6, 5, or fewer)consecutive amino acids from SEQ ID NO: 5 or 6. In some embodiments, thechimeric sequence in the first or second TCR-TM is from SEQ ID NO: 5 andthe chimeric sequence in the other TCR-TM is from SEQ ID NO: 6. In someembodiments, the chimeric sequence in the first TCR-TM is positionedsuch that it can interact with the chimeric sequence in the secondTCR-TM. In some embodiments, the first TCRD further comprises a firstTCR connecting peptide or a fragment thereof and/or the second TCRDfurther comprises a second TCR connecting peptide or a fragment thereof.In some embodiments, the first connecting peptide and the secondconnecting peptide each comprise, independently from one another, theamino acid sequence of any one of SEQ ID NOs: 27-34, or a variantthereof. In some embodiments, the first and second connecting peptidesare linked by a disulfide bond. In some embodiments, the first TCRDfurther comprises a first TCR intracellular domain and/or the secondTCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain and the second TCRintracellular domain each comprise, independently from one another, theamino acid sequence of SEQ ID NO: 35 or 36, or a variant thereof. Insome embodiments, the caTCR further comprises at least one accessoryintracellular domain comprising a T cell co-stimulatory signalingsequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30, or CD40).In some embodiments, the caTCR further comprises a stabilization modulecomprising a first stabilization domain and a second stabilizationdomain, wherein the first and second stabilization domains have abinding affinity for each other that stabilizes the caTCR. In someembodiments, the first and second stabilization domains are linked by adisulfide bond. In some embodiments, the first and second stabilizationdomains comprise antibody domains, such as C_(H)1 and C_(L) antibodydomains, or variants thereof. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD3δε, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising Tcell receptor transmembrane domains having the sequences of SEQ ID NOs:7 and 8. In some embodiments, the TCRM promotes caTCR-CD3 complexformation. In some embodiments, there is a spacer module between any twocaTCR modules or domains. In some embodiments, the antigen-bindingmodule is an antibody moiety. In some embodiments, the antibody moietyis a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv (scFv). In someembodiments, the antigen-binding module is multispecific (such asbispecific).

The different aspects are discussed in various sections below in furtherdetail.

TCR-TM Variants

In some embodiments, the TCR-TMs of a caTCR are derived from a T cellreceptor, wherein at least one of the TCR-TMs is non-naturallyoccurring. Non-naturally occurring TCR-TMs derived from a T cellreceptor include a transmembrane domain from a T cell receptor that hasbeen modified by substitution of one or more amino acids. In someembodiments, at least one of the substituted amino acids is substitutedwith a residue more hydrophobic than the corresponding unsubstitutedresidue. In some embodiments, each of the substituted amino acids issubstituted with a residue more hydrophobic than the correspondingunsubstituted residue. In some embodiments, at least one of thesubstituted amino acids is proximal (either in primary sequence orspatially) to an amino acid in the TCRM involved in binding CD3. Forexample, in some embodiments, at least one of the substituted aminoacids is separated from an amino acid in the TCRM involved in bindingCD3 by no more than 3 (such as 0, 1, 2, or 3) amino acids. In someembodiments, at least one of the substituted amino acids is separatedfrom an amino acid in the TCRM involved in binding CD3 by no more thanabout 15 (such as no more than about any of 14, 12, 10, 8, 6, 4, 2,or 1) angstroms. In some embodiments, each of the substituted aminoacids is proximal to an amino acid in the TCRM involved in binding CD3.

For example, in some embodiments, a non-naturally occurring TCR-TMderived from a T cell receptor comprises, consists essentially of, orconsists of the transmembrane domain of an α, β, γ, or δ TCR subunitmodified by substitution of one or more amino acid residues. In someembodiments, the transmembrane domain of the TCR subunit is modified bysubstitution of no more than 5 amino acid residues. In some embodiments,the transmembrane domain of the TCR subunit is modified by substitutionof a single amino acid residue. In some embodiments, at least one of thesubstituted amino acids is substituted with a residue more hydrophobicthan the corresponding unsubstituted residue. In some embodiments, eachof the substituted amino acids is substituted with a residue morehydrophobic than the corresponding unsubstituted residue. In someembodiments, at least one of the substituted amino acids is proximal toan amino acid in the TCRM involved in binding CD3. In some embodiments,each of the substituted amino acids is proximal to an amino acid in theTCRM involved in binding CD3.

Thus, in some embodiments, a non-naturally occurring TCR-TM derived froma T cell receptor described herein comprises, consists essentially of,or consists of the transmembrane domain of an α TCR subunit comprisingthe amino acid sequence of a transmembrane domain contained in SEQ IDNO: 1 (e.g., SEQ ID NO: 5), modified by substitution of one or moreamino acid residues. In some embodiments, the transmembrane domain ofthe α TCR subunit is modified by substitution of no more than 5 aminoacid residues in the transmembrane domain contained in SEQ ID NO: 1. Insome embodiments, the transmembrane domain of the α TCR subunit ismodified by substitution of a single amino acid residue in thetransmembrane domain contained in SEQ ID NO: 1. In some embodiments, atleast one of the substituted amino acids is substituted with a residuemore hydrophobic than the corresponding unsubstituted residue. In someembodiments, each of the substituted amino acids is substituted with aresidue more hydrophobic than the corresponding unsubstituted residue.In some embodiments, at least one of the substituted amino acids isproximal to an amino acid in the TCRM involved in binding CD3. In someembodiments, each of the substituted amino acids is proximal to an aminoacid in the TCRM involved in binding CD3.

In some embodiments, a non-naturally occurring TCR-TM derived from a Tcell receptor described herein comprises, consists essentially of, orconsists of the transmembrane domain of an α TCR subunit comprising theamino acid sequence of SEQ ID NO: 5, modified by substitution of one ormore amino acid residues. In some embodiments, the transmembrane domainof the α TCR subunit is modified by substitution of no more than 5 aminoacid residues in SEQ ID NO: 5. In some embodiments, the transmembranedomain of the α TCR subunit is modified by substitution of a singleamino acid residue in SEQ ID NO: 5. In some embodiments, at least one ofthe substituted amino acids is substituted with a residue morehydrophobic than the corresponding unsubstituted residue. In someembodiments, each of the substituted amino acids is substituted with aresidue more hydrophobic than the corresponding unsubstituted residue.In some embodiments, at least one of the substituted amino acids isproximal to an amino acid in the TCRM involved in binding CD3. In someembodiments, each of the substituted amino acids is proximal to an aminoacid in the TCRM involved in binding CD3.

In some embodiments, a non-naturally occurring TCR-TM derived from a Tcell receptor described herein comprises, consists essentially of, orconsists of the transmembrane domain of a β TCR subunit comprising theamino acid sequence of a transmembrane domain contained in SEQ ID NO: 2(e.g., SEQ ID NO: 6), modified by substitution of one or more amino acidresidues. In some embodiments, the transmembrane domain of the β TCRsubunit is modified by substitution of no more than 5 amino acidresidues in the transmembrane domain contained in SEQ ID NO: 2. In someembodiments, the transmembrane domain of the β TCR subunit is modifiedby substitution of a single amino acid residue in the transmembranedomain contained in SEQ ID NO: 2. In some embodiments, at least one ofthe substituted amino acids is substituted with a residue morehydrophobic than the corresponding unsubstituted residue. In someembodiments, each of the substituted amino acids is substituted with aresidue more hydrophobic than the corresponding unsubstituted residue.In some embodiments, at least one of the substituted amino acids isproximal to an amino acid in the TCRM involved in binding CD3. In someembodiments, each of the substituted amino acids is proximal to an aminoacid in the TCRM involved in binding CD3.

In some embodiments, a non-naturally occurring TCR-TM derived from a Tcell receptor described herein comprises, consists essentially of, orconsists of the transmembrane domain of a TCR subunit comprising theamino acid sequence of SEQ ID NO: 6, modified by substitution of one ormore amino acid residues. In some embodiments, the transmembrane domainof the β TCR subunit is modified by substitution of no more than 5 aminoacid residues in SEQ ID NO: 6. In some embodiments, the transmembranedomain of the β TCR subunit is modified by substitution of a singleamino acid residue in SEQ ID NO: 6. In some embodiments, at least one ofthe substituted amino acids is substituted with a residue morehydrophobic than the corresponding unsubstituted residue. In someembodiments, each of the substituted amino acids is substituted with aresidue more hydrophobic than the corresponding unsubstituted residue.In some embodiments, at least one of the substituted amino acids isproximal to an amino acid in the TCRM involved in binding CD3. In someembodiments, each of the substituted amino acids is proximal to an aminoacid in the TCRM involved in binding CD3.

In some embodiments, a non-naturally occurring TCR-TM derived from a Tcell receptor described herein comprises, consists essentially of, orconsists of the transmembrane domain of a δ TCR subunit comprising theamino acid sequence of a transmembrane domain contained in SEQ ID NO: 3(e.g., SEQ ID NO: 7), modified by substitution of one or more amino acidresidues. In some embodiments, the transmembrane domain of the δ TCRsubunit is modified by substitution of no more than 5 amino acidresidues in the transmembrane domain contained in SEQ ID NO: 3. In someembodiments, the transmembrane domain of the δ TCR subunit is modifiedby substitution of a single amino acid residue in the transmembranedomain contained in SEQ ID NO: 3. In some embodiments, at least one ofthe substituted amino acids is substituted with a residue morehydrophobic than the corresponding unsubstituted residue. In someembodiments, each of the substituted amino acids is substituted with aresidue more hydrophobic than the corresponding unsubstituted residue.In some embodiments, at least one of the substituted amino acids isproximal to an amino acid in the TCRM involved in binding CD3. In someembodiments, each of the substituted amino acids is proximal to an aminoacid in the TCRM involved in binding CD3.

In some embodiments, the non-naturally occurring TCR-TM comprises theamino acid sequence of the transmembrane domain contained in SEQ ID NO:3 (e.g., SEQ ID NO: 7), modified by one or more substitutions (such assubstitutions with more hydrophobic residues) in amino acidscorresponding to the following amino acids in SEQ ID NO: 7: L4, M6, V12,N15, F245, and L25. In some embodiments, the non-naturally occurringTCR-TM comprises the amino acid sequence of the transmembrane domaincontained in SEQ ID NO: 3 modified by substitutions (such assubstitutions with more hydrophobic residues) in amino acidscorresponding to V12 and N15 in SEQ ID NO: 7. In some embodiments, thenon-naturally occurring TCR-TM comprises the amino acid sequence of thetransmembrane domain contained in SEQ ID NO: 3 modified by one or moresubstitutions corresponding to the following substitutions in SEQ ID NO:7: L4C, M6V, V12F, N15S, F245S, and L25S. In some embodiments, thenon-naturally occurring TCR-TM comprises the amino acid sequence of thetransmembrane domain contained in SEQ ID NO: 3 modified by substitutionscorresponding to V12F and N15S substitutions in SEQ ID NO: 7. In someembodiments, the non-naturally occurring TCR-TM comprises the amino acidsequence of any one of SEQ ID NOs: 9-13.

In some embodiments, a non-naturally occurring TCR-TM derived from a Tcell receptor described herein comprises, consists essentially of, orconsists of the transmembrane domain of a δ TCR subunit comprising theamino acid sequence of SEQ ID NO: 7, modified by substitution of one ormore amino acid residues. In some embodiments, the transmembrane domainof the δ TCR subunit is modified by substitution of no more than 5 aminoacid residues in SEQ ID NO: 7. In some embodiments, the transmembranedomain of the δ TCR subunit is modified by substitution of a singleamino acid residue in SEQ ID NO: 7. In some embodiments, at least one ofthe substituted amino acids is substituted with a residue morehydrophobic than the corresponding unsubstituted residue. In someembodiments, each of the substituted amino acids is substituted with aresidue more hydrophobic than the corresponding unsubstituted residue.In some embodiments, at least one of the substituted amino acids isproximal to an amino acid in the TCRM involved in binding CD3. In someembodiments, each of the substituted amino acids is proximal to an aminoacid in the TCRM involved in binding CD3.

In some embodiments, the non-naturally occurring TCR-TM comprises theamino acid sequence of SEQ ID NO: 7 modified by one or moresubstitutions (such as substitutions with more hydrophobic residues) inamino acids corresponding to the following amino acids in SEQ ID NO: 7:L4, M6, V12, N15, F245, and L25. In some embodiments, the non-naturallyoccurring TCR-TM comprises the amino acid sequence of SEQ ID NO: 7modified by substitutions (such as substitutions with more hydrophobicresidues) in amino acids corresponding to V12 and N15 in SEQ ID NO: 7.In some embodiments, the non-naturally occurring TCR-TM comprises theamino acid sequence of SEQ ID NO: 7 modified by one or moresubstitutions corresponding to the following substitutions in SEQ ID NO:7: L4C, M6V, V12F, N15S, F245S, and L25S. In some embodiments, thenon-naturally occurring TCR-TM comprises the amino acid sequence of SEQID NO: 7 modified by substitutions corresponding to V12F and N15Ssubstitutions in SEQ ID NO: 7. In some embodiments, the non-naturallyoccurring TCR-TM comprises the amino acid sequence of any one of SEQ IDNOs: 9-13.

In some embodiments, a non-naturally occurring TCR-TM derived from a Tcell receptor described herein comprises, consists essentially of, orconsists of the transmembrane domain of a γ TCR subunit comprising theamino acid sequence of a transmembrane domain contained in SEQ ID NO: 4(e.g., SEQ ID NO: 8), modified by substitution of one or more amino acidresidues. In some embodiments, the transmembrane domain of the γ TCRsubunit is modified by substitution of no more than 5 amino acidresidues in the transmembrane domain contained in SEQ ID NO: 4. In someembodiments, the transmembrane domain of the γ TCR subunit is modifiedby substitution of a single amino acid residue in the transmembranedomain contained in SEQ ID NO: 4. In some embodiments, at least one ofthe substituted amino acids is substituted with a residue morehydrophobic than the corresponding unsubstituted residue. In someembodiments, each of the substituted amino acids is substituted with aresidue more hydrophobic than the corresponding unsubstituted residue.In some embodiments, at least one of the substituted amino acids isproximal to an amino acid in the TCRM involved in binding CD3. In someembodiments, each of the substituted amino acids is proximal to an aminoacid in the TCRM involved in binding CD3.

In some embodiments, the non-naturally occurring TCR-TM comprises theamino acid sequence of the transmembrane domain contained in SEQ ID NO:4 (e.g., SEQ ID NO: 8), modified by one or more substitutions (such assubstitutions with more hydrophobic residues) in amino acidscorresponding to the following amino acids in SEQ ID NO: 8: Y1, Y2, M3,L5, L8, V12, V13, F15, A16, I18, C19, C20, and C21. In some embodiments,the non-naturally occurring TCR-TM comprises the amino acid sequence ofthe transmembrane domain contained in SEQ ID NO: 4 modified bysubstitutions (such as substitutions with more hydrophobic residues) inamino acids corresponding to Y2, M3, A16, and I18 in SEQ ID NO: 8. Insome embodiments, the non-naturally occurring TCR-TM comprises the aminoacid sequence of the transmembrane domain contained in SEQ ID NO: 4modified by substitutions (such as substitutions with more hydrophobicresidues) in amino acids corresponding to L8, V12, and F15 in SEQ ID NO:8. In some embodiments, the non-naturally occurring TCR-TM comprises theamino acid sequence of the transmembrane domain contained in SEQ ID NO:4 modified by one or more substitutions corresponding to the followingsubstitutions in SEQ ID NO: 8: Y1Q, Y2L, Y2I, M3V, M3I, L5C, L8F, V12F,V13Y, F15S, A16V, A16, I18V, I18L, C19M, C20M, and C21G. In someembodiments, the non-naturally occurring TCR-TM comprises the amino acidsequence of the transmembrane domain contained in SEQ ID NO: 4 modifiedby substitutions corresponding to Y2L, M3V, A16V, and I18V substitutionsin SEQ ID NO: 8. In some embodiments, the non-naturally occurring TCR-TMcomprises the amino acid sequence of the transmembrane domain containedin SEQ ID NO: 4 modified by substitutions corresponding to Y2I, M3I,A16I, and I18L substitutions in SEQ ID NO: 8. In some embodiments, thenon-naturally occurring TCR-TM comprises the amino acid sequence of thetransmembrane domain contained in SEQ ID NO: 4 modified by substitutionscorresponding to L8F, V12F, and F15S substitutions in SEQ ID NO: 8. Insome embodiments, the non-naturally occurring TCR-TM comprises the aminoacid sequence of any one of SEQ ID NOs: 14-26.

In some embodiments, a non-naturally occurring TCR-TM derived from a Tcell receptor described herein comprises, consists essentially of, orconsists of the transmembrane domain of a γ TCR subunit comprising theamino acid sequence of SEQ ID NO: 8, modified by substitution of one ormore amino acid residues. In some embodiments, the transmembrane domainof the γ TCR subunit is modified by substitution of no more than 5 aminoacid residues in SEQ ID NO: 8. In some embodiments, the transmembranedomain of the γ TCR subunit is modified by substitution of a singleamino acid residue in SEQ ID NO: 8. In some embodiments, at least one ofthe substituted amino acids is substituted with a residue morehydrophobic than the corresponding unsubstituted residue. In someembodiments, each of the substituted amino acids is substituted with aresidue more hydrophobic than the corresponding unsubstituted residue.In some embodiments, at least one of the substituted amino acids isproximal to an amino acid in the TCRM involved in binding CD3. In someembodiments, each of the substituted amino acids is proximal to an aminoacid in the TCRM involved in binding CD3.

In some embodiments, the non-naturally occurring TCR-TM comprises theamino acid sequence of SEQ ID NO: 8 modified by one or moresubstitutions (such as substitutions with more hydrophobic residues) inamino acids corresponding to the following amino acids in SEQ ID NO: 8:Y1, Y2, M3, L5, L8, V12, V13, F15, A16, I18, C19, C20, and C21. In someembodiments, the non-naturally occurring TCR-TM comprises the amino acidsequence of SEQ ID NO: 8 modified by substitutions (such assubstitutions with more hydrophobic residues) in amino acidscorresponding to Y2, M3, A16, and 118 in SEQ ID NO: 8. In someembodiments, the non-naturally occurring TCR-TM comprises the amino acidsequence of SEQ ID NO: 8 modified by substitutions (such assubstitutions with more hydrophobic residues) in amino acidscorresponding to L8, V12, and F15 in SEQ ID NO: 8. In some embodiments,the non-naturally occurring TCR-TM comprises the amino acid sequence ofSEQ ID NO: 8 modified by one or more substitutions corresponding to thefollowing substitutions in SEQ ID NO: 8: Y1Q, Y2L, Y2I, M3V, M3I, L5C,L8F, V12F, V13Y, F15S, A16V, A16, 118V, I18L, C19M, C20M, and C21G. Insome embodiments, the non-naturally occurring TCR-TM comprises the aminoacid sequence of SEQ ID NO: 8 modified by substitutions corresponding toY2L, M3V, A16V, and I18V substitutions in SEQ ID NO: 8. In someembodiments, the non-naturally occurring TCR-TM comprises the amino acidsequence of SEQ ID NO: 8 modified by substitutions corresponding to Y2I,M3I, A16, and I18L substitutions in SEQ ID NO: 8. In some embodiments,the non-naturally occurring TCR-TM comprises the amino acid sequence ofSEQ ID NO: 8 modified by substitutions corresponding to L8F, V12F, andF15S substitutions in SEQ ID NO: 8. In some embodiments, thenon-naturally occurring TCR-TM comprises the amino acid sequence of anyone of SEQ ID NOs: 14-26.

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMcomprising, consisting essentially of, or consisting of any one of theamino acid sequences of SEQ ID NOs: 7 and 9-13, and a second TCRDcomprising a second TCR-TM comprising, consisting essentially of, orconsisting of the amino acid sequence of any one of SEQ ID NOs: 8 and14-26, wherein the first and second TCRDs form a TCRM that is capable ofrecruiting at least one TCR-associated signaling molecule; and b) anantigen-binding module that specifically binds to the target antigen,wherein the antigen-binding module is linked to the first and/or secondTCRDs. In some embodiments, at least one of the TCR-TMs is non-naturallyoccurring. In some embodiments, the first TCR-TM and second TCR-TM areselected according to any of the caTCRs listed in Table 2. In someembodiments, the first TCRD further comprises a first TCR connectingpeptide or a fragment thereof and/or the second TCRD further comprises asecond TCR connecting peptide or a fragment thereof. In someembodiments, the first connecting peptide comprises the amino acidsequence SEQ ID NO: 31 or 32, or a variant thereof, and/or the secondconnecting peptide comprises the amino acid sequence SEQ ID NO: 33 or34, or a variant thereof. In some embodiments, the first and secondconnecting peptides are linked by a disulfide bond. In some embodiments,the first TCRD further comprises a first TCR intracellular domain and/orthe second TCRD further comprises a second TCR intracellular domain. Insome embodiments, the second TCR intracellular domain comprises theamino acid sequence of SEQ ID NO: 36, or a variant thereof. In someembodiments, the caTCR further comprises at least one accessoryintracellular domain comprising a T cell co-stimulatory signalingsequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30, or CD40).In some embodiments, the caTCR further comprises a stabilization modulecomprising a first stabilization domain and a second stabilizationdomain, wherein the first and second stabilization domains have abinding affinity for each other that stabilizes the caTCR. In someembodiments, the first and second stabilization domains are linked by adisulfide bond. In some embodiments, the first and second stabilizationdomains comprise antibody domains, such as C_(H)1 and C_(L) antibodydomains, or variants thereof. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD3δε, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising Tcell receptor transmembrane domains having the sequences of SEQ ID NOs:7 and 8. In some embodiments, the TCRM promotes caTCR-CD3 complexformation. In some embodiments, there is a spacer module between any twocaTCR modules or domains. In some embodiments, the antigen-bindingmodule is an antibody moiety. In some embodiments, the antibody moietyis a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv (scFv).

TABLE 2 caTCR First TCR-TM Second TCR-TM ID (δ subunit) (γ subunit) TM0VLGLRMLFAKTVA YYMYLLLLLKSVVY VNFLLTAKLFFL FAIITCCLL (SEQ ID NO: 7)(SEQ ID NO: 8) TM1 VLGLRMLFAKTVA YYMYLLLLLKSVVY VNFLLTAKLFSL FAIITCCLL(SEQ ID NO: 9) (SEQ ID NO: 8) TM2 VLGLRMLFAKTVA YYMYLLLLLKSVYYVNFLLTAKLFFL FAIITCCLLRRTAF (SEQ ID NO: 7) (SEQ ID NO: 14) TM3VLGLRMLFAKTVA YYMYLLLLLKSVVY VNFLLTAKLFFL FAIITCGLLRRTAF (SEQ ID NO: 7)(SEQ ID NO: 15) TM4 VLGLRMLFAKTVA YLVYLLLLLKSVVY VNFLLTAKLFFLFVIVTCCLLRRTAF (SEQ ID NO: 7) (SEQ ID NO: 16) TM5 VLGLRVLFAKTVAYLVYLLLLLKSVVY VNFLLTAKLFFL FVIVTCCLLRRTAF (SEQ ID NO: 10)(SEQ ID NO: 16) TM6 VLGLRMLFAKTVA YLMYLLLLLKSVVY VNFLLTAKLFFLFAIITCCLLRRTAF (SEQ ID NO: 7) (SEQ ID NO: 17) TM7 VLGLRMLFAKTVAYYVYLLLLLKSVVY VNFLLTAKLFFL FAIITCCLLRRTAF (SEQ ID NO: 7)(SEQ ID NO: 18) TM8 VLGLRMLFAKTVA YYMYLLLLLKSVVY VNFLLTAKLFFLFVIITCCLLRRTAF (SEQ ID NO: 7) (SEQ ID NO: 19) TM9 VLGLRMLFAKTVAYYMYLLLLLKSVVY VNFLLTAKLFFL FAIVTCCLLRRTAF (SEQ ID NO: 7)(SEQ ID NO: 20) TM10 VLGLRMLFAKTVA YYTYLLLLLKSVVY VNFLLTAKLFFLFAIITCCLLRRTAF (SEQ ID NO: 7) (SEQ ID NO: 21) TM11 VLGLRMLFAKTVAYITYLLLLLKSVVY VNFLLTAKLFFL FIILTCCLLRRTAF (SEQ ID NO: 7)(SEQ ID NO: 22) TM12 VLGCRMLFAKTVA YYMYCLLLLKSVVY VNFLLTAKLFFLFAIITCCLLRRTAF (SEQ ID NO: 11) (SEQ ID NO: 23) TM13 VLGLRMLFAKTFAYYMYLLLFLKSFVY VSFLLTAKLFFL SAIITCCLLRRTAF (SEQ ID NO: 12)(SEQ ID NO: 24) TM14 VLGLRMLFAKTVA YYMYLLLLLKSVVY VNFLLTAKLFFLFAIITMCLLRRTAF (SEQ ID NO: 7) (SEQ ID NO: 25) TM15 VLGLRMLFAKTVAQYMYLLLLLKSVVY VNFLLTAKLFFS FAIITCCLLRRTAF (SEQ ID NO: 13)(SEQ ID NO: 26)

Antigen-Binding Modules

In some embodiments, according to any of the caTCRs described herein,the antigen-binding module is an antibody moiety. In some embodiments,the antibody moiety is selected from the group consisting of a Fab, aFab′, a (Fab′)2, an Fv, and a single chain Fv (scFv). In someembodiments, where the antibody moiety is a multimer comprising a firstantibody moiety chain and a second antibody moiety chain, the caTCRcomprises the first TCRD linked to the first or second antibody moietychain and the second TCRD linked to the other antibody moiety chain. Insome embodiments, the antibody moiety specifically binds a cell surfaceantigen including, without limitation, CD19, CD20, CD22, CD47, GPC-3,ROR1, ROR2, BCMA, GPRC5D, and FCRL5, including variants or mutantsthereof. In some embodiments, the antibody moiety specifically binds apeptide/MHC complex, wherein the peptide is derived from a proteinincluding, without limitation, WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME,EBV-LMP2A, HIV-1, KRAS, Histone H3.3, and PSA, including variants ormutants thereof.

In some embodiments, according to any of the caTCRs described herein,the antigen-binding module is an antibody moiety comprising C_(H)1 andC_(L) domains. In some embodiments, the C_(H)1 domain is derived from anIgG (e.g, IgG1, IgG2, IgG3, or IgG4) heavy chain, optionally human. Insome embodiments, the C_(H)1 domain is a variant comprising one or moremodifications (e.g., amino acid substitutions, insertions, and/ordeletions) compared to the sequence from which it is derived. In someembodiments, the C_(H)1 domain comprises the amino acid sequence of anyone of SEQ ID NOs: 37-47, or a variant thereof. In some embodiments, theC_(H)1 domain comprises the amino acid sequence of SEQ ID NO: 37, or avariant thereof. In some embodiments, the C_(L) domain is derived from akappa or lambda light chain, optionally human. In some embodiments, theC_(L) domain is a variant comprising one or more modifications (e.g.,amino acid substitutions, insertions, and/or deletions) compared to thesequence from which it is derived. In some embodiments, the C_(L) domaincomprises the amino acid sequence of SEQ ID NO: 48, or a variantthereof. In some embodiments, the C_(H)1 and/or C_(L) domains compriseone or more modifications that do not substantially alter their bindingaffinity for each other. In some embodiments, the C_(H)1 and/or C_(L)domains comprise one or more modifications that increase their bindingaffinity for each other and/or introduce a non-naturally occurringdisulfide bond.

In some embodiments, according to any of the caTCRs described hereincomprising an antibody moiety that specifically binds to a targetantigen, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for thetarget antigen. In some embodiments, the antibody moiety comprises theCDRs or variables domains (V_(H) and/or V_(L) domains) of an antibodymoiety specific for CD19 (see, e.g., WO2017066136A2). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for CD19(e.g., V_(H) domain comprising, consisting essentially of, or consistingof the amino acid sequence of SEQ ID NO: 58 and/or V_(L) domaincomprising, consisting essentially of, or consisting of the amino acidsequence of SEQ ID NO: 59, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for CD20(e.g., V_(H) domain comprising, consisting essentially of, or consistingof the amino acid sequence of SEQ ID NO: 60 and/or V_(L) domaincomprising, consisting essentially of, or consisting of the amino acidsequence of SEQ ID NO: 61, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for CD22(see, e.g., U.S. Ser. No. 62/650,955 filed Mar. 30, 2018, the contentsof which are incorporated herein by reference in their entirety). Insome embodiments, the antibody moiety comprises the CDRs or variablesdomains (V_(H) and/or V_(L) domains) of an antibody moiety specific forCD22 (e.g., V_(H) domain comprising, consisting essentially of, orconsisting of the amino acid sequence of SEQ ID NO: 101 and/or V_(L)domain comprising, consisting essentially of, or consisting of the aminoacid sequence of SEQ ID NO: 102, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for GPC3(see, e.g., U.S. Ser. No. 62/490,586 filed Apr. 26, 2017, the contentsof which are incorporated herein by reference in their entirety). Insome embodiments, the antibody moiety comprises the CDRs or variablesdomains (V_(H) and/or V_(L) domains) of an antibody moiety specific forGPC3 (e.g., V_(H) domain comprising, consisting essentially of, orconsisting of the amino acid sequence of SEQ ID NO: 64 and/or V_(L)domain comprising, consisting essentially of, or consisting of the aminoacid sequence of SEQ ID NO: 65, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for ROR1(see, e.g., WO2016/187220 and WO2016/187216). In some embodiments, theantibody moiety comprises the CDRs or variables domains (V_(H) and/orV_(L) domains) of an antibody moiety specific for ROR2 (see, e.g.,WO2016/142768). In some embodiments, the antibody moiety comprises theCDRs or variables domains (V_(H) and/or V_(L) domains) of an antibodymoiety specific for BCMA (see, e.g., WO2016/090327 and WO2016/090320).In some embodiments, the antibody moiety comprises the CDRs or variablesdomains (V_(H) and/or V_(L) domains) of an antibody moiety specific forGPRC5D (see, e.g., WO2016/090329 and WO2016/090312). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for FCRL5(see, e.g., WO2016/090337). In some embodiments, the antibody moietycomprises the CDRs or variables domains (V_(H) and/or V_(L) domains) ofan antibody moiety specific for WT-1 (see, e.g., WO2012/135854,WO2015/070078, and WO2015/070061). In some embodiments, the antibodymoiety comprises the CDRs or variables domains (V_(H) and/or V_(L)domains) of an antibody moiety specific for AFP (see, e.g.,WO2016/161390). In some embodiments, the antibody moiety comprises theCDRs or variables domains (V_(H) and/or V_(L) domains) of an antibodymoiety specific for HPV16-E7 (see, e.g., WO2016/182957). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for NY-ESO-1(see, e.g., WO2016/210365). In some embodiments, the antibody moietycomprises the CDRs or variables domains (V_(H) and/or V_(L) domains) ofan antibody moiety specific for PRAME (see, e.g., WO2016/191246). Insome embodiments, the antibody moiety comprises the CDRs or variablesdomains (V_(H) and/or V_(L) domains) of an antibody moiety specific forEBV-LMP2A (see, e.g., WO2016/201124). In some embodiments, the antibodymoiety comprises the CDRs or variables domains (V_(H) and/or V_(L)domains) of an antibody moiety specific for KRAS (see, e.g.,WO2016/154047). In some embodiments, the antibody moiety comprises theCDRs or variables domains (V_(H) and/or V_(L) domains) of an antibodymoiety specific for PSA (see, e.g., WO2017/015634). In some embodiments,the antibody moiety is a Fab comprising one Fab chain comprising a V_(H)domain and a C_(H)1 domain, and another Fab chain comprising a V_(L)domain and a C_(L) domain. In some embodiments, the C_(H)1 domaincomprises the amino acid sequence of any one of SEQ ID NOs: 37-47 and/orthe C_(L) domain comprises the amino acid sequence of SEQ ID NO: 48. Insome embodiments, the C_(H)1 domain comprises, consists essentially of,or consists of the amino acid sequence of SEQ ID NO: 37 and the C_(L)domain comprises, consists essentially of, or consists of the amino acidsequence of SEQ ID NO: 48.

caTCR Constructs

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the transmembrane domains of a TCR and a second TCRDcomprising a second TCR-TM derived from the other transmembrane domainof the TCR, wherein the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule;and b) an antibody moiety that specifically binds to the target antigen,wherein the antibody moiety is linked to the first and/or second TCRDs.In some embodiments, the antibody moiety is selected from the groupconsisting of a Fab, a Fab′, a (Fab′)2, an Fv, and a single chain Fv(scFv). In some embodiments, the antibody moiety specifically binds acell surface antigen including, without limitation, CD19, CD20, CD22,CD47, GPC-3, ROR1, ROR2, BCMA, GPRC5D, and FCRL5, including variants ormutants thereof. In some embodiments, the antibody moiety specificallybinds a peptide/MHC complex, wherein the peptide is derived from aprotein including, without limitation, WT-1, AFP, HPV16-E7, NY-ESO-1,PRAME, EBV-LMP2A, HIV-1, KRAS, Histone H3.3, and PSA, including variantsor mutants thereof. In some embodiments, the caTCR further comprises astabilization module comprising a first stabilization domain and asecond stabilization domain, wherein the first and second stabilizationdomains have a binding affinity for each other that stabilizes thecaTCR. In some embodiments, the stabilization module is located betweenthe TCRM and the antibody moiety. In some embodiments, both of theTCR-TMs are naturally occurring. In some embodiments, at least one ofthe TCR-TMs is non-naturally occurring.

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMcomprising, consisting essentially of, or consisting of any one of theamino acid sequences of SEQ ID NOs: 7 and 9-13 and a second TCRDcomprising a second TCR-TM comprising, consisting essentially of, orconsisting of the amino acid sequence of any one of SEQ ID NOs: 8 and14-26, wherein the first and second TCRDs form a TCRM that is capable ofrecruiting at least one TCR-associated signaling molecule; and b) anantibody moiety that specifically binds to the target antigen, whereinthe antibody moiety is linked to the first and/or second TCRDs. In someembodiments, the first TCR-TM and second TCR-TM are selected accordingto any of the caTCRs listed in Table 2. In some embodiments, theantibody moiety is selected from the group consisting of a Fab, a Fab′,a (Fab′)2, an Fv, and a single chain Fv (scFv). In some embodiments, theantibody moiety specifically binds a cell surface antigen including,without limitation, CD19, CD20, CD22, CD47, GPC-3, ROR1, ROR2, BCMA,GPRC5D, and FCRL5, including variants or mutants thereof. In someembodiments, the antibody moiety specifically binds a peptide/MHCcomplex, wherein the peptide is derived from a protein including,without limitation, WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A,HIV-1, KRAS, Histone H3.3, and PSA, including variants or mutantsthereof. In some embodiments, the first TCRD further comprises a firstTCR connecting peptide or a fragment thereof and/or the second TCRDfurther comprises a second TCR connecting peptide or a fragment thereof.In some embodiments, the first connecting peptide comprises the aminoacid sequence SEQ ID NO: 31 or 32, or a variant thereof, and/or thesecond connecting peptide comprises the amino acid sequence SEQ ID NO:33 or 34, or a variant thereof. In some embodiments, the first andsecond connecting peptides are linked by a disulfide bond. In someembodiments, the first TCRD further comprises a first TCR intracellulardomain and/or the second TCRD further comprises a second TCRintracellular domain. In some embodiments, the second TCR intracellulardomain comprises the amino acid sequence of SEQ ID NO: 36, or a variantthereof. In some embodiments, the caTCR further comprises at least oneaccessory intracellular domain comprising a T cell co-stimulatorysignaling sequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30,or CD40). In some embodiments, the caTCR further comprises astabilization module comprising a first stabilization domain and asecond stabilization domain, wherein the first and second stabilizationdomains have a binding affinity for each other that stabilizes thecaTCR. In some embodiments, the first and second stabilization domainsare linked by a disulfide bond. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD3δε, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising Tcell receptor transmembrane domains having the sequences of SEQ ID NOs:7 and 8. In some embodiments, the TCRM promotes caTCR-CD3 complexformation. In some embodiments, there is a spacer module between any twocaTCR modules or domains. In some embodiments, both of the TCR-TMs arenaturally occurring. In some embodiments, at least one of the TCR-TMs isnon-naturally occurring.

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TM anda second TCRD comprising a second TCR-TM, wherein the first and secondTCR-TMs comprise, consist essentially of, or consist of the amino acidsequences of SEQ ID NOs: 7 and 8, 9 and 8, 7 and 14, 7 and 15, 7 and 16,10 and 16, 7 and 17, 7 and 18, 7 and 19, 7 and 20, 7 and 21, 7 and 22,11 and 23, 12 and 24, 7 and 25, or 13 and 26, respectively, and whereinthe first and second TCRDs form a TCRM that is capable of recruiting atleast one TCR-associated signaling molecule; and b) an antibody moietythat specifically binds to the target antigen, wherein the antibodymoiety is linked to the first and/or second TCRDs. For example, in someembodiments, the caTCR described herein specifically binds a targetantigen, comprising a) a first TCRD comprising a first TCR-TMcomprising, consisting essentially of, or consisting of the amino acidsequence of SEQ ID NO: 7, and a second TCRD comprising a second TCR-TMcomprising, consisting essentially of, or consisting of the amino acidsequence of SEQ ID NO: 8, wherein the first and second TCRDs form a TCRMthat is capable of recruiting at least one TCR-associated signalingmolecule; and b) an antibody moiety that specifically binds to thetarget antigen, wherein the antibody moiety is linked to the firstand/or second TCRDs. In some embodiments, the antibody moiety isselected from the group consisting of a Fab, a Fab′, a (Fab′)2, an Fv,and a single chain Fv (scFv). In some embodiments, the antibody moietyspecifically binds a cell surface antigen including, without limitation,CD19, CD20, CD22, CD47, GPC-3, ROR1, ROR2, BCMA, GPRC5D, and FCRL5,including variants or mutants thereof. In some embodiments, the antibodymoiety specifically binds a peptide/MHC complex, wherein the peptide isderived from a protein including, without limitation, WT-1, AFP,HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, HIV-1, KRAS, Histone H3.3, andPSA, including variants or mutants thereof. In some embodiments, thefirst TCRD further comprises a first TCR connecting peptide or afragment thereof and/or the second TCRD further comprises a second TCRconnecting peptide or a fragment thereof. In some embodiments, the firstconnecting peptide comprises the amino acid sequence SEQ ID NO: 31 or32, or a variant thereof, and/or the second connecting peptide comprisesthe amino acid sequence SEQ ID NO: 33 or 34, or a variant thereof. Insome embodiments, the first and second connecting peptides are linked bya disulfide bond. In some embodiments, the first TCRD further comprisesa first TCR intracellular domain and/or the second TCRD furthercomprises a second TCR intracellular domain. In some embodiments, thesecond TCR intracellular domain comprises the amino acid sequence of SEQID NO: 36, or a variant thereof. In some embodiments, the caTCR furthercomprises at least one accessory intracellular domain comprising a Tcell co-stimulatory signaling sequence (such as from CD27, CD28, 4-1BB(CD137), OX40, CD30, or CD40). In some embodiments, the caTCR furthercomprises a stabilization module comprising a first stabilization domainand a second stabilization domain, wherein the first and secondstabilization domains have a binding affinity for each other thatstabilizes the caTCR. In some embodiments, the first and secondstabilization domains are linked by a disulfide bond. In someembodiments, the TCRM is capable of recruiting at least oneTCR-associated signaling molecule selected from the group consisting ofCD3δε, CD3γε, and ζζ. In some embodiments, the TCRM allows for enhancedrecruitment of the at least one TCR-associated signaling molecule ascompared to a TCRM comprising T cell receptor transmembrane domainshaving the sequences of SEQ ID NOs: 7 and 8. In some embodiments, theTCRM promotes caTCR-CD3 complex formation. In some embodiments, there isa spacer module between any two caTCR modules or domains.

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first polypeptide chain comprising afirst antigen-binding domain comprising a first Fab chain linked to afirst TCRD comprising a first TCR-TM derived from one of thetransmembrane domains of a TCR; and b) a second polypeptide chaincomprising a second antigen-binding domain comprising a second Fab chainlinked to a second TCRD comprising a second TCR-TM derived from theother transmembrane domain of the TCR, wherein the first and secondTCRDs form a TCRM that is capable of recruiting at least oneTCR-associated signaling molecule, and wherein the first and second Fabchains form a Fab-like antigen-binding module that specifically bindsthe target antigen. In some embodiments, a) the first Fab chaincomprises V_(H) and C_(H)1 antibody domains and the second Fab chaincomprises V_(L) and C_(L) antibody domains; or b) the first Fab chaincomprises V_(L) and C_(L) antibody domains and the second Fab chaincomprises V_(H) and C_(H)1 antibody domains. For example, in someembodiments, the caTCR comprises a) a first polypeptide chain comprisinga first Fab chain comprising V_(H) and C_(H)1 antibody domains linked tothe first TCRD and b) a second Fab chain comprising V_(L) and C_(L)antibody domains linked to the second TCRD. In some embodiments, thecaTCR comprises a) a first Fab chain comprising V_(L) and C_(L) antibodydomains linked to the first TCRD and b) a second Fab chain comprisingV_(H) and C_(H)1 antibody domains linked to the second TCRD. In someembodiments, there is a peptide linker between one or both of the TCRDsand their linked Fab chain. In some embodiments, there is a disulfidebond between a residue in the C_(H)1 domain and a residue in the C_(L)domain. In some embodiments, the C_(H)1 and/or C_(L) domains compriseone or more modifications that increase the binding affinity of the Fabchains for each other. In some embodiments, the C_(H)1 and C_(L) domainsare swapped, such that one of the Fab chains comprises V_(H) and C_(L)antibody domains and the other Fab chain comprises V_(L) and C_(H)1antibody domains. In some embodiments, the Fab-like antigen-bindingmodule specifically binds a cell surface antigen including, withoutlimitation, CD19, CD20, CD22, CD47, GPC-3, ROR1, ROR2, BCMA, GPRC5D, andFCRL5, including variants or mutants thereof. In some embodiments, theFab-like antigen-binding module specifically binds a peptide/MHCcomplex, wherein the peptide is derived from a protein including,without limitation, WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A,HIV-1, KRAS, Histone H3.3, and PSA, including variants or mutantsthereof. In some embodiments, the caTCR further comprises astabilization module comprising a first stabilization domain and asecond stabilization domain, wherein the first and second stabilizationdomains have a binding affinity for each other that stabilizes thecaTCR. In some embodiments, the first or second stabilization domain islocated between first TCRD and its linked Fab chain and the otherstabilization domain is located between the second TCRD and its linkedFab chain. In some embodiments, both of the TCR-TMs are naturallyoccurring. In some embodiments, at least one of the TCR-TMs isnon-naturally occurring.

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first polypeptide chain comprising afirst antigen-binding domain comprising a first Fab chain linked to afirst TCRD comprising a first TCR-TM comprising, consisting essentiallyof, or consisting of any one of the amino acid sequences of SEQ ID NOs:7 and 9-13; and b) a second polypeptide chain comprising a secondantigen-binding domain comprising a second Fab chain linked to a secondTCRD comprising a second TCR-TM comprising, consisting essentially of,or consisting of the amino acid sequence of any one of SEQ ID NOs: 8 and14-26, wherein the first and second TCRDs form a TCRM that is capable ofrecruiting at least one TCR-associated signaling molecule, and whereinthe first and second Fab chains form a Fab-like antigen-binding modulethat specifically binds the target antigen. In some embodiments, thefirst TCR-TM and second TCR-TM are selected according to any of thecaTCRs listed in Table 2. In some embodiments, a) the first Fab chaincomprises V_(H) and C_(H)1 antibody domains and the second Fab chaincomprises V_(L) and C_(L) antibody domains; or b) the first Fab chaincomprises V_(L) and C_(L) antibody domains and the second Fab chaincomprises V_(H) and C_(H)1 antibody domains. In some embodiments, theC_(H)1 domain comprises the amino acid sequence of any one of SEQ IDNOs: 37-47 and/or the C_(L) domain comprises the amino acid sequence ofSEQ ID NO: 48. In some embodiments, the C_(H)1 domain comprises,consists essentially of, or consists of the amino acid sequence of SEQID NO: 37 and the C_(L) domain comprises, consists essentially of, orconsists of the amino acid sequence of SEQ ID NO: 48. In someembodiments, the Fab-like antigen-binding module specifically binds acell surface antigen including, without limitation, CD19, CD20, CD22,CD47, GPC-3, ROR1, ROR2, BCMA, GPRC5D, and FCRL5, including variants ormutants thereof. In some embodiments, the Fab-like antigen-bindingmodule specifically binds a peptide/MHC complex, wherein the peptide isderived from a protein including, without limitation, WT-1, AFP,HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, HIV-1, KRAS, Histone H3.3, andPSA, including variants or mutants thereof. In some embodiments, thefirst TCRD further comprises a first TCR connecting peptide or afragment thereof and/or the second TCRD further comprises a second TCRconnecting peptide or a fragment thereof. In some embodiments, the firstconnecting peptide comprises the amino acid sequence SEQ ID NO: 31 or32, or a variant thereof, and/or the second connecting peptide comprisesthe amino acid sequence SEQ ID NO: 33 or 34, or a variant thereof. Insome embodiments, the first and second connecting peptides are linked bya disulfide bond. In some embodiments, the first TCRD further comprisesa first TCR intracellular domain and/or the second TCRD furthercomprises a second TCR intracellular domain. In some embodiments, thesecond TCR intracellular domain comprises the amino acid sequence of SEQID NO: 36, or a variant thereof. In some embodiments, the caTCR furthercomprises at least one accessory intracellular domain comprising a Tcell co-stimulatory signaling sequence (such as from CD27, CD28, 4-1BB(CD137), OX40, CD30, or CD40). In some embodiments, the caTCR furthercomprises a stabilization module comprising a first stabilization domainand a second stabilization domain, wherein the first and secondstabilization domains have a binding affinity for each other thatstabilizes the caTCR. In some embodiments, the first and secondstabilization domains are linked by a disulfide bond. In someembodiments, the TCRM is capable of recruiting at least oneTCR-associated signaling molecule selected from the group consisting ofCD3δε, CD3γε, and ζζ. In some embodiments, the TCRM allows for enhancedrecruitment of the at least one TCR-associated signaling molecule ascompared to a TCRM comprising T cell receptor transmembrane domainshaving the sequences of SEQ ID NOs: 7 and 8. In some embodiments, theTCRM promotes caTCR-CD3 complex formation. In some embodiments, there isa spacer module between any two caTCR modules or domains. In someembodiments, both of the TCR-TMs are naturally occurring. In someembodiments, at least one of the TCR-TMs is non-naturally occurring.

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first polypeptide chain comprising afirst antigen-binding domain comprising a first Fab chain linked to afirst TCRD comprising a first TCR-TM and a second polypeptide chaincomprising a second antigen-binding domain comprising a second Fab chainlinked to a second TCRD comprising a second TCR-TM, wherein the firstand second TCR-TMs comprise, consist essentially of, or consist of theamino acid sequences of SEQ ID NOs: 7 and 8, 9 and 8, 7 and 14, 7 and15, 7 and 16, 10 and 16, 7 and 17, 7 and 18, 7 and 19, 7 and 20, 7 and21, 7 and 22, 11 and 23, 12 and 24, 7 and 25, or 13 and 26,respectively, wherein the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule,and wherein the first and second Fab chains form a Fab-likeantigen-binding module that specifically binds the target antigen. Insome embodiments, a) the first Fab chain comprises V_(H) and C_(H)1antibody domains and the second Fab chain comprises V_(L) and C_(L)antibody domains; or b) the first Fab chain comprises V_(L) and C_(L)antibody domains and the second Fab chain comprises V_(H) and C_(H)1antibody domains. In some embodiments, the C_(H)1 domain comprises theamino acid sequence of any one of SEQ ID NOs: 37-47 and/or the C_(L)domain comprises the amino acid sequence of SEQ ID NO: 48. In someembodiments, the C_(H)1 domain comprises, consists essentially of, orconsists of the amino acid sequence of SEQ ID NO: 37 and the C_(L)domain comprises, consists essentially of, or consists of the amino acidsequence of SEQ ID NO: 48. In some embodiments, the Fab-likeantigen-binding module specifically binds a cell surface antigenincluding, without limitation, CD19, CD20, CD22, CD47, GPC-3, ROR1,ROR2, BCMA, GPRC5D, and FCRL5, including variants or mutants thereof. Insome embodiments, the Fab-like antigen-binding module specifically bindsa peptide/MHC complex, wherein the peptide is derived from a proteinincluding, without limitation, WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME,EBV-LMP2A, HIV-1, KRAS, Histone H3.3, and PSA, including variants ormutants thereof. In some embodiments, the first TCRD further comprises afirst TCR connecting peptide or a fragment thereof and/or the secondTCRD further comprises a second TCR connecting peptide or a fragmentthereof. In some embodiments, the first connecting peptide comprises theamino acid sequence SEQ ID NO: 31 or 32, or a variant thereof, and/orthe second connecting peptide comprises the amino acid sequence SEQ IDNO: 33 or 34, or a variant thereof. In some embodiments, the first andsecond connecting peptides are linked by a disulfide bond. In someembodiments, the first TCRD further comprises a first TCR intracellulardomain and/or the second TCRD further comprises a second TCRintracellular domain. In some embodiments, the second TCR intracellulardomain comprises the amino acid sequence of SEQ ID NO: 36, or a variantthereof. In some embodiments, the caTCR further comprises at least oneaccessory intracellular domain comprising a T cell co-stimulatorysignaling sequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30,or CD40). In some embodiments, the caTCR further comprises astabilization module comprising a first stabilization domain and asecond stabilization domain, wherein the first and second stabilizationdomains have a binding affinity for each other that stabilizes thecaTCR. In some embodiments, the first and second stabilization domainsare linked by a disulfide bond. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD3δε, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising Tcell receptor transmembrane domains having the sequences of SEQ ID NOs:7 and 8. In some embodiments, the TCRM promotes caTCR-CD3 complexformation. In some embodiments, there is a spacer module between any twocaTCR modules or domains.

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the transmembrane domains of a TCR and a second TCRDcomprising a second TCR-TM derived from the other transmembrane domainof the TCR, wherein the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule;and b) a Fab′ that specifically binds to the target antigen, wherein theFab′ comprises a first Fab′ chain comprising V_(H), C_(H)1, and partialhinge antibody domains and a second Fab′ chain comprising V_(L) andC_(L) antibody domains, and wherein the first Fab′ chain is linked tothe first or second TCRD and the second Fab′ chain is linked to theother TCRD. In some embodiments, there is a peptide linker between oneor both of the TCRDs and their linked Fab′ chain. In some embodiments,there is a disulfide bond between a residue in the C_(H)1 domain and aresidue in the C_(L) domain. In some embodiments, the C_(H)1 and/orC_(L) domains comprise one or more modifications that increase thebinding affinity of the Fab′ chains for each other. In some embodiments,the C_(H)1 and C_(L) domains are swapped, such that the first Fab′ chaincomprises V_(H), C_(L), and partial hinge antibody domains and thesecond Fab′ chain comprises V_(L) and C_(H)1 domains. In someembodiments, the Fab′ specifically binds a cell surface antigenincluding, without limitation, CD19, CD20, CD22, CD47, GPC-3, ROR1,ROR2, BCMA, GPRC5D, and FCRL5, including variants or mutants thereof. Insome embodiments, the Fab′ specifically binds a peptide/MHC complex,wherein the peptide is derived from a protein including, withoutlimitation, WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, HIV-1,KRAS, Histone H3.3, and PSA, including variants or mutants thereof. Insome embodiments, the caTCR further comprises a stabilization modulecomprising a first stabilization domain and a second stabilizationdomain, wherein the first and second stabilization domains have abinding affinity for each other that stabilizes the caTCR. In someembodiments, the first or second stabilization domain is located betweenfirst TCRD and its linked Fab′ chain and the other stabilization domainis located between the second TCRD and its linked Fab′ chain. In someembodiments, both of the TCR-TMs are naturally occurring. In someembodiments, at least one of the TCR-TMs is non-naturally occurring.

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the transmembrane domains of a TCR and a second TCRDcomprising a second TCR-TM derived from the other transmembrane domainof the TCR, wherein the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule;and b) a (Fab′)2 that specifically binds to the target antigen, whereinthe (Fab′)2 comprises first and second (Fab′)2 chains comprising V_(H),C_(H)1, and partial hinge antibody domains and third and fourth (Fab′)2chains comprising V_(L) and C_(L) antibody domains, and wherein thefirst (Fab′)2 chain is linked to the first or second TCRD and the second(Fab′)2 chain is linked to the other TCRD. In some embodiments, there isa peptide linker between one or both of the TCRDs and their linked(Fab′)2 chain. In some embodiments, there is a disulfide bond between aresidue in a C_(H)1 domain and a residue in a C_(L) domain. In someembodiments, the C_(H)1 and/or C_(L) domains comprise one or moremodifications that increase the binding affinity of the (Fab′)2 chainsfor each other. In some embodiments, the C_(H)1 and C_(L) domains areswapped, such that the first and second (Fab′)2 chains comprise V_(H),C_(L), and partial hinge antibody domains and the third and fourth(Fab′)2 chains comprise V_(L) and C_(H)1 domains. In some embodiments,the (Fab′)2 specifically binds a cell surface antigen including, withoutlimitation, CD19, CD20, CD22, CD47, GPC-3, ROR1, ROR2, BCMA, GPRC5D, andFCRL5, including variants or mutants thereof. In some embodiments, the(Fab′)2 specifically binds a peptide/MHC complex, wherein the peptide isderived from a protein including, without limitation, WT-1, AFP,HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, HIV-1, KRAS, Histone H3.3, andPSA, including variants or mutants thereof. In some embodiments, thecaTCR further comprises a stabilization module comprising a firststabilization domain and a second stabilization domain, wherein thefirst and second stabilization domains have a binding affinity for eachother that stabilizes the caTCR. In some embodiments, the first orsecond stabilization domain is located between first TCRD and its linked(Fab′)2 chain and the other stabilization domain is located between thesecond TCRD and its linked (Fab′)2 chain. In some embodiments, both ofthe TCR-TMs are naturally occurring. In some embodiments, at least oneof the TCR-TMs is non-naturally occurring.

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the transmembrane domains of a TCR and a second TCRDcomprising a second TCR-TM derived from the other transmembrane domainof the TCR, wherein the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule;and b) an Fv that specifically binds to the target antigen, wherein theFv comprises a first Fv chain comprising a V_(H) antibody domain and asecond Fv chain comprising a V_(L) antibody domain, and wherein thefirst Fv chain is linked to the first or second TCRD and the second Fvchain is linked to the other TCRD. In some embodiments, there is apeptide linker between one or both of the TCRDs and their linked Fvchain. In some embodiments, the Fv specifically binds a cell surfaceantigen including, without limitation, CD19, CD20, CD22, CD47, GPC-3,ROR1, ROR2, BCMA, GPRC5D, and FCRL5, including variants or mutantsthereof. In some embodiments, the Fv specifically binds a peptide/MHCcomplex, wherein the peptide is derived from a protein including,without limitation, WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A,HIV-1, KRAS, Histone H3.3, and PSA, including variants or mutantsthereof. In some embodiments, the caTCR further comprises astabilization module comprising a first stabilization domain and asecond stabilization domain, wherein the first and second stabilizationdomains have a binding affinity for each other that stabilizes thecaTCR. In some embodiments, the first or second stabilization domain islocated between first TCRD and its linked Fv chain and the otherstabilization domain is located between the second TCRD and its linkedFv chain. In some embodiments, both of the TCR-TMs are naturallyoccurring. In some embodiments, at least one of the TCR-TMs isnon-naturally occurring.

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the transmembrane domains of a TCR and a second TCRDcomprising a second TCR-TM derived from the other transmembrane domainof the TCR, wherein the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule;and b) a first scFv that specifically binds to the target antigen,wherein the first scFv comprises V_(H) and V_(L) antibody domains, andwherein the first scFv is linked to the first or second TCRD. In someembodiments, the caTCR further comprises a second antigen-binding modulelinked to the first scFv or to the TCRD that is not linked to the firstscFv. In some embodiments, the second antigen-binding modulespecifically binds to the target antigen. In some embodiments, thesecond antigen-binding module specifically binds to an antigen otherthan the target antigen. In some embodiments, the second antigen-bindingmodule is a second scFv. In some embodiments, there is a peptide linkerbetween the first scFv and its linked TCRD and/or between the secondantigen-binding module and its linked scFv or TCRD. In some embodiments,the scFv specifically binds a cell surface antigen including, withoutlimitation, CD19, CD20, CD22, CD47, GPC-3, ROR1, ROR2, BCMA, GPRC5D, andFCRL5, including variants or mutants thereof. In some embodiments, thescFv specifically binds a peptide/MHC complex, wherein the peptide isderived from a protein including, without limitation, WT-1, AFP,HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, HIV-1, KRAS, Histone H3.3, andPSA, including variants or mutants thereof. In some embodiments, thecaTCR further comprises a stabilization module comprising a firststabilization domain and a second stabilization domain, wherein thefirst and second stabilization domains have a binding affinity for eachother that stabilizes the caTCR. In some embodiments, the first orsecond stabilization domain is located between first scFv and its linkedTCRD and the other stabilization domain is linked to the second TCRD. Insome embodiments, both of the TCR-TMs are naturally occurring. In someembodiments, at least one of the TCR-TMs is non-naturally occurring.

In some embodiments, the caTCR described herein specifically binds atarget antigen, comprising a) a first TCRD comprising a first TCR-TMderived from one of the transmembrane domains of a TCR and a second TCRDcomprising a second TCR-TM derived from the other transmembrane domainof the TCR, wherein the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule;and b) a first scFv that specifically binds to the target antigen and asecond scFv, wherein the first and second scFvs comprise V_(H) and V_(L)antibody domains, and wherein the first scFv is linked to the first orsecond TCRD and the second scFv is linked to the other TCRD. In someembodiments, the second TCRD specifically binds to the target antigen.In some embodiments, the second scFv comprises, consists essentially of,or consists of the amino acid sequence of the first scFv. In someembodiments, the second scFv specifically binds to an antigen other thanthe target antigen. In some embodiments, the first and/or second scFvsspecifically bind, individually, a cell surface antigen including,without limitation, CD19, CD20, CD22, CD47, GPC-3, ROR1, ROR2, BCMA,GPRC5D, and FCRL5, including variants or mutants thereof. In someembodiments, the first and/or second scFvs specifically bind,individually, a peptide/MHC complex, wherein the peptide is derived froma protein including, without limitation, WT-1, AFP, HPV16-E7, NY-ESO-1,PRAME, EBV-LMP2A, HIV-1, KRAS, Histone H3.3, and PSA, including variantsor mutants thereof. In some embodiments, the caTCR further comprises astabilization module comprising a first stabilization domain and asecond stabilization domain, wherein the first and second stabilizationdomains have a binding affinity for each other that stabilizes thecaTCR. In some embodiments, the first or second stabilization domain islocated between first scFv and its linked TCRD and the otherstabilization domain is located between the second scFv and its linkedTCRD. In some embodiments, both of the TCR-TMs are naturally occurring.In some embodiments, at least one of the TCR-TMs is non-naturallyoccurring.

Multispecific caTCRs

In some embodiments, the caTCR is a multispecific caTCR thatspecifically binds to two or more (e.g., 2, 3, 4, or more) differenttarget antigens or epitopes. In some embodiments, the multispecificcaTCR specifically binds to two or more (e.g., 2, 3, 4, or more)different target antigens. In some embodiments, the multispecific caTCRspecifically binds to two or more (e.g., 2, 3, 4, or more) differentepitopes on the same target antigen. In some embodiments, themultispecific caTCR comprises an antigen-binding module for each antigenor epitope. In some embodiments, the multispecific caTCR comprises morethan two antigen-binding module for at least one antigen or epitope. Insome embodiments, the multispecific caTCR comprises a multispecificantigen-binding module comprising two or more (e.g., 2, 3, 4, or more)antigen-binding domains each specifically binding to an antigen orepitope. In some embodiments, the multispecific caTCR is bispecific. Insome embodiments, the multispecific caTCR is trispecific.

Multi-specific molecules are molecules that have binding specificitiesfor at least two different antigens or epitopes (e.g., bispecificantibodies have binding specificities for two antigens or epitopes).Multi-specific caTCRs with more than two valencies and/or specificitiesare also contemplated. Bispecific antibodies have been described, e.g.,see, Brinkmann U. and Kontermann R. E. (2017) MABS, 9(2), 182-212.Trispecific antibodies can be prepared. See, Tutt et al. J. Immunol.147: 60 (1991). It is to be appreciated that one of skill in the artcould select appropriate features of individual multi-specific moleculesknown in the art to form a multi-specific caTCR.

In some embodiments, the caTCR (also referred herein as “multispecificcaTCR”) comprises: a) a multispecific (e.g., bispecific) antigen-bindingmodule comprising a first antigen-binding domain that specifically bindsto a first target antigen and a second antigen-binding domain thatspecifically binds to a second target antigen; and b) a TCRM comprisinga first TCRD (TCRD1) comprising a first TCR-TM and a second TCRD (TCRD2)comprising a second TCR-TM; wherein the TCRM facilitates recruitment ofat least one TCR-associated signaling molecule. In some embodiments, thefirst TCRD further comprises a first TCR connecting peptide or afragment thereof and/or the second TCRD further comprises a second TCRconnecting peptide or a fragment thereof. In some embodiments, the firstconnecting peptide comprises all or a portion of the connecting peptideof the TCR subunit from which the first TCR-TM is derived, or a variantthereof, and/or the second connecting peptide comprises all or a portionof the connecting peptide of the TCR subunit from which the secondTCR-TM is derived, or a variant thereof. In some embodiments, the firstand second connecting peptides are linked by a disulfide bond. In someembodiments, the first TCRD further comprises a first TCR intracellulardomain and/or the second TCRD further comprises a second TCRintracellular domain. In some embodiments, the first TCR intracellulardomain comprises a sequence from the intracellular domain of the TCRsubunit from which the first TCR-TM is derived and/or the second TCRintracellular domain comprises a sequence from the intracellular domainof the TCR subunit from which the second TCR-TM is derived. In someembodiments, the first TCRD is a fragment of the TCR subunit from whichthe first TCR-TM is derived and/or the second TCRD is a fragment of theTCR subunit from which the second TCR-TM is derived. In someembodiments, the caTCR further comprises at least one accessoryintracellular domain comprising a T cell co-stimulatory signalingsequence (such as from CD27, CD28, 4-1BB (CD137), OX40, CD30, or CD40).In some embodiments, the caTCR further comprises a stabilization modulecomprising a first stabilization domain and a second stabilizationdomain, wherein the first and second stabilization domains have abinding affinity for each other that stabilizes the caTCR. In someembodiments, the first and second stabilization domains are linked by adisulfide bond. In some embodiments, the first and second stabilizationdomains comprise an antibody moiety, such as C_(H)1 and C_(L) antibodydomains, or variants thereof. In some embodiments, the TCRM is capableof recruiting at least one TCR-associated signaling molecule selectedfrom the group consisting of CD3δε, CD3γε, and ζζ. In some embodiments,the TCRM allows for enhanced recruitment of the at least oneTCR-associated signaling molecule as compared to a TCRM comprising thenaturally occurring a T cell receptor transmembrane domains. In someembodiments, the TCRM promotes caTCR-CD3 complex formation. In someembodiments, there is a spacer module between any two caTCR modules ordomains. In some embodiments, both the first TCR-TM and the secondTCR-TM are naturally occurring. In some embodiments, at least one of theTCR-TMs is non-naturally occurring. In some embodiments, the firstTCR-TM comprises up to 5 amino acid substitutions (e.g., a single aminoacid substitution) compared to the transmembrane domain from which it isderived and/or the second TCR-TM comprises up to 5 amino acidsubstitutions (e.g., a single amino acid substitution) compared to thetransmembrane domain from which it is derived. In some embodiments, asubstituted amino acid in the first TCR-TM is proximal to a substitutedamino acid in the second TCR-TM. In some embodiments, one or moresubstituted amino acids are proximal to an amino acid in the first orsecond TCR-TM involved in binding to CD3. In some embodiments, one ormore (e.g., each) substituted amino acids are more hydrophobic thantheir corresponding unsubstituted amino acid. In some embodiments, thefirst TCR-TM comprises the amino acid sequence of any one of SEQ ID NOs:7 and 9-13, and wherein the second TCR-TM comprises the amino acidsequence of any one of SEQ ID NOs: 8 and 14-26.

Exemplary structures of bispecific caTCRs are shown in FIGS. 13A-13E, inwhich the target antigens are CD19 and CD22, but a skilled person in theart would readily appreciate that bispecific caTCRs targeting othertarget antigens or epitopes may be prepared using the same structuralformats.

For example, dual-variable domains (DVD) derived from DVD IgGs (see,DiGiammarino et al., mAbs 3(5): 487-494) can be used as a bispecificantigen-binding module in the caTCR (FIG. 13A). Various linkers forfusion of the outer variable domain and inner variable domain have beendeveloped and optimized for DVD-Igs, which may be useful in constructingbispecific caTCRs having a DVD module. However, the variable domainstacking approach in DVD modules may affect the folding and targetbinding affinity of the inner variable domain. The linkers between thetwo variable domains and the order of the two variable domains mayaffect the efficacy of the caTCR.

In some embodiments, the caTCR comprises: a) a multispecific (e.g.,bispecific) antigen-binding module comprising a Fv that specificallybinds to a first target antigen and a Fab that specifically binds to asecond target antigen; and b) a TCRM comprising a first TCRD (TCRD1)comprising a first TCR-TM and a second TCRD (TCRD2) comprising a secondTCR-TM; wherein the TCRM facilitates recruitment of at least oneTCR-associated signaling molecule.

In some embodiments, the caTCR comprises: (i) a first polypeptide chaincomprising from the N-terminus to the C-terminus: V_(H)1-L1-V_(H)2-C_(H)1-TCRD1; and a second polypeptide chain comprising fromthe N-terminus to the C-terminus: V_(L)1-L2-V_(L)2-C_(L)-TCRD2; (ii) afirst polypeptide chain comprising from the N-terminus to theC-terminus: V_(H)1-L1-V_(L)2-C_(L)-TCRD1; and a second polypeptide chaincomprising from the N-terminus to the C-terminus:V_(L)1-L2-V_(H)2-C_(H)1-TCRD2; (iii) a first polypeptide chaincomprising from the N-terminus to the C-terminus:V_(L)1-L1-V_(H)2-C_(H)1-TCRD1; and a second polypeptide chain comprisingfrom the N-terminus to the C-terminus: V_(H)1-L2-V_(L)2-C_(L)-TCRD2; or(iv) a first polypeptide chain comprising from the N-terminus to theC-terminus: V_(L)1-L1-V_(L)2-C_(L)-TCRD1; and a second polypeptide chaincomprising from the N-terminus to the C-terminus:V_(H)1-L2-V_(H)2-C_(H)1-TCRD2, wherein V_(H)1 and V_(L)1 form a firstantigen-binding domain that specifically binds to a first targetantigen, and V_(H2) and V_(L2) form a second antigen-binding domain thatspecifically binds to a second target antigen, wherein TCRD1 and TCRD2form a TCRM that facilitates recruitment of at least one TCR-associatedsignaling molecule, and wherein L1 and L2 are peptide linkers. In someembodiments, L1 and/or L2 are about 5 to about 50 (e.g., about 5-10,about 10-15, or about 15-30) amino acids long. In some embodiments, L1and L2 have the same length. In some embodiment, L1 and L2 have the sameamino acid sequence. In some embodiments, L1 and L2 have differentlengths. In some embodiments, L1 and L2 have different amino acidsequences. An exemplary bispecific caTCR is shown in FIG. 13A.

Cross-over dual variable domains (CODV) derived from CODV-IgGs (see,Steinmetz, et al.; mAbs (2016), 8(5): 867-878) can be used as abispecific antigen-binding module in the caTCR (FIG. 13B). CODV allowsrelatively unobstructed antigen-binding sites for each Fv. Variouslinkers for fusion of the heavy chain and light chain variable regionshave been developed and optimized for CODV-Igs, which may be useful inconstructing bispecific caTCRs having a CODV module. However, properfolding of the CODV module can be challenging, and long linkers used inthe CODV module can be a potential source of immunogenicity andsusceptible to proteolytic cleavage.

In some embodiments, the caTCR comprises: a) a multispecific (e.g.,bispecific) antigen-binding module comprising a first Fv thatspecifically binds to a first target antigen and a second Fv thatspecifically binds to a second target antigen; and b) a TCRM comprisinga first TCRD (TCRD1) comprising a first TCR-TM and a second TCRD (TCRD2)comprising a second TCR-TM; wherein the TCRM facilitates recruitment ofat least one TCR-associated signaling molecule. In some embodiments, thecaTCR further comprises a C_(H)1 and a C_(L).

In some embodiments, the caTCR comprises: (i) a first polypeptide chaincomprising from the N-terminus to the C-terminus:V_(H)1-L1-V_(H)2-C_(H)1-TCRD1, and a second polypeptide chain comprisingfrom the N-terminus to the C-terminus: V_(L)2-L2-V_(L)1-C_(L)-TCRD2; or(ii) a first polypeptide chain comprising from the N-terminus to theC-terminus: V_(L)1-L1-V_(L)2-C_(L)-TCRD1, and a second polypeptide chaincomprising from the N-terminus to the C-terminus:V_(H)2-L2-V_(H)1-C_(H)1-TCRD2, wherein V_(H)1 and V_(L)1 form a firstantigen-binding domain that specifically binds to a first targetantigen, and V_(H)2 and V_(L)2 form a second antigen-binding domain thatspecifically binds to a second target antigen, wherein TCRD1 and TCRD2form a TCRM that facilitates recruitment of at least one TCR-associatedsignaling molecule, and wherein L1 and L2 are peptide linkers. In someembodiments, L1 and/or L2 are about 5 to about 50 (e.g., about 5-20,about 15-30, or about 30-50) amino acids long. In some embodiments, L1and L2 have the same length. In some embodiment, L1 and L2 have the sameamino acid sequence. In some embodiments, L1 and L2 have differentlengths. In some embodiments, L1 and L2 have different amino acidsequences. An exemplary bispecific caTCR is shown in FIG. 13B.

Bispecific antigen-binding modules derived from scFv-fusion proteins,such as those described in Chen et al., mAbs 8(4): 761-774, may be usedin a bispecific caTCR (FIG. 13C). Expression of bispecific antibodieshaving a similar fusion format has demonstrated proper folding andstability of this format. Various linkers for fusion of the scFvs to theconstant domains have been developed and optimized for these bispecificantibodies, which may be useful in constructing bispecific caTCRs havinga similar scFv fusion domain. However, steric hindrance between thescFvs may compromise binding of the scFvs to their target antigens.

In some embodiments, the caTCR comprises: a) a multispecific (e.g.,bispecific) antigen-binding module comprising a first scFv thatspecifically binds to a first target antigen and a second scFv thatspecifically binds to a second target antigen; and b) a TCRM comprisinga first TCRD (TCRD1) comprising a first TCR-TM and a second TCRD (TCRD2)comprising a second TCR-TM; wherein the TCRM facilitates recruitment ofat least one TCR-associated signaling molecule. In some embodiments, thecaTCR further comprises a C_(H)1 and a C_(L).

In some embodiments, the caTCR comprises: (i) a first polypeptide chaincomprising from the N-terminus to the C-terminus: scFv1-L1-C_(H)1-TCRD1,and a second polypeptide chain comprising from the N-terminus to theC-terminus: scFv2-L2-C_(L)-TCRD2; or (ii) a first polypeptide chaincomprising from the N-terminus to the C-terminus: scFv2-L1-C_(H)1-TCRD1,and a second polypeptide chain comprising from the N-terminus to theC-terminus: scFv1-L2-C_(L)-TCRD2; wherein scFv1 specifically binds to afirst target antigen and scFv2 specifically binds to a second targetantigen, wherein TCRD1 and TCRD2 form a TCRM that facilitatesrecruitment of at least one TCR-associated signaling molecule, andwherein L1 and L2 are peptide linkers. In some embodiments, L1 and/or L2are about 5 to about 50 (e.g., about 5-10, about 10-15, or about 15-30)amino acids long. In some embodiments, L1 and L2 have the same length.In some embodiment, L1 and L2 have the same amino acid sequence. In someembodiments, L1 and L2 have different lengths. In some embodiments, L1and L2 have different amino acid sequences. An exemplary bispecificcaTCR is shown in FIG. 13C.

Bispecific antigen-binding modules derived from an IgG-scFv bispecificantibody or a Fab-scFv-Fc bispecific antibody may be used in abispecific caTCR. In one format (FIG. 13D), an scFv is attached toeither the V_(H) or V_(L) of a Fab, which allows greater flexibility ofthe scFv and thus greater access of the Fab to its target antigen.However, the scFv-Fab module may have stability issues. In a secondformat (FIG. 13E), a Fab is fused to a first TCRD and an scFv is fusedto a second TCRD.

In some embodiments, the caTCR comprises: a) a multispecific (e.g.,bispecific) antigen-binding module comprising a scFv that specificallybinds to a first target antigen and a Fab that specifically binds to asecond target antigen; and b) a TCRM comprising a first TCRD (TCRD1)comprising a first TCR-TM and a second TCRD (TCRD2) comprising a secondTCR-TM; wherein the TCRM facilitates recruitment of at least oneTCR-associated signaling molecule.

In some embodiments, the caTCR comprises: (i) a first polypeptide chaincomprising from the N-terminus to the C-terminus:scFv-L1-V_(H)-C_(H)1-TCRD1, and a second polypeptide chain comprisingfrom the N-terminus to the C-terminus: V_(L)—C_(L)-TCRD2; or (ii) afirst polypeptide chain comprising from the N-terminus to theC-terminus: V_(H)—C_(H)l-TCRD1, and a second polypeptide chaincomprising from the N-terminus to the C-terminus:scFv-L2-V_(L)-C_(L)-TCRD2; wherein the scFv specifically binds to afirst target antigen, and the V_(H) and V_(L) form a secondantigen-binding domain that specifically binds to a second targetantigen, wherein TCRD1 and TCRD2 form a TCRM that facilitatesrecruitment of at least one TCR-associated signaling molecule, andwherein L1 and L2 are peptide linkers. In some embodiments, L1 and/or L2are about 5 to about 50 (e.g., about 5-10, about 10-15, or about 15-30)amino acids long. An exemplary bispecific caTCR is shown in FIG. 13D.

In some embodiments, the caTCR comprises: (i) a first polypeptide chaincomprising from the N-terminus to the C-terminus: V_(L)-C_(L)-L1-TCRD1,a second polypeptide chain comprising from the N-terminus to theC-terminus: V_(H)-C_(H)1, and a third polypeptide chain comprising fromthe N-terminus to the C-terminus: scFv-L2-TCRD2; (ii) a firstpolypeptide chain comprising from the N-terminus to the C-terminus:V_(H)-C_(H)1-L1-TCRD1, a second polypeptide chain comprising from theN-terminus to the C-terminus: V_(L)-C_(L), and a third polypeptide chaincomprising from the N-terminus to the C-terminus: scFv-L2-TCRD2; (iii) afirst polypeptide chain comprising from the N-terminus to theC-terminus: scFv-L1-TCRD1, a second polypeptide chain comprising fromthe N-terminus to the C-terminus: V_(H)-C_(H)1, and a third polypeptidechain comprising from the N-terminus to the C-terminus:V_(L)-C_(L)-L2-TCRD2; or (iv) a first polypeptide chain comprising fromthe N-terminus to the C-terminus: scFv-L1-TCRD1, a second polypeptidechain comprising from the N-terminus to the C-terminus: V_(L)-C_(L), anda third polypeptide chain comprising from the N-terminus to theC-terminus: V_(H)-C_(H)1-L2-TCRD2; wherein the scFv specifically bindsto a first target antigen, and the V_(H) and V_(L) form a secondantigen-binding domain that specifically binds to a second targetantigen, wherein TCRD1 and TCRD2 form a TCRM that facilitatesrecruitment of at least one TCR-associated signaling molecule, andwherein L1 and L2 are peptide linkers. In some embodiments, L1 and/or L2are about 5 to about 50 (e.g., about 5-10, about 10-15, or about 15-30)amino acids long. An exemplary bispecific caTCR is shown in FIG. 13E.The length of the peptide linker between the scFv and the TCRD and thelength of the peptide linker between the Fab and the TCRD can beoptimized as they may affect the accessibility of the scFv and the Fabto their target antigens.

The multispecific antigen-binding module of the multispecific caTCR mayspecifically bind to any suitable combination of target antigens orepitopes. In some embodiments, the multispecific antigen-binding modulespecifically binds to at least one cell surface antigen. In someembodiments, the at least one cell surface antigen is selected from thegroup consisting of CD19, CD20, CD22, CD47, GPC-3, ROR1, ROR2, BCMA,GPRC5D, and FCRL5, including variants or mutants thereof. In someembodiments, the multispecific antigen-binding module specifically bindsto at least one peptide/MHC complex. In some embodiments, the at leastone peptide/MHC complex comprises a peptide derived from a proteinselected from the group consisting of WT-1, AFP, HPV16-E7, NY-ESO-1,PRAME, EBV-LMP2A, HIV-1, KRAS, Histone H3.3, and PSA, including variantsor mutants thereof. In some embodiments, the multispecificantigen-binding module specifically binds to a first cell surfaceantigen and a second cell surface antigen. In some embodiments, themultispecific antigen-binding module specifically binds to CD19 andCD22. In some embodiments, the multispecific antigen-binding modulespecifically binds to CD19 and CD20. In some embodiments, themultispecific antigen-binding module specifically binds to a firstpeptide/MHC complex and a second peptide/MHC complex. In someembodiments, the multispecific antigen-binding module specifically bindsa cell surface antigen and a peptide/MHC complex.

Chimeric Co-Stimulatory Receptor (CSR) Constructs

The ligand-specific chimeric co-stimulatory receptor (CSR) describedherein specifically binds to a target ligand (such as a cell surfaceantigen or a peptide/MHC complex) and is capable of stimulating animmune cell on the surface of which it is functionally expressed upontarget ligand binding. The CSR comprises a ligand-binding module thatprovides the ligand-binding specificity, a transmembrane module, and aco-stimulatory immune cell signaling module that allows for stimulatingthe immune cell. The CSR lacks a functional primary immune cellsignaling sequence. In some embodiments, the CSR lacks any primaryimmune cell signaling sequence. In some embodiments, the CSR comprises asingle polypeptide chain comprising the ligand-binding module,transmembrane module, and co-stimulatory signaling module. In someembodiments, the CSR comprises a first polypeptide chain and a secondpolypeptide chain, wherein the first and second polypeptide chainstogether form the ligand-binding module, transmembrane module, andco-stimulatory signaling module. In some embodiments, the first andsecond polypeptide chains are separate polypeptide chains, and the CSRis a multimer, such as a dimer. In some embodiments, the first andsecond polypeptide chains are covalently linked, such as by a peptidelinkage, or by another chemical linkage, such as a disulfide linkage. Insome embodiments, the first polypeptide chain and the second polypeptidechain are linked by at least one disulfide bond. In some embodiments,the expression of the CSR in the caTCR plus CSR immune cell isinducible. In some embodiments, the expression of the CSR in the caTCRplus CSR immune cell is inducible upon signaling through the caTCR.

Examples of co-stimulatory immune cell signaling domains for use in theCSRs of the invention include the cytoplasmic sequences of co-receptorsof the T cell receptor (TCR), which can act in concert with a caTCR toinitiate signal transduction following caTCR engagement, as well as anyderivative or variant of these sequences and any synthetic sequence thathas the same functional capability.

Under some circumstances, signals generated through the TCR alone areinsufficient for full activation of the T cell and that a secondary orco-stimulatory signal is also required. Thus, in some embodiments, Tcell activation is mediated by two distinct classes of intracellularsignaling sequence: those that initiate antigen-dependent primaryactivation through the TCR (referred to herein as “primary T cellsignaling sequences”) and those that act in an antigen-independentmanner to provide a secondary or co-stimulatory signal (referred toherein as “co-stimulatory T cell signaling sequences”).

Primary immune cell signaling sequences that act in a stimulatory mannermay contain signaling motifs which are known as immunoreceptortyrosine-based activation motifs or ITAMs. Examples of ITAM-containingprimary immune cell signaling sequences include those derived from TCRζ,FcRγ, FcRβ, CD37, CD36, CD3, CD5, CD22, CD79a, CD79b, and CD66d. A“functional” primary immune cell signaling sequence is a sequence thatis capable of transducing an immune cell activation signal when operablycoupled to an appropriate receptor. “Non-functional” primary immune cellsignaling sequences, which may comprises fragments or variants ofprimary immune cell signaling sequences, are unable to transduce animmune cell activation signal. The CSRs described herein lack afunctional primary immune cell signaling sequence, such as a functionalsignaling sequence comprising an ITAM. In some embodiments, the CSRslack any primary immune cell signaling sequence.

The co-stimulatory immune cell signaling sequence can be a portion ofthe intracellular domain of a co-stimulatory molecule including, forexample, CD27, CD28, 4-1BB (CD137), OX40, CD27, CD40, PD-1, ICOS,lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT,NKG2C, B7-H3, a ligand that specifically binds with CD83, and the like.

In some embodiments, the target ligand is a cell surface antigen. Insome embodiments, the target ligand is a peptide/MHC complex. In someembodiments, the target ligand is the same as the target antigen of acaTCR expressed in the same immune cell. In some embodiments, the targetligand is different than the target antigen of a caTCR expressed in thesame immune cell. In some embodiments, the target ligand is a moleculepresented on the surface of a cell presenting the target antigen. Forexample, in some embodiments, the target antigen of the caTCR is acancer-associated antigen presented on a cancer cell, and the targetligand is a ubiquitous molecule expressed on the surface of the cancercell, such as an integrin. In some embodiments, the target ligand is adisease-associated ligand. In some embodiments, the target ligand is acancer-associated ligand. In some embodiments, the cancer-associatedligand is, for example, CD19, CD20, CD22, CD47, IL4, GPC-3, ROR1, ROR2,BCMA, GPRC5D, or FCRL5. In some embodiments, the cancer-associatedligand is a peptide/NMC complex comprising a peptide derived from aprotein including WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, andPSA. In some embodiments, the target ligand is a virus-associatedligand. In some embodiments, the target ligand is an immune checkpointmolecule. In some embodiments, the immune checkpoint molecule includesPD-L1, PD-L2, CD80, CD86, ICOSL, B7-H3, B7-H4, HVEM, 4-1BBL, OX40L,CD70, CD40, and GAL9. In some embodiments, the target ligand is anapoptotic molecule. In some embodiments, the apoptotic molecule includesFasL, FasR, TNFR1, and TNFR2.

In some embodiments, the ligand-binding module is an antibody moiety. Insome embodiments, the antibody moiety is a Fab, a Fab′, a (Fab′)2, anFv, or a single chain Fv (scFv). In some embodiments, the antibodymoiety specifically binds a cell surface antigen including, withoutlimitation, CD19, CD20, CD22, CD47, GPC-3, ROR1, ROR2, BCMA, GPRC5D, andFCRL5. In some embodiments, the antibody moiety specifically binds apeptide/NMC complex, wherein the peptide is derived from a proteinincluding, without limitation, WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME,EBV-LMP2A, and PSA. In some embodiments, the antibody moiety comprisesthe CDRs or variables domains (V_(H) and/or V_(L) domains) of anantibody moiety specific for CD19 (see, e.g., WO2017066136A2). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for CD19(e.g., V_(H) domain comprising, consisting essentially of, or consistingof the amino acid sequence of SEQ ID NO: 58 and/or V_(L) domaincomprising, consisting essentially of, or consisting of the amino acidsequence of SEQ ID NO: 59, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for CD20(e.g., V_(H) domain comprising, consisting essentially of, or consistingof the amino acid sequence of SEQ ID NO: 60 and/or V_(L) domaincomprising, consisting essentially of, or consisting of the amino acidsequence of SEQ ID NO: 61, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for CD22(see, e.g., U.S. Ser. No. 62/650,955 filed Mar. 30, 2018). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for CD22(e.g., V_(H) domain comprising, consisting essentially of, or consistingof the amino acid sequence of SEQ ID NO: 101 and/or V_(L) domaincomprising, consisting essentially of, or consisting of the amino acidsequence of SEQ ID NO: 102, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for GPC3(see, e.g., U.S. Ser. No. 62/490,586 filed Apr. 26, 2017). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for GPC3(e.g., V_(H) domain comprising, consisting essentially of, or consistingof the amino acid sequence of SEQ ID NO: 64 and/or V_(L) domaincomprising, consisting essentially of, or consisting of the amino acidsequence of SEQ ID NO: 65, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for ROR1(see, e.g., WO2016/187220 and WO2016/187216). In some embodiments, theantibody moiety comprises the CDRs or variables domains (V_(H) and/orV_(L) domains) of an antibody moiety specific for ROR2 (see, e.g.,WO2016/142768). In some embodiments, the antibody moiety comprises theCDRs or variables domains (V_(H) and/or V_(L) domains) of an antibodymoiety specific for BCMA (see, e.g., WO2016/090327 and WO2016/090320).In some embodiments, the antibody moiety comprises the CDRs or variablesdomains (V_(H) and/or V_(L) domains) of an antibody moiety specific forGPRC5D (see, e.g., WO2016/090329 and WO2016/090312). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for FCRL5(see, e.g., WO2016/090337). In some embodiments, the antibody moietycomprises the CDRs or variables domains (V_(H) and/or V_(L) domains) ofan antibody moiety specific for WT-1 (see, e.g., WO2012/135854,WO2015/070078, and WO2015/070061). In some embodiments, the antibodymoiety comprises the CDRs or variables domains (V_(H) and/or V_(L)domains) of an antibody moiety specific for AFP (see, e.g.,WO2016/161390). In some embodiments, the antibody moiety comprises theCDRs or variables domains (V_(H) and/or V_(L) domains) of an antibodymoiety specific for HPV16-E7 (see, e.g., WO2016/182957). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for NY-ESO-1(see, e.g., WO2016/210365). In some embodiments, the antibody moietycomprises the CDRs or variables domains (V_(H) and/or V_(L) domains) ofan antibody moiety specific for PRAME (see, e.g., WO2016/191246). Insome embodiments, the antibody moiety comprises the CDRs or variablesdomains (V_(H) and/or V_(L) domains) of an antibody moiety specific forEBV-LMP2A (see, e.g., WO2016/201124). In some embodiments, the antibodymoiety comprises the CDRs or variables domains (V_(H) and/or V_(L)domains) of an antibody moiety specific for KRAS (see, e.g.,WO2016/154047). In some embodiments, the antibody moiety comprises theCDRs or variables domains (V_(H) and/or V_(L) domains) of an antibodymoiety specific for PSA (see, e.g., WO2017/015634).

In some embodiments, the ligand-binding module is (or is derived from)all or a portion of the extracellular domain of a receptor for thetarget ligand. In some embodiments, the receptor includes, for example,FasR, TNFR1, TNFR2, PD-1, CD28, CTLA-4, ICOS, BTLA, KIR, LAG-3, 4-1BB,OX40, CD27, and TIM-3.

In some embodiments, the transmembrane module comprises one or moretransmembrane domains derived from, for example, CD28, CD3ε, CD3ζ, CD45,CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134,CD137, or CD154.

In some embodiments, the co-stimulatory signaling module comprises,consists essentially of, or consists of all or a portion of theintracellular domain of an immune cell co-stimulatory moleculeincluding, for example, CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40,ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT,NKG2C, B7-H3, a ligand that specifically binds with CD83, and the like.In some embodiments, the co-stimulatory signaling molecule comprises afragment of CD28 comprising the amino acid sequence of SEQ ID NO: 51. Insome embodiments, the co-stimulatory signaling molecule comprises afragment of CD28 comprising the amino acid sequence of SEQ ID NO: 52. Insome embodiments, the co-stimulatory signaling molecule comprises afragment of 4-1BB comprising the amino acid sequence of SEQ ID NO: 53.In some embodiments, the co-stimulatory signaling molecule comprises afragment of 4-1BB comprising the amino acid sequence of SEQ ID NO: 54.In some embodiments, the co-stimulatory signaling molecule comprises afragment of CD8 comprising the amino acid sequence of SEQ ID NO: 57. Insome embodiments, the co-stimulatory signaling molecule comprises afragment of OX40 comprising the amino acid sequence of SEQ ID NO: 55. Insome embodiments, the co-stimulatory signaling molecule comprises afragment of OX40 comprising the amino acid sequence of SEQ ID NO: 56. Insome embodiments, the co-stimulatory signaling molecule comprises afragment of CD27 comprising the amino acid sequence of SEQ ID NO: 86 or87. In some embodiments, the co-stimulatory signaling molecule comprisesa fragment of CD30 comprising the amino acid sequence of SEQ ID NO: 88or 89.

In some embodiments, the CSR further comprises a spacer module betweenany of the ligand-binding module, the transmembrane module, and theco-stimulatory signaling module. In some embodiments, the spacer modulecomprises one or more peptide linkers connecting two CSR modules. Insome embodiments, the spacer module comprises one or more peptidelinkers between about 5 to about 70 (such as about any of 5, 10, 15, 20,25, 30, 35, 40, 45, 50, 55, 60, 65, or 70, including any ranges betweenthese values) amino acids in length.

In some embodiments, the ligand-binding module (such as an antibodymoiety) specifically binds to a target antigen with a) an affinity thatis at least about 10 (including for example at least about any of 10,20, 30, 40, 50, 75, 100, 200, 300, 400, 500, 750, 1000 or more) timesits binding affinity for other molecules; or b) a K_(d) no more thanabout 1/10 (such as no more than about any of 1/10, 1/20, 1/30, 1/40,1/50, 1/75, 1/100, 1/200, 1/300, 1/400, 1/500, 1/750, 1/1000 or less)times its K_(d) for binding to other molecules. Binding affinity can bedetermined by methods known in the art, such as ELISA, fluorescenceactivated cell sorting (FACS) analysis, or radioimmunoprecipitationassay (RIA). K_(d) can be determined by methods known in the art, suchas surface plasmon resonance (SPR) assay utilizing, for example, Biacoreinstruments, or kinetic exclusion assay (KinExA) utilizing, for example,Sapidyne instruments.

In some embodiments, the CSR described herein specifically binds to atarget ligand (such as a cell surface antigen or a peptide/MHC complex),comprising a) a target ligand-binding domain (LBD); b) a transmembranedomain; and c) and a co-stimulatory signaling domain, wherein the CSR iscapable of stimulating an immune cell on the surface of which it isfunctionally expressed upon target ligand binding. In some embodiments,the target ligand is a cell surface antigen. In some embodiments, thetarget ligand is a peptide/MHC complex. In some embodiments, the targetligand is the same as the target antigen of a caTCR expressed in thesame immune cell. In some embodiments, the target ligand is differentfrom the target antigen of a caTCR expressed in the same immune cell. Insome embodiments, the target ligand is a disease-associated ligand. Insome embodiments, the target ligand is a cancer-associated ligand. Insome embodiments, the cancer-associated ligand is, for example, CD19,CD20, CD22, CD47, IL4, GPC-3, ROR1, ROR2, BCMA, GPRC5D, or FCRL5. Insome embodiments, the cancer-associated ligand is a peptide/MHC complexcomprising a peptide derived from a protein including WT-1, AFP,HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, and PSA. In some embodiments, thetarget ligand is a virus-associated ligand. In some embodiments, thetarget ligand is an immune checkpoint molecule. In some embodiments, theimmune checkpoint molecule includes PD-L1, PD-L2, CD80, CD86, ICOSL,B7-H3, B7-H4, HVEM, 4-1BBL, OX40L, CD70, CD40, and GAL9. In someembodiments, the target ligand is an apoptotic molecule. In someembodiments, the apoptotic molecule includes FasL, FasR, TNFR1, andTNFR2. In some embodiments, the ligand-binding domain is an antibodymoiety. In some embodiments, the antibody moiety is a Fab, a Fab′, a(Fab′)2, an Fv, or a single chain Fv (scFv). In some embodiments, theligand-binding domain is (or is derived from) all or a portion of theextracellular domain of a receptor for the target ligand. In someembodiments, the receptor includes, for example, FasR, TNFR1, TNFR2,PD-1, CD28, CTLA-4, ICOS, BTLA, KIR, LAG-3, 4-1BB, OX40, CD27, andTIM-3. In some embodiments, the transmembrane domain comprises atransmembrane domain derived from a transmembrane protein including, forexample, CD28, CD3ε, CD3ζ, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33,CD37, CD64, CD80, CD86, CD134, CD137, or CD154. In some embodiments, theCSR comprises a fragment of a transmembrane protein (fTMP), wherein thefTMP comprises the CSR transmembrane domain. In some embodiments, theco-stimulatory signaling domain comprises, consists essentially of, orconsists of all or a portion of the intracellular domain of an immunecell co-stimulatory molecule including, for example, CD27, CD28, 4-1BB(CD137), OX40, CD30, CD40, ICOS, lymphocyte function-associatedantigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand thatspecifically binds with CD83, and the like. In some embodiments, the CSRcomprises a fragment of an immune cell co-stimulatory molecule (fCSM),wherein the fCSM comprises the CSR transmembrane domain and CSRco-stimulatory signaling domain. In some embodiments, the CSR furthercomprises a spacer domain between any of the ligand-binding domain, thetransmembrane domain, and the co-stimulatory signaling domain. In someembodiments, the spacer domain comprises a peptide linker connecting twoCSR domains.

In some embodiments, the CSR described herein specifically binds to atarget ligand, comprising a) a target ligand-binding domain; b) atransmembrane domain; and c) and a co-stimulatory signaling domain,wherein the target ligand is a cell surface antigen, and wherein the CSRis capable of stimulating an immune cell on the surface of which it isfunctionally expressed upon target ligand binding. In some embodiments,the target ligand is the same as the target antigen of a caTCR expressedin the same immune cell. In some embodiments, the target ligand isdifferent from the target antigen of a caTCR expressed in the sameimmune cell. In some embodiments, the target ligand is adisease-associated ligand. In some embodiments, the target ligand is acancer-associated ligand. In some embodiments, the cancer-associatedligand is, for example, CD19, CD20, CD22, CD47, IL4, GPC-3, ROR1, ROR2,BCMA, GPRC5D, or FCRL5. In some embodiments, the target ligand is avirus-associated ligand. In some embodiments, the target ligand is animmune checkpoint molecule. In some embodiments, the immune checkpointmolecule includes PD-L1, PD-L2, CD80, CD86, ICOSL, B7-H3, B7-H4, HVEM,4-1BBL, OX40L, CD70, CD40, and GAL9. In some embodiments, the targetligand is an apoptotic molecule. In some embodiments, the apoptoticmolecule includes FasL, FasR, TNFR1, and TNFR2. In some embodiments, theligand-binding domain is an antibody moiety. In some embodiments, theantibody moiety is a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv(scFv). In some embodiments, the ligand-binding domain is (or is derivedfrom) all or a portion of the extracellular domain of a receptor for thetarget ligand. In some embodiments, the receptor includes, for example,FasR, TNFR1, TNFR2, PD-1, CD28, CTLA-4, ICOS, BTLA, KIR, LAG-3, 4-1BB,OX40, CD27, and TIM-3. In some embodiments, the transmembrane domaincomprises a transmembrane domain derived from a transmembrane proteinincluding, for example, CD28, CD3ε, CD3ζ, CD45, CD4, CD5, CD8, CD9,CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154. Insome embodiments, the CSR comprises a fragment of a transmembraneprotein (fTMP), wherein the fTMP comprises the CSR transmembrane domain.In some embodiments, the co-stimulatory signaling domain comprises,consists essentially of, or consists of all or a portion of theintracellular domain of an immune cell co-stimulatory moleculeincluding, for example, CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40,ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT,NKG2C, B7-H3, a ligand that specifically binds with CD83, and the like.In some embodiments, the CSR comprises a fragment of an immune cellco-stimulatory molecule (fCSM), wherein the fCSM comprises the CSRtransmembrane domain and CSR co-stimulatory signaling domain. In someembodiments, the CSR further comprises a spacer domain between any ofthe ligand-binding domain, the transmembrane domain, and theco-stimulatory signaling domain. In some embodiments, the spacer domaincomprises a peptide linker connecting two CSR domains.

In some embodiments, the CSR described herein specifically binds to atarget ligand, comprising a) a target ligand-binding domain; b) atransmembrane domain; and c) and a co-stimulatory signaling domain,wherein the target ligand is a peptide/MHC complex, and wherein the CSRis capable of stimulating an immune cell on the surface of which it isfunctionally expressed upon target ligand binding. In some embodiments,the target ligand is the same as the target antigen of a caTCR expressedin the same immune cell. In some embodiments, the target ligand isdifferent from the target antigen of a caTCR expressed in the sameimmune cell. In some embodiments, the target ligand is adisease-associated ligand. In some embodiments, the target ligand is acancer-associated ligand. In some embodiments, the cancer-associatedligand is a peptide/MHC complex comprising a peptide derived from aprotein including WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, andPSA. In some embodiments, the target ligand is a virus-associatedligand. In some embodiments, the ligand-binding domain is an antibodymoiety. In some embodiments, the antibody moiety is a Fab, a Fab′, a(Fab′)2, an Fv, or a single chain Fv (scFv). In some embodiments, thetransmembrane domain comprises a transmembrane domain derived from atransmembrane protein including, for example, CD28, CD3ε, CD3ζ, CD45,CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134,CD137, or CD154. In some embodiments, the CSR comprises a fragment of atransmembrane protein (fTMP), wherein the fTMP comprises the CSRtransmembrane domain. In some embodiments, the co-stimulatory signalingdomain comprises, consists essentially of, or consists of all or aportion of the intracellular domain of an immune cell co-stimulatorymolecule including, for example, CD27, CD28, 4-1BB (CD137), OX40, CD30,CD40, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7,LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, and thelike. In some embodiments, the CSR comprises a fragment of an immunecell co-stimulatory molecule (fCSM), wherein the fCSM comprises the CSRtransmembrane domain and CSR co-stimulatory signaling domain. In someembodiments, the CSR further comprises a spacer domain between any ofthe ligand-binding domain, the transmembrane domain, and theco-stimulatory signaling domain. In some embodiments, the spacer domaincomprises a peptide linker connecting two CSR domains.

In some embodiments, the CSR described herein specifically binds to atarget ligand (such as a cell surface antigen or a peptide/MHC complex),comprising a) a target ligand-binding domain; b) a transmembrane domain;and c) and a co-stimulatory signaling domain, wherein the ligand-bindingdomain is an antibody moiety, and wherein the CSR is capable ofstimulating an immune cell on the surface of which it is functionallyexpressed upon target ligand binding. In some embodiments, the targetligand is a cell surface antigen. In some embodiments, the target ligandis a peptide/MHC complex. In some embodiments, the target ligand is thesame as the target antigen of a caTCR expressed in the same immune cell.In some embodiments, the target ligand is different from the targetantigen of a caTCR expressed in the same immune cell. In someembodiments, the target ligand is a disease-associated ligand. In someembodiments, the target ligand is a cancer-associated ligand. In someembodiments, the cancer-associated ligand is, for example, CD19, CD20,CD22, CD47, IL4, GPC-3, ROR1, ROR2, BCMA, GPRC5D, or FCRL5. In someembodiments, the cancer-associated ligand is a peptide/MHC complexcomprising a peptide derived from a protein including WT-1, AFP,HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, and PSA. In some embodiments, thetarget ligand is a virus-associated ligand. In some embodiments, thetarget ligand is an immune checkpoint molecule. In some embodiments, theimmune checkpoint molecule includes PD-L1, PD-L2, CD80, CD86, ICOSL,B7-H3, B7-H4, HVEM, 4-1BBL, OX40L, CD70, CD40, and GAL9. In someembodiments, the target ligand is an apoptotic molecule. In someembodiments, the apoptotic molecule includes FasL, FasR, TNFR1, andTNFR2. In some embodiments, the antibody moiety is a Fab, a Fab′, a(Fab′)2, an Fv, or a single chain Fv (scFv). In some embodiments, thetransmembrane domain comprises a transmembrane domain derived from atransmembrane protein including, for example, CD28, CD3ε, CD3ζ, CD45,CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134,CD137, or CD154. In some embodiments, the CSR comprises a fragment of atransmembrane protein (fTMP), wherein the fTMP comprises the CSRtransmembrane domain. In some embodiments, the co-stimulatory signalingdomain comprises, consists essentially of, or consists of all or aportion of the intracellular domain of an immune cell co-stimulatorymolecule including, for example, CD27, CD28, 4-1BB (CD137), OX40, CD30,CD40, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7,LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, and thelike. In some embodiments, the CSR comprises a fragment of an immunecell co-stimulatory molecule (fCSM), wherein the fCSM comprises the CSRtransmembrane domain and CSR co-stimulatory signaling domain. In someembodiments, the CSR further comprises a spacer domain between any ofthe ligand-binding domain, the transmembrane domain, and theco-stimulatory signaling domain. In some embodiments, the spacer domaincomprises a peptide linker connecting two CSR domains. In someembodiments, the CSR domains are selected according to any of the CSRslisted in Table 3.

TABLE 3 Full Spacer CSR following domain CSR LBD fTMP fCSM (no LBD; ID(SEQ ID NO) (SEQ ID NO) (SEQ ID NO) SEQ ID NO) 1 103 — 51 90 2 104 57 5491 3 104 — 53 92 4 104 57 87 93 5 104 — 86 94 6 104 57 89 95 7 104 — 8896 8 104 57 56 97 9 104 — 55 98

In some embodiments, the CSR comprises an fCSM of CD28. In someembodiments, the CSR comprises: a) a target ligand-binding domain; b) aCD8 transmembrane domain comprising the amino acid sequence of SEQ IDNO: 57; and c) a fragment of CD28 comprising the amino acid sequence ofSEQ ID NO: 52. In some embodiments, the CSR comprises: a) a targetligand-binding domain; and b) a fragment of CD28 comprising the aminoacid sequence of SEQ ID NO: 51. In some embodiments, the CSR comprises:a target ligand-binding domain and a CSR domain comprising the aminoacid sequence of SEQ ID NO: 90.

In some embodiments, the CSR comprises an fCSM of 4-1BB. In someembodiments, the CSR comprises: a) a target ligand-binding domain; b) aCD8 transmembrane domain comprising the amino acid sequence of SEQ IDNO: 57; and c) a fragment of 4-1BB comprising the amino acid sequence ofSEQ ID NO: 54. In some embodiments, the CSR comprises: a) a targetligand-binding domain; and b) a fragment of 4-1BB comprising the aminoacid sequence of SEQ ID NO: 53. In some embodiments, the CSR comprises:a target ligand-binding domain and a CSR domain comprising the aminoacid sequence of SEQ ID NO: 91 or 92.

In some embodiments, the CSR comprises an fCSM of CD27. In someembodiments, the CSR comprises: a) a target ligand-binding domain; b) aCD8 transmembrane domain comprising the amino acid sequence of SEQ IDNO: 57; and c) a fragment of CD27 comprising the amino acid sequence ofSEQ ID NO: 87. In some embodiments, the CSR comprises: a) a targetligand-binding domain; and b) a fragment of CD27 comprising the aminoacid sequence of SEQ ID NO: 86. In some embodiments, the CSR comprises:a target ligand-binding domain and a CSR domain comprising the aminoacid sequence of SEQ ID NO: 93 or 94.

In some embodiments, the CSR comprises an fCSM of CD30. In someembodiments, the CSR comprises: a) a target ligand-binding domain; b) aCD8 transmembrane domain comprising the amino acid sequence of SEQ IDNO: 57; and c) a fragment of CD30 comprising the amino acid sequence ofSEQ ID NO: 89. In some embodiments, the CSR comprises: a) a targetligand-binding domain; and b) a fragment of CD30 comprising the aminoacid sequence of SEQ ID NO: 88. In some embodiments, the CSR comprises:a target ligand-binding domain and a CSR domain comprising the aminoacid sequence of SEQ ID NO: 95 or 96.

In some embodiments, the CSR comprises an fCSM of OX40. In someembodiments, the CSR comprises: a) a target ligand-binding domain; b) aCD8 transmembrane domain comprising the amino acid sequence of SEQ IDNO: 57; and c) a fragment of OX40 comprising the amino acid sequence ofSEQ ID NO: 56. In some embodiments, the CSR comprises: a) a targetligand-binding domain; and b) a fragment of OX40 comprising the aminoacid sequence of SEQ ID NO: 55. In some embodiments, the CSR comprises:a target ligand-binding domain and a CSR domain comprising the aminoacid sequence of SEQ ID NO: 97 or 98.

In some embodiments, the CSR described herein specifically binds to atarget ligand (such as a cell surface antigen or a peptide/MHC complex),comprising a) a target ligand-binding domain; b) a transmembrane domain;and c) and a co-stimulatory signaling domain, wherein the ligand-bindingdomain is (or is derived from) all or a portion of the extracellulardomain of a receptor for the target ligand, and wherein the CSR iscapable of stimulating an immune cell on the surface of which it isfunctionally expressed upon target ligand binding. In some embodiments,the target ligand is a cell surface antigen. In some embodiments, thetarget ligand is the same as the target antigen of a caTCR expressed inthe same immune cell. In some embodiments, the target ligand isdifferent from the target antigen of a caTCR expressed in the sameimmune cell. In some embodiments, the target ligand is adisease-associated ligand. In some embodiments, the target ligand is acancer-associated ligand. In some embodiments, the cancer-associatedligand is, for example, CD19, CD20, CD22, CD47, IL4, GPC-3, ROR1, ROR2,BCMA, GPRC5D, or FCRL5. In some embodiments, the target ligand is animmune checkpoint molecule. In some embodiments, the immune checkpointmolecule includes PD-L1, PD-L2, CD80, CD86, ICOSL, B7-H3, B7-H4, HVEM,4-1BBL, OX40L, CD70, CD40, and GAL9. In some embodiments, the targetligand is an apoptotic molecule. In some embodiments, the apoptoticmolecule includes FasL, FasR, TNFR1, and TNFR2. In some embodiments, thetarget ligand receptor includes, for example, FasR, TNFR1, TNFR2, PD-1,CD28, CTLA-4, ICOS, BTLA, KIR, LAG-3, 4-1BB, OX40, CD27, and TIM-3. Insome embodiments, the transmembrane domain comprises a transmembranedomain derived from, for example, CD28, CD3ε, CD3ζ, CD45, CD4, CD5, CD8,CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154.In some embodiments, the co-stimulatory signaling domain comprises,consists essentially of, or consists of all or a portion of theintracellular domain of an immune cell co-stimulatory moleculeincluding, for example, CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40,ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT,NKG2C, B7-H3, a ligand that specifically binds with CD83, and the like.In some embodiments, the CSR further comprises a spacer domain betweenany of the ligand-binding domain, the transmembrane domain, and theco-stimulatory signaling domain. In some embodiments, the spacer domaincomprises a peptide linker connecting two CSR domains.

In some embodiments, the CSR described herein specifically binds toCD19, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 59; and b) a fragment of CD28 comprising,consisting essentially of, or consisting of the amino acid sequence ofSEQ ID NO: 51 or 52. In some embodiments, the scFv comprises, from aminoterminus to carboxy terminus, the V_(L) domain, a peptide linkercomprising the amino acid sequence of SEQ ID NO: 76, and the V_(H)domain. In some embodiments, the scFv comprises, consists essentiallyof, or consists of the amino acid sequence of SEQ ID NO: 77. In someembodiments, the fragment of CD28 comprises the amino acid sequence ofSEQ ID NO: 51. In some embodiments, the CSR comprises the amino acidsequence of SEQ ID NO: 90. In some embodiments, the CSR comprises, fromamino terminus to carboxy terminus, the scFv, a peptide linkercomprising SEQ ID NO: 103, and the fragment of CD28. In someembodiments, the CSR comprises, consists essentially of, or consists ofthe amino acid sequence of SEQ ID NO: 80.

In some embodiments, the CSR described herein specifically binds toCD20, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 60 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 61; and b) a fragment of CD28 comprising,consisting essentially of, or consisting of the amino acid sequence ofSEQ ID NO: 51 or 52. In some embodiments, the scFv comprises, from aminoterminus to carboxy terminus, the V_(L) domain, a peptide linkercomprising the amino acid sequence of SEQ ID NO: 76, and the V_(H)domain. In some embodiments, the scFv comprises, consists essentiallyof, or consists of the amino acid sequence of SEQ ID NO: 78. In someembodiments, the fragment of CD28 comprises the amino acid sequence ofSEQ ID NO: 51. In some embodiments, the CSR comprises, from aminoterminus to carboxy terminus, the scFv, a peptide linker comprising SEQID NO: 103, and the fragment of CD28. In some embodiments, the CSRcomprises, consists essentially of, or consists of the amino acidsequence of SEQ ID NO: 81.

In some embodiments, the CSR described herein specifically binds toGPC3, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 64 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 65; and b) a fragment of CD28 comprising,consisting essentially of, or consisting of the amino acid sequence ofSEQ ID NO: 51 or 52. In some embodiments, the scFv comprises, from aminoterminus to carboxy terminus, the V_(L) domain, a peptide linkercomprising the amino acid sequence of SEQ ID NO: 76, and the V_(H)domain. In some embodiments, the scFv comprises, consists essentiallyof, or consists of the amino acid sequence of SEQ ID NO: 79. In someembodiments, the fragment of CD28 comprises the amino acid sequence ofSEQ ID NO: 51. In some embodiments, the CSR comprises, from aminoterminus to carboxy terminus, the scFv, a peptide linker comprising SEQID NO: 103, and the fragment of CD28. In some embodiments, the CSRcomprises, consists essentially of, or consists of the amino acidsequence of SEQ ID NO: 82.

In some embodiments, the CSR described herein specifically binds toCD20, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 60 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 61; and b) a fragment of CD28 comprising,consisting essentially of, or consisting of the amino acid sequence ofSEQ ID NO: 51 or 52. In some embodiments, the scFv comprises, from aminoterminus to carboxy terminus, the V_(L) domain, a peptide linkercomprising the amino acid sequence of SEQ ID NO: 76, and the V_(H)domain. In some embodiments, the scFv comprises, consists essentiallyof, or consists of the amino acid sequence of SEQ ID NO: 78. In someembodiments, the fragment of CD28 comprises the amino acid sequence ofSEQ ID NO: 51. In some embodiments, the CSR comprises, from aminoterminus to carboxy terminus, the scFv, a peptide linker comprising SEQID NO: 103, and the fragment of CD28. In some embodiments, the CSRcomprises, consists essentially of, or consists of the amino acidsequence of SEQ ID NO: 81.

In some embodiments, the CSR described herein specifically binds toCD19, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 59; and b) a fragment of 4-1BB comprising,consisting essentially of, or consisting of the amino acid sequence ofSEQ ID NO: 53 or 54. In some embodiments, the scFv comprises, from aminoterminus to carboxy terminus, the V_(L) domain, a peptide linkercomprising the amino acid sequence of SEQ ID NO: 76, and the V_(H)domain. In some embodiments, the fragment of 4-1BB comprises the aminoacid sequence of SEQ ID NO: 53. In some embodiments, the CSR comprises,from amino terminus to carboxy terminus, the scFv, a peptide linkercomprising SEQ ID NO: 104, and the fragment of 4-1BB.

In some embodiments, the CSR described herein specifically binds toCD19, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 59; b) a fragment of CD8 comprising, consistingessentially of, or consisting of the amino acid sequence of SEQ ID NO:57; and c) a fragment of 4-1BB comprising, consisting essentially of, orconsisting of the amino acid sequence of SEQ ID NO: 54. In someembodiments, the scFv comprises, from amino terminus to carboxyterminus, the V_(L) domain, a peptide linker comprising the amino acidsequence of SEQ ID NO: 76, and the V_(H) domain. In some embodiments,the CSR comprises, from amino terminus to carboxy terminus, the scFv, apeptide linker comprising SEQ ID NO: 104, the fragment of CD8, and thefragment of 4-1BB.

In some embodiments, the CSR described herein specifically binds toCD19, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 59; b) a fragment of CD8 comprising, consistingessentially of, or consisting of the amino acid sequence of SEQ ID NO:57; and c) a fragment of OX40 comprising, consisting essentially of, orconsisting of the amino acid sequence of SEQ ID NO: 57. In someembodiments, the scFv comprises, from amino terminus to carboxyterminus, the V_(L) domain, a peptide linker comprising the amino acidsequence of SEQ ID NO: 76, and the V_(H) domain. In some embodiments,the CSR comprises, from amino terminus to carboxy terminus, the scFv, apeptide linker comprising SEQ ID NO: 104, the fragment of CD8, and thefragment of OX40.

In some embodiments, the CSR described herein specifically binds toCD19, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 59; and b) a fragment of OX40 comprising,consisting essentially of, or consisting of the amino acid sequence ofSEQ ID NO: 56 or 57. In some embodiments, the scFv comprises, from aminoterminus to carboxy terminus, the V_(L) domain, a peptide linkercomprising the amino acid sequence of SEQ ID NO: 76, and the V_(H)domain. In some embodiments, the fragment of OX40 comprises the aminoacid sequence of SEQ ID NO: 56. In some embodiments, the CSR comprises,from amino terminus to carboxy terminus, the scFv, a peptide linkercomprising SEQ ID NO: 104, and the fragment of OX40.

In some embodiments, the CSR described herein specifically binds toCD19, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 59; b) a fragment of CD8 comprising, consistingessentially of, or consisting of the amino acid sequence of SEQ ID NO:57; and c) a fragment of CD27 comprising, consisting essentially of, orconsisting of the amino acid sequence of SEQ ID NO: 87. In someembodiments, the scFv comprises, from amino terminus to carboxyterminus, the V_(L) domain, a peptide linker comprising the amino acidsequence of SEQ ID NO: 76, and the V_(H) domain. In some embodiments,the CSR comprises, from amino terminus to carboxy terminus, the scFv, apeptide linker comprising SEQ ID NO: 104, the fragment of CD8, and thefragment of CD27.

In some embodiments, the CSR described herein specifically binds toCD19, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 59; and b) a fragment of CD27 comprising,consisting essentially of, or consisting of the amino acid sequence ofSEQ ID NO: 86 or 87. In some embodiments, the scFv comprises, from aminoterminus to carboxy terminus, the V_(L) domain, a peptide linkercomprising the amino acid sequence of SEQ ID NO: 76, and the V_(H)domain. In some embodiments, the fragment of CD27 comprises the aminoacid sequence of SEQ ID NO: 86. In some embodiments, the CSR comprises,from amino terminus to carboxy terminus, the scFv, a peptide linkercomprising SEQ ID NO: 104, and the fragment of CD27.

In some embodiments, the CSR described herein specifically binds toCD19, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 59; b) a fragment of CD8 comprising, consistingessentially of, or consisting of the amino acid sequence of SEQ ID NO:57; and c) a fragment of CD30 comprising, consisting essentially of, orconsisting of the amino acid sequence of SEQ ID NO: 89. In someembodiments, the scFv comprises, from amino terminus to carboxyterminus, the V_(L) domain, a peptide linker comprising the amino acidsequence of SEQ ID NO: 76, and the V_(H) domain. In some embodiments,the CSR comprises, from amino terminus to carboxy terminus, the scFv, apeptide linker comprising SEQ ID NO: 104, the fragment of CD8, and thefragment of CD30.

In some embodiments, the CSR described herein specifically binds toCD19, comprising a) an scFv comprising a V_(H) domain having the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain having the amino acidsequence of SEQ ID NO: 59; and b) a fragment of CD30 comprising,consisting essentially of, or consisting of the amino acid sequence ofSEQ ID NO: 88 or 89. In some embodiments, the scFv comprises, from aminoterminus to carboxy terminus, the V_(L) domain, a peptide linkercomprising the amino acid sequence of SEQ ID NO: 76, and the V_(H)domain. In some embodiments, the fragment of CD30 comprises the aminoacid sequence of SEQ ID NO: 88. In some embodiments, the CSR comprises,from amino terminus to carboxy terminus, the scFv, a peptide linkercomprising SEQ ID NO: 104, and the fragment of CD30.

In some embodiments, the expression of the CSR in the caTCR plus CSRimmune cell is inducible. In some embodiments, the caTCR plus CSR immunecell comprises a nucleic acid sequence encoding the CSR operably linkedto an inducible promoter, including any of the inducible promotersdescribed herein. In some embodiments, the expression of the CSR in thecaTCR plus CSR immune cell is inducible upon signaling through thecaTCR. In some such embodiments, the caTCR plus CSR immune cellcomprises a nucleic acid sequence encoding the CSR operably linked to apromoter or regulatory element responsive to signaling through thecaTCR. In some embodiments, the nucleic acid sequence encoding the CSRis operably linked to a nuclear-factor of the activated T-cell(NFAT)-derived promoter. In some embodiments, the NFAT-derived promoteris an NFAT-derived minimal promoter (see for example Durand, D. et. al.,Molec. Cell. Biol. 8, 1715-1724 (1988); Clipstone, N A, Crabtree, G R.Nature. 1992 357(6380): 695-7; Chmielewski, M., et al. Cancer research71.17 (2011): 5697-5706; and Zhang, L., et al. Molecular therapy 19.4(2011): 751-759). In some embodiments, the NFAT-derived promotercomprises the nucleotide sequence of SEQ ID NO: 85. In some embodiments,the nucleic acid sequence encoding the CSR is operably linked to an IL-2promoter.

Secretory Secondary Effector (SSE) Constructs

In some embodiments, the caTCR plus CSR immune cell (such as a T cell)is capable of secreting a secretory secondary effector (SSE). Such animmune cell is also referred herein as a “caTCR plus CSR and SSE immunecell.” The SSE enhances the immune response mediated by a caTCR plus CSRand SSE immune cell in which it is functionally expressed and secretedfrom. In some embodiments, the SSE is capable of redirecting otherimmune cells (such as bystander T cells or NK cells) to target diseasecells (such as target cancer cells). In some embodiments, the SSE is amultispecific antibody (such as a bispecific antibody) targeting animmune cell (such as a T cell or NK cell) and a disease cell (such as acancer cell). In some embodiments, the SSE protects the caTCR plus CSRand SSE immune cell from an immunosuppressive environment, such as animmunosuppressive tumor environment. In some embodiments, the SSEprovides autocrine activation of stimulatory receptors on the caTCR plusCSR and SSE immune cell. In some embodiments, the SSE is an exogenousgrowth factor or stimulatory cytokine. In some embodiments, theexpression of the SSE in the caTCR plus CSR and SSE immune cell isinducible. In some embodiments, the expression of the SSE in the caTCRplus CSR and SSE immune cell is inducible upon signaling through thecaTCR.

In some embodiments, the SSE is a multispecific antibody (such as abispecific antibody) targeting a T cell and a disease cell. In someembodiments, the SSE comprises an antibody moiety that specificallybinds to a surface antigen of a T cell. In some embodiments, the T cellsurface antigen is CD3. In some embodiments, the SSE comprises anantibody moiety that specifically binds to a disease-associated antigen(such as a cancer-associated antigen). In some embodiments, thedisease-associated antigen is a surface antigen of a disease cell (suchas a cancer cell). In some embodiments, the disease-associated antigenis glypican-3 (GPC3), CD47, mucin-16 (MUC16), CD19, CD20, CD22, EpCAM,EGFR, HER2, CEA, PSMA, AFP, PSA, BCMA, FCRL5, NY-ESO, HPV16, or FoxP3,including variants or mutants thereof. In some embodiments, the SSE is amultispecific antibody selected from the group consisting of a tandemscFv, a diabody (Db), a single chain diabody (scDb), a dual-affinityretargeting (DART) antibody, and a dual variable domain (DVD) antibody.In some embodiments, the SSE is a bispecific antibody. In someembodiments, the SSE is a tandem scFv comprising a first scFv targetingthe T cell surface antigen and a second scFv targeting thedisease-associated antigen.

In some embodiments, the SSE is a tandem scFv comprising a first scFvtargeting CD3 and a second scFv targeting a disease-associated antigen.In some embodiments, the disease-associated antigen is GPC3, CD47,MUC16, CD19, CD20, CD22, EpCAM, EGFR, HER2, CEA, PSMA, AFP, PSA, BCMA,FCRL5, NY-ESO, HPV16, or FoxP3, including variants or mutants thereof.

In some embodiments, the SSE is a tandem scFv comprising a first scFvtargeting CD3 and a second scFv targeting GPC3. In some embodiments, thesecond scFv comprises a V_(H) domain comprising, consisting essentiallyof, or consisting of the amino acid sequence of SEQ ID NO: 64 and aV_(L) domain comprising, consisting essentially of, or consisting of theamino acid sequence of SEQ ID NO: 65. In some embodiments, the V_(H)domain is amino-terminal to the V_(L) domain. In some embodiments, theV_(L) domain is amino-terminal to the V_(H) domain. In some embodiments,the second scFv comprises, consists essentially of, or consists of theamino acid sequence of SEQ ID NO: 79. In some embodiments, the firstscFv is amino-terminal to the second scFv. In some embodiments, thesecond scFv is amino-terminal to the first scFv. In some embodiments,the SSE comprises, consists essentially of, or consists of the aminoacid sequence of SEQ ID NO: 105.

In some embodiments, the SSE is a tandem scFv comprising a first scFvtargeting CD3 and a second scFv targeting CD47. In some embodiments, theSSE is a tandem scFv comprising a first scFv targeting CD3 and a secondscFv targeting MUC16.

In some embodiments, the SSE is a multispecific antibody (such as abispecific antibody) targeting an NK cell and a disease-associatedantigen (such as a cancer-associated antigen). In some embodiments, theSSE comprises an antibody moiety that specifically binds to a surfaceantigen of an NK cell. In some embodiments, the NK cell surface antigenis CD16a. In some embodiments, the SSE comprises an antibody moiety thatspecifically binds to a disease-associated antigen (such as acancer-associated antigen). In some embodiments, the disease-associatedantigen is a surface antigen of a disease cell (such as a cancer cell).In some embodiments, the disease-associated antigen is GPC3, CD47,MUC16, CD19, CD20, CD22, EpCAM, EGFR, HER2, CEA, PSMA, AFP, PSA, BCMA,FCRL5, NY-ESO, HPV16, or FoxP3, including variants or mutants thereof.In some embodiments, the SSE is a multispecific antibody selected fromthe group consisting of a tandem scFv, a diabody (Db), a single chaindiabody (scDb), a dual-affinity retargeting (DART) antibody, and a dualvariable domain (DVD) antibody. In some embodiments, the SSE is abispecific antibody. In some embodiments, the SSE is a tandem scFvcomprising a first scFv targeting the NK cell surface antigen and asecond scFv targeting the disease-associated antigen.

In some embodiments, the SSE is a tandem scFv comprising a first scFvtargeting CD16a and a second scFv targeting a disease-associatedantigen. In some embodiments, the disease-associated antigen is GPC3,CD47, MUC16, CD19, CD20, CD22, EpCAM, EGFR, HER2, CEA, PSMA, AFP, PSA,BCMA, FCRL5, NY-ESO, HPV16, or FoxP3, including variants or mutantsthereof.

In some embodiments, the SSE is a tandem scFv comprising a first scFvtargeting CD16a and a second scFv targeting GPC3. In some embodiments,the SSE is a tandem scFv comprising a first scFv targeting CD16a and asecond scFv targeting CD47. In some embodiments, the SSE is a tandemscFv comprising a first scFv targeting CD16a and a second scFv targetingMUC16.

In some embodiments, the SSEs described herein comprises an antibodymoiety that specifically binds to a disease-associated antigen, whereinthe antibody moiety comprises the CDRs or variables domains (V_(H)and/or V_(L) domains) of an antibody moiety specific for thedisease-associated antigen. In some embodiments, the antibody moietycomprises the CDRs or variables domains (V_(H) and/or V_(L) domains) ofan antibody moiety specific for CD19 (see, e.g., WO2017066136A2). Insome embodiments, the antibody moiety comprises the CDRs or variablesdomains (V_(H) and/or V_(L) domains) of an antibody moiety specific forCD19 (e.g., V_(H) domain comprising, consisting essentially of, orconsisting of the amino acid sequence of SEQ ID NO: 58 and/or V_(L)domain comprising, consisting essentially of, or consisting of the aminoacid sequence of SEQ ID NO: 59, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for CD20(e.g., V_(H) domain comprising, consisting essentially of, or consistingof the amino acid sequence of SEQ ID NO: 60 and/or V_(L) domaincomprising, consisting essentially of, or consisting of the amino acidsequence of SEQ ID NO: 61, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for CD22(see, e.g., U.S. Ser. No. 62/650,955 filed Mar. 30, 2018, the contentsof which are incorporated herein by reference in their entirety). Insome embodiments, the antibody moiety comprises the CDRs or variablesdomains (V_(H) and/or V_(L) domains) of an antibody moiety specific forCD22 (e.g., V_(H) domain comprising, consisting essentially of, orconsisting of the amino acid sequence of SEQ ID NO: 101 and/or V_(L)domain comprising, consisting essentially of, or consisting of the aminoacid sequence of SEQ ID NO: 102, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for GPC3(see, e.g., U.S. Ser. No. 62/490,586 filed Apr. 26, 2017, the contentsof which are incorporated herein by reference in their entirety). Insome embodiments, the antibody moiety comprises the CDRs or variablesdomains (V_(H) and/or V_(L) domains) of an antibody moiety specific forGPC3 (e.g., V_(H) domain comprising, consisting essentially of, orconsisting of the amino acid sequence of SEQ ID NO: 64 and/or V_(L)domain comprising, consisting essentially of, or consisting of the aminoacid sequence of SEQ ID NO: 65, or CDRs contained therein). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for ROR1(see, e.g., WO2016/187220 and WO2016/187216). In some embodiments, theantibody moiety comprises the CDRs or variables domains (V_(H) and/orV_(L) domains) of an antibody moiety specific for ROR2 (see, e.g.,WO2016/142768). In some embodiments, the antibody moiety comprises theCDRs or variables domains (V_(H) and/or V_(L) domains) of an antibodymoiety specific for BCMA (see, e.g., WO2016/090327 and WO2016/090320).In some embodiments, the antibody moiety comprises the CDRs or variablesdomains (V_(H) and/or V_(L) domains) of an antibody moiety specific forGPRC5D (see, e.g., WO2016/090329 and WO2016/090312). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for FCRL5(see, e.g., WO2016/090337). In some embodiments, the antibody moietycomprises the CDRs or variables domains (V_(H) and/or V_(L) domains) ofan antibody moiety specific for WT-1 (see, e.g., WO2012/135854,WO2015/070078, and WO2015/070061). In some embodiments, the antibodymoiety comprises the CDRs or variables domains (V_(H) and/or V_(L)domains) of an antibody moiety specific for AFP (see, e.g.,WO2016/161390). In some embodiments, the antibody moiety comprises theCDRs or variables domains (V_(H) and/or V_(L) domains) of an antibodymoiety specific for HPV16-E7 (see, e.g., WO2016/182957). In someembodiments, the antibody moiety comprises the CDRs or variables domains(V_(H) and/or V_(L) domains) of an antibody moiety specific for NY-ESO-1(see, e.g., WO2016/210365). In some embodiments, the antibody moietycomprises the CDRs or variables domains (V_(H) and/or V_(L) domains) ofan antibody moiety specific for PRAME (see, e.g., WO2016/191246). Insome embodiments, the antibody moiety comprises the CDRs or variablesdomains (V_(H) and/or V_(L) domains) of an antibody moiety specific forEBV-LMP2A (see, e.g., WO2016/201124). In some embodiments, the antibodymoiety comprises the CDRs or variables domains (V_(H) and/or V_(L)domains) of an antibody moiety specific for KRAS (see, e.g.,WO2016/154047). In some embodiments, the antibody moiety comprises theCDRs or variables domains (V_(H) and/or V_(L) domains) of an antibodymoiety specific for PSA (see, e.g., WO2017/015634). In some embodiments,the antibody moiety is an scFv. In some embodiments, the SSE is a tandemscFv comprising a) a first scFv that specifically binds to a surfaceantigen of a T cell (such as CD3) or an NK cell (such as CD16a) and b)the antibody moiety, wherein the antibody moiety is a second scFv. Insome embodiments, the SSE comprises the first and second scFvs connectedby a peptide linker. In some embodiments, the first scFv isamino-terminal to the second scFv. In some embodiments, the second scFvis amino-terminal to the first scFv.

In some embodiments, the SSE is a multispecific antibody (such as abispecific antibody) targeting one or more soluble immunosuppressiveagents. Such an SSE can act as a trap to sequester the solubleimmunosuppressive agents from their targets, thereby reducing theirimmunosuppressive effects. In some embodiments, the SSE comprises one ormore antibody moieties that specifically bind to one or more solubleimmunosuppressive agents. In some embodiments, the immunosuppressiveagents are immunosuppressive cytokines. In some embodiments, theimmunosuppressive cytokines include TGF-β family members (such as TGF-β1to 4), IL-4, and IL-10, including variants or mutants thereof. In someembodiments, the SSE is a multispecific antibody selected from the groupconsisting of a tandem scFv, a diabody (Db), a single chain diabody(scDb), a dual-affinity retargeting (DART) antibody, and a dual variabledomain (DVD) antibody. In some embodiments, the SSE is a bispecificantibody. For example, in some embodiments, the SSE is a tandem scFvcomprising a first scFv targeting a first immunosuppressive cytokine(such as TGFβ) and a second scFv targeting a second immunosuppressivecytokine (such as IL-4).

In some embodiments, the SSE is an antibody moiety targeting an immunecheckpoint molecule. In some embodiments, the SSE is an antagonist of aninhibitory immune checkpoint molecule. In some embodiments, theinhibitory immune checkpoint molecule is selected from the groupconsisting of PD-1, PD-L1, CTLA-4, HVEM, BTLA, KIR, LAG-3, TIM-3, andA2aR. In some embodiments, the SSE is an agonist of a stimulatory immunecheckpoint molecule. In some embodiments, the stimulatory immunecheckpoint molecule is selected from the group consisting of CD28, ICOS,4-1BB, OX40, CD27, and CD40. In some embodiments, the antibody moiety isa full-length antibody, a Fab, a Fab′, a (Fab′)2, an Fv, or a singlechain Fv (scFv). In some embodiments, the antibody moiety is an scFv.

In some embodiments, the SSE is an antagonistic antibody moietytargeting PD-1. In some embodiments, the antibody moiety comprises theCDRs or variables domains (V_(H) and/or V_(L) domains) of anantagonistic antibody moiety specific for PD-1 (see, e.g.,WO2016/210129). In some embodiments, the antagonistic antibody moiety isa full-length antibody, a Fab, a Fab′, a (Fab′)2, an Fv, or a singlechain Fv (scFv). In some embodiments, the antagonistic antibody moietyis an scFv.

In some embodiments, the SSE is an antagonistic antibody moietytargeting CD47. In some embodiments, the antagonistic antibody moietycomprises the CDRs or variables domains (V_(H) and/or V_(L) domains) ofan antagonistic antibody moiety specific for CD47 (e.g., V_(H) domaincomprising, consisting essentially of, or consisting of the amino acidsequence of SEQ ID NO: 66 and/or V_(L) domain comprising, consistingessentially of, or consisting of the amino acid sequence of SEQ ID NO:67, or CDRs contained therein). In some embodiments, the antagonisticantibody moiety is a full-length antibody, a Fab, a Fab′, a (Fab′)2, anFv, or a single chain Fv (scFv). In some embodiments, the antagonisticantibody moiety is an scFv.

In some embodiments, the SSE comprises an antibody moiety that binds toa target antigen with a) an affinity that is at least about 10(including for example at least about any of 10, 20, 30, 40, 50, 75,100, 200, 300, 400, 500, 750, 1000 or more) times its binding affinityfor other molecules; or b) a K_(d) no more than about 1/10 (such as nomore than about any of 1/10, 1/20, 1/30, 1/40, 1/50, 1/75, 1/100, 1/200,1/300, 1/400, 1/500, 1/750, 1/1000 or less) times its K_(d) for bindingto other molecules. Binding affinity can be determined by methods knownin the art, such as ELISA, fluorescence activated cell sorting (FACS)analysis, or radioimmunoprecipitation assay (RIA). K_(d) can bedetermined by methods known in the art, such as surface plasmonresonance (SPR) assay utilizing, for example, Biacore instruments, orkinetic exclusion assay (KinExA) utilizing, for example, Sapidyneinstruments.

In some embodiments, the SSE is a soluble molecule that specificallybinds a ligand of an immunosuppressive receptor. In some embodiments,the SSE comprises a ligand-binding domain derived from the extracellulardomain of the immunosuppressive receptor. In some embodiments, theligand-binding domain is a portion of the extracellular domain of thereceptor. In some embodiments, the immunosuppressive receptor isselected from the group consisting of FasR, TNFR1, TNFR2, SIRPα, PD-1,CD28, CTLA-4, ICOS, BTLA, KIR, LAG-3, 4-1BB, OX40, CD27, CD40, andTIM-3.

In some embodiments, the SSE is a soluble molecule that specificallybinds to and antagonizes an immunosuppressive receptor. In someembodiments, the SSE comprises a receptor-binding domain derived fromthe extracellular domain of a ligand for the immunosuppressive receptor.In some embodiments, the receptor-binding domain is a portion of theextracellular domain of the ligand. In some embodiments, the ligand isselected from the group consisting of FasL, PD-L1, PD-L2, CD47, CD80,CD86, ICOSL, HVEM, 4-1BBL, OX40L, CD70, CD40L, and GAL9.

In some embodiments, the SSE is an exogenous stimulatory cytokine. Anexogenous cytokine described herein is a cytokine expressed from anexogenous gene. In some embodiments, the exogenous stimulatory cytokineis an IL-12 family member. In some embodiments, the IL-12 family memberis IL-12, IL-23, IL-27, or IL-35. In some embodiments, the exogenousstimulatory cytokine is IL-2, IL-15, IL-18, or IL-21. In someembodiments, the exogenous stimulatory cytokine is capable of providingautocrine activation of receptors for the cytokine on the caTCR plus CSRand SSE immune cell.

In some embodiments, the expression of the SSE in the caTCR plus CSR andSSE immune cell is inducible. In some embodiments, the caTCR plus CSRand SSE immune cell comprises a nucleic acid sequence encoding the SSEoperably linked to an inducible promoter, including any of the induciblepromoters described herein. In some embodiments, the expression of theSSE in the caTCR plus CSR and SSE immune cell is inducible uponsignaling through the caTCR. In some such embodiments, the caTCR plusCSR and SSE immune cell comprises a nucleic acid sequence encoding theSSE operably linked to a promoter or regulatory element responsive tosignaling through the caTCR. In some embodiments, the nucleic acidsequence encoding the SSE is operably linked to a nuclear-factor of theactivated T-cell (NFAT)-derived promoter. In some embodiments, theNFAT-derived promoter is an NFAT-derived minimal promoter (see forexample Durand, D. et. al., Molec. Cell. Biol. 8, 1715-1724 (1988);Clipstone, N A, Crabtree, G R. Nature. 1992 357(6380): 695-7;Chmielewski, M., et al. Cancer research 71.17 (2011): 5697-5706; andZhang, L., et al. Molecular therapy 19.4 (2011): 751-759). In someembodiments, the NFAT-derived promoter comprises the nucleotide sequenceof SEQ ID NO: 85. In some embodiments, the nucleic acid sequenceencoding the SSE is operably linked to an IL-2 promoter.

Nucleic Acids

Nucleic acid molecules encoding the caTCRs, CSRs and/or SSEs describedherein are also contemplated. In some embodiments, according to any ofthe caTCRs, CSRs and SSEs described herein, there is provided a nucleicacid (or a set of nucleic acids) encoding the caTCR, CSR and/or SSE.

The present invention also provides vectors in which a nucleic acid ofthe present invention is inserted.

In brief summary, the expression of a caTCR and/or CSR and/or SSEdescribed herein by a nucleic acid encoding the caTCR and/or CSR and/orSSE can be achieved by inserting the nucleic acid into an appropriateexpression vector, such that the nucleic acid is operably linked to 5′and 3′ regulatory elements, including for example a promoter (e.g., alymphocyte-specific promoter) and a 3′ untranslated region (UTR). Thevectors can be suitable for replication and integration in eukaryotichost cells. Typical cloning and expression vectors contain transcriptionand translation terminators, initiation sequences, and promoters usefulfor regulation of the expression of the desired nucleic acid sequence.

The nucleic acids of the present invention may also be used for nucleicacid immunization and gene therapy, using standard gene deliveryprotocols. Methods for gene delivery are known in the art. See, e.g.,U.S. Pat. Nos. 5,399,346, 5,580,859, 5,589,466, incorporated byreference herein in their entireties. In some embodiments, the inventionprovides a gene therapy vector.

The nucleic acid can be cloned into a number of types of vectors. Forexample, the nucleic acid can be cloned into a vector including, but notlimited to, a plasmid, a phagemid, a phage derivative, an animal virus,and a cosmid. Vectors of particular interest include expression vectors,replication vectors, probe generation vectors, and sequencing vectors.

Further, the expression vector may be provided to a cell in the form ofa viral vector. Viral vector technology is well known in the art and isdescribed, for example, in Sambrook et al. (2001, Molecular Cloning: ALaboratory Manual, Cold Spring Harbor Laboratory, New York), and inother virology and molecular biology manuals. Viruses which are usefulas vectors include, but are not limited to, retroviruses, adenoviruses,adeno-associated viruses, herpes viruses, and lentiviruses. In general,a suitable vector contains an origin of replication functional in atleast one organism, a promoter sequence, convenient restrictionendonuclease sites, and one or more selectable markers (see, e.g., WO01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193).

A number of viral based systems have been developed for gene transferinto mammalian cells. For example, retroviruses provide a convenientplatform for gene delivery systems. A selected gene can be inserted intoa vector and packaged in retroviral particles using techniques known inthe art. The recombinant virus can then be isolated and delivered tocells of the subject either in vivo or ex vivo. A number of retroviralsystems are known in the art. In some embodiments, adenovirus vectorsare used. A number of adenovirus vectors are known in the art. In someembodiments, lentivirus vectors are used. Vectors derived fromretroviruses such as the lentivirus are suitable tools to achievelong-term gene transfer since they allow long-term, stable integrationof a transgene and its propagation in daughter cells. Lentiviral vectorshave the added advantage over vectors derived from onco-retrovirusessuch as murine leukemia viruses in that they can transducenon-proliferating cells, such as hepatocytes. They also have the addedadvantage of low immunogenicity.

Additional promoter elements, e.g., enhancers, regulate the frequency oftranscriptional initiation. Typically, these are located in the region30-110 bp upstream of the start site, although a number of promotershave recently been shown to contain functional elements downstream ofthe start site as well. The spacing between promoter elements frequentlyis flexible, so that promoter function is preserved when elements areinverted or moved relative to one another. In the thymidine kinase (tk)promoter, the spacing between promoter elements can be increased to 50bp apart before activity begins to decline.

One example of a suitable promoter is the immediate earlycytomegalovirus (CMV) promoter sequence. This promoter sequence is astrong constitutive promoter sequence capable of driving high levels ofexpression of any polynucleotide sequence operatively linked thereto.Another example of a suitable promoter is Elongation Growth Factor-1α(EF-1α). However, other constitutive promoter sequences may also beused, including, but not limited to the simian virus 40 (SV40) earlypromoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus(HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avianleukemia virus promoter, an Epstein-Barr virus immediate early promoter,a Rous sarcoma virus promoter, as well as human gene promoters such as,but not limited to, the actin promoter, the myosin promoter, thehemoglobin promoter, and the creatine kinase promoter.

Further, the invention should not be limited to the use of constitutivepromoters. Inducible promoters are also contemplated as part of theinvention. The use of an inducible promoter provides a molecular switchcapable of turning on expression of the polynucleotide sequence which itis operatively linked when such expression is desired, or turning offthe expression when expression is not desired. Exemplary induciblepromoter systems for use in eukaryotic cells include, but are notlimited to, hormone-regulated elements (e.g., see Mader, S. and White,J. H. (1993) Proc. Natl. Acad. Sci. USA 90:5603-5607), syntheticligand-regulated elements (see, e.g., Spencer, D. M. et al 1993) Science262: 1019-1024) and ionizing radiation-regulated elements (e.g., seeManome, Y. et al. (1993) Biochemistry 32: 10607-10613; Datta, R. et al.(1992) Proc. Natl. Acad. Sci. USA 89: 1014-10153). Further exemplaryinducible promoter systems for use in in vitro or in vivo mammaliansystems are reviewed in Gingrich et al. (1998) Annual Rev. Neurosci21:377-405.

An exemplary inducible promoter system for use in the present inventionis the Tet system. Such systems are based on the Tet system described byGossen et al. (1993). In an exemplary embodiment, a polynucleotide ofinterest is under the control of a promoter that comprises one or moreTet operator (TetO) sites. In the inactive state, Tet repressor (TetR)will bind to the TetO sites and repress transcription from the promoter.In the active state, e.g., in the presence of an inducing agent such astetracycline (Tc), anhydrotetracycline, doxycycline (Dox), or an activeanalog thereof, the inducing agent causes release of TetR from TetO,thereby allowing transcription to take place. Doxycycline is a member ofthe tetracycline family of antibiotics having the chemical name of1-dimethylamino-2,4a,5,7,12-pentahydroxy-11-methyl-4,6-dioxo-1,4a,11,11a,12,12a-hexahydrotetracene-3-carboxamide.

In one embodiment, a TetR is codon-optimized for expression in mammaliancells, e.g., murine or human cells. Most amino acids are encoded by morethan one codon due to the degeneracy of the genetic code, allowing forsubstantial variations in the nucleotide sequence of a given nucleicacid without any alteration in the amino acid sequence encoded by thenucleic acid. However, many organisms display differences in codonusage, also known as “codon bias” (i.e., bias for use of a particularcodon(s) for a given amino acid). Codon bias often correlates with thepresence of a predominant species of tRNA for a particular codon, whichin turn increases efficiency of mRNA translation. Accordingly, a codingsequence derived from a particular organism (e.g., a prokaryote) may betailored for improved expression in a different organism (e.g., aeukaryote) through codon optimization.

Other specific variations of the Tet system include the following“Tet-Off” and “Tet-On” systems. In the Tet-Off system, transcription isinactive in the presence of Tc or Dox. In that system, atetracycline-controlled transactivator protein (tTA), which is composedof TetR fused to the strong transactivating domain of VP16 from Herpessimplex virus, regulates expression of a target nucleic acid that isunder transcriptional control of a tetracycline-responsive promoterelement (TRE). The TRE is made up of TetO sequence concatamers fused toa promoter (commonly the minimal promoter sequence derived from thehuman cytomegalovirus (hCMV) immediate-early promoter). In the absenceof Tc or Dox, tTA binds to the TRE and activates transcription of thetarget gene. In the presence of Tc or Dox, tTA cannot bind to the TRE,and expression from the target gene remains inactive.

Conversely, in the Tet-On system, transcription is active in thepresence of Tc or Dox. The Tet-On system is based on a reversetetracycline-controlled transactivator, rtTA. Like tTA, rtTA is a fusionprotein comprised of the TetR repressor and the VP16 transactivationdomain. However, a four amino acid change in the TetR DNA binding moietyalters rtTA's binding characteristics such that it can only recognizethe tetO sequences in the TRE of the target transgene in the presence ofDox. Thus, in the Tet-On system, transcription of the TRE-regulatedtarget gene is stimulated by rtTA only in the presence of Dox.

Another inducible promoter system is the lac repressor system from E.coli. (See, Brown et al., Cell 49:603-612 (1987). The lac repressorsystem functions by regulating transcription of a polynucleotide ofinterest operably linked to a promoter comprising the lac operator(lacO). The lac repressor (lacR) binds to LacO, thus preventingtranscription of the polynucleotide of interest. Expression of thepolynucleotide of interest is induced by a suitable inducing agent,e.g., isopropyl-β-D-thiogalactopyranoside (IPTG).

Another exemplary inducible promoter system for use in the presentinvention is the nuclear-factor of the activated T-cell (NFAT) system.The NFAT family of transcription factors are important regulators of Tcell activation. NFAT response elements are found, for example, in theIL-2 promoter (see for example Durand, D. et. al., Molec. Cell. Biol. 8,1715-1724 (1988); Clipstone, N A, Crabtree, G R. Nature. 1992 357(6380):695-7; Chmielewski, M., et al. Cancer research 71.17 (2011): 5697-5706;and Zhang, L., et al. Molecular therapy 19.4 (2011): 751-759). In someembodiments, an inducible promoter described herein comprises one ormore (such as 2, 3, 4, 5, 6, or more) NFAT response elements. In someembodiments, the inducible promoter comprises 6 NFAT response elements,for example, comprising the nucleotide sequence of SEQ ID NO: 83. Insome embodiments, an inducible promoter described herein comprises oneor more (such as 2, 3, 4, 5, 6, or more) NFAT response elements linkedto a minimal promoter, such as a minimal TA promoter. In someembodiments, the minimal TA promoter comprises the nucleotide sequenceof SEQ ID NO: 84. In some embodiments, the inducible promoter comprisesthe nucleotide sequence of SEQ ID NO: 85.

In order to assess the expression of a polypeptide or portions thereof,the expression vector to be introduced into a cell can also containeither a selectable marker gene or a reporter gene or both to facilitateidentification and selection of expressing cells from the population ofcells sought to be transfected or infected through viral vectors. Inother aspects, the selectable marker may be carried on a separate pieceof DNA and used in a co-transfection procedure. Both selectable markersand reporter genes may be flanked with appropriate regulatory sequencesto enable expression in the host cells. Useful selectable markersinclude, for example, antibiotic-resistance genes, such as neo and thelike.

Reporter genes are used for identifying potentially transfected cellsand for evaluating the functionality of regulatory sequences. Ingeneral, a reporter gene is a gene that is not present in or expressedby the recipient organism or tissue and that encodes a polypeptide whoseexpression is manifested by some easily detectable property, e.g.,enzymatic activity. Expression of the reporter gene is assayed at asuitable time after the DNA has been introduced into the recipientcells. Suitable reporter genes may include genes encoding luciferase,β-galactosidase, chloramphenicol acetyl transferase, secreted alkalinephosphatase, or the green fluorescent protein gene (e.g., Ui-Tel et al.,2000 FEBS Letters 479: 79-82). Suitable expression systems are wellknown and may be prepared using known techniques or obtainedcommercially. In general, the construct with the minimal 5′ flankingregion showing the highest level of expression of reporter gene isidentified as the promoter. Such promoter regions may be linked to areporter gene and used to evaluate agents for the ability to modulatepromoter-driven transcription.

In some embodiments, there is provided nucleic acid encoding a caTCRand/or a CSR according to any of the caTCRs, CSRs and SSEs describedherein. In some embodiments, the nucleic acid comprises one or morenucleic acid sequences encoding all of the polypeptide chains of thecaTCR. In some embodiments, the nucleic acid comprises one or morenucleic acid sequences encoding all of the polypeptide chains of theCSR. In some embodiments, the nucleic acid comprises one or more nucleicacid sequences encoding all of the polypeptide chains of the caTCR andthe CSR. In some embodiments, each of the one or more nucleic acidsequences is contained in separate vectors. In some embodiments, atleast some of the nucleic acid sequences are contained in the samevector. In some embodiments, all of the nucleic acid sequences arecontained in the same vector. Vectors may be selected, for example, fromthe group consisting of mammalian expression vectors and viral vectors(such as those derived from retroviruses, adenoviruses, adeno-associatedviruses, herpes viruses, and lentiviruses).

For example, in some embodiments, the caTCR is a dimer comprising afirst caTCR polypeptide chain and a second caTCR polypeptide chain andthe CSR is a monomer comprising a single CSR polypeptide chain, and thenucleic acid comprises a first nucleic acid sequence encoding the firstcaTCR polypeptide chain, a second nucleic acid encoding the second caTCRchain, and a third nucleic acid sequence encoding the CSR polypeptidechain. In some embodiments, the first nucleic acid sequence is containedin a first vector, the second nucleic acid sequence is contained in asecond vector, and the third nucleic acid sequence is contained in athird vector. In some embodiments, the first and second nucleic acidsequences are contained in a first vector, and the third nucleic acidsequence is contained in a second vector. In some embodiments, the firstand third nucleic acid sequences are contained in a first vector, andthe second nucleic acid sequence is contained in a second vector. Insome embodiments, the second and third nucleic acid sequences arecontained in a first vector, and the first nucleic acid sequence iscontained in a second vector. In some embodiments, the first, second,and third nucleic acid sequences are contained in the same vector. Insome embodiments, the first nucleic acid sequence is under the controlof a first promoter, the second nucleic acid sequence is under thecontrol of a second promoter, and the third nucleic acid sequence isunder the control of a third promoter. In some embodiments, some or allof the first, second, and third promoters have the same sequence. Insome embodiments, some or all of the first, second, and third promotershave different sequences. In some embodiments, some or all of the first,second, and third nucleic acid sequences are expressed as a singletranscript under the control of a single promoter in a multicistronicvector. See for example Kim, J H, et al., PLoS One 6(4):e18556, 2011. Insome embodiments, one or more of the promoters are inducible. In someembodiments, the third nucleic acid sequence encoding the CSRpolypeptide chain is operably linked to an inducible promoter. In someembodiments, the inducible promoter comprises one or more elementsresponsive to immune cell activation, such as NFAT response elements.

In some embodiments, some or all of the first, second, and third nucleicacid sequences have similar (such as substantially or about the same)expression levels in a host cell (such as a T cell). In someembodiments, some of the first, second, and third nucleic acid sequenceshave expression levels in a host cell (such as a T cell) that differ byat least about two (such as at least about any of 2, 3, 4, 5, or more)times. Expression can be determined at the mRNA or protein level. Thelevel of mRNA expression can be determined by measuring the amount ofmRNA transcribed from the nucleic acid using various well-known methods,including Northern blotting, quantitative RT-PCR, microarray analysisand the like. The level of protein expression can be measured by knownmethods including immunocytochemical staining, enzyme-linkedimmunosorbent assay (ELISA), western blot analysis, luminescent assays,mass spectrometry, high performance liquid chromatography, high-pressureliquid chromatography-tandem mass spectrometry, and the like.

It is to be understood that the features of the embodiments describedherein can be adapted and combined to encompass embodiments comprisingany number of nucleic acid sequences, e.g., where the nucleic acidencoding the caTCR and/or CSR and/or SSE comprises five or more nucleicacid sequences (e.g., where the caTCR and SSE each comprises 2 or moredistinct polypeptide chains).

Thus, in some embodiments, there is provided nucleic acid encoding a) adimeric caTCR comprising a first caTCR polypeptide chain and a secondcaTCR polypeptide chain according to any of the caTCRs described herein,the nucleic acid comprising i) a first caTCR nucleic acid sequenceencoding the first caTCR polypeptide chain, and ii) a second caTCRnucleic acid sequence encoding the second caTCR polypeptide chain; andb) a monomeric CSR comprising a single CSR polypeptide chain accordingto any of the CSRs described herein, the nucleic acid further comprisinga CSR nucleic acid sequence encoding the CSR polypeptide chain. In someembodiments, the first caTCR nucleic acid sequence is contained in afirst vector (such as a lentiviral vector), the second caTCR nucleicacid sequence is contained in a second vector (such as a lentiviralvector), and the CSR nucleic acid sequence is contained in a thirdvector (such as a lentiviral vector). In some embodiments, some or allof the first and second caTCR nucleic acid sequences and CSR nucleicacid sequence are contained in the same vector (such as a lentiviralvector). In some embodiments, each of the first and second caTCR nucleicacid sequences and CSR nucleic acid sequence are, individually, operablylinked to a promoter. In some embodiments, some or all of the promotershave the same sequence. In some embodiments, some or all of thepromoters have different sequences. In some embodiments, some or all ofthe promoters are inducible. In some embodiments, the CSR nucleic acidsequence is operably linked to an inducible promoter. In someembodiments, the inducible promoter comprises one or more elementsresponsive to immune cell activation. In some embodiments, the CSRnucleic acid sequence is operably linked to an NFAT-derived promoter. Insome embodiments, some or all of the vectors are viral vectors (such aslentiviral vectors).

In some embodiments, there is provided a) a first vector (such as alentiviral vector) comprising nucleic acid encoding a dimeric caTCRcomprising a first caTCR polypeptide chain and a second caTCRpolypeptide chain according to any of the caTCRs described hereincomprising i) a first promoter operably linked to a first caTCR nucleicacid sequence encoding the first caTCR polypeptide chain; and ii) asecond promoter operably linked to a second caTCR nucleic acid sequenceencoding the second caTCR polypeptide chain; and b) a second vector(such as a lentiviral vector) comprising nucleic acid encoding amonomeric CSR comprising a CSR polypeptide chain according to any of theCSRs described herein comprising a third promoter operably linked to aCSR nucleic acid sequence encoding the CSR polypeptide chain. In someembodiments, some or all of the promoters have the same sequence. Insome embodiments, some or all of the promoters have different sequences.In some embodiments, some or all of the promoters are inducible. In someembodiments, the first and/or second vectors are viral vectors (such aslentiviral vectors).

In some embodiments, there is provided a) a first vector (such as alentiviral vector) comprising nucleic acid encoding a dimeric caTCRcomprising a first caTCR polypeptide chain and a second caTCRpolypeptide chain according to any of the caTCRs described hereincomprising i) a first caTCR nucleic acid sequence encoding the firstcaTCR polypeptide chain; and ii) a second caTCR nucleic acid sequenceencoding the second caTCR polypeptide chain, wherein the first andsecond caTCR nucleic acid sequences are under the control of a firstpromoter; and b) a second vector (such as a lentiviral vector)comprising nucleic acid encoding a monomeric CSR comprising a CSRpolypeptide chain according to any of the CSRs described hereincomprising a second promoter operably linked to a CSR nucleic acidsequence encoding the CSR polypeptide chain. In some embodiments, thefirst promoter is operably linked to the 5′ end of the first caTCRnucleic acid sequence, and there is nucleic acid linker selected fromthe group consisting of an internal ribosomal entry site (IRES) and anucleic acid encoding a self-cleaving 2A peptide (such as P2A, T2A, E2A,or F2A) linking the 3′ end of first caTCR nucleic acid sequence to the5′ end of the second caTCR nucleic acid sequence, wherein the firstcaTCR nucleic acid sequence and the second caTCR nucleic acid sequenceare transcribed as a single RNA under the control of the first promoter.In some embodiments, the first promoter is operably linked to the 5′ endof the second caTCR nucleic acid sequence, and there is nucleic acidlinker selected from the group consisting of an internal ribosomal entrysite (IRES) and a nucleic acid encoding a self-cleaving 2A peptide (suchas P2A, T2A, E2A, or F2A) linking the 3′ end of second caTCR nucleicacid sequence to the 5′ end of the first caTCR nucleic acid sequence,wherein the first caTCR nucleic acid sequence and the second caTCRnucleic acid sequence are transcribed as a single RNA under the controlof the first promoter. In some embodiments, the first and/or secondpromoters are inducible. In some embodiments, the first and/or secondvectors are viral vectors (such as lentiviral vectors). It is to beappreciated that embodiments where any of the nucleic acid sequences areswapped are also contemplated, such as where the first or second caTCRnucleic acid sequence is swapped with the CSR nucleic acid sequence.

In some embodiments, there is provided a vector (such as a viral vector,e.g., a lentiviral vector) comprising a) nucleic acid encoding a dimericcaTCR comprising a first caTCR polypeptide chain and a second caTCRpolypeptide chain according to any of the caTCRs described hereincomprising i) a first caTCR nucleic acid sequence encoding the firstcaTCR polypeptide chain; and ii) a second caTCR nucleic acid sequenceencoding the second caTCR polypeptide chain; and b) nucleic acidencoding a monomeric CSR comprising a CSR polypeptide chain according toany of the CSRs described herein comprising a CSR nucleic acid sequenceencoding the CSR polypeptide chain, wherein the first and second caTCRnucleic acid sequences are under the control of a first promoter, andwherein the CSR nucleic acid sequence is under the control of a secondpromoter. In some embodiments, the first promoter is operably linked toone of the caTCR nucleic acid sequences, which is linked to the othercaTCR nucleic acid sequence by a nucleic acid linker selected from thegroup consisting of an internal ribosomal entry site (IRES) and anucleic acid encoding a self-cleaving 2A peptide (such as P2A, T2A, E2A,or F2A), such that the first and second caTCR nucleic acid sequences aretranscribed as a single RNA under the control of the first promoter. Insome embodiments, the first and/or second promoters are inducible. Insome embodiments, the second promoter is an inducible promoter. In someembodiments, the inducible promoter comprises one or more elementsresponsive to immune cell activation. In some embodiments, the secondpromoter is an NFAT-derived promoter. In some embodiments, theNFAT-derived promoter comprises the nucleotide sequence of SEQ ID NO:85. In some embodiments, the vector is a viral vector (such as alentiviral vector).

In some embodiments, there is provided a vector (such as a lentiviralvector) comprising a) nucleic acid encoding a dimeric caTCR comprising afirst caTCR polypeptide chain and a second caTCR polypeptide chainaccording to any of the caTCRs described herein comprising i) a firstcaTCR nucleic acid sequence encoding the first caTCR polypeptide chain;and ii) a second caTCR nucleic acid sequence encoding the second caTCRpolypeptide chain; and b) nucleic acid encoding a monomeric CSRcomprising a CSR polypeptide chain according to any of the CSRsdescribed herein comprising a CSR nucleic acid sequence encoding the CSRpolypeptide chain, wherein the first and second caTCR nucleic acidsequences and the CSR nucleic acid sequence are under the control of asingle promoter. In some embodiments, the promoter is operably linked toone of the nucleic acid sequences, which is linked to the other nucleicacid sequences by nucleic acid linkers selected, individually, from thegroup consisting of an internal ribosomal entry site (IRES) and anucleic acid encoding a self-cleaving 2A peptide (such as P2A, T2A, E2A,or F2A), such that the first and second caTCR nucleic acid sequences andthe CSR nucleic acid sequence are transcribed as a single RNA under thecontrol of the promoter. In some embodiments, the promoter is inducible.In some embodiments, the vector is a viral vector (such as a lentiviralvector).

Methods of introducing and expressing genes into a cell are known in theart. In the context of an expression vector, the vector can be readilyintroduced into a host cell, e.g., mammalian, bacterial, yeast, orinsect cell by any method in the art. For example, the expression vectorcan be transferred into a host cell by physical, chemical, or biologicalmeans.

Physical methods for introducing a polynucleotide into a host cellinclude calcium phosphate precipitation, lipofection, particlebombardment, microinjection, electroporation, and the like. Methods forproducing cells comprising vectors and/or exogenous nucleic acids arewell-known in the art. See, for example, Sambrook et al. (2001,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory,New York). In some embodiments, the introduction of a polynucleotideinto a host cell is carried out by calcium phosphate transfection.

Biological methods for introducing a polynucleotide of interest into ahost cell include the use of DNA and RNA vectors. Viral vectors, andespecially retroviral vectors, have become the most widely used methodfor inserting genes into mammalian, e.g., human, cells. Other viralvectors can be derived from lentivirus, poxviruses, herpes simplex virus1, adenoviruses and adeno-associated viruses, and the like. See, forexample, U.S. Pat. Nos. 5,350,674 and 5,585,362.

Chemical means for introducing a polynucleotide into a host cell includecolloidal dispersion systems, such as macromolecule complexes,nanocapsules, microspheres, beads, and lipid-based systems includingoil-in-water emulsions, micelles, mixed micelles, and liposomes. Anexemplary colloidal system for use as a delivery vehicle in vitro and invivo is a liposome (e.g., an artificial membrane vesicle).

In the case where a non-viral delivery system is utilized, an exemplarydelivery vehicle is a liposome. The use of lipid formulations iscontemplated for the introduction of the nucleic acids into a host cell(in vitro, ex vivo or in vivo). In another aspect, the nucleic acid maybe associated with a lipid. The nucleic acid associated with a lipid maybe encapsulated in the aqueous interior of a liposome, interspersedwithin the lipid bilayer of a liposome, attached to a liposome via alinking molecule that is associated with both the liposome and theoligonucleotide, entrapped in a liposome, complexed with a liposome,dispersed in a solution containing a lipid, mixed with a lipid, combinedwith a lipid, contained as a suspension in a lipid, contained orcomplexed with a micelle, or otherwise associated with a lipid. Lipid,lipid/DNA or lipid/expression vector associated compositions are notlimited to any particular structure in solution. For example, they maybe present in a bilayer structure, as micelles, or with a “collapsed”structure. They may also simply be interspersed in a solution, possiblyforming aggregates that are not uniform in size or shape. Lipids arefatty substances which may be naturally occurring or synthetic lipids.For example, lipids include the fatty droplets that naturally occur inthe cytoplasm as well as the class of compounds which contain long-chainaliphatic hydrocarbons and their derivatives, such as fatty acids,alcohols, amines, amino alcohols, and aldehydes.

Regardless of the method used to introduce exogenous nucleic acids intoa host cell or otherwise expose a cell to the inhibitor of the presentinvention, in order to confirm the presence of the recombinant DNAsequence in the host cell, a variety of assays may be performed. Suchassays include, for example, “molecular biological” assays well known tothose of skill in the art, such as Southern and Northern blotting,RT-PCR and PCR; “biochemical” assays, such as detecting the presence orabsence of a particular peptide, e.g., by immunological means (ELISAsand Western blots) or by assays described herein to identify agentsfalling within the scope of the invention.

Preparation of caTCRs, CSRs and SSEs

In some embodiments, according to any of the caTCRs, CSRs and SSEsdescribed herein comprising an antibody moiety, the antibody moiety(e.g., Fab, Fab′, (Fab′)2, Fv, or scFv) comprises sequences derived froma monoclonal antibody. In some embodiments, the antibody moietycomprises V_(H) and V_(L) domains, or variants thereof, from themonoclonal antibody. In some embodiments, the antibody moiety furthercomprises C_(H)1 and C_(L) domains, or variants thereof, from themonoclonal antibody. Monoclonal antibodies can be prepared, e.g., usinghybridoma methods, such as those described by Kohler and Milstein,Nature, 256:495 (1975) and Sergeeva et al., Blood, 117(16):4262-4272.

In a hybridoma method, a hamster, mouse, or other appropriate hostanimal is typically immunized with an immunizing agent to elicitlymphocytes that produce or are capable of producing antibodies thatwill specifically bind to the immunizing agent. Alternatively, thelymphocytes can be immunized in vitro. The immunizing agent can includea polypeptide or a fusion protein of the protein of interest, or acomplex comprising at least two molecules, such as a complex comprisinga peptide and an MHC protein. Generally, peripheral blood lymphocytes(“PBLs”) are used if cells of human origin are desired, or spleen cellsor lymph node cells are used if non-human mammalian sources are desired.The lymphocytes are then fused with an immortalized cell line using asuitable fusing agent, such as polyethylene glycol, to form a hybridomacell. See, e.g., Goding, Monoclonal Antibodies: Principles and Practice(New York: Academic Press, 1986), pp. 59-103. Immortalized cell linesare usually transformed mammalian cells, particularly myeloma cells ofrodent, bovine, and human origin. Usually, rat or mouse myeloma celllines are employed. The hybridoma cells can be cultured in a suitableculture medium that preferably contains one or more substances thatinhibit the growth or survival of the unfused, immortalized cells. Forexample, if the parental cells lack the enzyme hypoxanthine guaninephosphoribosyl transferase (HGPRT or HPRT), the culture medium for thehybridomas typically will include hypoxanthine, aminopterin, andthymidine (“HAT medium”), which prevents the growth of HGPRT-deficientcells.

In some embodiments, the immortalized cell lines fuse efficiently,support stable high-level expression of antibody by the selectedantibody-producing cells, and are sensitive to a medium such as HATmedium. In some embodiments, the immortalized cell lines are murinemyeloma lines, which can be obtained, for instance, from the SalkInstitute Cell Distribution Center, San Diego, Calif. and the AmericanType Culture Collection, Manassas, Va. Human myeloma and mouse-humanheteromyeloma cell lines also have been described for the production ofhuman monoclonal antibodies. Kozbor, J. Immunol., 133:3001 (1984);Brodeur et al. Monoclonal Antibody Production Techniques andApplications (Marcel Dekker, Inc.: New York, 1987) pp. 51-63.

The culture medium in which the hybridoma cells are cultured can then beassayed for the presence of monoclonal antibodies directed against thepolypeptide. The binding specificity of monoclonal antibodies producedby the hybridoma cells can be determined by immunoprecipitation or by anin vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linkedimmunoabsorbent assay (ELISA). Such techniques and assays are known inthe art. The binding affinity of the monoclonal antibody can, forexample, be determined by the Scatchard analysis of Munson and Pollard,Anal. Biochem., 107:220 (1980).

After the desired hybridoma cells are identified, the clones can besub-cloned by limiting dilution procedures and grown by standardmethods. Goding, supra. Suitable culture media for this purpose include,for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium.Alternatively, the hybridoma cells can be grown in vivo as ascites in amammal.

The monoclonal antibodies secreted by the sub-clones can be isolated orpurified from the culture medium or ascites fluid by conventionalimmunoglobulin purification procedures such as, for example, proteinA-Sepharose, hydroxylapatite chromatography, gel electrophoresis,dialysis, or affinity chromatography.

In some embodiments, according to any of the caTCRs, CSRs and SSEsdescribed herein comprising an antibody moiety, the antibody moietycomprises sequences from a clone selected from an antibody moietylibrary (such as a phage library presenting scFv or Fab fragments). Theclone may be identified by screening combinatorial libraries forantibody fragments with the desired activity or activities. For example,a variety of methods are known in the art for generating phage displaylibraries and screening such libraries for antibodies possessing thedesired binding characteristics. Such methods are reviewed, e.g., inHoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien etal., ed., Human Press, Totowa, N.J., 2001) and further described, e.g.,in McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352:624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Marksand Bradbury, Methods in Molecular Biology 248:161-175 (Lo, ed., HumanPress, Totowa, N.J., 2003); Sidhu et al., J. Mol. Biol. 338(2): 299-310(2004); Lee et al., J. Mol. Biol. 340(5): 1073-1093 (2004); Fellouse,Proc. Nat. Acad. Sci. USA 101(34): 12467-12472 (2004); and Lee et al.,J. Immunol. Methods 284(1-2): 119-132 (2004).

In certain phage display methods, repertoires of V_(H) and V_(L) genesare separately cloned by polymerase chain reaction (PCR) and recombinedrandomly in phage libraries, which can then be screened forantigen-binding phage as described in Winter et al., Ann. Rev. Immunol.,12: 433-455 (1994). Phage typically display antibody fragments, eitheras single-chain Fv (scFv) fragments or as Fab fragments. Libraries fromimmunized sources provide high-affinity antibodies to the immunogenwithout the requirement of constructing hybridomas. Alternatively, thenaive repertoire can be cloned (e.g., from human) to provide a singlesource of antibodies to a wide range of non-self and also self-antigenswithout any immunization as described by Griffiths et al., EMBO J, 12:725-734 (1993). Finally, naive libraries can also be made syntheticallyby cloning unrearranged V-gene segments from stem cells, and using PCRprimers containing random sequence to encode the highly variable CDR3regions and to accomplish rearrangement in vitro, as described byHoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992). Patentpublications describing human antibody phage libraries include, forexample: U.S. Pat. No. 5,750,373, and US Patent Publication Nos.2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598,2007/0237764, 2007/0292936, and 2009/0002360.

The antibody moiety can be prepared using phage display to screenlibraries for antibodies specific to the target antigen (such as apeptide/MHC class I/II complex or a cell surface antigen). The librarycan be a human scFv phage display library having a diversity of at leastone×10⁹ (such as at least about any of 1×10⁹, 2.5×10⁹, 5×10⁹, 7.5×10⁹,1×10¹⁰, 2.5×10¹⁰, 5×10¹⁰, 7.5×10¹⁰, or 1×10¹¹) unique human antibodyfragments. In some embodiments, the library is a naive human libraryconstructed from DNA extracted from human PMBCs and spleens from healthydonors, encompassing all human heavy and light chain subfamilies. Insome embodiments, the library is a naïve human library constructed fromDNA extracted from PBMCs isolated from patients with various diseases,such as patients with autoimmune diseases, cancer patients, and patientswith infectious diseases. In some embodiments, the library is asemi-synthetic human library, wherein heavy chain CDR3 is completelyrandomized, with all amino acids (with the exception of cysteine)equally likely to be present at any given position (see, e.g., Hoet, R.M. et al., Nat. Biotechnol. 23(3):344-348, 2005). In some embodiments,the heavy chain CDR3 of the semi-synthetic human library has a lengthfrom about 5 to about 24 (such as about any of 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24) amino acids. Insome embodiments, the library is a fully-synthetic phage displaylibrary. In some embodiments, the library is a non-human phage displaylibrary.

Phage clones that bind to the target antigen with high affinity can beselected by iterative binding of phage to the target antigen, which isbound to a solid support (such as, for example, beads for solutionpanning or mammalian cells for cell panning), followed by removal ofnon-bound phage and by elution of specifically bound phage. In anexample of solution panning, the target antigen can be biotinylated forimmobilization to a solid support. The biotinylated target antigen ismixed with the phage library and a solid support, such asstreptavidin-conjugated Dynabeads M-280, and then targetantigen-phage-bead complexes are isolated. The bound phage clones arethen eluted and used to infect an appropriate host cell, such as E. coliXL1-Blue, for expression and purification. In an example of cellpanning, T2 cells (a TAP-deficient, HLA-A*02:01⁺ lymphoblast cell line)loaded with an AFP peptide are mixed with the phage library, after whichthe cells are collected and the bound clones are eluted and used toinfect an appropriate host cell for expression and purification. Thepanning can be performed for multiple (such as about any of 2, 3, 4, 5,6 or more) rounds with either solution panning, cell panning, or acombination of both, to enrich for phage clones binding specifically tothe target antigen. Enriched phage clones can be tested for specificbinding to the target antigen by any methods known in the art, includingfor example ELISA and FACS.

Human and Humanized Antibody Moieties

The caTCR, CSR and SSE antibody moieties can be human or humanized.Humanized forms of non-human (e.g., murine) antibody moieties arechimeric immunoglobulins, immunoglobulin chains, or fragments thereof(such as Fv, Fab, Fab′, F(ab′)₂, scFv, or other antigen-bindingsubsequences of antibodies) that typically contain minimal sequencederived from non-human immunoglobulin. Humanized antibody moietiesinclude human immunoglobulins, immunoglobulin chains, or fragmentsthereof (recipient antibody) in which residues from a CDR of therecipient are replaced by residues from a CDR of a non-human species(donor antibody) such as mouse, rat, or rabbit having the desiredspecificity, affinity, and capacity. In some instances, Fv frameworkresidues of the human immunoglobulin are replaced by correspondingnon-human residues. Humanized antibody moieties can also compriseresidues that are found neither in the recipient antibody moiety nor inthe imported CDR or framework sequences. In general, the humanizedantibody moiety can comprise substantially all of at least one, andtypically two, variable domains, in which all or substantially all ofthe CDR regions correspond to those of a non-human immunoglobulin, andall or substantially all of the FR regions are those of a humanimmunoglobulin consensus sequence. See, e.g., Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332: 323-329 (1988); Presta,Curr. Op. Struct. Biol., 2:593-596 (1992).

Generally, a humanized antibody moiety has one or more amino acidresidues introduced into it from a source that is non-human. Thesenon-human amino acid residues are often referred to as “import”residues, which are typically taken from an “import” variable domain.According to some embodiments, humanization can be essentially performedfollowing the method of Winter and co-workers (Jones et al., Nature,321: 522-525 (1986); Riechmann et al., Nature, 332: 323-327 (1988);Verhoeyen et al., Science, 239: 1534-1536 (1988)), by substitutingrodent CDRs or CDR sequences for the corresponding sequences of a humanantibody moiety. Accordingly, such “humanized” antibody moieties areantibody moieties (U.S. Pat. No. 4,816,567), wherein substantially lessthan an intact human variable domain has been substituted by thecorresponding sequence from a non-human species. In practice, humanizedantibody moieties are typically human antibody moieties in which someCDR residues and possibly some FR residues are substituted by residuesfrom analogous sites in rodent antibodies.

As an alternative to humanization, human antibody moieties can begenerated. For example, it is now possible to produce transgenic animals(e.g., mice) that are capable, upon immunization, of producing a fullrepertoire of human antibodies in the absence of endogenousimmunoglobulin production. For example, it has been described that thehomozygous deletion of the antibody heavy-chain joining region (JH) genein chimeric and germ-line mutant mice results in complete inhibition ofendogenous antibody production. Transfer of the human germ-lineimmunoglobulin gene array into such germ-line mutant mice will result inthe production of human antibodies upon antigen challenge. See, e.g.,Jakobovits et al., PNAS USA, 90:2551 (1993); Jakobovits et al., Nature,362:255-258 (1993); Bruggemann et al., Year in Immunol., 7:33 (1993);U.S. Pat. Nos. 5,545,806, 5,569,825, 5,591,669; 5,545,807; and WO97/17852. Alternatively, human antibodies can be made by introducinghuman immunoglobulin loci into transgenic animals, e.g., mice in whichthe endogenous immunoglobulin genes have been partially or completelyinactivated. Upon challenge, human antibody production is observed thatclosely resembles that seen in humans in all respects, including generearrangement, assembly, and antibody repertoire. This approach isdescribed, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806;5,569,825; 5,625,126; 5,633,425; and 5,661,016, and Marks et al.,BioTechnology, 10: 779-783 (1992); Lonberg et al., Nature, 368: 856-859(1994); Morrison, Nature, 368: 812-813 (1994); Fishwild et al., NatureBiotechnology, 14: 845-851 (1996); Neuberger, Nature Biotechnology, 14:826 (1996); Lonberg and Huszar, Intern. Rev. Immunol., 13: 65-93 (1995).

Human antibodies may also be generated by in vitro activated B cells(see U.S. Pat. Nos. 5,567,610 and 5,229,275) or by using varioustechniques known in the art, including phage display libraries.Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J.Mol. Biol., 222:581 (1991). The techniques of Cole et al. and Boerner etal. are also available for the preparation of human monoclonalantibodies. Cole et al., Monoclonal Antibodies and Cancer Therapy, AlanR. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1): 86-95(1991).

Additional Variants

In some embodiments, amino acid sequence variants of the antigen-bindingmodules provided herein are contemplated. For example, it may bedesirable to improve the binding affinity and/or other biologicalproperties of the antigen-binding module. Amino acid sequence variantsof an antigen-binding module may be prepared by introducing appropriatemodifications into the nucleotide sequence encoding the antigen-bindingmodule, or by peptide synthesis. Such modifications include, forexample, deletions from, and/or insertions into and/or substitutions ofresidues within the amino acid sequences of the antigen-binding module.Any combination of deletion, insertion, and substitution can be made toarrive at the final construct, provided that the final constructpossesses the desired characteristics, e.g., antigen-binding.

In some embodiments, antigen-binding module variants having one or moreamino acid substitutions are provided. Sites of interest forsubstitutional mutagenesis include the HVRs and FRs of antibodymoieties. Amino acid substitutions may be introduced into anantigen-binding module of interest and the products screened for adesired activity, e.g., retained/improved antigen binding or decreasedimmunogenicity.

Conservative substitutions are shown in Table 4 below.

TABLE 4 CONSERVATIVE SUBSTITITIONS Original Exemplary Preferred ResidueSubstitutions Substitutions Ala (A) Val; Leu; Ile Val Arg (R) Lys; Gln;Asn Lys Asn (N) Gln; His; Asp, Lys; Arg Gln Asp (D) Glu; Asn Glu Cys (C)Ser; Ala Ser Gln (Q) Asn; Glu Asn Glu (E) Asp; Gln Asp Gly (G) Ala AlaHis (H) Asn; Gln; Lys; Arg Arg Ile (I) Leu; Val; Met; Leu Ala; Phe;Norleucine Leu (L) Norleucine; Ile; Ile Val; Met; Ala; Phe Lys (K) Arg;Gln; Asn Arg Met (M) Leu; Phe; Ile Leu Phe (F) Trp; Leu; Val; Tyr Ile;Ala; Tyr Pro (P) Ala Ala Ser (S) Thr Thr Thr (T) Val; Ser Ser Trp (W)Tyr; Phe Tyr Tyr (Y) Trp; Phe; Thr; Ser Phe Val (V) Ile; Leu; Met; LeuPhe; Ala; Norleucine

Amino acids may be grouped into different classes according to commonside-chain properties:

-   -   a. hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;    -   b. neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;    -   c. acidic: Asp, Glu;    -   d. basic: His, Lys, Arg;    -   e. residues that influence chain orientation: Gly, Pro;    -   f. aromatic: Trp, Tyr, Phe.

Non-conservative substitutions will entail exchanging a member of one ofthese classes for another class.

An exemplary substitutional variant is an affinity matured antibodymoiety, which may be conveniently generated, e.g., using phagedisplay-based affinity maturation techniques. Briefly, one or more CDRresidues are mutated and the variant antibody moieties displayed onphage and screened for a particular biological activity (e.g., bindingaffinity). Alterations (e.g., substitutions) may be made in HVRs, e.g.,to improve antibody moiety affinity. Such alterations may be made in HVR“hotspots,” i.e., residues encoded by codons that undergo mutation athigh frequency during the somatic maturation process (see, e.g.,Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and/or specificitydetermining residues (SDRs), with the resulting variant V_(H) or V_(L)being tested for binding affinity. Affinity maturation by constructingand reselecting from secondary libraries has been described, e.g., inHoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien etal., ed., Human Press, Totowa, N.J., (2001).)

In some embodiments of affinity maturation, diversity is introduced intothe variable genes chosen for maturation by any of a variety of methods(e.g., error-prone PCR, chain shuffling, or oligonucleotide-directedmutagenesis). A secondary library is then created. The library is thenscreened to identify any antibody moiety variants with the desiredaffinity. Another method to introduce diversity involves HVR-directedapproaches, in which several HVR residues (e.g., 4-6 residues at a time)are randomized. HVR residues involved in antigen binding may bespecifically identified, e.g., using alanine scanning mutagenesis ormodeling. CDR-H3 and CDR-L3 in particular are often targeted.

In some embodiments, substitutions, insertions, or deletions may occurwithin one or more HVRs so long as such alterations do not substantiallyreduce the ability of the antibody moiety to bind antigen. For example,conservative alterations (e.g., conservative substitutions as providedherein) that do not substantially reduce binding affinity may be made inHVRs. Such alterations may be outside of HVR “hotspots” or SDRs. In someembodiments of the variant V_(H) and V_(L) sequences provided above,each HVR either is unaltered, or contains no more than one, two or threeamino acid substitutions.

A useful method for identification of residues or regions of anantigen-binding module that may be targeted for mutagenesis is called“alanine scanning mutagenesis” as described by Cunningham and Wells(1989) Science, 244:1081-1085. In this method, a residue or group oftarget residues (e.g., charged residues such as arg, asp, his, lys, andglu) are identified and replaced by a neutral or negatively chargedamino acid (e.g., alanine or polyalanine) to determine whether theinteraction of the antigen-binding module with antigen is affected.Further substitutions may be introduced at the amino acid locationsdemonstrating functional sensitivity to the initial substitutions.Alternatively, or additionally, a crystal structure of anantigen-antigen-binding module complex can be determined to identifycontact points between the antigen-binding module and antigen. Suchcontact residues and neighboring residues may be targeted or eliminatedas candidates for substitution. Variants may be screened to determinewhether they contain the desired properties.

Amino acid sequence insertions include amino- and/or carboxyl-terminalfusions ranging in length from one residue to polypeptides containing ahundred or more residues, as well as intrasequence insertions of singleor multiple amino acid residues. Examples of terminal insertions includean antigen-binding module with an N-terminal methionyl residue. Otherinsertional variants of the antigen-binding module include the fusion tothe N- or C-terminus of the antigen-binding module to an enzyme (e.g.,for ADEPT) or a polypeptide which increases the serum half-life of theantigen-binding module.

Derivatives

In some embodiments, a caTCR according to any of the caTCRs describedherein and/or a CSR according to any of the CSRs described herein and/oran SSE according to any of the SSEs described herein may be furthermodified to contain additional nonproteinaceous moieties that are knownin the art and readily available. The moieties suitable forderivatization of the caTCR and/or CSR and/or SSE include but are notlimited to water soluble polymers. Non-limiting examples of watersoluble polymers include, but are not limited to, polyethylene glycol(PEG), copolymers of ethylene glycol/propylene glycol,carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleicanhydride copolymer, polyaminoacids (either homopolymers or randomcopolymers), and dextran or poly(n-vinyl pyrrolidone)polyethyleneglycol, propropylene glycol homopolymers, prolypropylene oxide/ethyleneoxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinylalcohol, and mixtures thereof. Polyethylene glycol propionaldehyde mayhave advantages in manufacturing due to its stability in water. Thepolymer may be of any molecular weight, and may be branched orunbranched. The number of polymers attached to the caTCR and/or CSRand/or SSE may vary, and if more than one polymer are attached, they canbe the same or different molecules. In general, the number and/or typeof polymers used for derivatization can be determined based onconsiderations including, but not limited to, the particular propertiesor functions of the caTCR and/or CSR and/or SSE to be improved, whetherthe caTCR and/or CSR and/or SSE derivative will be used in a therapyunder defined conditions, etc.

In some embodiments, conjugates of a caTCR and/or CSR and/or SSE andnonproteinaceous moiety that may be selectively heated by exposure toradiation are provided. In some embodiments, the nonproteinaceous moietyis a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102:11600-11605 (2005)). The radiation may be of any wavelength, andincludes, but is not limited to, wavelengths that do not harm ordinarycells, but which heat the nonproteinaceous moiety to a temperature atwhich cells proximal to the caTCR- and/or CSR- and/orSSE-nonproteinaceous moiety are killed.

Preparation of caTCR Plus CSR Immune Cells

The present invention in one aspect provides immune cells (such aslymphocytes, for example T cells) expressing a caTCR and a CSR accordingto any of the embodiments described herein. Exemplary methods ofpreparing immune cells (such as T cells) expressing a caTCR and a CSR(caTCR plus CSR immune cells, such as caTCR plus CSR T cells) areprovided herein.

In some embodiments, a caTCR plus CSR immune cell (such as a caTCR plusCSR T cell) can be generated by introducing one or more nucleic acids(including for example a lentiviral vector) encoding a caTCR (such asany of the caTCRs described herein) that specifically binds to a targetantigen (such as a disease-associated antigen) and a CSR (such as any ofthe CSRs described herein) that specifically binds to a target ligandinto the immune cell. The introduction of the one or more nucleic acidsinto the immune cell can be accomplished using techniques known in theart, such as those described herein for Nucleic Acids. In someembodiments, the caTCR plus CSR immune cells (such as caTCR plus CSR Tcells) of the invention are able to replicate in vivo, resulting inlong-term persistence that can lead to sustained control of a diseaseassociated with expression of the target antigen (such as cancer orviral infection).

In some embodiments, the invention relates to administering agenetically modified T cell expressing a caTCR that specifically bindsto a target antigen according to any of the caTCRs described herein anda CSR that specifically binds to a target ligand according to any of theCSRs described herein for the treatment of a patient having or at riskof developing a disease and/or disorder associated with expression ofthe target antigen (also referred to herein as a “targetantigen-positive” or “TA-positive” disease or disorder), including, forexample, cancer or viral infection, using lymphocyte infusion. In someembodiments, autologous lymphocyte infusion is used in the treatment.Autologous PBMCs are collected from a patient in need of treatment and Tcells are activated and expanded using the methods described herein andknown in the art and then infused back into the patient.

In some embodiments, there is provided a T cell expressing a caTCR thatspecifically binds to a target antigen according to any of the caTCRsdescribed herein and a CSR that specifically binds to a target ligandaccording to any of the CSRs described herein (also referred to hereinas an “caTCR plus CSR T cell”). The caTCR plus CSR T cells of theinvention can undergo robust in vivo T cell expansion and can establishtarget antigen-specific memory cells that persist at high levels for anextended amount of time in blood and bone marrow. In some embodiments,the caTCR plus CSR T cells of the invention infused into a patient caneliminate target antigen-presenting cells, such as targetantigen-presenting cancer or virally-infected cells, in vivo in patientshaving a target antigen-associated disease. In some embodiments, thecaTCR plus CSR T cells of the invention infused into a patient caneliminate target antigen-presenting cells, such as targetantigen-presenting cancer or virally-infected cells, in vivo in patientshaving a target antigen-associated disease that is refractory to atleast one conventional treatment.

Prior to expansion and genetic modification of the T cells, a source ofT cells is obtained from a subject. T cells can be obtained from anumber of sources, including peripheral blood mononuclear cells, bonemarrow, lymph node tissue, cord blood, thymus tissue, tissue from a siteof infection, ascites, pleural effusion, spleen tissue, and tumors. Insome embodiments of the present invention, any number of T cell linesavailable in the art may be used. In some embodiments of the presentinvention, T cells can be obtained from a unit of blood collected from asubject using any number of techniques known to the skilled artisan,such as FICOLL™ separation. In some embodiments, cells from thecirculating blood of an individual are obtained by apheresis. Theapheresis product typically contains lymphocytes, including T cells,monocytes, granulocytes, B cells, other nucleated white blood cells, redblood cells, and platelets. In some embodiments, the cells collected byapheresis may be washed to remove the plasma fraction and to place thecells in an appropriate buffer or media for subsequent processing steps.In some embodiments, the cells are washed with phosphate buffered saline(PBS). In some embodiments, the wash solution lacks calcium and may lackmagnesium or may lack many if not all divalent cations. As those ofordinary skill in the art would readily appreciate a washing step may beaccomplished by methods known to those in the art, such as by using asemi-automated “flow-through” centrifuge (for example, the Cobe 2991cell processor, the Baxter CytoMate, or the Haemonetics Cell Saver 5)according to the manufacturer's instructions. After washing, the cellsmay be resuspended in a variety of biocompatible buffers, such asCa²⁺-free, Mg²⁺-free PBS, PlasmaLyte A, or other saline solutions withor without buffer. Alternatively, the undesirable components of theapheresis sample may be removed and the cells directly resuspended inculture media.

In some embodiments, T cells are isolated from peripheral bloodlymphocytes by lysing the red blood cells and depleting the monocytes,for example, by centrifugation through a PERCOLL™ gradient or bycounterflow centrifugal elutriation. A specific subpopulation of Tcells, such as CD3⁺, CD28⁺, CD4⁺, CD8⁺, CD45RA⁺, and CD45RO⁺ T cells,can be further isolated by positive or negative selection techniques.For example, in some embodiments, T cells are isolated by incubationwith anti-CD3/anti-CD28 (i.e., 3×28)-conjugated beads, such asDYNABEADS® M-450 CD3/CD28 T, for a time period sufficient for positiveselection of the desired T cells. In some embodiments, the time periodis about 30 minutes. In some embodiments, the time period ranges from 30minutes to 36 hours or longer (including all ranges between thesevalues). In some embodiments, the time period is at least one, 2, 3, 4,5, or 6 hours. In some embodiments, the time period is 10 to 24 hours.In some embodiments, the incubation time period is 24 hours. Forisolation of T cells from patients with leukemia, use of longerincubation times, such as 24 hours, can increase cell yield. Longerincubation times may be used to isolate T cells in any situation wherethere are few T cells as compared to other cell types, such as inisolating tumor infiltrating lymphocytes (TIL) from tumor tissue or fromimmune-compromised individuals. Further, use of longer incubation timescan increase the efficiency of capture of CD8⁺ T cells. Thus, by simplyshortening or lengthening the time T cells are allowed to bind to theCD3/CD28 beads and/or by increasing or decreasing the ratio of beads toT cells, subpopulations of T cells can be preferentially selected for oragainst at culture initiation or at other time points during theprocess. Additionally, by increasing or decreasing the ratio of anti-CD3and/or anti-CD28 antibodies on the beads or other surface,subpopulations of T cells can be preferentially selected for or againstat culture initiation or at other desired time points. The skilledartisan would recognize that multiple rounds of selection can also beused in the context of this invention. In some embodiments, it may bedesirable to perform the selection procedure and use the “unselected”cells in the activation and expansion process. “Unselected” cells canalso be subjected to further rounds of selection.

Enrichment of a T cell population by negative selection can beaccomplished with a combination of antibodies directed to surfacemarkers unique to the negatively selected cells. One method is cellsorting and/or selection via negative magnetic immunoadherence or flowcytometry that uses a cocktail of monoclonal antibodies directed to cellsurface markers present on the cells negatively selected. For example,to enrich for CD4+ cells by negative selection, a monoclonal antibodycocktail typically includes antibodies to CD 14, CD20, CD11b, CD 16,HLA-DR, and CD8. In some embodiments, it may be desirable to enrich foror positively select for regulatory T cells which typically expressCD4⁺, CD25⁺, CD62Lhi, GITR⁺, and FoxP3⁺. Alternatively, in someembodiments, T regulatory cells are depleted by anti-CD25 conjugatedbeads or other similar methods of selection.

For isolation of a desired population of cells by positive or negativeselection, the concentration of cells and surface (e.g., particles suchas beads) can be varied. In some embodiments, it may be desirable tosignificantly decrease the volume in which beads and cells are mixedtogether (i.e., increase the concentration of cells), to ensure maximumcontact of cells and beads. For example, in some embodiments, aconcentration of about 2 billion cells/ml is used. In some embodiments,a concentration of about 1 billion cells/ml is used. In someembodiments, greater than about 100 million cells/ml is used. In someembodiments, a concentration of cells of about any of 10, 15, 20, 25,30, 35, 40, 45, or 50 million cells/ml is used. In some embodiments, aconcentration of cells of about any of 75, 80, 85, 90, 95, or 100million cells/ml is used. In some embodiments, a concentration of about125 or about 150 million cells/ml is used. Using high concentrations canresult in increased cell yield, cell activation, and cell expansion.Further, use of high cell concentrations allows more efficient captureof cells that may weakly express target antigens of interest, such asCD28-negative T cells, or from samples where there are many tumor cellspresent (i.e., leukemic blood, tumor tissue, etc.). Such populations ofcells may have therapeutic value and would be desirable to obtain. Forexample, using high concentration of cells allows more efficientselection of CD8⁺ T cells that normally have weaker CD28 expression.

In some embodiments of the present invention, T cells are obtained froma patient directly following treatment. In this regard, it has beenobserved that following certain cancer treatments, in particulartreatments with drugs that damage the immune system, shortly aftertreatment during the period when patients would normally be recoveringfrom the treatment, the quality of T cells obtained may be optimal orimproved for their ability to expand ex vivo. Likewise, following exvivo manipulation using the methods described herein, these cells may bein a preferred state for enhanced engraftment and in vivo expansion.Thus, it is contemplated within the context of the present invention tocollect blood cells, including T cells, dendritic cells, or other cellsof the hematopoietic lineage, during this recovery phase. Further, insome embodiments, mobilization (for example, mobilization with GM-CSF)and conditioning regimens can be used to create a condition in a subjectwherein repopulation, recirculation, regeneration, and/or expansion ofparticular cell types is favored, especially during a defined window oftime following therapy. Illustrative cell types include T cells, Bcells, dendritic cells, and other cells of the immune system.

Whether prior to or after genetic modification of the T cells to expressa desirable caTCR, CSR and optionally SSE, the T cells can be activatedand expanded generally using methods as described, for example, in U.S.Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358;6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566;7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. PatentApplication Publication No. 20060121005.

Generally, the T cells of the invention are expanded by contact with asurface having attached thereto an agent that stimulates a CD3/TCRcomplex associated signal and a ligand that stimulates a co-stimulatorymolecule on the surface of the T cells. In particular, T cellpopulations may be stimulated, such as by contact with an anti-CD3antibody, or antigen-binding fragment thereof, or an anti-CD2 antibodyimmobilized on a surface, or by contact with a protein kinase Cactivator (e.g., bryostatin) in conjunction with a calcium ionophore.For co-stimulation of an accessory molecule on the surface of the Tcells, a ligand that binds the accessory molecule is used. For example,a population of T cells can be contacted with an anti-CD3 antibody andan anti-CD28 antibody, under conditions appropriate for stimulatingproliferation of the T cells. To stimulate proliferation of either CD4⁺T cells or CD8⁺ T cells, an anti-CD3 antibody and an anti-CD28 antibody.Examples of an anti-CD28 antibody include 9.3, B-T3, XR-CD28 (Diaclone,Besançon, France) can be used as can other methods commonly known in theart (Berg et al., Transplant Proc. 30(8):3975-3977, 1998; Haanen et al.,J. Exp. Med. 190(9):13191328, 1999; Garland et al., J. Immunol. Meth.227(1-2):53-63, 1999).

Genetic Modification

In some embodiments, the caTCR plus CSR immune cells (such as caTCR plusCSR T cells) of the invention are generated by transducing immune cells(such as T cells prepared by the methods described herein) with one ormore viral vectors encoding a caTCR as described herein and a CSR asdescribed herein. Viral vector delivery systems include DNA and RNAviruses, which have either episomal or integrated genomes after deliveryto the immune cell. For a review of gene therapy procedures, seeAnderson, Science 256:808-813 (1992); Nabel & Feigner, TIBTECH11:211-217 (1993); Mitani & Caskey, TIBTECH 11:162-166 (1993); Dillon,TIBTECH 11: 167-175 (1993); Miller, Nature 357:455-460 (1992); VanBrunt, Biotechnology 6(10): 1149-1 154 (1988); Vigne, RestorativeNeurology and Neuroscience 8:35-36 (1995); Kremer & Perricaudet, BritishMedical Bulletin 51(1):31-44 (1995); and Yu et al., Gene Therapy 1:13-26(1994). In some embodiments, the caTCR plus CSR immune cell comprisesthe one or more vectors integrated into the caTCR plus CSR immune cellgenome. In some embodiments, the one or more viral vectors arelentiviral vectors. In some embodiments, the caTCR plus CSR immune cellis a caTCR plus CSR T cell comprising the lentiviral vectors integratedinto its genome.

In some embodiments, the caTCR plus CSR immune cell is a T cell modifiedto block or decrease the expression of one or both of its endogenous TCRchains. For example, in some embodiments, the caTCR plus CSR immune cellis an αβ T cell modified to block or decrease the expression of the TCRα and/or β chains, or the caTCR plus CSR immune cell is a γδ T cellmodified to block or decrease the expression of the TCR γ and/or δchains. Modifications of cells to disrupt gene expression include anysuch techniques known in the art, including for example RNA interference(e.g., siRNA, shRNA, miRNA), gene editing (e.g., CRISPR- or TALEN-basedgene knockout), and the like.

In some embodiments, caTCR plus CSR T cells with reduced expression ofone or both of the endogenous TCR chains of the T cell are generatedusing the CRISPR/Cas system. For a review of the CRISPR/Cas system ofgene editing, see for example Jian W & Marraffini L A, Annu. Rev.Microbiol. 69, 2015; Hsu P D et al., Cell, 157(6):1262-1278, 2014; andO'Connell M R et al., Nature Volume: 516: Pages: 263-266, 2014. In someembodiments, caTCR plus CSR T cells with reduced expression of one orboth of the endogenous TCR chains of the T cell are generated usingTALEN-based genome editing.

Enrichment

In some embodiments, there is provided a method of enriching aheterogeneous cell population for a caTCR plus CSR immune cell accordingto any of the caTCR plus CSR immune cells described herein.

A specific subpopulation of caTCR plus CSR immune cells (such as caTCRplus CSR T cells) that specifically bind to a target antigen and targetligand can be enriched for by positive selection techniques. Forexample, in some embodiments, caTCR plus CSR immune cells (such as caTCRplus CSR T cells) are enriched for by incubation with targetantigen-conjugated beads and/or target ligand-conjugated beads for atime period sufficient for positive selection of the desired caTCR plusCSR immune cells. In some embodiments, the time period is about 30minutes. In some embodiments, the time period ranges from 30 minutes to36 hours or longer (including all ranges between these values). In someembodiments, the time period is at least one, 2, 3, 4, 5, or 6 hours. Insome embodiments, the time period is 10 to 24 hours. In someembodiments, the incubation time period is 24 hours. For isolation ofcaTCR plus CSR immune cells present at low levels in the heterogeneouscell population, use of longer incubation times, such as 24 hours, canincrease cell yield. Longer incubation times may be used to isolatecaTCR plus CSR immune cells in any situation where there are few caTCRplus CSR immune cells as compared to other cell types. The skilledartisan would recognize that multiple rounds of selection can also beused in the context of this invention.

For isolation of a desired population of caTCR plus CSR immune cells bypositive selection, the concentration of cells and surface (e.g.,particles such as beads) can be varied. In some embodiments, it may bedesirable to significantly decrease the volume in which beads and cellsare mixed together (i.e., increase the concentration of cells), toensure maximum contact of cells and beads. For example, in someembodiments, a concentration of about 2 billion cells/ml is used. Insome embodiments, a concentration of about 1 billion cells/ml is used.In some embodiments, greater than about 100 million cells/ml is used. Insome embodiments, a concentration of cells of about any of 10, 15, 20,25, 30, 35, 40, 45, or 50 million cells/ml is used. In some embodiments,a concentration of cells of about any of 75, 80, 85, 90, 95, or 100million cells/ml is used. In some embodiments, a concentration of about125 or about 150 million cells/ml is used. Using high concentrations canresult in increased cell yield, cell activation, and cell expansion.Further, use of high cell concentrations allows more efficient captureof caTCR plus CSR immune cells that may weakly express the caTCR and/orCSR.

In some of any such embodiments described herein, enrichment results inminimal or substantially no exhaustion of the caTCR plus CSR immunecells. For example, in some embodiments, enrichment results in fewerthan about 50% (such as fewer than about any of 45, 40, 35, 30, 25, 20,15, 10, or 5%) of the caTCR plus CSR immune cells becoming exhausted.Immune cell exhaustion can be determined by any means known in the art,including any means described herein.

In some of any such embodiments described herein, enrichment results inminimal or substantially no terminal differentiation of the caTCR plusCSR immune cells. For example, in some embodiments, enrichment resultsin fewer than about 50% (such as fewer than about any of 45, 40, 35, 30,25, 20, 15, 10, or 5%) of the caTCR plus CSR immune cells becomingterminally differentiated. Immune cell differentiation can be determinedby any means known in the art, including any means described herein.

In some of any such embodiments described herein, enrichment results inminimal or substantially no internalization of caTCRs and/or CSRs on thecaTCR plus CSR immune cells. For example, in some embodiments,enrichment results in less than about 50% (such as less than about anyof 45, 40, 35, 30, 25, 20, 15, 10, or 5%) of caTCRs and/or CSRs on thecaTCR plus CSR immune cells becoming internalized. Internalization ofcaTCRs and/or CSRs on caTCR plus CSR immune cells can be determined byany means known in the art, including any means described herein.

In some of any such embodiments described herein, enrichment results inincreased proliferation of the caTCR plus CSR immune cells. For example,in some embodiments, enrichment results in an increase of at least about10% (such as at least about any of 20, 30, 40, 50, 60, 70, 80, 90, 100,200, 300, 400, 500, 1000% or more) in the number of caTCR plus CSRimmune cells following enrichment.

Thus, in some embodiments, there is provided a method of enriching aheterogeneous cell population for caTCR plus CSR immune cells expressinga caTCR that specifically binds to a target antigen and a CSR thatspecifically binds to a target ligand comprising: a) contacting theheterogeneous cell population with a first molecule comprising thetarget antigen or one or more epitopes contained therein and/or a secondmolecule comprising the target ligand or one or more epitopes containedtherein to form complexes comprising the caTCR plus CSR immune cellbound to the first molecule and/or complexes comprising the caTCR plusCSR immune cell bound to the second molecule; and b) separating thecomplexes from the heterogeneous cell population, thereby generating acell population enriched for the caTCR plus CSR immune cells. In someembodiments, the first and/or second molecules are immobilized,individually, to a solid support. In some embodiments, the solid supportis particulate (such as beads). In some embodiments, the solid supportis a surface (such as the bottom of a well). In some embodiments, thefirst and/or second molecules are labelled, individually, with a tag. Insome embodiments, the tag is a fluorescent molecule, an affinity tag, ora magnetic tag. In some embodiments, the method further compriseseluting the caTCR plus CSR immune cells from the first and/or secondmolecules and recovering the eluate.

Library Screening

In some embodiments, to isolate candidate caTCR constructs specific fora target antigen, a caTCR library, for example cells expressing alibrary of nucleic acids encoding a plurality of caTCRs, may be exposedto a capture molecule comprising the target antigen or one or moreepitopes contained therein, followed by isolation of affinity members ofthe library that specifically bind the capture molecule. In someembodiments, the capture molecule is immobilized on a solid support. Insome embodiments, the support may be the surfaces of beads, microtitreplates, immunotubes, or any material known in the art useful for suchpurposes. In some embodiments, the interaction takes place in solutionwith a tagged capture molecule (e.g. biotinylated capture molecule). Insome embodiments, the procedure involves one or more washing steps toremove unspecific and non-reactive library members (panning). In someembodiments, to purify complexes in solution, they are collected byeither immobilization or by centrifugation. In some embodiments,affinity members are captured on a soluble biotinylated capturemolecule, followed by immobilization of the affinity complex (affinitymember and capture molecule) on streptavidin beads. In some embodiments,the solid support is a bead. In some embodiments, the beads include, forexample, magnetic beads (e.g. from Bangs Laboratories, Polysciencesinc., Dynal Biotech, Miltenyi Biotech or Quantum Magnetic), nonmagneticbeads (e.g. Pierce and Upstate technology), monodisperse beads (e.g.Dynal Biotech and Microparticle Gmbh), and polydisperse beads (e.g.Chemagen). The use of magnetic beads has been described exhaustingly inliterature (Uhlen, M, et al (1994) in Advances in BiomagneticSeparation, BioTechniques press, Westborough, Mass.). In someembodiments, the affinity members are purified by positive selection. Insome embodiments, the affinity members are purified by negativeselection to remove unwanted library members. In some embodiments, theaffinity members are purified by both positive and negative selectionsteps.

In some embodiments, to isolate candidate CSR constructs specific for atarget ligand, a CSR library, for example cells expressing a library ofnucleic acids encoding a plurality of CSRs, may be exposed to a capturemolecule comprising the target ligand or one or more epitopes containedtherein, followed by isolation of affinity members of the library thatspecifically bind the capture molecule. In some embodiments, the capturemolecule is immobilized on a solid support. In some embodiments, thesupport may be the surfaces of beads, microtitre plates, immunotubes, orany material known in the art useful for such purposes. In someembodiments, the interaction takes place in solution with a taggedcapture molecule (e.g. biotinylated capture molecule). In someembodiments, the procedure involves one or more washing steps to removeunspecific and non-reactive library members (panning). In someembodiments, to purify complexes in solution, they are collected byeither immobilization or by centrifugation. In some embodiments,affinity members are captured on a soluble biotinylated capturemolecule, followed by immobilization of the affinity complex (affinitymember and capture molecule) on streptavidin beads. In some embodiments,the solid support is a bead. In some embodiments, the beads include, forexample, magnetic beads (e.g. from Bangs Laboratories, Polysciencesinc., Dynal Biotech, Miltenyi Biotech or Quantum Magnetic), nonmagneticbeads (e.g. Pierce and Upstate technology), monodisperse beads (e.g.Dynal Biotech and Microparticle Gmbh), and polydisperse beads (e.g.Chemagen). In some embodiments, the affinity members are purified bypositive selection. In some embodiments, the affinity members arepurified by negative selection to remove unwanted library members. Insome embodiments, the affinity members are purified by both positive andnegative selection steps.

Generally, the techniques used to prepare the library constructs will bebased on known genetic engineering techniques. In this regard, nucleicacid sequences encoding the caTCRs or CSRs to be expressed in thelibrary are incorporated into expression vectors appropriate for thetype of expression system to be used. Appropriate expression vectors foruse in display in cells, such as CD3+ cells, are well known anddescribed in the art. For example, in some embodiments, the expressionvector is a viral vector, such as a lentiviral vector.

In some embodiments, there is provided a nucleic acid library comprisingsequences encoding a plurality of caTCRs according to any one of theembodiments described herein. In some embodiments, the nucleic acidlibrary comprises viral vectors encoding the plurality of caTCRs. Insome embodiments, the viral vectors are lentiviral vectors.

In some embodiments, there is provided a nucleic acid library comprisingsequences encoding a plurality of CSRs according to any one of theembodiments described herein. In some embodiments, the nucleic acidlibrary comprises viral vectors encoding the plurality of CSRs. In someembodiments, the viral vectors are lentiviral vectors.

In some embodiments, there is provided a method of screening a nucleicacid library according to any of the embodiments described herein forsequences encoding caTCRs specific for a target antigen, comprising: a)introducing the nucleic acid library into a plurality of cells, suchthat the caTCRs are expressed on the surface of the plurality of cells;b) incubating the plurality of cells with a capture molecule comprisingthe target antigen or one or more epitopes contained therein; c)collecting cells bound to the capture molecule; and d) isolatingsequences encoding the caTCRs from cells collected in step c), therebyidentifying caTCRs specific for the target antigen. In some embodiments,the method further comprises one or more wash steps. In someembodiments, the one or more wash steps are carried out between steps b)and c). In some embodiments, the plurality of cells is a plurality ofCD3+ cells. In some embodiments, the capture molecule is immobilized ona solid support. In some embodiments, the solid support is a bead. Insome embodiments, collecting cells bound to the capture moleculecomprises eluting cells from the capture ligand bound to the solidsupport and collecting the eluate. In some embodiments, the capturemolecule is labelled with a tag. In some embodiments, the tag is afluorescent molecule, an affinity tag, or a magnetic tag. In someembodiments, collecting cells bound to the capture molecule comprisesisolating complexes comprising the cells and the labelled ligand. Insome embodiments, the cells are dissociated from the complexes.

In some embodiments, there is provided a method of screening a nucleicacid library according to any of the embodiments described herein forsequences encoding CSRs specific for a target ligand, comprising: a)introducing the nucleic acid library into a plurality of cells, suchthat the CSRs are expressed on the surface of the plurality of cells; b)incubating the plurality of cells with a capture molecule comprising thetarget ligand or one or more epitopes contained therein; c) collectingcells bound to the capture molecule; and d) isolating sequences encodingthe CSRs from cells collected in step c), thereby identifying CSRsspecific for the target ligand. In some embodiments, the method furthercomprises one or more wash steps. In some embodiments, the one or morewash steps are carried out between steps b) and c). In some embodiments,the plurality of cells is a plurality of CD3+ cells. In someembodiments, the capture molecule is immobilized on a solid support. Insome embodiments, the solid support is a bead. In some embodiments,collecting cells bound to the capture molecule comprises eluting cellsfrom the capture ligand bound to the solid support and collecting theeluate. In some embodiments, the capture molecule is labelled with atag. In some embodiments, the tag is a fluorescent molecule, an affinitytag, or a magnetic tag. In some embodiments, collecting cells bound tothe capture molecule comprises isolating complexes comprising the cellsand the labelled ligand. In some embodiments, the cells are dissociatedfrom the complexes.

MHC Proteins

MHC class I proteins are one of two primary classes of majorhistocompatibility complex (MHC) molecules (the other being MHC classII) and are found on nearly every nucleated cell of the body. Theirfunction is to display fragments of proteins from within the cell to Tcells; healthy cells will be ignored, while cells containing foreign ormutated proteins will be attacked by the immune system. Because MHCclass I proteins present peptides derived from cytosolic proteins, thepathway of MHC class I presentation is often called the cytosolic orendogenous pathway. Class I MHC molecules bind peptides generated mainlyfrom degradation of cytosolic proteins by the proteasome. The MHCI:peptide complex is then inserted into the plasma membrane of the cell.The peptide is bound to the extracellular part of the class I MHCmolecule. Thus, the function of the class I MHC is to displayintracellular proteins to cytotoxic T cells (CTLs). However, class I MHCcan also present peptides generated from exogenous proteins, in aprocess known as cross-presentation.

MHC class I proteins consist of two polypeptide chains, α andβ2-microglobulin (β2M). The two chains are linked noncovalently viainteraction of β2M and the α3 domain. Only the α chain is polymorphicand encoded by a HLA gene, while the β2M subunit is not polymorphic andencoded by the β-2 microglobulin gene. The α3 domain is plasmamembrane-spanning and interacts with the CD8 co-receptor of T-cells. Theα3-CD8 interaction holds the MHC I molecule in place while the T cellreceptor (TCR) on the surface of the cytotoxic T cell binds its α1-α2heterodimer ligand, and checks the coupled peptide for antigenicity. Theα1 and α2 domains fold to make up a groove for peptides to bind. MHCclass I proteins bind peptides that are 8-10 amino acid in length.

MHC class II molecules are a family of molecules normally found only onantigen-presenting cells such as dendritic cells, mononuclearphagocytes, some endothelial cells, thymic epithelial cells, and Bcells. The antigens presented by class II peptides are derived fromextracellular proteins (not cytosolic as in class I); hence, the MHCclass II-dependent pathway of antigen presentation is called theendocytic or exogenous pathway. Loading of an MHC class II moleculeoccurs by phagocytosis; extracellular proteins are endocytosed, digestedin lysosomes, and the resulting epitopic peptide fragments are loadedonto MHC class II molecules prior to their migration to the cellsurface.

Like MHC class I molecules, class II molecules are also heterodimers,but in this case consist of two homogenous peptides, an α and β chain.The subdesignation α1, α2, etc. refers to separate domains within theHLA gene; each domain is usually encoded by a different exon within thegene, and some genes have further domains that encode leader sequences,transmembrane sequences, etc. Because the antigen-binding groove of MHCclass II molecules is open at both ends while the corresponding grooveon class I molecules is closed at each end, the antigens presented byMHC class II molecules are longer, generally between 15 and 24 aminoacid residues long.

The human leukocyte antigen (HLA) genes are the human versions of theMHC genes. The three major MHC class I proteins in humans are HLA-A,HLA-B, and HLA-C, while the 3 minor ones are HLA-E, HLA-F, and HLA-G.The three major MHC class II proteins involved in antigen presentationin humans are HLA-DP, HLDA-DQ, and HLA-DR, while the other MHC class IIproteins, HLA-DM and HLA-DO, are involved in the internal processing andloading of antigens. HLA-A is ranked among the genes in humans with thefastest-evolving coding sequence. As of December 2013, there were 2432known HLA-A alleles coding for 1740 active proteins and 117 nullproteins. The HLA-A gene is located on the short arm of chromosome 6 andencodes the larger, α-chain, constituent of HLA-A. Variation of HLA-Aα-chain is key to HLA function. This variation promotes geneticdiversity in the population. Since each HLA has a different affinity forpeptides of certain structures, greater variety of HLAs means greatervariety of antigens to be ‘presented’ on the cell surface, enhancing thelikelihood that a subset of the population will be resistant to anygiven foreign invader. This decreases the likelihood that a singlepathogen has the capability to wipe out the entire human population.Each individual can express up to two types of HLA-A, one from each oftheir parents. Some individuals will inherit the same HLA-A from bothparents, decreasing their individual HLA diversity; however, themajority of individuals will receive two different copies of HLA-A. Thissame pattern follows for all HLA groups. In other words, a person canonly express either one or two of the 2432 known HLA-A alleles.

All alleles receive at least a four digit classification, e.g.,HLA-A*02:12. The A signifies which HLA gene the allele belongs to. Thereare many HLA-A alleles, so that classification by serotype simplifiescategorization. The next pair of digits indicates this assignment. Forexample, HLA-A*02:02, HLA-A*02:04, and HLA-A*02:324 are all members ofthe A2 serotype (designated by the *02 prefix). This group is theprimary factor responsible for HLA compatibility. All numbers after thiscannot be determined by serotyping and are designated through genesequencing. The second set of digits indicates what HLA protein isproduced. These are assigned in order of discovery and as of December2013 there are 456 different HLA-A02 proteins known (assigned namesHLA-A*02:01 to HLA-A*02:456). The shortest possible HLA name includesboth of these details. Each extension beyond that signifies a nucleotidechange that may or may not change the protein.

In some embodiments, the Fab-like antigen-binding module specificallybinds to a complex comprising a peptide derived from adisease-associated antigen (such as a tumor-associated orvirally-encoded antigen) and an MHC class I protein, wherein the MHCclass I protein is HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, or HLA-G. In someembodiments, the MHC class I protein is HLA-A, HLA-B, or HLA-C. In someembodiments, the MHC class I protein is HLA-A. In some embodiments, theMHC class I protein is HLA-B. In some embodiments, the MHC class Iprotein is HLA-C. In some embodiments, the MHC class I protein isHLA-A01, HLA-A02, HLA-A03, HLA-A09, HLA-A10, HLA-A11, HLA-A19, HLA-A23,HLA-A24, HLA-A25, HLA-A26, HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-A32,HLA-A33, HLA-A34, HLA-A36, HLA-A43, HLA-A66, HLA-A68, HLA-A69, HLA-A74,or HLA-A80. In some embodiments, the MHC class I protein is HLA-A02. Insome embodiments, the MHC class I protein is any one of HLA-A*02:01-555,such as HLA-A*02:01, HLA-A*02:02, HLA-A*02:03, HLA-A*02:04, HLA-A*02:05,HLA-A*02:06, HLA-A*02:07, HLA-A*02:08, HLA-A*02:09, HLA-A*02:10,HLA-A*02:11, HLA-A*02:12, HLA-A*02:13, HLA-A*02:14, HLA-A*02:15,HLA-A*02:16, HLA-A*02:17, HLA-A*02:18, HLA-A*02:19, HLA-A*02:20,HLA-A*02:21, HLA-A*02:22, or HLA-A*02:24. In some embodiments, the MHCclass I protein is HLA-A*02:01. HLA-A*02:01 is expressed in 39-46% ofall Caucasians, and therefore represents a suitable choice of MHC classI protein for use in the present invention.

In some embodiments, the Fab-like antigen-binding module specificallybinds to a complex comprising a peptide derived from adisease-associated antigen (such as a tumor-associated orvirally-encoded antigen) and an MHC class II protein, wherein the MHCclass II protein is HLA-DP, HLA-DQ, or HLA-DR. In some embodiments, theMHC class II protein is HLA-DP. In some embodiments, the MHC class IIprotein is HLA-DQ. In some embodiments, the MHC class II protein isHLA-DR.

Peptides suitable for use in generating Fab-like antigen-binding modulescan be determined, for example, based on the presence of HLA (such asHLA-A*02:01) binding motifs and cleavage sites for proteasomes andimmune-proteasomes using computer prediction models known to those ofskill in the art. For predicting MHC binding sites, such models include,but are not limited to, ProPred1 (described in more detail in Singh andRaghava, ProPred: prediction of HLA-DR binding sites. BIOINFORMATICS17(12):1236-1237, 2001), and SYFPEITHI (see Schuler et al. SYFPEITHI,Database for Searching and T-Cell Epitope Prediction. inImmunoinformatics Methods in Molecular Biology, vol 409(1): 75-93,2007).

Once appropriate peptides have been identified, peptide synthesis may bedone in accordance with protocols well known to those of skill in theart. Because of their relatively small size, the peptides of theinvention may be directly synthesized in solution or on a solid supportin accordance with conventional peptide synthesis techniques. Variousautomatic synthesizers are commercially available and can be used inaccordance with known protocols. The synthesis of peptides in solutionphase has become a well-established procedure for large-scale productionof synthetic peptides and as such is a suitable alternative method forpreparing the peptides of the invention (See for example, Solid PhasePeptide Synthesis by John Morrow Stewart and Martin et al. Applicationof Almez-mediated Amidation Reactions to Solution Phase PeptideSynthesis, Tetrahedron Letters Vol. 39, pages 1517-1520, 1998).

Pharmaceutical Compositions

Also provided herein are caTCR plus CSR immune cell compositions (suchas pharmaceutical compositions, also referred to herein as formulations)comprising an immune cell (such as a T cell) presenting on its surface acaTCR according to any of the caTCRs described herein and a CSRaccording to any of the CSRs described herein. In some embodiments, thecaTCR plus CSR immune cell composition is a pharmaceutical composition.

The composition may comprise a homogenous cell population comprisingcaTCR plus CSR immune cells of the same cell type and expressing thesame caTCR and CSR, or a heterogeneous cell population comprising aplurality of caTCR plus CSR immune cell populations comprising caTCRplus CSR immune cells of different cell types, expressing differentcaTCRs, and/or expressing different CSRs. The composition may furthercomprise cells that are not caTCR plus CSR immune cells.

Thus, in some embodiments, there is provided a caTCR plus CSR immunecell composition comprising a homogeneous cell population of caTCR plusCSR immune cells (such as caTCR plus CSR T cells) of the same cell typeand expressing the same caTCR and CSR. In some embodiments, the caTCRplus CSR immune cell is a T cell. In some embodiments, the caTCR plusCSR immune cell is selected from the group consisting of a cytotoxic Tcell, a helper T cell, a natural killer T cell, and a suppressor T cell.In some embodiments, the caTCR plus CSR immune cell composition is apharmaceutical composition.

In some embodiments, there is provided a caTCR plus CSR immune cellcomposition comprising a heterogeneous cell population comprising aplurality of caTCR plus CSR immune cell populations comprising caTCRplus CSR immune cells of different cell types, expressing differentcaTCRs, and/or expressing different CSRs. In some embodiments, the caTCRplus CSR immune cells are T cells. In some embodiments, each populationof caTCR plus CSR immune cells is, independently from one another, of acell type selected from the group consisting of cytotoxic T cells,helper T cells, natural killer T cells, and suppressor T cells. In someembodiments, all of the caTCR plus CSR immune cells in the compositionare of the same cell type (e.g., all of the caTCR plus CSR immune cellsare cytotoxic T cells). In some embodiments, at least one population ofcaTCR plus CSR immune cells is of a different cell type than the others(e.g., one population of caTCR plus CSR immune cells consists ofcytotoxic T cells and the other populations of caTCR plus CSR immunecells consist of natural killer T cells). In some embodiments, eachpopulation of caTCR plus CSR immune cells expresses the same caTCR. Insome embodiments, at least one population of caTCR plus CSR immune cellsexpresses a different caTCR than the others. In some embodiments, eachpopulation of caTCR plus CSR immune cells expresses a different caTCRthan the others. In some embodiments, each population of caTCR plus CSRimmune cells expresses a caTCR that specifically binds to the sametarget antigen. In some embodiments, at least one population of caTCRplus CSR immune cells expresses a caTCR that specifically binds to adifferent target antigen than the others (e.g., one population of caTCRplus CSR immune cells specifically binds to a pMMC complex and the otherpopulations of caTCR plus CSR immune cells specifically bind to a cellsurface receptor). In some embodiments, where at least one population ofcaTCR plus CSR immune cells expresses a caTCR that specifically binds toa different target antigen, each population of caTCR plus CSR immunecells expresses a caTCR that specifically binds to a target antigenassociated with the same disease or disorder (e.g., each of the targetantigens are associated with a cancer, such as breast cancer). In someembodiments, each population of caTCR plus CSR immune cells expressesthe same CSR. In some embodiments, at least one population of caTCR plusCSR immune cells expresses a different CSR than the others. In someembodiments, each population of caTCR plus CSR immune cells expresses adifferent CSR than the others. In some embodiments, each population ofcaTCR plus CSR immune cells expresses a CSR that specifically binds tothe same target ligand. In some embodiments, at least one population ofcaTCR plus CSR immune cells expresses a CSR that specifically binds to adifferent target ligand than the others (e.g., one population of caTCRplus CSR immune cells specifically binds to a pMHC complex and the otherpopulations of caTCR plus CSR immune cells specifically bind to a cellsurface receptor). In some embodiments, where at least one population ofcaTCR plus CSR immune cells expresses a CSR that specifically binds to adifferent target ligand, each population of caTCR plus CSR immune cellsexpresses a CSR that specifically binds to a target ligand associatedwith the same disease or disorder (e.g., each of the target ligands areassociated with a cancer, such as breast cancer). In some embodiments,the caTCR plus CSR immune cell composition is a pharmaceuticalcomposition.

Thus, in some embodiments, there is provided a caTCR plus CSR immunecell composition comprising a plurality of caTCR plus CSR immune cellpopulations according to any of the embodiments described herein,wherein all of the caTCR plus CSR immune cells in the composition are ofthe same cell type (e.g., all of the caTCR plus CSR immune cells arecytotoxic T cells), and wherein each population of caTCR plus CSR immunecells expresses a different caTCR than the others. In some embodiments,the caTCR plus CSR immune cells are T cells. In some embodiments, thecaTCR plus CSR immune cells are selected from the group consisting ofcytotoxic T cells, helper T cells, natural killer T cells, andsuppressor T cells. In some embodiments, each population of caTCR plusCSR immune cells expresses a caTCR that specifically binds to the sametarget antigen. In some embodiments, at least one population of caTCRplus CSR immune cells expresses a caTCR that specifically binds to adifferent target antigen than the others (e.g., one population of caTCRplus CSR immune cells specifically binds to a pMHC complex and the otherpopulations of caTCR plus CSR immune cells specifically bind to a cellsurface receptor). In some embodiments, where at least one population ofcaTCR plus CSR immune cells expresses a caTCR that specifically binds toa different target antigen, each population of caTCR plus CSR immunecells expresses a caTCR that specifically binds to a target antigenassociated with the same disease or disorder (e.g., each of the targetantigens are associated with a cancer, such as breast cancer). In someembodiments, the caTCR plus CSR immune cell composition is apharmaceutical composition.

In some embodiments, there is provided a caTCR plus CSR immune cellcomposition comprising a plurality of caTCR plus CSR immune cellpopulations according to any of the embodiments described herein,wherein all of the caTCR plus CSR immune cells in the composition are ofthe same cell type (e.g., all of the caTCR plus CSR immune cells arecytotoxic T cells), and wherein each population of caTCR plus CSR immunecells expresses a different CSR than the others. In some embodiments,the caTCR plus CSR immune cells are T cells. In some embodiments, thecaTCR plus CSR immune cells are selected from the group consisting ofcytotoxic T cells, helper T cells, natural killer T cells, andsuppressor T cells. In some embodiments, each population of caTCR plusCSR immune cells expresses a CSR that specifically binds to the sametarget ligand. In some embodiments, at least one population of caTCRplus CSR immune cells expresses a CSR that specifically binds to adifferent target ligand than the others (e.g., one population of caTCRplus CSR immune cells specifically binds to a pMHC complex and the otherpopulations of caTCR plus CSR immune cells specifically bind to a cellsurface receptor). In some embodiments, where at least one population ofcaTCR plus CSR immune cells expresses a CSR that specifically binds to adifferent target ligand, each population of caTCR plus CSR immune cellsexpresses a CSR that specifically binds to a target ligand associatedwith the same disease or disorder (e.g., each of the target ligands areassociated with a cancer, such as breast cancer). In some embodiments,the caTCR plus CSR immune cell composition is a pharmaceuticalcomposition.

In some embodiments, there is provided a composition comprising aplurality of caTCR plus CSR immune cell populations according to any ofthe embodiments described herein, wherein at least one population ofcaTCR plus CSR immune cells is of a different cell type than the others.In some embodiments, all of the populations of caTCR plus CSR immunecells are of different cell types. In some embodiments, the caTCR plusCSR immune cells are T cells. In some embodiments, each population ofcaTCR plus CSR immune cells is, independently from one another, of acell type selected from the group consisting of cytotoxic T cells,helper T cells, natural killer T cells, and suppressor T cells. In someembodiments, each population of caTCR plus CSR immune cells expressesthe same caTCR. In some embodiments, at least one population of caTCRplus CSR immune cells expresses a different caTCR than the others. Insome embodiments, each population of caTCR plus CSR immune cellsexpresses a different caTCR than the others. In some embodiments, eachpopulation of caTCR plus CSR immune cells expresses a caTCR thatspecifically binds to the same target antigen. In some embodiments, atleast one population of caTCR plus CSR immune cells expresses a caTCRthat specifically binds to a different target antigen than the others(e.g., one population of caTCR plus CSR immune cells specifically bindsto a pMHC complex and the other populations of caTCR plus CSR immunecells specifically bind to a cell surface receptor). In someembodiments, where at least one population of caTCR plus CSR immunecells expresses a caTCR that specifically binds to a different targetantigen, each population of caTCR plus CSR immune cells expresses acaTCR that specifically binds to a target antigen associated with thesame disease or disorder (e.g., each of the target antigens areassociated with a cancer, such as breast cancer). In some embodiments,each population of caTCR plus CSR immune cells expresses the same CSR.In some embodiments, at least one population of caTCR plus CSR immunecells expresses a different CSR than the others. In some embodiments,each population of caTCR plus CSR immune cells expresses a different CSRthan the others. In some embodiments, each population of caTCR plus CSRimmune cells expresses a CSR that specifically binds to the same targetligand. In some embodiments, at least one population of caTCR plus CSRimmune cells expresses a CSR that specifically binds to a differenttarget ligand than the others (e.g., one population of caTCR plus CSRimmune cells specifically binds to a pMHC complex and the otherpopulations of caTCR plus CSR immune cells specifically bind to a cellsurface receptor). In some embodiments, where at least one population ofcaTCR plus CSR immune cells expresses a CSR that specifically binds to adifferent target ligand, each population of caTCR plus CSR immune cellsexpresses a CSR that specifically binds to a target ligand associatedwith the same disease or disorder (e.g., each of the target ligands areassociated with a cancer, such as breast cancer). In some embodiments,the caTCR plus CSR immune cell composition is a pharmaceuticalcomposition.

At various points during preparation of a composition, it can benecessary or beneficial to cryopreserve a cell. The terms“frozen/freezing” and “cryopreserved/cryopreserving” can be usedinterchangeably. Freezing includes freeze drying.

As is understood by one of ordinary skill in the art, the freezing ofcells can be destructive (see Mazur, P., 1977, Cryobiology 14:251-272)but there are numerous procedures available to prevent such damage. Forexample, damage can be avoided by (a) use of a cryoprotective agent, (b)control of the freezing rate, and/or (c) storage at a temperaturesufficiently low to minimize degradative reactions. Exemplarycryoprotective agents include dimethyl sulfoxide (DMSO) (Lovelock andBishop, 1959, Nature 183:1394-1395; Ashwood-Smith, 1961, Nature190:1204-1205), glycerol, polyvinylpyrrolidine (Rinfret, 1960, Ann. N.Y.Acad. Sci. 85:576), polyethylene glycol (Sloviter and Ravdin, 1962,Nature 196:548), albumin, dextran, sucrose, ethylene glycol,i-erythritol, D-ribitol, D-mannitol (Rowe et al., 1962, Fed. Proc.21:157), D-sorbitol, i-inositol, D-lactose, choline chloride (Bender etal., 1960, J. Appl. Physiol. 15:520), amino acids (Phan The Tran andBender, 1960, Exp. Cell Res. 20:651), methanol, acetamide, glycerolmonoacetate (Lovelock, 1954, Biochem. J. 56:265), and inorganic salts(Phan The Tran and Bender, 1960, Proc. Soc. Exp. Biol. Med. 104:388;Phan The Tran and Bender, 1961, in Radiobiology, Proceedings of theThird Australian Conference on Radiobiology, Ilbery ed., Butterworth,London, p. 59). In particular embodiments, DMSO can be used. Addition ofplasma (e.g., to a concentration of 20-25%) can augment the protectiveeffects of DMSO. After addition of DMSO, cells can be kept at 0° C.until freezing, because DMSO concentrations of 1% can be toxic attemperatures above 4° C.

In the cryopreservation of cells, slow controlled cooling rates can becritical and different cryoprotective agents (Rapatz et al., 1968,Cryobiology 5(1): 18-25) and different cell types have different optimalcooling rates (see e.g., Rowe and Rinfret, 1962, Blood 20:636; Rowe,1966, Cryobiology 3(1):12-18; Lewis, et al., 1967, Transfusion7(1):17-32; and Mazur, 1970, Science 168:939-949 for effects of coolingvelocity on survival of stem cells and on their transplantationpotential). The heat of fusion phase where water turns to ice should beminimal. The cooling procedure can be carried out by use of, e.g., aprogrammable freezing device or a methanol bath procedure. Programmablefreezing apparatuses allow determination of optimal cooling rates andfacilitate standard reproducible cooling.

In particular embodiments, DMSO-treated cells can be pre-cooled on iceand transferred to a tray containing chilled methanol which is placed,in turn, in a mechanical refrigerator (e.g., Harris or Revco) at −80° C.Thermocouple measurements of the methanol bath and the samples indicatea cooling rate of 1° to 3° C./minute can be preferred. After at leasttwo hours, the specimens can have reached a temperature of −80° C. andcan be placed directly into liquid nitrogen (−196° C.).

After thorough freezing, the cells can be rapidly transferred to along-term cryogenic storage vessel. In a preferred embodiment, samplescan be cryogenically stored in liquid nitrogen (−196° C.) or vapor (−1°C.). Such storage is facilitated by the availability of highly efficientliquid nitrogen refrigerators.

Further considerations and procedures for the manipulation,cryopreservation, and long-term storage of cells, can be found in thefollowing exemplary references: U.S. Pat. Nos. 4,199,022; 3,753,357; and4,559,298; Gorin, 1986, Clinics In Haematology 15(1):19-48; Bone-MarrowConservation, Culture and Transplantation, Proceedings of a Panel,Moscow, Jul. 22-26, 1968, International Atomic Energy Agency, Vienna,pp. 107-186; Livesey and Linner, 1987, Nature 327:255; Linner et al.,1986, J. Histochem. Cytochem. 34(9):1 123-1 135; Simione, 1992, J.Parenter. Sci. Technol. 46(6):226-32).

Following cryopreservation, frozen cells can be thawed for use inaccordance with methods known to those of ordinary skill in the art.Frozen cells are preferably thawed quickly and chilled immediately uponthawing. In particular embodiments, the vial containing the frozen cellscan be immersed up to its neck in a warm water bath; gentle rotationwill ensure mixing of the cell suspension as it thaws and increase heattransfer from the warm water to the internal ice mass. As soon as theice has completely melted, the vial can be immediately placed on ice.

In particular embodiments, methods can be used to prevent cellularclumping during thawing. Exemplary methods include: the addition beforeand/or after freezing of DNase (Spitzer et al., 1980, Cancer45:3075-3085), low molecular weight dextran and citrate, hydroxyethylstarch (Stiff et al., 1983, Cryobiology 20:17-24), etc. [0162] As isunderstood by one of ordinary skill in the art, if a cryoprotectiveagent that is toxic to humans is used, it should be removed prior totherapeutic use. DMSO has no serious toxicity.

Exemplary carriers and modes of administration of cells are described atpages 14-15 of U.S. Patent Publication No. 2010/0183564. Additionalpharmaceutical carriers are described in Remington: The Science andPractice of Pharmacy, 21 st Edition, David B. Troy, ed., LippicottWilliams & Wilkins (2005).

In particular embodiments, cells can be harvested from a culture medium,and washed and concentrated into a carrier in atherapeutically-effective amount. Exemplary carriers include saline,buffered saline, physiological saline, water, Hanks' solution, Ringer'ssolution, Nonnosol-R (Abbott Labs), Plasma-Lyte A(R) (BaxterLaboratories, Inc., Morton Grove, Ill.), glycerol, ethanol, andcombinations thereof.

In particular embodiments, carriers can be supplemented with human serumalbumin (HSA) or other human serum components or fetal bovine serum. Inparticular embodiments, a carrier for infusion includes buffered salinewith 5% HAS or dextrose. Additional isotonic agents include polyhydricsugar alcohols including trihydric or higher sugar alcohols, such asglycerin, erythritol, arabitol, xylitol, sorbitol, or mannitol.

Carriers can include buffering agents, such as citrate buffers,succinate buffers, tartrate buffers, fumarate buffers, gluconatebuffers, oxalate buffers, lactate buffers, acetate buffers, phosphatebuffers, histidine buffers, and/or trimethylamine salts.

Stabilizers refer to a broad category of excipients which can range infunction from a bulking agent to an additive which helps to prevent celladherence to container walls. Typical stabilizers can include polyhydricsugar alcohols; amino acids, such as arginine, lysine, glycine,glutamine, asparagine, histidine, alanine, ornithine, L-leucine,2-phenylalanine, glutamic acid, and threonine; organic sugars or sugaralcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol,xylitol, ribitol, myoinisitol, galactitol, glycerol, and cyclitols, suchas inositol; PEG; amino acid polymers; sulfur-containing reducingagents, such as urea, glutathione, thioctic acid, sodium thioglycolate,thioglycerol, alpha-monothioglycerol, and sodium thiosulfate; lowmolecular weight polypeptides (i.e., <10 residues); proteins such asHSA, bovine serum albumin, gelatin or immunoglobulins; hydrophilicpolymers such as polyvinylpyrrolidone; monosaccharides such as xylose,mannose, fructose and glucose; disaccharides such as lactose, maltoseand sucrose; trisaccharides such as raffinose, and polysaccharides suchas dextran.

Where necessary or beneficial, compositions can include a localanesthetic such as lidocaine to ease pain at a site of injection.

Exemplary preservatives include phenol, benzyl alcohol, meta-cresol,methyl paraben, propyl paraben, octadecyldimethylbenzyl ammoniumchloride, benzalkonium halides, hexamethonium chloride, alkyl parabenssuch as methyl or propyl paraben, catechol, resorcinol, cyclohexanol,and 3-pentanol.

Therapeutically effective amounts of cells within compositions can begreater than 10² cells, greater than 10³ cells, greater than 10⁴ cells,greater than 10⁵ cells, greater than 10⁶ cells, greater than 10⁷ cells,greater than 10⁸ cells, greater than 10⁹ cells, greater than 10¹⁰ cells,or greater than 10¹¹ cells.

In compositions and formulations disclosed herein, cells are generallyin a volume of a liter or less, 500 ml or less, 250 ml or less or 100 mlor less. Hence the density of administered cells is typically greaterthan 10⁴ cells/ml, 10⁷ cells/ml or 10⁸ cells/ml.

Also provided herein are nucleic acid compositions (such aspharmaceutical compositions, also referred to herein as formulations)comprising any of the nucleic acids encoding a caTCR and/or CSR and/orSSE described herein. In some embodiments, the nucleic acid compositionis a pharmaceutical composition. In some embodiments, the nucleic acidcomposition further comprises any of an isotonizing agent, an excipient,a diluent, a thickener, a stabilizer, a buffer, and/or a preservative;and/or an aqueous vehicle, such as purified water, an aqueous sugarsolution, a buffer solution, physiological saline, an aqueous polymersolution, or RNase free water. The amounts of such additives and aqueousvehicles to be added can be suitably selected according to the form ofuse of the nucleic acid composition.

The compositions and formulations disclosed herein can be prepared foradministration by, for example, injection, infusion, perfusion, orlavage. The compositions and formulations can further be formulated forbone marrow, intravenous, intradermal, intraarterial, intranodal,intralymphatic, intraperitoneal, intralesional, intraprostatic,intravaginal, intrarectal, topical, intrathecal, intratumoral,intramuscular, intravesicular, and/or subcutaneous injection.

The formulations to be used for in vivo administration must be sterile.This is readily accomplished by, e.g., filtration through sterilefiltration membranes.

Methods of Treatment Using caTCR Plus CSR Immune Cells

The caTCR plus CSR immune cells of the invention can be administered toindividuals (e.g., mammals such as humans) to treat a disease and/ordisorder associated with target antigen (TA) expression (also referredto herein as a “target-antigen positive” or “TA-positive” disease ordisorder), including, for example, cancer and infectious disease (suchas viral infection). The present application thus in some embodimentsprovides a method for treating a target antigen-positive disease (suchas cancer or viral infection) in an individual comprising administeringto the individual an effective amount of a composition (such as apharmaceutical composition) comprising caTCR plus CSR immune cellsaccording to any one of the embodiments described herein. In someembodiments, the cancer is selected, for example, from the groupconsisting of adrenocortical carcinoma, bladder cancer, breast cancer,cervical cancer, cholangiocarcinoma, colorectal cancers, esophagealcancer, glioblastoma, glioma, hepatocellular carcinoma, head and neckcancer, kidney cancer, leukemia, lung cancer, lymphoma, melanoma,mesothelioma, multiple myeloma, pancreatic cancer, pheochromocytoma,plasmacytoma, neuroblastoma, ovarian cancer, prostate cancer, sarcoma,stomach cancer, uterine cancer and thyroid cancer. In some embodiments,the viral infection is caused by a virus selected, for example, from thegroup consisting of Cytomegalovirus (CMV), Epstein-Barr Virus (EBV),Hepatitis B Virus (HBV), Kaposi's Sarcoma associated herpesvirus (KSHV),Human papillomavirus (HPV), Molluscum contagiosum virus (MCV), Human Tcell leukemia virus 1 (HTLV-1), HIV (Human immunodeficiency virus), andHepatitis C Virus (HCV).

For example, in some embodiments, there is provided a method of treatinga target antigen-associated disease (such as cancer or viral infection)in an individual in need thereof comprising administering to theindividual an effective amount of a composition comprising immune cells(such as T cells or natural killer cells) presenting on their surface a)a caTCR comprising i) a first TCRD comprising a first TCR-TM derivedfrom one of the transmembrane domains of a TCR and a second TCRDcomprising a second TCR-TM derived from the other transmembrane domainof the TCR, wherein the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule,and ii) an antigen-binding module that specifically binds to the targetantigen, wherein the antigen-binding module is linked to the firstand/or second TCRDs; and b) a chimeric signaling receptor (CSR)comprising i) a ligand-binding domain that specifically binds to atarget ligand, ii) a transmembrane domain, and iii) an intracellularsignaling domain that is capable of providing a co-stimulatory signal tothe immune cell. In some embodiments, both of the TCR-TMs are naturallyoccurring. In some embodiments, at least one of the TCR-TMs isnon-naturally occurring. In some embodiments, the TCR is an αβ TCR andthe first and second TCR-TMs are derived from TCR α and β subunittransmembrane domains. In some embodiments, the TCR is a γδ TCR and thefirst and second TCR-TMs are derived from TCR γ and δ subunittransmembrane domains. In some embodiments, the first TCRD furthercomprises a first TCR connecting peptide or a fragment thereof and/orthe second TCRD further comprises a second TCR connecting peptide or afragment thereof. In some embodiments, the first connecting peptidecomprises all or a portion of the connecting peptide of the TCR subunitfrom which the first TCR-TM is derived, or a variant thereof, and/or thesecond connecting peptide comprises all or a portion of the connectingpeptide of the TCR subunit from which the second TCR-TM is derived, or avariant thereof. In some embodiments, the first and second connectingpeptides are linked by a disulfide bond. In some embodiments, the firstTCRD further comprises a first TCR intracellular domain and/or thesecond TCRD further comprises a second TCR intracellular domain. In someembodiments, the first TCR intracellular domain comprises a sequencefrom the intracellular domain of the TCR subunit from which the firstTCR-TM is derived and/or the second TCR intracellular domain comprises asequence from the intracellular domain of the TCR subunit from which thesecond TCR-TM is derived. In some embodiments, the first TCRD is afragment of the TCR subunit from which the first TCR-TM is derivedand/or the second TCRD is a fragment of the TCR subunit from which thesecond TCR-TM is derived. In some embodiments, the caTCR furthercomprises at least one accessory intracellular domain comprising a Tcell co-stimulatory signaling sequence (such as from CD27, CD28, 4-1BB(CD137), OX40, CD30, or CD40). In some embodiments, the caTCR furthercomprises a stabilization module comprising a first stabilization domainand a second stabilization domain, wherein the first and secondstabilization domains have a binding affinity for each other thatstabilizes the caTCR. In some embodiments, the first and secondstabilization domains are linked by a disulfide bond. In someembodiments, the first and second stabilization domains compriseantibody domains, such as C_(H)1 and C_(L) antibody domains, or variantsthereof. In some embodiments, the TCRM is capable of recruiting at leastone TCR-associated signaling molecule selected from the group consistingof CD3δε, CD3γε, and ζζ. In some embodiments, the TCRM allows forenhanced recruitment of the at least one TCR-associated signalingmolecule as compared to a TCRM comprising the T cell receptortransmembrane domains. In some embodiments, the TCRM promotes caTCR-CD3complex formation. In some embodiments, there is a spacer module betweenany two caTCR modules or domains. In some embodiments, theantigen-binding module is an antibody moiety. In some embodiments, theantibody moiety is a Fab, a Fab′, a (Fab′)2, an Fv, or a single chain Fv(scFv). In some embodiments, the antigen-binding module is multispecific(e.g., bispecific). In some embodiments, the target antigen is a cellsurface antigen. In some embodiments, the cell surface antigen isselected from the group consisting of a protein, a carbohydrate, and alipid. In some embodiments, the cell surface antigen is adisease-associated antigen, such as a tumor-associated orvirally-encoded antigen. In some embodiments, the cell surface antigenis CD19, ROR1, ROR2, BCMA, GPRC5D, or FCRL5. In some embodiments, thetarget antigen is a surface-presented peptide/MHC complex. In someembodiments, the peptide/MHC complex comprises a peptide derived from adisease-associated antigen (such as a tumor-associated orvirally-encoded antigen) and an MHC protein. In some embodiments, thepeptide/MHC complex comprises a peptide and an MHC protein, wherein thepeptide is derived from a protein selected from the group consisting ofWT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, and PSA. In someembodiments, the MHC protein is an MHC class I protein. In someembodiments, the MHC class I protein is HLA-A. In some embodiments, theHLA-A is HLA-A02. In some embodiments, the HLA-A02 is HLA-A*02:01. Insome embodiments, the target ligand of the CSR is a cell surfaceantigen. In some embodiments, the target ligand is a peptide/MHCcomplex. In some embodiments, the target ligand of the CSR and thetarget antigen of the caTCR are the same. In some embodiments, thetarget ligand and the target antigen are different. In some embodiments,the target ligand is a disease-associated ligand. In some embodiments,the target ligand is a cancer-associated ligand. In some embodiments,the cancer-associated ligand is, for example, CD19, CD20, CD22, CD47,IL4, GPC-3, ROR1, ROR2, BCMA, GPRC5D, or FCRL5. In some embodiments, thecancer-associated ligand is a peptide/MHC complex comprising a peptidederived from a protein including WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME,EBV-LMP2A, and PSA. In some embodiments, the target ligand is avirus-associated ligand. In some embodiments, the target ligand is animmune checkpoint molecule. In some embodiments, the immune checkpointmolecule includes PD-L1, PD-L2, CD80, CD86, ICOSL, B7-H3, B7-H4, HVEM,4-1BBL, OX40L, CD70, CD40, and GAL9. In some embodiments, the targetligand is an apoptotic molecule. In some embodiments, the apoptoticmolecule includes FasL, FasR, TNFR1, and TNFR2. In some embodiments, theligand-binding domain is an antibody moiety. In some embodiments, theligand-binding domain antibody moiety is a Fab, a Fab′, a (Fab′)2, anFv, or a single chain Fv (scFv). In some embodiments, the ligand-bindingdomain is (or is derived from) all or a portion of the extracellulardomain of a receptor for the target ligand. In some embodiments, thereceptor includes, for example, FasR, TNFR1, TNFR2, PD-1, CD28, CTLA-4,ICOS, BTLA, KIR, LAG-3, 4-1BB, OX40, CD27, and TIM-3. In someembodiments, the transmembrane domain of the CSR comprises atransmembrane domain derived from, for example, CD28, CD3ε, CD3ζ, CD45,CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134,CD137, or CD154. In some embodiments, the co-stimulatory signalingdomain of the CSR comprises, consists essentially of, or consists of allor a portion of the intracellular domain of an immune cellco-stimulatory molecule including, for example, CD27, CD28, 4-1BB(CD137), OX40, CD30, CD40, ICOS, lymphocyte function-associatedantigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand thatspecifically binds with CD83, and the like. In some embodiments, the CSRfurther comprises a spacer domain between any of the ligand-bindingdomain, the transmembrane domain, and the co-stimulatory signalingdomain. In some embodiments, the spacer domain comprises a peptidelinker connecting two CSR domains. In some embodiments, the immune cellis a γδ T cell. In some embodiments, the immune cell is an αβ T cellmodified to block or decrease the expression of the TCR α and/or βchains. In some embodiments, the immune cell is selected from the groupconsisting of a cytotoxic T cell, a helper T cell, a natural killer Tcell, and a suppressor T cell.

In some embodiments, there is provided a method of treating a targetantigen-associated disease (such as cancer or viral infection) in anindividual in need thereof comprising administering to the individual aneffective amount of a composition comprising immune cells (such as Tcells or natural killer cells) presenting on their surface a) a caTCRthat specifically binds the target antigen comprising i) a first TCRDcomprising a first TCR-TM derived from one of the transmembrane domainsof a naturally occurring αβ TCR and a second TCRD comprising a secondTCR-TM derived from the other transmembrane domain of the naturallyoccurring a TCR, wherein the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule,and ii) an antigen-binding module that specifically binds to the targetantigen, wherein the antigen-binding module is linked to the firstand/or second TCRDs; and b) a chimeric signaling receptor (CSR)comprising i) a ligand-binding domain that specifically binds to atarget ligand, ii) a transmembrane domain, and iii) an intracellularsignaling domain that is capable of providing a co-stimulatory signal tothe immune cell.

In some embodiments, there is provided a method of treating a targetantigen-associated disease (such as cancer or viral infection) in anindividual in need thereof comprising administering to the individual aneffective amount of a composition comprising immune cells (such as Tcells or natural killer cells) presenting on their surface a) a caTCRthat specifically binds the target antigen comprising i) a first TCRDcomprising a first TCR-TM derived from one of the transmembrane domainsof a naturally occurring γδ TCR and a second TCRD comprising a secondTCR-TM derived from the other transmembrane domain of the naturallyoccurring γδ TCR, wherein the first and second TCRDs form a TCRM that iscapable of recruiting at least one TCR-associated signaling molecule,and ii) an antigen-binding module that specifically binds to the targetantigen, wherein the antigen-binding module is linked to the firstand/or second TCRDs; and b) a chimeric signaling receptor (CSR)comprising i) a ligand-binding domain that specifically binds to atarget ligand, ii) a transmembrane domain, and iii) an intracellularsignaling domain that is capable of providing a co-stimulatory signal tothe immune cell.

In some embodiments, there is provided a method of treating a targetantigen-associated disease (such as cancer or viral infection) in anindividual in need thereof comprising administering to the individual aneffective amount of a composition comprising immune cells (such as Tcells or natural killer cells) presenting on their surface a) a caTCRthat specifically binds the target antigen comprising i) a first TCRDcomprising a first TCR-TM derived from the amino acid sequence of SEQ IDNO: 5 and a second TCRD comprising a second TCR-TM derived from theamino acid sequence of SEQ ID NO: 6, wherein the first and second TCRDsform a TCRM that is capable of recruiting at least one TCR-associatedsignaling molecule; and b) an antigen-binding module that specificallybinds to the target antigen, wherein the antigen-binding module islinked to the first and/or second TCRDs; and b) a chimeric signalingreceptor (CSR) comprising i) a ligand-binding domain that specificallybinds to a target ligand, ii) a transmembrane domain, and iii) anintracellular signaling domain that is capable of providing aco-stimulatory signal to the immune cell. In some embodiments, at leastone of the TCR-TMs comprises one or more (such as 2, 3, 4, 5, or more)amino acid substitutions compared to the amino acid sequence from whichit is derived. In some embodiments, each of the TCR-TMs comprises,independently from one another, one or more (such as 2, 3, 4, 5, ormore) amino acid substitutions compared to the amino acid sequence fromwhich it is derived. In some embodiments, the first TCR-TM and/or thesecond TCR-TM each comprise, independently from one another, no morethan 5 amino acid substitutions compared to the amino acid sequencesfrom which they are derived. In some embodiments, at least one of theTCR-TMs comprises a single amino acid substitution compared to the aminoacid sequence from which it is derived. In some embodiments, each of theTCR-TMs comprises a single amino acid substitution compared to the aminoacid sequence from which it is derived. In some embodiments, at leastone of the substituted amino acids in the first TCR-TM is positionedsuch that in the caTCR it can interact with at least one of thesubstituted amino acids in the second TCR-TM.

In some embodiments, there is provided a method of treating a targetantigen-associated disease (such as cancer or viral infection) in anindividual in need thereof comprising administering to the individual aneffective amount of a composition comprising immune cells (such as Tcells or natural killer cells) presenting on their surface a) a caTCRthat specifically binds the target antigen comprising i) a first TCRDcomprising a first TCR-TM derived from the amino acid sequence of SEQ IDNO: 7 and a second TCRD comprising a second TCR-TM derived from theamino acid sequence of SEQ ID NO: 8, wherein the first and second TCRDsform a TCRM that is capable of recruiting at least one TCR-associatedsignaling molecule; and b) an antigen-binding module that specificallybinds to the target antigen, wherein the antigen-binding module islinked to the first and/or second TCRDs; and b) a chimeric signalingreceptor (CSR) comprising i) a ligand-binding domain that specificallybinds to a target ligand, ii) a transmembrane domain, and iii) anintracellular signaling domain that is capable of providing aco-stimulatory signal to the immune cell. In some embodiments, at leastone of the TCR-TMs comprises one or more (such as 2, 3, 4, 5, or more)amino acid substitutions compared to the amino acid sequence from whichit is derived. In some embodiments, each of the TCR-TMs comprises,independently from one another, one or more (such as 2, 3, 4, 5, ormore) amino acid substitutions compared to the amino acid sequence fromwhich it is derived. In some embodiments, the first TCR-TM and/or thesecond TCR-TM each comprise, independently from one another, no morethan 5 amino acid substitutions compared to the amino acid sequencesfrom which they are derived. In some embodiments, at least one of theTCR-TMs comprises a single amino acid substitution compared to the aminoacid sequence from which it is derived. In some embodiments, each of theTCR-TMs comprises a single amino acid substitution compared to the aminoacid sequence from which it is derived. In some embodiments, at leastone of the substituted amino acids in the first TCR-TM is positionedsuch that in the caTCR it can interact with at least one of thesubstituted amino acids in the second TCR-TM. In some embodiments, thefirst TCR-TM and second TCR-TM are selected according to any of thecaTCRs listed in Table 2. In some embodiments, the CSR domains areselected according to any of the CSRs listed in Table 3.

In some embodiments, there is provided a method of treating a targetantigen-associated disease (such as cancer or viral infection) in anindividual in need thereof comprising administering to the individual aneffective amount of a composition comprising immune cells (such as Tcells or natural killer cells) presenting on their surface a) a caTCRthat specifically binds the target antigen comprising i) a first TCRDcomprising a first TCR-TM having the amino acid sequence of SEQ ID NO:10 and a second TCRD comprising a second TCR-TM having the amino acidsequence of SEQ ID NO: 16, wherein the first and second TCRDs form aTCRM that is capable of recruiting at least one TCR-associated signalingmolecule; and b) an antigen-binding module that specifically binds tothe target antigen, wherein the antigen-binding module is linked to thefirst and/or second TCRDs; and b) a chimeric signaling receptor (CSR)comprising i) a ligand-binding domain that specifically binds to atarget ligand, ii) a transmembrane domain, and iii) a fragment of animmune cell co-stimulatory molecule (fCSM) comprising an intracellularsignaling domain that is capable of providing a co-stimulatory signal tothe immune cell, wherein the co-stimulatory molecule fragment comprisesthe amino acid sequence of any one of SEQ ID NOs: 51-56 and 86-89. Insome embodiments, the CSR transmembrane domain is derived from CD8. Insome embodiments, the CSR comprises a fragment of a transmembraneprotein (fTMP), wherein the transmembrane protein fragment comprises theamino acid sequence of SEQ ID NO: 57. In some embodiments, the CSRcomprises a spacer peptide following the ligand-binding domain. In someembodiments, the spacer peptide comprises the amino acid sequence of SEQID NO: 103 or 104. In some embodiments, the CSR domains are selectedaccording to any of the CSRs listed in Table 3. In some embodiments, thetarget antigen is CD19. In some embodiments, the target ligand is CD19.In some embodiments, the caTCR antigen-binding module is a Fab-likeantigen-binding moiety comprising a V_(H) domain comprising the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain comprising the aminoacid sequence of SEQ ID NO: 59. In some embodiments, the target antigenis CD19 and the target ligand is CD19. In some embodiments, the CSRligand-binding domain is an scFv comprising the amino acid sequence ofSEQ ID NO: 77. In some embodiments, the target antigen is CD19 and thetarget ligand is CD20. In some embodiments, the CSR ligand-bindingdomain is an scFv comprising the amino acid sequence of SEQ ID NO: 78.In some embodiments, the target antigen is an AFP peptide/MHC complex(e.g., AFP158/HLA-A02 complex) and the target ligand is GPC3. In someembodiments, the caTCR antigen-binding module is a Fab-likeantigen-binding moiety comprising a V_(H) domain comprising the aminoacid sequence of SEQ ID NO: 62 and a V_(L) domain comprising the aminoacid sequence of SEQ ID NO: 63. In some embodiments, the CSRligand-binding domain is an scFv comprising the amino acid sequence ofSEQ ID NO: 79.

In some embodiments, there is provided a method of treating aCD19-associated disease (such as cancer) in an individual in needthereof comprising administering to the individual an effective amountof a composition comprising immune cells (such as T cells or naturalkiller cells) presenting on their surface a) a caTCR that specificallybinds CD19 comprising i) a first TCRD comprising a first TCR-TM havingthe amino acid sequence of SEQ ID NO: 10 and a second TCRD comprising asecond TCR-TM having the amino acid sequence of SEQ ID NO: 16, whereinthe first and second TCRDs form a TCRM that is capable of recruiting atleast one TCR-associated signaling molecule; and b) a Fab-likeantigen-binding module comprising a first Fab chain comprising a V_(H)domain comprising the amino acid sequence of SEQ ID NO: 58 and a secondFab chain comprising a V_(L) domain comprising the amino acid sequenceof SEQ ID NO: 59, wherein the first Fab chain is linked to one of thefirst and second TCRDs, and the second Fab chain is linked to the otherTCRD; and b) a chimeric signaling receptor (CSR) comprising i) an scFvthat specifically binds CD19 comprising a V_(H) domain comprising theamino acid sequence of SEQ ID NO: 58 and a V_(L) domain comprising theamino acid sequence of SEQ ID NO: 59, ii) a transmembrane domain, andiii) a fragment of an immune cell co-stimulatory molecule (fCSM)comprising an intracellular signaling domain that is capable ofproviding a co-stimulatory signal to the immune cell, wherein theco-stimulatory molecule fragment comprises the amino acid sequence ofany one of SEQ ID NOs: 51-56 and 86-89. In some embodiments, the CSRtransmembrane domain is derived from CD8. In some embodiments, the CSRcomprises a fragment of a transmembrane protein (fTMP), wherein thetransmembrane protein fragment comprises the amino acid sequence of SEQID NO: 57. In some embodiments, the CSR comprises a spacer peptidefollowing the ligand-binding domain. In some embodiments, the spacerpeptide comprises the amino acid sequence of SEQ ID NO: 103 or 104. Insome embodiments, the CSR domains are selected according to any of theCSRs listed in Table 3. In some embodiments, the CSR ligand-bindingdomain is an scFv comprising the amino acid sequence of SEQ ID NO: 77.In some embodiments, the CD19-associated disease is leukemia, e.g.,acute lymphoblastic leukemia (ALL).

In some embodiments, there is provided a method of treating aCD19/CD20-associated disease (such as cancer) in an individual in needthereof comprising administering to the individual an effective amountof a composition comprising immune cells (such as T cells or naturalkiller cells) presenting on their surface a) a caTCR that specificallybinds CD19 comprising i) a first TCRD comprising a first TCR-TM havingthe amino acid sequence of SEQ ID NO: 10 and a second TCRD comprising asecond TCR-TM having the amino acid sequence of SEQ ID NO: 16, whereinthe first and second TCRDs form a TCRM that is capable of recruiting atleast one TCR-associated signaling molecule; and b) a Fab-likeantigen-binding module comprising a first Fab chain comprising a V_(H)domain comprising the amino acid sequence of SEQ ID NO: 58 and a secondFab chain comprising a V_(L) domain comprising the amino acid sequenceof SEQ ID NO: 59, wherein the first Fab chain is linked to one of thefirst and second TCRDs, and the second Fab chain is linked to the otherTCRD; and b) a chimeric signaling receptor (CSR) comprising i) an scFvthat specifically binds CD20 comprising a V_(H) domain comprising theamino acid sequence of SEQ ID NO: 60 and a V_(L) domain comprising theamino acid sequence of SEQ ID NO: 61, ii) a transmembrane domain, andiii) a fragment of an immune cell co-stimulatory molecule (fCSM)comprising an intracellular signaling domain that is capable ofproviding a co-stimulatory signal to the immune cell, wherein theco-stimulatory molecule fragment comprises the amino acid sequence ofany one of SEQ ID NOs: 51-56 and 86-89. In some embodiments, the CSRtransmembrane domain is derived from CD8. In some embodiments, the CSRcomprises a fragment of a transmembrane protein (fTMP), wherein thetransmembrane protein fragment comprises the amino acid sequence of SEQID NO: 57. In some embodiments, the CSR comprises a spacer peptidefollowing the ligand-binding domain. In some embodiments, the spacerpeptide comprises the amino acid sequence of SEQ ID NO: 103 or 104. Insome embodiments, the CSR domains are selected according to any of theCSRs listed in Table 3. In some embodiments, the CSR ligand-bindingdomain is an scFv comprising the amino acid sequence of SEQ ID NO: 81.

In some embodiments, there is provided a method of treating aAFP/GPC3-associated disease (such as cancer, e.g., liver cancer) in anindividual in need thereof comprising administering to the individual aneffective amount of a composition comprising immune cells (such as Tcells or natural killer cells) presenting on their surface a) a caTCRthat specifically binds an AFP peptide/MHC complex (e.g., AFP158/HLA-A02complex) comprising i) a first TCRD comprising a first TCR-TM having theamino acid sequence of SEQ ID NO: 10 and a second TCRD comprising asecond TCR-TM having the amino acid sequence of SEQ ID NO: 16, whereinthe first and second TCRDs form a TCRM that is capable of recruiting atleast one TCR-associated signaling molecule; and b) a Fab-likeantigen-binding module comprising a first Fab chain comprising a V_(H)domain comprising the amino acid sequence of SEQ ID NO: 62 and a secondFab chain comprising a V_(L) domain comprising the amino acid sequenceof SEQ ID NO: 63, wherein the first Fab chain is linked to one of thefirst and second TCRDs, and the second Fab chain is linked to the otherTCRD; and b) a chimeric signaling receptor (CSR) comprising i) an scFvthat specifically binds GPC3 comprising a V_(H) domain comprising theamino acid sequence of SEQ ID NO: 64 and a V_(L) domain comprising theamino acid sequence of SEQ ID NO: 65, ii) a transmembrane domain, andiii) a fragment of an immune cell co-stimulatory molecule (fCSM)comprising an intracellular signaling domain that is capable ofproviding a co-stimulatory signal to the immune cell, wherein theco-stimulatory molecule fragment comprises the amino acid sequence ofany one of SEQ ID NOs: 51-56 and 86-89. In some embodiments, the CSRtransmembrane domain is derived from CD8. In some embodiments, the CSRcomprises a fragment of a transmembrane protein (fTMP), wherein thetransmembrane protein fragment comprises the amino acid sequence of SEQID NO: 57. In some embodiments, the CSR comprises a spacer peptidefollowing the ligand-binding domain. In some embodiments, the spacerpeptide comprises the amino acid sequence of SEQ ID NO: 103 or 104. Insome embodiments, the CSR domains are selected according to any of theCSRs listed in Table 3. In some embodiments, the CSR ligand-bindingdomain is an scFv comprising the amino acid sequence of SEQ ID NO: 82.

Also contemplated are methods of treating a target antigen-associateddisease in an individual in need thereof comprising administering to theindividual a composition comprising a plurality of immune cellsexpressing different caTCRs and/or different CSRs. Thus, in someembodiments, according to any of the methods for treating a targetantigen-associated disease in an individual described herein, thecomposition is a heterogeneous caTCR plus CSR immune cell composition asdescribed herein.

In some embodiments, the individual is a mammal (e.g., human, non-humanprimate, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc.). Insome embodiments, the individual is a human. In some embodiments, theindividual is a clinical patient, a clinical trial volunteer, anexperimental animal, etc. In some embodiments, the individual is youngerthan about 60 years old (including for example younger than about any of50, 40, 30, 25, 20, 15, or 10 years old). In some embodiments, theindividual is older than about 60 years old (including for example olderthan about any of 70, 80, 90, or 100 years old). In some embodiments,the individual is diagnosed with or environmentally or genetically proneto one or more of the diseases or disorders described herein (such ascancer or viral infection). In some embodiments, the individual has oneor more risk factors associated with one or more diseases or disordersdescribed herein.

In some embodiments, the caTCR plus CSR immune cell compositions of theinvention are administered in combination with a second, third, orfourth agent (including, e.g., an antineoplastic agent, a growthinhibitory agent, a cytotoxic agent, or a chemotherapeutic agent) totreat diseases or disorders involving target antigen expression. In someembodiments, the caTCR plus CSR immune cell composition is administeredin combination with a cytokine (such as IL-2). In some embodiments, thecaTCR plus CSR immune cell composition is administered in combinationwith an agent that increases the expression of MHC proteins and/orenhances the surface presentation of peptides by MHC proteins. In someembodiments, the agent includes, for example, IFN receptor agonists,Hsp90 inhibitors, enhancers of p53 expression, and chemotherapeuticagents. In some embodiments, the agent is an IFN receptor agonistincluding, for example, IFNγ, IFNβ, and IFNα. In some embodiments, theagent is an Hsp90 inhibitor including, for example, tanespimycin(17-AAG), alvespimycin (17-DMAG), retaspimycin (IPI-504), IPI-493,CNF2024/BIIB021, MPC-3100, Debio 0932 (CUDC-305), PU-H71, Ganetespib(STA-9090), NVP-AUY922 (VER-52269), HSP990, KW-2478, AT13387, SNX-5422,DS-2248, and XL888. In some embodiments, the agent is an enhancer of p53expression including, for example, 5-fluorouracil and nutlin-3. In someembodiments, the agent is a chemotherapeutic agent including, forexample, topotecan, etoposide, cisplatin, paclitaxel, and vinblastine.

In some embodiments, there is provided a method of treating a targetantigen-positive disease in an individual in need thereof comprisingadministering to the individual a caTCR plus CSR immune cell compositionaccording to any of the embodiments described herein in combination witha cytokine (such as IL-2). In some embodiments, the caTCR plus CSRimmune cell composition and the cytokine are administeredsimultaneously. In some embodiments, the caTCR plus CSR immune cellcomposition and the cytokine are administered sequentially.

In some embodiments, there is provided a method of treating a targetantigen-positive disease in an individual in need thereof, wherein thecells expressing the target antigen do not normally present, or presentat relatively low levels, a complex comprising the target antigen and anMIIC class I protein on their surface, the method comprisingadministering to the individual a caTCR plus CSR immune cellcompositions according to any of the embodiments described herein incombination with an agent that increases the expression of MIIC class Iproteins and/or enhances the surface presentation of target antigens byMHC class I proteins. In some embodiments, the agent includes, forexample, IFN receptor agonists, Hsp90 inhibitors, enhancers of p53expression, and chemotherapeutic agents. In some embodiments, the agentis an IFN receptor agonist including, for example, IFNγ, IFNβ, and IFNα.In some embodiments, the agent is an Hsp90 inhibitor including, forexample, tanespimycin (17-AAG), alvespimycin (17-DMAG), retaspimycin(IPI-504), IPI-493, CNF2024/BIIB021, MPC-3100, Debio 0932 (CUDC-305),PU-H71, Ganetespib (STA-9090), NVP-AUY922 (VER-52269), HSP990, KW-2478,AT13387, SNX-5422, DS-2248, and XL888. In some embodiments, the agent isan enhancer of p53 expression including, for example, 5-fluorouracil andnutlin-3. In some embodiments, the agent is a chemotherapeutic agentincluding, for example, topotecan, etoposide, cisplatin, paclitaxel, andvinblastine. In some embodiments, the caTCR plus CSR immune cellcomposition and the agent are administered simultaneously. In someembodiments, the caTCR plus CSR immune cell composition and the agentare administered sequentially.

In some embodiments, there is provided a method of treating a targetantigen-associated disease (such as cancer or viral infection) in anindividual in need thereof comprising administering to the individual aneffective amount of a composition comprising nucleic acid encoding acaTCR and a CSR according to any of the embodiments described herein.Methods for gene delivery are known in the art. See, e.g., U.S. Pat.Nos. 5,399,346, 5,580,859, 5,589,466, incorporated by reference hereinin their entireties.

Cancer treatments can be evaluated, for example, by tumor regression,tumor weight or size shrinkage, time to progression, duration ofsurvival, progression free survival, overall response rate, duration ofresponse, quality of life, protein expression and/or activity.Approaches to determining efficacy of the therapy can be employed,including for example, measurement of response through radiologicalimaging.

In some embodiments, the efficacy of treatment is measured as thepercentage tumor growth inhibition (% TGI), calculated using theequation 100−(T/C×100), where T is the mean relative tumor volume of thetreated tumor, and C is the mean relative tumor volume of a non-treatedtumor. In some embodiments, the % TGI is about 10%, about 20%, about30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%,about 91%, about 92%, about 93%, about 94%, about 95%, or more than 95%.

Viral infection treatments can be evaluated, for example, by viral load,duration of survival, quality of life, protein expression and/oractivity.

Diseases

The caTCR plus CSR immune cells in some embodiments can be useful fortreating cancers associated with a target antigen. Cancers that may betreated using any of the methods described herein include tumors thatare not vascularized, or not yet substantially vascularized, as well asvascularized tumors. The cancers may comprise non-solid tumors (such ashematological tumors, for example, leukemias and lymphomas) or maycomprise solid tumors. Types of cancers to be treated with the caTCRplus CSR immune cells of the invention include, but are not limited to,carcinoma, blastoma, and sarcoma, and certain leukemia or lymphoidmalignancies, benign and malignant tumors, and malignancies e.g.,sarcomas, carcinomas, and melanomas. Adult tumors/cancers and pediatrictumors/cancers are also included.

Hematologic cancers are cancers of the blood or bone marrow. Examples ofhematological (or hematogenous) cancers include leukemias, includingacute leukemias (such as acute lymphocytic leukemia, acute myelocyticleukemia, acute myelogenous leukemia and myeloblastic, promyelocytic,myelomonocytic, monocytic and erythroleukemia), chronic leukemias (suchas chronic myelocytic (granulocytic) leukemia, chronic myelogenousleukemia, and chronic lymphocytic leukemia), polycythemia vera,lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (indolent and highgrade forms), multiple myeloma, plasmacytoma, Waldenstrom'smacroglobulinemia, heavy chain disease, myelodysplastic syndrome, hairycell leukemia and myelodysplasia.

Solid tumors are abnormal masses of tissue that usually do not containcysts or liquid areas. Solid tumors can be benign or malignant.Different types of solid tumors are named for the type of cells thatform them (such as sarcomas, carcinomas, and lymphomas). Examples ofsolid tumors, such as sarcomas and carcinomas, include adrenocorticalcarcinoma, cholangiocarcinoma, fibrosarcoma, myxosarcoma, liposarcoma,chondrosarcoma, osteosarcoma, and other sarcomas, synovioma,mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, coloncarcinoma, stomach cancer, lymphoid malignancy, pancreatic cancer,breast cancer, lung cancers, ovarian cancer, prostate cancer,hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma,adenocarcinoma, sweat gland carcinoma, thyroid cancer (e.g., medullarythyroid carcinoma and papillary thyroid carcinoma), pheochromocytomassebaceous gland carcinoma, papillary carcinoma, papillaryadenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cellcarcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, Wilms' tumor,cervical cancer (e.g., cervical carcinoma and pre-invasive cervicaldysplasia), colorectal cancer, cancer of the anus, anal canal, oranorectum, vaginal cancer, cancer of the vulva (e.g., squamous cellcarcinoma, intraepithelial carcinoma, adenocarcinoma, and fibrosarcoma),penile cancer, oropharyngeal cancer, esophageal cancer, head cancers(e.g., squamous cell carcinoma), neck cancers (e.g., squamous cellcarcinoma), testicular cancer (e.g., seminoma, teratoma, embryonalcarcinoma, teratocarcinoma, choriocarcinoma, sarcoma, Leydig cell tumor,fibroma, fibroadenoma, adenomatoid tumors, and lipoma), bladdercarcinoma, kidney cancer, melanoma, cancer of the uterus (e.g.,endometrial carcinoma), urothelial cancers (e.g., squamous cellcarcinoma, transitional cell carcinoma, adenocarcinoma, ureter cancer,and urinary bladder cancer), and CNS tumors (such as a glioma (such asbrainstem glioma and mixed gliomas), glioblastoma (also known asglioblastoma multiforme) astrocytoma, CNS lymphoma, germinoma,medulloblastoma, Schwannoma craniopharyogioma, ependymoma, pinealoma,hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma,neuroblastoma, retinoblastoma and brain metastases).

Cancer treatments can be evaluated, for example, by tumor regression,tumor weight or size shrinkage, time to progression, duration ofsurvival, progression free survival, overall response rate, duration ofresponse, quality of life, protein expression and/or activity.Approaches to determining efficacy of the therapy can be employed,including for example, measurement of response through radiologicalimaging.

The caTCR plus CSR immune cells in other embodiments can be useful fortreating infectious diseases by targeting pathogen-associated (such asvirally-encoded) antigens. The infection to be prevented or treated, forexample, may be caused by a virus, bacteria, protozoa, or parasite. Thetarget antigen may be a pathogenic protein, polypeptide or peptide thatis responsible for a disease caused by the pathogen, or is capable ofinducing an immunological response in a host infected by the pathogen.Pathogenic antigens which can be targeted by caTCR plus CSR immune cellsinclude, but are not limited to, antigens derived from Acinetobacterbaumannii, Anaplasma genus, Anaplasma phagocytophilum, Ancylostomabraziliense, Ancylostoma duodenale, Arcanobacterium haemolyticum,Ascaris lumbricoides, Aspergillus genus, Astroviridae, Babesia genus,Bacillus anthracis, Bacillus cereus, Bartonella henselae, BK virus,Blastocystis hominis, Blastomyces dermatitidis, Bordetella pertussis,Borrelia burgdorferi, Borrelia genus, Borrelia spp, Brucella genus,Brugia malayi, Bunyaviridae family, Burkholderia cepacia and otherBurkholderia species, Burkholderia mallei, Burkholderia pseudomallei,Caliciviridae family, Campylobacter genus, Candida albicans, Candidaspp, Chlamydia trachomatis, Chlamydophila pneumoniae, Chlamydophilapsittaci, CJD prion, Clonorchis sinensis, Clostridium botulinum,Clostridium difficile, Clostridium perfringens, Clostridium perfringens,Clostridium spp, Clostridium tetani, Coccidioides spp, coronaviruses,Corynebacterium diphtheriae, Coxiella burnetii, Crimean-Congohemorrhagic fever virus, Cryptococcus neoformans, Cryptosporidium genus,Cytomegalovirus (CMV), Dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4),Dientamoeba fragilis, Ebolavirus (EBOV), Echinococcus genus, Ehrlichiachaffeensis, Ehrlichia ewingii, Ehrlichia genus, Entamoeba histolytica,Enterococcus genus, Enterovirus genus, Enteroviruses, mainly Coxsackie Avirus and Enterovirus 71 (EV71), Epidermophyton spp, Epstein-Barr Virus(EBV), Escherichia coli O157:H7, O111 and O104:H4, Fasciola hepatica andFasciola gigantica, FFI prion, Filarioidea superfamily, Flaviviruses,Francisella tularensis, Fusobacterium genus, Geotrichum candidum,Giardia intestinalis, Gnathostoma spp, GSS prion, Guanarito virus,Haemophilus ducreyi, Haemophilus influenzae, Helicobacter pylori,Henipavirus (Hendra virus Nipah virus), Hepatitis A Virus, Hepatitis BVirus (HBV), Hepatitis C Virus (HCV), Hepatitis D Virus, Hepatitis EVirus, Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), Histoplasmacapsulatum, HIV (Human immunodeficiency virus), Hortaea werneckii, Humanbocavirus (HBoV), Human herpesvirus 6 (HHV-6) and Human herpesvirus 7(HHV-7), Human metapneumovirus (hMPV), Human papillomavirus (HPV), Humanparainfluenza viruses (HPIV), Human T cell leukemia virus 1 (HTLV-1),Japanese encephalitis virus, JC virus, Junin virus, Kaposi's Sarcomaassociated herpesvirus (KSHV), Kingella kingae, Klebsiella granulomatis,Kuru prion, Lassa virus, Legionella pneumophila, Leishmania genus,Leptospira genus, Listeria monocytogenes, Lymphocytic choriomeningitisvirus (LCMV), Machupo virus, Malassezia spp, Marburg virus, Measlesvirus, Metagonimus yokagawai, Microsporidia phylum, Molluscumcontagiosum virus (MCV), Mumps virus, Mycobacterium leprae andMycobacterium lepromatosis, Mycobacterium tuberculosis, Mycobacteriumulcerans, Mycoplasma pneumoniae, Naegleria fowleri, Necator americanus,Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroides,Nocardia spp, Onchocerca volvulus, Orientia tsutsugamushi,Orthomyxoviridae family (Influenza), Paracoccidioides brasiliensis,Paragonimus spp, Paragonimus westermani, Parvovirus B19, Pasteurellagenus, Plasmodium genus, Pneumocystis jirovecii, Poliovirus, Rabiesvirus, Respiratory syncytial virus (RSV), Rhinovirus, rhinoviruses,Rickettsia akari, Rickettsia genus, Rickettsia prowazekii, Rickettsiarickettsii, Rickettsia typhi, Rift Valley fever virus, Rotavirus,Rubella virus, Sabia virus, Salmonella genus, Sarcoptes scabiei, SARScoronavirus, Schistosoma genus, Shigella genus, Sin Nombre virus,Hantavirus, Sporothrix schenckii, Staphylococcus genus, Staphylococcusgenus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcuspyogenes, Strongyloides stercoralis, Taenia genus, Taenia solium,Tick-borne encephalitis virus (TBEV), Toxocara canis or Toxocara cati,Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonasvaginalis, Trichophyton spp, Trichuris trichiura, Trypanosoma brucei,Trypanosoma cruzi, Ureaplasma urealyticum, Varicella zoster virus (VZV),Varicella zoster virus (VZV), Variola major or Variola minor, vCJDprion, Venezuelan equine encephalitis virus, Vibrio cholerae, West Nilevirus, Western equine encephalitis virus, Wuchereria bancrofti, Yellowfever virus, Yersinia enterocolitica, Yersinia pestis, and Yersiniapseudotuberculosis.

In some embodiments, the caTCR plus CSR immune cells are used fortreating oncogenic infectious diseases, such as infection by oncogenicviruses. Oncogenic viruses include, but are not limited to, CMV, EBV,HBV, KSHV, HPV, MCV, HTLV-1, HIV-1, and HCV. The target antigen of thecaTCR can be a viral oncoprotein including, but not limited to, Tax, E7,E6/E7, E6, HBx, EBNA proteins (e.g., EBNA3 A, EBNA3 C, and EBNA 2),v-cyclin, LANA1, LANA2, LMP-1, k-bZIP, RTA, KSHV K8, and fragmentsthereof. See Ahuja, Richa, et al., Curr. Sci., 2014.

Articles of Manufacture and Kits

In some embodiments of the invention, there is provided an article ofmanufacture containing materials useful for the treatment of a targetantigen-positive disease such as cancer (for example adrenocorticalcarcinoma, bladder cancer, breast cancer, cervical cancer,cholangiocarcinoma, colorectal cancers, esophageal cancer, glioblastoma,glioma, hepatocellular carcinoma, head and neck cancer, kidney cancer,leukemia, lung cancer, lymphoma, melanoma, mesothelioma, multiplemyeloma, pancreatic cancer, pheochromocytoma, plasmacytoma,neuroblastoma, ovarian cancer, prostate cancer, sarcoma, stomach cancer,uterine cancer or thyroid cancer) or viral infection (for exampleinfection by CMV, EBV, HBV, KSHV, HPV, MCV, HTLV-1, HIV-1, or HCV). Thearticle of manufacture can comprise a container and a label or packageinsert on or associated with the container. Suitable containers include,for example, bottles, vials, syringes, etc. The containers may be formedfrom a variety of materials such as glass or plastic. Generally, thecontainer holds a composition which is effective for treating a diseaseor disorder described herein, and may have a sterile access port (forexample the container may be an intravenous solution bag or a vialhaving a stopper pierceable by a hypodermic injection needle). At leastone active agent in the composition is an immune cell presenting on itssurface a caTCR and a CSR of the invention. The label or package insertindicates that the composition is used for treating the particularcondition. The label or package insert will further compriseinstructions for administering the caTCR plus CSR immune cellcomposition to the patient. Articles of manufacture and kits comprisingcombinatorial therapies described herein are also contemplated.

Package insert refers to instructions customarily included in commercialpackages of therapeutic products that contain information about theindications, usage, dosage, administration, contraindications and/orwarnings concerning the use of such therapeutic products. In someembodiments, the package insert indicates that the composition is usedfor treating a target antigen-positive cancer (such as adrenocorticalcarcinoma, bladder cancer, breast cancer, cervical cancer,cholangiocarcinoma, colorectal cancers, esophageal cancer, glioblastoma,glioma, hepatocellular carcinoma, head and neck cancer, kidney cancer,leukemia, lung cancer, lymphoma, melanoma, mesothelioma, multiplemyeloma, pancreatic cancer, pheochromocytoma, plasmacytoma,neuroblastoma, ovarian cancer, prostate cancer, sarcoma, stomach cancer,uterine cancer or thyroid cancer). In other embodiments, the packageinsert indicates that the composition is used for treating a targetantigen-positive viral infection (for example infection by CMV, EBV,HBV, KSHV, HPV, MCV, HTLV-1, HIV-1, or HCV).

Additionally, the article of manufacture may further comprise a secondcontainer comprising a pharmaceutically acceptable buffer, such asbacteriostatic water for injection (BWFI), phosphate-buffered saline,Ringer's solution and dextrose solution. It may further include othermaterials desirable from a commercial and user standpoint, includingother buffers, diluents, filters, needles, and syringes.

Kits are also provided that are useful for various purposes, e.g., fortreatment of a target antigen-positive disease or disorder describedherein, optionally in combination with the articles of manufacture. Kitsof the invention include one or more containers comprising a caTCR plusCSR immune cell composition (or unit dosage form and/or article ofmanufacture), and in some embodiments, further comprise another agent(such as the agents described herein) and/or instructions for use inaccordance with any of the methods described herein. The kit may furthercomprise a description of selection of individuals suitable fortreatment. Instructions supplied in the kits of the invention aretypically written instructions on a label or package insert (e.g., apaper sheet included in the kit), but machine-readable instructions(e.g., instructions carried on a magnetic or optical storage disk) arealso acceptable.

For example, in some embodiments, the kit comprises a compositioncomprising an immune cell presenting on its surface a caTCR and a CSR.In some embodiments, the kit comprises a) a composition comprising animmune cell presenting on its surface a caTCR and a CSR, and b) aneffective amount of at least one other agent, wherein the other agentincreases the expression of MHC proteins and/or enhances the surfacepresentation of peptides by MHC proteins (e.g., IFNγ, IFNβ, IFNα, orHsp90 inhibitor). In some embodiments, the kit comprises a) acomposition comprising an immune cell presenting on its surface a caTCRand a CSR, and b) instructions for administering the caTCR plus CSRimmune cell composition to an individual for treatment of a targetantigen-positive disease (such as cancer or viral infection). In someembodiments, the kit comprises a) a composition comprising an immunecell presenting on its surface a caTCR and a CSR, b) an effective amountof at least one other agent, wherein the other agent increases theexpression of MHC proteins and/or enhances the surface presentation ofpeptides by MHC proteins (e.g., IFNγ, IFNβ, IFNα, or Hsp90 inhibitor),and c) instructions for administering the caTCR plus CSR immune cellcomposition and the other agent(s) to an individual for treatment of atarget antigen-positive disease (such as cancer or viral infection). ThecaTCR plus CSR immune cell composition and the other agent(s) can bepresent in separate containers or in a single container. For example,the kit may comprise one distinct composition or two or morecompositions wherein one composition comprises the caTCR plus CSR immunecell and another composition comprises the other agent.

In some embodiments, the kit comprises a) one or more compositionscomprising a caTCR and a CSR, and b) instructions for combining thecaTCR and CSR with immune cells (such as immune cells, e.g., T cells ornatural killer cells, derived from an individual) to form a compositioncomprising the immune cells presenting on their surface the caTCR andCSR, and administering the caTCR plus CSR immune cell composition to theindividual for treatment of a target antigen-positive disease (such ascancer or viral infection). In some embodiments, the kit comprises a)one or more compositions comprising a caTCR and a CSR, and b) an immunecell (such as a cytotoxic cell). In some embodiments, the kit comprisesa) one or more compositions comprising a caTCR and a CSR, b) an immunecell (such as a cytotoxic cell), and c) instructions for combining thecaTCR and CSR with the immune cell to form a composition comprising theimmune cell presenting on its surface the caTCR and CSR, andadministering the caTCR plus CSR immune cell composition to anindividual for the treatment of a target antigen-positive disease (suchas cancer or viral infection).

In some embodiments, the kit comprises a nucleic acid (or set of nucleicacids) encoding a caTCR and a CSR. In some embodiments, the kitcomprises a) a nucleic acid (or set of nucleic acids) encoding a caTCRand a CSR, and b) a host cell (such as an immune cell) for expressingthe nucleic acid (or set of nucleic acids). In some embodiments, the kitcomprises a) a nucleic acid (or set of nucleic acids) encoding a caTCRand a CSR, and b) instructions for i) expressing the caTCR and CSR in ahost cell (such as an immune cell, e.g., a T cell), ii) preparing acomposition comprising the host cell expressing the caTCR and CSR, andiii) administering the composition comprising the host cell expressingthe caTCR and CSR to an individual for the treatment of a targetantigen-positive disease (such as cancer or viral infection). In someembodiments, the host cell is derived from the individual. In someembodiments, the kit comprises a) a nucleic acid (or set of nucleicacids) encoding a caTCR and a CSR, b) a host cell (such as an immunecell) for expressing the nucleic acid (or set of nucleic acids), and c)instructions for i) expressing the caTCR and CSR in the host cell, ii)preparing a composition comprising the host cell expressing the caTCRand CSR, and iii) administering the composition comprising the host cellexpressing the caTCR and CSR to an individual for the treatment of atarget antigen-positive disease (such as cancer or viral infection).

The kits of the invention are in suitable packaging. Suitable packagingincludes, but is not limited to, vials, bottles, jars, flexiblepackaging (e.g., sealed Mylar or plastic bags), and the like. Kits mayoptionally provide additional components such as buffers andinterpretative information. The present application thus also providesarticles of manufacture, which include vials (such as sealed vials),bottles, jars, flexible packaging, and the like.

The instructions relating to the use of the caTCR plus CSR immune cellcompositions generally include information as to dosage, dosingschedule, and route of administration for the intended treatment. Thecontainers may be unit doses, bulk packages (e.g., multi-dose packages)or sub-unit doses. For example, kits may be provided that containsufficient dosages of a caTCR plus CSR immune cell composition asdisclosed herein to provide effective treatment of an individual for anextended period, such as any of a week, 8 days, 9 days, 10 days, 11days, 12 days, 13 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3months, 4 months, 5 months, 7 months, 8 months, 9 months, or more. Kitsmay also include multiple unit doses of the caTCR and CSR, andpharmaceutical compositions and instructions for use and packaged inquantities sufficient for storage and use in pharmacies, for example,hospital pharmacies and compounding pharmacies.

Those skilled in the art will recognize that several embodiments arepossible within the scope and spirit of this invention. The inventionwill now be described in greater detail by reference to the followingnon-limiting examples. The following examples further illustrate theinvention but, of course, should not be construed as in any way limitingits scope.

Exemplary Embodiments

Embodiment 1. In one embodiment, there is provided an immune cellcomprising:

a) a chimeric antibody-T cell receptor (TCR) construct (caTCR)comprising:i) an antigen binding module that specifically binds to a targetantigen; andii) a T cell receptor module (TCRM) comprising a first TCR domain (TCRD)comprising a first TCR transmembrane domain (TCR-TM) and a second TCRDcomprising a second TCR-TM, wherein the TCRM facilitates recruitment ofat least one TCR-associated signaling molecule; andb) a chimeric signaling receptor (CSR) comprising:i) a ligand-binding module that is capable of binding or interactingwith a target ligand;ii) a transmembrane module; andiii) a co-stimulatory immune cell signaling module that is capable ofproviding a co-stimulatory signal to the immune cell, wherein theligand-binding module and the co-stimulatory immune cell signalingmodule are not derived from the same molecule, and wherein the CSR lacksa functional primary immune cell signaling domain.

Embodiment 2. The immune cell of embodiment 1, wherein the CSR lacks anyprimary immune cell signaling sequences.

Embodiment 3. The immune cell of embodiment 1 or 2, wherein the targetantigen is a cell surface antigen.

Embodiment 4. The immune cell of embodiment 3, wherein the cell surfaceantigen is selected from the group consisting of a protein, acarbohydrate, and a lipid.

Embodiment 5. The immune cell of embodiment 4, wherein the cell surfaceantigen is selected from the group consisting of CD19, ROR1, ROR2, BCMA,GPRC5D, and FCRL5.

Embodiment 6. The immune cell of embodiment 1 or 2, wherein the targetantigen is a complex comprising a peptide and a major histocompatibilitycomplex (MHC) protein.

Embodiment 7. The immune cell of embodiment 6, wherein the peptide isderived from a protein selected from the group consisting of WT-1, AFP,HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, and PSA.

Embodiment 8. The immune cell of any one of embodiments 1-7, wherein thefirst TCR-TM is derived from one of the transmembrane domains of a firstT cell receptor and the second TCR-TM is derived from the othertransmembrane domain of the first T cell receptor.

Embodiment 9. The immune cell of embodiment 8, wherein at least one ofthe TCR-TMs is non-naturally occurring.

Embodiment 10. The immune cell of embodiment 9, wherein the TCRM allowsfor enhanced recruitment of the at least one TCR-associated signalingmolecule as compared to a TCRM comprising the first T cell receptortransmembrane domains.

Embodiment 11. The immune cell of anyone of embodiments 8-10, whereinthe first TCR-TM comprises up to 5 amino acid substitutions compared tothe transmembrane domain from which it is derived and/or the secondTCR-TM comprises up to 5 amino acid substitutions compared to thetransmembrane domain from which it is derived.

Embodiment 12. The immune cell of embodiment 11, wherein the firstTCR-TM comprises a single amino acid substitution and/or the secondTCR-TM comprises a single amino acid substitution.

Embodiment 13. The immune cell of any one of embodiments 8-12, whereinthe first T cell receptor is a γ/δ T cell receptor.

Embodiment 14. The immune cell of any one of embodiments 8-12, whereinthe first T cell receptor is an α/β cell receptor.

Embodiment 15. The immune cell of any one of embodiments 1-14, whereinthe antigen-binding module is an antibody moiety selected from the groupconsisting of a Fab, a Fab′, a (Fab′)2, an Fv, and a single chain Fv(scFv).

Embodiment 16. The immune cell of embodiment 15, wherein the antigenbinding module comprises a V_(H) domain and a V_(L) domain, and whereinthe V_(H) domain is linked to the amino-terminus of one of the TCRDs andthe V_(L) domain is linked to the amino-terminus of the other TCRD.

Embodiment 17. The immune cell of embodiment 16, wherein the V_(H)domain is linked to one of the TCRDs via a C_(H)1 domain and the V_(L)domain is linked to the other TCRD via a C_(L) domain.

Embodiment 18. The immune cell of embodiment 15, wherein the caTCRfurther comprises at least one additional antigen-binding module.

Embodiment 19. The immune cell of embodiment 18, wherein the at leastone additional antigen-binding module is an antibody moiety.

Embodiment 20. The immune cell of embodiment 18 or 19, wherein the caTCRis multispecific.

Embodiment 21. The immune cell of anyone of embodiments 15-20, whereinthe antigen binding module comprises an scFv fused to the amino-terminusof one of the TCRDs.

Embodiment 22. The immune cell of embodiment 21, wherein the caTCRcomprises a first scFv fused to the amino terminus of the first TCRD anda second scFv fused to the amino-terminus of the second TCRD.

Embodiment 23. The immune cell of embodiment 22, wherein the first scFvbinds to a different target than the second scFv.

Embodiment 24. The immune cell of any one of embodiments 1-23, whereinthe caTCR is a heterodimer comprising a first polypeptide chaincomprising the first TCRD and a second polypeptide chain comprising thesecond TCRD, and wherein the antigen-binding module is linked to theamino-terminus of one or both of the first and second TCRDs.

Embodiment 25. The immune cell of any one of embodiments 1-24, whereinthe caTCR further comprises a stabilization module comprising a firststabilization domain and a second stabilization domain, wherein thefirst and second stabilization domains have a binding affinity for eachother that stabilizes the caTCR.

Embodiment 26. The immune cell of embodiment 25, wherein thestabilization module is selected from the group consisting of aC_(H)1-C_(L) module, a C_(H)2-C_(H)2 module, a C_(H)3-C_(H)3 module, anda C_(H)4-C_(H)4 module.

Embodiment 27. The immune cell of embodiment 25 or 26, wherein there isa covalent linkage between the first and second stabilization domains.

Embodiment 28. The immune cell of embodiment 27, wherein the covalentlinkage is a disulfide linkage.

Embodiment 29. The immune cell of any one of embodiments 25-28, whereinthe stabilization module is located between the antigen-binding moduleand the TCRM.

Embodiment 30. The immune cell of any one of embodiments 25-29, whereinthe caTCR is a heterodimer comprising:

a) a first polypeptide chain comprising the first stabilization domainfused to the amino-terminus of the first TCRD and a second polypeptidechain comprising the second stabilization domain fused to theamino-terminus of the second TCRD, and wherein the antigen-bindingmodule is fused to the amino-terminus of one or both of the first andsecond stabilization domains.

Embodiment 31. The immune cell of anyone of embodiments 1-30, whereinthe caTCR binds to the target antigen with an equilibrium dissociationconstant (Kd) from about 0.1 pM to about 500 nM.

Embodiment 32. The immune cell of anyone of embodiments 1-31, whereinthe TCR-associated signaling molecule is selected from the groupconsisting of CD3δε, CD3γε, and ζζ.

Embodiment 33. The immune cell of anyone of embodiments 1-32, whereinthe target antigen and the target ligand are the same.

Embodiment 34. The immune cell of any one of embodiments 1-32, whereinthe target antigen and the target ligand are different.

Embodiment 35. The immune cell of embodiment 34, wherein the targetligand is a ligand expressed on the surface of a cell presenting thetarget antigen.

Embodiment 36. The immune cell of anyone of embodiments 1-35, where thetarget ligand is a disease-associated ligand.

Embodiment 37. The immune cell of embodiment 36, wherein the targetligand is a cancer-associated ligand.

Embodiment 38. The immune cell of embodiment 37, wherein thecancer-associated ligand is selected from the group consisting of CD19,CD20, CD22, CD47, IL4, GPC-3, ROR1, ROR2, BCMA, GPRC5D, and FCRL5.

Embodiment 39. The immune cell of embodiment 37, wherein thecancer-associated ligand is a peptide/MHC complex comprising a peptidederived from a protein selected from the group consisting of WT-1, AFP,HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, and PSA.

Embodiment 40. The immune cell of embodiment 36, wherein the targetligand is a virus-associated ligand.

Embodiment 41. The immune cell of anyone of embodiments 1-35, where thetarget ligand is an immunomodulatory molecule.

Embodiment 42. The immune cell of embodiment 41, wherein theimmunomodulatory molecule is an immunosuppressive receptor, and the CSRis an antagonist of the immunosuppressive receptor.

Embodiment 43. The immune cell of embodiment 41, wherein theimmunomodulatory molecule is an immunostimulatory receptor, and the CSRis an agonist of the immunostimulatory receptor.

Embodiment 44. The immune cell of embodiment 41, where the target ligandis an immune checkpoint molecule.

Embodiment 45. The immune cell of embodiment 44, wherein the immunecheckpoint molecule is selected from the group consisting of PD-L1,PD-L2, CD80, CD86, ICOSL, B7-H3, B7-H4, HVEM, 4-1BBL, OX40L, CD70, CD40,and GAL9.

Embodiment 46. The immune cell of embodiment 41, wherein the targetligand is an inhibitory cytokine.

Embodiment 47. The immune cell of anyone of embodiments 1-35, where thetarget ligand is an apoptotic molecule.

Embodiment 48. The immune cell of embodiment 47, wherein the apoptoticmolecule is selected from the group consisting of FasL, FasR, TNFR1, andTNFR2.

Embodiment 49. The immune cell of any one of embodiments 1-48, whereinthe ligand-binding module is an antibody moiety.

Embodiment 50. The immune cell of embodiment 49, wherein the antibodymoiety of the CSR is selected from the group consisting of a Fab, aFab′, a (Fab′)2, an Fv, and a single chain Fv (scFv).

Embodiment 51. The immune cell of embodiment 50, wherein the antibodymoiety of the CSR is an scFv.

Embodiment 52. The immune cell of any one of embodiments 1-48, whereinthe ligand-binding module is derived from the extracellular domain of areceptor.

Embodiment 53. The immune cell of embodiment 52, wherein the receptor isselected from the group consisting of FasR, TNFR1, TNFR2, PD-1, CD28,CTLA-4, ICOS, BTLA, KIR, LAG-3, 4-1BB, OX40, CD27, TIM-3, IL-10R, IL-6R,and IL-4R.

Embodiment 54. The immune cell of any one of embodiments 1-53, whereinthe transmembrane module of the CSR comprises transmembrane domainsderived from CD28, CD3ε, CD3ζ, CD45, CD4, CD5, CD8, CD9, CD16, CD22,CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154.

Embodiment 55. The immune cell of any one of embodiments 1-54, whereinthe co-stimulatory immune cell signaling module is derived from theintracellular domain of a co-stimulatory receptor of a TCR.

Embodiment 56. The immune cell of embodiment 55, wherein theco-stimulatory receptor is selected from the group consisting of CD28,4-1BB, OX40, ICOS, CD27, and CD40.

Embodiment 57. The immune cell of any one of embodiments 1-56, whereinthe expression of the CSR is inducible.

Embodiment 58. The immune cell of embodiment 57, wherein the expressionof the CSR is inducible upon activation of the immune cell.

Embodiment 59. The immune cell of any one of embodiments 1-32, whereinthe antigen-binding module of the caTCR comprises an antibody moietythat binds to CD19, wherein the ligand-binding module of the CSRcomprises an scFv that binds to CD19, and wherein the transmembranemodule and co-stimulatory immune cell signaling module are both derivedfrom CD28.

Embodiment 60. The immune cell of embodiment 59, wherein the antibodymoiety that binds to CD19 comprises a V_(H) domain comprising the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain comprising the aminoacid sequence of SEQ ID NO: 59, wherein the scFv that binds to CD19comprises a V_(L) domain comprising the amino acid sequence of SEQ IDNO: 58 and a V_(L) domain comprising the amino acid sequence of SEQ IDNO: 59, and wherein the CSR comprises a fragment of CD28 comprising theamino acid sequence of SEQ ID NO: 51.

Embodiment 61. The immune cell of embodiment 60, wherein the caTCRcomprises two polypeptide chains comprising the amino acid sequences ofSEQ ID NOs: 72 and 73 or SEQ ID NOs: 74 and 75, and/or wherein the CSRcomprises the amino acid sequence of SEQ ID NO: 80.

Embodiment 62. The immune cell of any one of embodiments 1-32, whereinthe antigen-binding module of the caTCR comprises an antibody moietythat binds to AFP, wherein the ligand-binding module of the CSRcomprises an scFv that binds to GPC3, and wherein the transmembranemodule and co-stimulatory immune cell signaling module are both derivedfrom CD28.

Embodiment 63. The immune cell of embodiment 62, wherein the antibodymoiety that binds to AFP comprises a V_(H) domain comprising the aminoacid sequence of SEQ ID NO: 62 and a V_(L) domain comprising the aminoacid sequence of SEQ ID NO: 63, wherein the scFv that binds to GPC3comprises a V_(L) domain comprising the amino acid sequence of SEQ IDNO: 64 and a V_(L) domain comprising the amino acid sequence of SEQ IDNO: 65, and wherein the CSR comprises a fragment of CD28 comprising theamino acid sequence of SEQ ID NO: 51.

Embodiment 64. The immune cell of embodiment 63, wherein the caTCRcomprises two polypeptide chains comprising the amino acid sequences ofSEQ ID NOs: 68 and 69 or SEQ ID NOs: 70 and 71, and/or wherein the CSRcomprises the amino acid sequence of SEQ ID NO: 82.

Embodiment 65. The immune cell of any one of embodiments 1-32, whereinthe antigen-binding module of the caTCR comprises an antibody moietythat binds to CD19, wherein the ligand-binding module of the CSRcomprises an scFv that binds to CD20, and wherein the transmembranemodule and co-stimulatory immune cell signaling module are both derivedfrom CD28.

Embodiment 66. The immune cell of embodiment 65, wherein the antibodymoiety that binds to CD19 comprises a V_(H) domain comprising the aminoacid sequence of SEQ ID NO: 58 and a V_(L) domain comprising the aminoacid sequence of SEQ ID NO: 59, wherein the scFv that binds to CD20comprises a V_(H) domain comprising the amino acid sequence of SEQ IDNO: 60 and a V_(L) domain comprising the amino acid sequence of SEQ IDNO: 61, and wherein the CSR comprises a fragment of CD28 comprising theamino acid sequence of SEQ ID NO: 51.

Embodiment 67. The immune cell of embodiment 66, wherein the caTCRcomprises two polypeptide chains comprising the amino acid sequences ofSEQ ID NOs: 72 and 73 or SEQ ID NOs: 74 and 75, and/or wherein the CSRcomprises the amino acid sequence of SEQ ID NO: 81.

Embodiment 68. In one embodiment, there is provided one or more nucleicacids encoding the caTCR and CSR of any one of embodiments 1-67, whereinthe caTCR and CSR each consist of one or more polypeptide chains encodedby the one or more nucleic acids.

Embodiment 69. In one embodiment, there is provided one or more nucleicacids encoding:

a) a chimeric antibody-T cell receptor (TCR) construct (caTCR)comprising:i) an antigen binding module that specifically binds to a targetantigen; andii) a T cell receptor module (TCRM) comprising a first TCR domain (TCRD)comprising a first TCR transmembrane domain (TCR-TM) and a second TCRDcomprising a second TCR-TM, wherein the TCRM facilitates recruitment ofat least one TCR-associated signaling molecule, and wherein the caTCRconsists of one or more polypeptide chains; andb) a chimeric signaling receptor (CSR) comprising:i) a ligand-binding module that is capable of binding or interactingwith a target ligand;ii) a transmembrane module; andiii) a co-stimulatory immune cell signaling module that is capable ofproviding a co-stimulatory signal to the immune cell, wherein theligand-binding module and the co-stimulatory immune cell signalingmodule are not derived from the same molecule, wherein the CSR lacks afunctional primary immune cell signaling domain, and wherein the CSRconsists of one or more polypeptide chains.

Embodiment 70. The one or more nucleic acids of embodiment 68 or 69,wherein the caTCR and CSR are encoded on the same nucleic acid molecule.

Embodiment 71. The one or more nucleic acids of embodiment 68 or 69,wherein the caTCR and CSR are encoded on different nucleic acidmolecules

Embodiment 72. The one or more nucleic acids of anyone of embodiments68-71, comprising a nucleotide sequence encoding the CSR operably linkedto an inducible promoter.

Embodiment 73. The one or more nucleic acids of embodiment 72, whereinthe inducible promoter is inducible upon activation of the immune cell.

Embodiment 74. The one or more nucleic acids of embodiment 72, whereinthe inducible promoter is a nuclear-factor of the activated T-cell(NFAT)-derived promoter.

Embodiment 75. In one embodiment, there is provided one or more vectorscomprising the one or more nucleic acids of any one of embodiments68-74.

Embodiment 76. The one or more vectors of embodiment 75, wherein atleast one of the vectors comprises a nucleic acid sequence encoding thecaTCR and at least one other vector comprises a nucleic acid sequenceencoding the CSR.

Embodiment 77. The one or more vectors of embodiment 75, comprising asingle vector comprising the one or more nucleic acids.

Embodiment 78. In one embodiment, there is provided a compositioncomprising the one or more nucleic acids of any one of embodiments 68-74or the one or more vectors of any one of embodiments 75-77.

Embodiment 79. In one embodiment, there is provided an immune cellcomprising the one or more nucleic acids of any one of embodiments 68-74or the one or more vectors of any one of embodiments 75-77.

Embodiment 80. The immune cell of embodiment 79, wherein the immune cellfurther comprises a caTCR expressed from the one or more nucleic acidsof any one of embodiments 68-74 or the one or more vectors of any one ofembodiments 75-77.

Embodiment 81. The immune cell of embodiment 79 or 80, wherein theimmune cell further comprises a CSR expressed from the one or morenucleic acids of any one of embodiments 68-74 or the one or more vectorsof any one of embodiments 75-77.

Embodiment 82. The immune cell of anyone of embodiments 1-67 and 79-81,wherein the immune cell is selected from the group consisting of acytotoxic T cell, a helper T cell, a natural killer T cell, and asuppressor T cell.

Embodiment 83. The immune cell of any one of embodiments 1-67 and 79-82,wherein

a) the caTCR is a heterodimer comprising a first polypeptide chaincomprising the first TCRD and a second polypeptide chain comprising thesecond TCRD, and wherein the antigen-binding module comprises one or twopolypeptide chains linked to the amino-terminus of one or both of theTCRDs, andb) the CSR comprises a single polypeptide chain, the immune cellcomprising:i) a first nucleic acid sequence encoding the first polypeptide chain ofthe caTCR;ii) a second nucleic acid sequence encoding the second polypeptide chainof the caTCR; andiii) a third nucleic acid sequence encoding the CSR.

Embodiment 84. The immune cell of embodiment 83, comprising:

a) a first vector comprising the first nucleic acid sequence under thecontrol of a first promoter;b) a second vector comprising the second nucleic acid sequence under thecontrol of a second promoter; andc) a third vector comprising the third nucleic acid sequence under thecontrol of a third promoter.

Embodiment 85. The immune cell of embodiment 83, comprising:

a) a first vector comprising:i) the first nucleic acid sequence under the control of a firstpromoter; andii) the second nucleic acid sequence under the control of a secondpromoter; andb) a second vector comprising the third nucleic acid sequence under thecontrol of a third promoter.

Embodiment 86. The immune cell of embodiment 83, comprising a vectorcomprising:

a) the first nucleic acid sequence under the control of a firstpromoter;b) the second nucleic acid sequence under the control of a secondpromoter; andc) the third nucleic acid sequence under the control of a thirdpromoter.

Embodiment 87. The immune cell of any one of embodiments 84-86, whereinthe first promoter and/or the second promoter are constitutively activepromoters.

Embodiment 88. The immune cell of any one of embodiments 84-87, whereinthe third promoter is an inducible promoter.

Embodiment 89. The immune cell of embodiment 83, comprising:

a) a first vector comprising the first nucleic acid sequence and thesecond nucleic acid sequence under the control of a single firstpromoter; andb) a second vector comprising the third nucleic acid sequence under thecontrol of a second promoter.

Embodiment 90. The immune cell of embodiment 83, comprising a vectorcomprising:

a) the first nucleic acid sequence and the second nucleic acid sequenceunder the control of a single first promoter; andb) the third nucleic acid sequence under the control of a secondpromoter.

Embodiment 91. The immune cell of embodiment 89 or 90, wherein the firstpromoter is a constitutively active promoter.

Embodiment 92. The immune cell of any one of embodiments 89-91, whereinthe second promoter is an inducible promoter.

Embodiment 93. The immune cell of embodiment 88 or 92, wherein theinducible promoter is inducible upon activation of the immune cell.

Embodiment 94. The immune cell of embodiment 88 or 92, wherein theinducible promoter is an NFAT-derived promoter.

Embodiment 95. The immune cell of embodiment 83, comprising a vectorcomprising the first nucleic acid sequence, the second nucleic acidsequence, and the third nucleic acid sequence all under the control of asingle promoter.

Embodiment 96. The immune cell of any one of embodiments 84-95, whereinthe vectors are integrated into the immune cell genome.

Embodiment 97. In one embodiment, there is provided a pharmaceuticalcomposition comprising the immune cell of any one of embodiments 1-67and 79-96, and a pharmaceutically acceptable carrier.

Embodiment 98. In one embodiment, there is provided a method of killinga target cell presenting a target antigen (or treating a targetantigen-associated disease), comprising contacting the target cell withthe immune cell of any one of embodiments 1-67 and 79-96.

Embodiment 99. The method of embodiment 98, wherein the contacting iscarried out in vivo.

Embodiment 100. The method of embodiment 98, wherein the contacting iscarried out in vitro.

Embodiment 101. In one embodiment, there is provided a method oftreating a target antigen-associated disease in an individual in needthereof, comprising administering to the individual an effective amountof the pharmaceutical composition of embodiment 97.

Embodiment 102. The method of embodiment 101, wherein the targetantigen-associated disease is cancer.

Embodiment 103. The method of embodiment 102, wherein the cancer isselected from the group consisting of adrenocortical carcinoma, bladdercancer, breast cancer, cervical cancer, cholangiocarcinoma, colorectalcancers, esophageal cancer, glioblastoma, glioma, hepatocellularcarcinoma, head and neck cancer, kidney cancer, leukemia, lung cancer,lymphoma, melanoma, mesothelioma, multiple myeloma, pancreatic cancer,pheochromocytoma, plasmacytoma, neuroblastoma, ovarian cancer, prostatecancer, sarcoma, stomach cancer, uterine cancer and thyroid cancer.

Embodiment 104. The method of embodiment 101, wherein the targetantigen-associated disease is viral infection.

Embodiment 105. The method of embodiment 104, wherein the viralinfection is caused by a virus selected from the group consisting ofCytomegalovirus (CMV), Epstein-Barr Virus (EBV), Hepatitis B Virus(HBV), Kaposi's Sarcoma associated herpesvirus (KSHV), Humanpapillomavirus (HPV), Molluscum contagiosum virus (MCV), Human T cellleukemia virus 1 (HTLV-1), Human immunodeficiency virus (HIV), andHepatitis C Virus (HCV).

Embodiment 106. The method of anyone of embodiments 101-105, wherein theimmune cell is autologous to the individual.

Embodiment 107. In one embodiment, there is provided a method ofproviding a co-stimulatory signal to an immune cell comprising a caTCRor transduced with a nucleic acid encoding a caTCR, comprisingintroducing into said cell the one or more nucleic acids of any one ofembodiments 68-74 or the one or more vectors of any one of embodiments75-77.

Examples Materials and Methods Cell Samples, Cell Lines, and Antibodies

The cell lines HepG2 (ATCC HB-8065; HLA-A2+, AFP+), SK-HEP-1 (ATCCHTB-52; HLA-A2+, AFP⁻), Raji (ATCC CCL-86; CD19⁺), CA46 (ATCC CRL-1648;CD19⁺), Jurkat (ATCC CRL-2899, CD19⁻), J.RT3-T3.5 (ATCC TIB-153), Jeko-1(ATCC CRL-3006; CD19⁺), THP-1 (ATCC TIB-202, CD19⁻), Daudi (ATCCCCL-213; CD19⁺), HeLa (ATCC CCL-2), MDA-MB-231 (ATCC HTB-26) and MCF-7(ATCC HTB-22) were obtained from the American Type Culture Collection.Jurkat is a human T lymphocyte cell line derived from T cell leukemia.J.RT3-T3.5 is a mutant line derived from Jurkat cells that lacks the Tcell receptor R chain. Raji is a Burkitt lymphoma cell line thatexpresses CD19. Raji-CD19 knockout (Raji-CD19KO) line was generated byCRISPR technology. Three different guide sequences were designed totarget CD19 in Raji cells. CRISPR-Cas9 vector was purchased from Origeneand each guide was cloned separately into the pCas-Guide vector. Threedays after electroporation, efficiency of knock-out by each guide wasevaluated by flow cytometry and the best CD19-knock-out pool was chosenfor clonal selection by limiting dilution. The selected clone wasconfirmed as a complete CD19 knock-out by sequencing. All cell lineswere cultured in RPMI 1640 or DMEM supplemented with 10% FBS and 2 mMglutamine at 37° C./5% CO₂.

Monoclonal Ab against human HLA-A02 (clone BB7.2) conjugated to FITC orAPC, and its isotype control mouse IgG 2b conjugated to FITC or APC,antibodies against human or mouse CD3, human T cell receptor varioussubunit, 3×Flag tag, HA tag, goat F(ab)2 anti-human IgG conjugated withPE or FITC, and fluorescence-conjugated goat F(ab′)2 anti-mouse Ig's(Invitrogen) were purchased. The anti-idiotypic antibody against anAFP158/HLLA-A*02:01-specific antibody was developed and produced inhouse at Eureka Therapeutics. Flow cytometry data were collected usingBD FACSCanto II and analyzed using FlowJo software package.

All peptides were purchased and synthesized by Elim Biopharma. Peptideswere >90% pure. The peptides were dissolved in DMSO or diluted in salineat 10 mg/mL and frozen at −80° C. Biotinylated single chainAFP158/HLA-A*02:01 and control peptides/HLA-A*02:01 complex monomerswere generated by refolding the peptides with recombinant HLA-A*02:01and beta-2 microglobulin (02M). The monomers were biotinylated via theBSP peptide linked to the C-terminal end of HLA-A*02:01 extracellulardomain (ECD) by the BirA enzyme. Fluorescence-labelled streptavidin wasmixed with biotinylated peptide/HLA-A*02:01 complex monomer to formfluorescence-labelled peptide/HLA-A*02:01 tetramer.

Lentiviruses containing human CD19-specific orAFP158/HLA-A*02:01-specific CAR or caTCRs were produced, for example, bytransfection of 293T cells with vectors encoding the chimericconstructs. Primary human T-cells were used for transduction afterone-day stimulation with CD3/CD28 beads (Dynabeads®, Invitrogen) in thepresence of interleukin-2 (IL-2) at 100 U/ml. Concentrated lentiviruseswere applied to T-cells in Retronectin- (Takara) coated 6-well platesfor 96 hours. Transduction efficiencies of the anti-AFP and anti-CD19chimeric constructs were assessed by flow cytometry, using biotinylatedAFP158/HLA-A*02:01 tetramer (“AFP158 tetramer”) with PE-conjugatedstreptavidin or anti-myc antibody respectively. Repeat flow cytometryanalyses were done on day 5 and every 3-4 days thereafter.

Cell lines were transduced with either one or two vectors that encodethe two subunits of caTCR construct. Five days post-transduction, celllysates were generated for western blot using anti-HA (Anti-HA tagantibody—ChIP Grade, Abcam) or anti-Flag antibody (Anti-Flag AntibodyProduced in Rabbit, Sigma).

Tumor cytotoxicities were assayed by Cytox 96 Non-radioactive LDHCytotoxicity Assay (Promega). CD3⁺ T cells were prepared fromPBMC-enriched whole blood using EasySep Human T Cell Isolation Kit(StemCell Technologies) which negatively depletes CD14, CD16, CD19,CD20, CD36, CD56, CD66b, CD123, glycophorin A expressing cells. Human Tcells were activated and expanded with, for example, CD3/CD28 Dynabeads(Invitrogen) according to manufacturer's protocol. Activated T cells(ATC) were cultured and maintained in RPMI1640 medium with 10% FBS plus100 U/ml IL-2, and used at day 7-14. Activated T cells (immune cells)and target cells were co-cultured at various effector-to-target ratios(e.g., 2.5:1 or 5:1) for 16 hours and assayed for cytotoxicities.

Example 1. Chimeric Antibody-T Cell Receptor (caTCR) Designs

Various chimeric antibody-T cell receptor (caTCRs) designs arecontemplated, and six different examples are shown in FIG. 1 (caTCR-1,caTCR-2, caTCR-3, caTCR-4, caTCR-5, and caTCR-6). In these designs,various antibody moieties (Fab, Fab′, (Fab′)2, Fv, or scFv) are fused tothe amino terminus of T cell receptor α/β chains or γ/δ chains lackingvariable and constant domains and including all or part of theirconnecting peptide (region after the constant domain), theirtransmembrane domain, or a variant thereof, and any intracellular domainto form caTCR heterodimers which can be expressed on the surface of Tcells. In a native TCR, the Vα/Vβ or Vδ/Vγ domains form theantigen-binding domain of the TCR. Our designs replace the Vα-Cα/Vβ-Cβor Vδ-Cδ/Vγ-Cγ regions with various antibody moieties, and introduce atleast one variant TCR transmembrane domain, thus conferring anantibody's binding specificity to the construct, and resulting in anenhanced ability of the construct to recruit accessory molecules in aTCR complex, such as CD3δε, CD3γε and CD3ζζ, as compared to TCRs orrelated constructs with only naturally occurring TCR transmembranedomains. The caTCR constructs were named as follows: caTCR-[design#]-[variant location][#]. Design #1 corresponds to caTCR with a Fabantibody moiety, design #2 corresponds to caTCR with a Fab′ antibodymoiety, design #3 corresponds to caTCR with a (Fab′)2 antibody moiety,design #4 corresponds to caTCR with an Fv antibody moiety, design #5corresponds to caTCR with a single scFv antibody moiety, and design #6corresponds to caTCR with two scFv antibody moieties (see FIG. 1). Novariant location and #0 (e.g., caTCR-1-0) corresponds to a constructwith naturally occurring TCR domains, and #≥1 corresponds to caTCR withspecific variants in the variant location (e.g., caTCR-1-TM1 correspondsto one transmembrane domain variant, caTCR-1-EC1 corresponds to oneextracellular domain variant; see Table 2).

In the caTCR-1 (IgV_(H)-IgC_(H)1-TCRδ/IgV_(L)-IgC_(L)-TCRγ) design, thevariable domain and the first constant domain (IgV_(H)-IgC_(H)1) of anantibody heavy chain replaces the amino terminal portion of the TCRSchain up to a position bordering or within the connecting peptide in theextracellular domain of the TCRS chain after the Vδ-Cδ region,optionally wherein the transmembrane domain of the TCRS chain ismodified, such as by substitution of one or more amino acids. Thevariable domain and the constant domain (IgV_(L)-IgC_(L)) of thecorresponding antibody light chain replaces the amino terminal portionof the TCRγ chain up to a position bordering or within the connectingpeptide in the extracellular domain of the TCRγ chain after the Vγ-Cγregion, optionally wherein the transmembrane domain of the TCRγ chain ismodified, such as by substitution of one or more amino acids.

In one embodiment of caTCR-1, one chain includes the IgV_(H) domain ofan anti-AFP158/LA-A*02:01 antibody (SEQ ID NO: 62) fused to an IgC_(H)1domain (any one of SEQ ID NOs: 37-47) fused to a carboxy-terminalportion of the TCRS chain including the transmembrane domain and all orpart of the connecting peptide of the TCRS chain, and the other chainincludes the IgV_(L) domain of the anti-AFP158/HLA-A*02:01 antibody (SEQID NO: 63) fused to an IgC_(L) domain (SEQ ID NO: 48) fused to acarboxy-terminal portion of the TCRγ chain including the transmembranedomain and all or part of the connecting peptide of the TCRγ chain. Insome embodiments, both of the TCR transmembrane domains are naturallyoccurring. In some embodiments, at least one of the TCR transmembranedomains is a non-naturally occurring variant comprising one or moreamino acid substitutions. In some embodiments, the carboxy terminalportion of the TCRS chain includes a connecting peptide having the aminoacid sequence of SEQ ID NO: 31 or 32. In some embodiments, the carboxyterminal portion of the TCRS chain includes a transmembrane domainhaving the amino acid sequence of any one of SEQ ID NOs: 7, and 9-13. Insome embodiments, the carboxy terminal portion of the TCR chain includesa connecting peptide having the amino acid sequence of SEQ ID NO: 33 or34. In some embodiments, the carboxy terminal portion of the TCRγ chainincludes a transmembrane domain having the amino acid sequence of anyone of SEQ ID NOs: 8, and 14-26.

In the caTCR-2 (IgV_(H)-IgC_(H)1-hinge-TCRS/IgV_(L)-IgC_(L)-linker-TCRγ)design, the variable domain, the first constant domain, and the hinge(IgV_(H)-IgC_(H)1-hinge) of an antibody heavy chain replaces the aminoterminal portion of the TCRS chain up to a position bordering or withinthe connecting peptide in the extracellular domain of the TCRS chainafter the Vδ-Cδ region, optionally wherein the transmembrane domain ofthe TCRS chain is modified, such as by substitution of one or more aminoacids. The variable domain and the constant domain of the correspondingantibody light chain fused to a linker (IgV_(L)-IgC_(L)-linker) replacesthe amino terminal portion of the TCRγ chain up to a position borderingor within the connecting peptide in the extracellular domain of the TCRγchain after the Vγ-Cγ region, optionally wherein the transmembranedomain of the TCRγ chain is modified, such as by substitution of one ormore amino acids.

In the caTCR-3(IgV_(H)-IgC_(H)1-hinge-TCRδ/IgV_(H)-IgC_(H)1-hinge-TCRγ+IgV_(L)-IgC_(L))design, the variable domain, the first constant domain, and the hinge(IgV_(H)-IgC_(H)1-hinge) of an antibody heavy chain replaces the aminoterminal portion of the TCRS chain up to a position bordering or withinthe connecting peptide in the extracellular domain of the TCRS chainafter the Vδ-Cδ region, optionally wherein the transmembrane domain ofthe TCRS chain is modified, such as by substitution of one or more aminoacids. The variable domain, the first constant domain, and the hinge(IgV_(H)-IgC_(H)1-hinge) of the antibody heavy chain replaces the aminoterminal portion of the TCRγ chain up to a position bordering or withinthe connecting peptide in the extracellular domain of the TCRγ chainafter the Vγ-Cγ region, optionally wherein the transmembrane domain ofthe TCRγ chain is modified, such as by substitution of one or more aminoacids. The variable domain and the constant domain of the correspondingantibody light chain (IgV_(L)-IgC_(L)) are associated with theIgV_(H)-IgC_(H)1 domains.

In the caTCR-4 (IgV_(H)-TCR6/IgV_(L)-TCRγ) design, the variable domain(IgV_(H)) of an antibody heavy chain replaces the amino terminal portionof the TCR6 chain up to a position bordering or within the connectingpeptide in the extracellular domain of the TCR6 chain after the Vδ-Cδregion, optionally wherein the transmembrane domain of the TCR6 chain ismodified, such as by substitution of one or more amino acids. Thevariable domain (IgV_(L)) of the corresponding antibody light chainreplaces the amino terminal portion of the TCRγ chain up to a positionbordering or within the connecting peptide in the extracellular domainof the TCRγ chain after the Vγ-Cγ region, optionally wherein thetransmembrane domain of the TCRγ chain is modified, such as bysubstitution of one or more amino acids.

In the caTCR-5 (IgV_(H)-IgV_(L)-TCRδ/TCRγ) design, the variable domainof an antibody heavy chain fused to the variable domain of thecorresponding antibody light chain (IgV_(H)-IgV_(L) or IgV_(L)-IgV_(H))replaces the amino terminal portion of the TCRδ chain up to a positionbordering or within the connecting peptide in the extracellular domainof the TCRδ chain after the Vδ-Cδ region, optionally wherein thetransmembrane domain of the TCRδ chain is modified, such as bysubstitution of one or more amino acids. The amino terminal portion ofthe TCRγ chain up to a position bordering or within the connectingpeptide in the extracellular domain of the TCRγ chain after the Vγ-Cγregion is deleted, optionally wherein the transmembrane domain of theTCRγ chain is modified, such as by substitution of one or more aminoacids.

In the caTCR-6 (IgV_(H)-IgV_(L)-TCR6/IgV_(H)-IgV_(L)-TCR) design, thevariable domain of an antibody heavy chain fused to the variable domainof the corresponding antibody light chain (IgV_(H)-IgV_(L) orIgV_(L)-IgV_(H)) replaces the amino terminal portion of the TCRδ chainup to a position bordering or within the connecting peptide in theextracellular domain of the TCRδ chain after the Vδ-Cδ region,optionally wherein the transmembrane domain of the TCRδ chain ismodified, such as by substitution of one or more amino acids. Thevariable domain of an antibody heavy chain fused to the variable domainof the corresponding antibody light chain (IgV_(H)-IgV_(L) orIgV_(L)-IgV_(H)) replaces the amino terminal portion of the TCRγ chainup to a position bordering or within the connecting peptide in theextracellular domain of the TCRγ chain after the Vγ-Cγ region,optionally wherein the transmembrane domain of the TCRγ chain ismodified, such as by substitution of one or more amino acids.

Example 2: Construction and Characterization of T Cells Transduced withAnti-CD19 caTCR-1 and Anti-CD19 Chimeric Stimulation Receptor

A nucleic acid fragment encoding the anti-CD19 binding moiety (SEQ IDNOs: 58 and 59) was used to generate both a chimeric co-stimulatoryreceptor (CSR; also referred herein as “CSR1”) comprising CD28transmembrane and intracellular signaling sequences (SEQ ID NO: 51) andcaTCR-1 constructs (caTCR-1-0 or caTCR-1-TM5). Primary T cells weretransduced with either CSR alone, caTCR-1-0 alone, caTCR-1-0 incombination with CSR, or caTCR-1-TM5 in combination with CSR.Transduction efficiency was determined by cell surface staining and allcaTCR-1 T-cells were matched at approximately 40% receptor positive bymixing with mock T-cells.

In Vitro Killing

CD80/86 negative NALM6 cells (leukemia cells expressing CD19) were usedas target cells for T-cell stimulation at an effector-to-target ratio of2.5:1. Specific T-cell lysis was measured after 16 hr incubation usingthe Cytox 96 Non-radioactive Cytotoxicity Assay (Promega).

Expression of anti-CD19-CSR with either anti-CD19-caTCR-1-0 oranti-CD19-caTCR-1-TM5 created fully functional cytotoxic T-cells capableof lysing NALM6 tumor cells in vitro (FIG. 2). Because the T cellsexpressing only the caTCR-1-0 and those expressing both caTCR-1(caTCR-1-0 or caTCR-1-TM5) and CSR were all capable of lysing almost100% of NALM6 target cells, no significant difference of the number ofkilled target cells was observed between the two types of T cells.

Cytokine Secretion

The concentration of cytokines released into the supernatant of the invitro killing reactions was measured with a Bioplex200 (Luminex) usingthe Bio-plex Pro Human Cytokine 8-plex kit (BioRad). T cells expressingthe CSR in combination with the caTCR (CSR-positive and caTCR-positiveT-cells) released more cytotoxic cytokines than T-cells expressingca-TCR-1-0 alone (FIG. 3).

Intracellular Cytokine Expression

T-cells were stimulated with target cells at an E:T ratio 1:2 in thepresence of secretion inhibitor brefeldin A (BFA) for 4 hours. T-cellswere permeabilized and cytokine specific antibodies were used to detectcytokines expressed in response to tumor stimulation. The percentage ofcytokine-positive cells was determined using flow cytometry. TheCSR-positive and caTCR-positive T-cells expressed more intracellularcytokines than T-cells expressing ca-TCR-1-0 alone (Table 5).

TABLE 5 %, Positive Raji NALM6 T-cell Alone Intracellular TNFαExpression in CD8+ T-cells CSR 0.58 0.44 0.04 caTCR-1-0 24.3 20.1 0.04caTCR-1-0 + CSR 28.7 28.2 0.07 caTCR-1-TM5 + CSR 29 31.5 0.04Intracellular IL-2 Expression in CD8+ T-cells CSR 0.97 0.71 0.49caTCR-1-0 8.5 4.36 0.61 caTCR-1-0 + CSR 12.5 8.2 0.53 caTCR-1-TM5 + CSR10.6 8.2 0.65 Intracellular IFN-γ Expression in CD8+ T-cells CSR 1.432.28 0.17 caTCR-1-0 18.2 15.5 0.78 caTCR-1-0+CSR 21.8 18.8 1.72caTCR-1-TM5+CSR 18.5 16.4 0.51

Taken together, the results indicate that the addition of the CSRincreases the sensitivity and responsiveness of the caTCR T-cells. Theincreased amount of cytokines expressed in and released from CSR-caTCRdouble positive T cells indicates that the co-stimulation of bothcaTCR-1 and CSR raises the cytotoxic potential of the T-cells.

Degranulation

The primary mechanism by which T cells lyse tumor cells is by producingsecretory granules of cytotoxic molecules that are released into targetcells. CD107a can be used as a marker of degranulation activity andincreased expression of CD107a correlates with an increase in cytotoxicT-cell function.

T cells were mixed with fluorescently-conjugated anti-CD107a andstimulated with target cells at an E:T ratio of 1:2 in the presence ofthe endocytosis inhibitor monensin for 4 hours. The amount of CD107adetected on the T-cell surface is a direct measure of the degree ofcytotoxic degranulation induced by antigen recognition. Engagement ofthe CSR on caTCR T-cells increased T-cell degranulation, furtherdemonstrating that the CSR makes the therapeutic T-cells more reactivetowards the intended tumor cells (FIG. 4).

Proliferation

The proliferation and persistence of genetically modified T-cells iscrucial for the success of adoptive T-cell transfer therapies whentreating cancers. To assay the effect of the CSR on T-cell proliferationand persistence we labeled T-cells with the intracellular dye CFSE andobserved the dilution of the dye as the T-cells divided when stimulatedwith tumor cells. We were also able to measure persistence of theT-cells by counting the number of CFSE-positive cells remaining at theindicated day.

Respective T-cells were serum starved overnight and labeled with CFSEusing CellTrace CFSE (Thermo Fisher C34554). 100,000 T-cells wereincubated at an E:T ratio of 2:1 and flow cytometry was used to observeserial dilution of the CFSE dye as the T-cells divide at the indicatedday. The total number of T-cells were counted with FACs.

CFSE dilution increased with CSR stimulation, indicating these T-cellshad a higher proliferation potential (FIG. 5). Importantly there is alsoan increase in the cell number meaning that the cells not onlyproliferate better but their persistence is also maintained (Table 6).

TABLE 6 # of T cells Persisting After Engagement BV173 NALM6 −0 −TM5 −0−TM5 −0 +CSR +CSR −0 +CSR +CSR Day 3 10354 28847 38830 6591 17260 32331Day 5 2945 16049 26551 1240 2988 8620 Day 7 253 2135 5985 329 158 684

The results show that we were able to simultaneously stimulate both CSRand caTCR with tumor cells expressing both target ligand and targetantigen, and that the co-stimulation of CSR and caTCR enhanced thecytotoxicity, proliferation potential, and persistence of caTCR T-cells.These are all characteristics that will increase the therapeuticpotential of caTCR-based therapies using adoptive transfer.

Example 3. Construction and Characterization of T Cells Transduced withAnti-AFP caTCR-1 and Anti-GPC3 CSR

A nucleic acid fragment encoding the anti-AFP binding moiety (SEQ IDNOs: 62 and 63) was used to generate caTCR-1 constructs (caTCR-1-0 orcaTCR-1-TM5). A nucleic acid fragment encoding the anti-GPC3 bindingmoiety (SEQ ID NOs: 64 and 65) was used to generate a CSR (i.e., CSR1)comprising CD28 transmembrane and intracellular signaling sequences (SEQID NO: 51).

In Vitro Killing

HEPG2 cells (human liver cancer cells expressing AFP and GPC3) andHEPG2-GPC3.KO cells (HEPG2 cells with a targeted knockout of the GPC3gene) were used as target cells for T-cell stimulation at aneffector-to-target ratio of 2.5:1. Specific T-cell lysis was measuredafter 16 hr incubation using the Cytox 96 Non-radioactive CytotoxicityAssay (Promega).

Expression of anti-GPC3-CSR with either anti-AFP-caTCR-1-0 oranti-AFP-caTCR-1-TM5 resulted in fully functional cytotoxic T-cellscapable of lysing HEPG2 cells in vitro (FIG. 6). T cells expressing onlythe caTCR-1-0 had much less specific killing (about 15%) than thoseexpressing both caTCR-1 (caTCR-1-0 or caTCR-1-TM5) and the CSR (betweenabout 55% to about 65%). By contrast, specific killing was reduced toabout 10% for T cells expressing both the caTCR and CSR when usingHEPG2-GPC3.KO target cells (FIG. 6), indicating that engagement of theCSR with its target ligand is responsible for the increasedcytotoxicity.

Cytokine Secretion

The concentration of cytokines released into the supernatant of the invitro killing experiments was measured with a Bioplex200 (Luminex) usingthe Bio-plex Pro Human Cytokine 8-plex kit (BioRad). The CSR-positiveand caTCR-positive T-cells released more cytotoxic cytokines thanT-cells expressing ca-TCR-1-0 alone for the HEPG2 target cellsexpressing both the caTCR target antigen and the CSR target ligand (FIG.7). By contrast, there we little or no difference between the T cellsexpressing ca-TCR-1-0 alone or both a caTCR and the CSR for theHEPG2-GPC3.KO target cells lacking the CSR target ligand (FIG. 7).

Intracellular Cytokine Expression

T-cells were stimulated with target cells (HEPG2) at an E:T ratio 1:2 inthe presence of secretion inhibitor brefeldin A (BFA) for 4 hours.T-cells were permeabilized and cytokine specific antibodies were used todetect cytokines expressed in response to tumor stimulation. The percentof cytokine-positive cells was determined using flow cytometry. TheCSR-positive and caTCR-positive T-cells expressed more intracellularcytokines than T-cells expressing ca-TCR-1-0 alone (Table 7).

TABLE 7 %, Positive HEP G2 T-cell Alone Intracellular TNFα Expression inCD8+ T-cells CSR 0.3 0.2 caTCR-1-0 14.7 0.1 caTCR-1-0 + CSR 17.0 0.1caTCR-1-TM5 + CSR 15.7 0.1 Intracellular IL-2 Expression in CD4+ T-cellsCSR 0.1 0.04 caTCR-1-0 8.2 0.11 caTCR-1-0 + CSR 9.8 0.05 caTCR-1-TM5 +CSR 11.2 0.03 Intracellular IFNγ Expression in CD8+ T-cells CSR 0.2 0.08caTCR-1-0 3.1 0.2 caTCR-1-0 + CSR 4.5 0.1 caTCR-1-TM5 + CSR 5.1 0.06

Taken together, the results indicate that the addition of the CSRincreases the sensitivity and responsiveness of caTCR plus CSR T-cellshaving a different caTCR target antigen and CSR target ligand. Theincreased amount of cytokines expressed in and released from theseCSR-caTCR double positive T cells provides further evidence that theco-stimulation of both caTCR-1 and CSR raises the cytotoxic potential ofthe T-cells.

Degranulation

T cells were mixed with fluorescently-conjugated anti-CD107a andstimulated with HEPG2 target cells at an E:T ratio of 1:2 in thepresence of the endocytosis inhibitor monensin for 4 hours. Engagementof the CSR on caTCR T-cells increased T-cell degranulation, furtherdemonstrating that the CSR makes the therapeutic T-cells more reactivetowards the intended tumor cells (FIG. 8).

Proliferation

T-cells were labeled with the intracellular dye CFSE, and dye dilutionand number of CFSE-positive cells remaining at the indicated day wasmeasured.

Respective T-cells were serum starved overnight and labeled with CFSEusing CellTrace CFSE (Thermo Fisher C34554). 100,000 T-cells wereincubated at an E:T ratio of 2:1 and flow cytometry was used to observeserial dilution of the CFSE dye as the T-cells divide at the indicatedday. The total number of T-cells was counted by FACs.

CFSE dilution increased with CSR stimulation, indicating these T-cellshad a higher proliferation potential (FIG. 9). Importantly there is alsoan increase in the cell number, meaning that the cells not onlyproliferate better but their persistence is also maintained (Table 8).

TABLE 8 # of T-Cells Persisting After Engagement with HEPG2 Day3 Day5Day7 CSR 7,147 4,519 3,055 caTCR1-0 5,674 4,362 3,372 caTCR1-0 + CSR31,422 18,689 8,833 caTCR-1-TM5 + CSR 28,874 21,978 9,471

The results show that we were able to simultaneously stimulate both CSRand caTCR with ligand positive tumor cells, and that the co-stimulationof CSR and caTCR enhanced the cytotoxicity, proliferation potential, andpersistence of caTCR T-cells. These are all characteristics that willincrease the therapeutic potential of caTCR-based therapies usingadoptive transfer.

Example 4. Construction and Characterization of T Cells Transduced withAnti-CD19 caTCR-1 and Anti-CD20 CSR

A nucleic acid fragment encoding an anti-CD20 binding moiety (SEQ IDNOs: 60 and 61) was used to generate an anti-CD20 CSR (i.e., “CSR1”)that comprises CD28 transmembrane and intracellular signaling sequences(SEQ ID NO: 51), which was expressed on the same vector that expressedanti-CD19 caTCR-1-0 or caTCR-1-TM5 generated using an anti-CD19 bindingmoiety (SEQ ID NOs: 58 and 59).

In Vitro Killing

Raji, BV173, NALM6, and Jeko-1 cells (cell lines that express CD19 andCD20) were used as target cells for T-cell killing at aneffector-to-target ratio of 2.5:1. Specific T-cell lysis was measuredafter 16 hr incubation using the Cytox 96 Non-radioactive CytotoxicityAssay (Promega).

Expression of anti-CD20-CSR with either anti-CD19-caTCR-1-0 oranti-CD19-caTCR-1-TM5 created fully functional cytotoxic T-cells capableof lysing a variety of CD19-positive, CD20-positive tumor cells in vitro(FIG. 10).

Cytokine Secretion

The concentration of cytokines released into the supernatant of the Rajiin vitro killing experiments was measured with a Bioplex200 (Luminex)using the Bio-plex Pro Human Cytokine 8-plex kit (BioRad). TheCSR-positive and caTCR-positive T-cells released more GM-CSF, IFNγ, andTNFα than T-cells expressing ca-TCR-1-0 alone (FIG. 11).

Degranulation

T cells were mixed with fluorescently-conjugated anti-CD107a andstimulated with Raji target cells at an E:T ratio of 1:2 in the presenceof the endocytosis inhibitor monensin for 4 hours. Engagement of the CSRon caTCR T-cells increased T-cell degranulation, further demonstratingthat the CSR makes the therapeutic T-cells more reactive towards theintended tumor cells (FIG. 12).

Examples 2-4 show that the CSR is a modular molecule that can be used incombination with various antigen-targeting moieties to increase thetherapeutic potential of caTCR-expressing T cells for a broad spectrumof diseased cells.

Example 5: Construction and Characterization of T Cells Transduced withAnti-CD19 caTCR-1 and Anti-CD19 Chimeric Stimulation Receptor Variants

Nucleic acid fragments encoding the anti-CD19 binding moiety (SEQ IDNOs: 58 and 59) was used to generate both a chimeric co-stimulatoryreceptor (CSR) and a caTCR-1-0 construct (referred in this example as“caTCR-1”). Different CSRs were prepared by fusing the anti-CD19 bindingmoiety to the CSR sequence. CSR1 comprises CD28 transmembrane andintracellular signaling sequences (SEQ ID NO: 90). CSR2 comprises a CD8transmembrane sequence and a 4-1BB instracellular signaling sequence(SEQ ID NO: 91). CSR3 comprises 4-1BB transmembrane and intracellularsignaling sequences (SEQ ID NO: 92). CSR4 comprises a CD8 transmembranesequence and a CD27 instracellular signaling sequence (SEQ ID NO: 93).CSR5 comprises CD27 transmembrane and intracellular signaling sequences(SEQ ID NO: 94). CSR6 comprises a CD8 transmembrane sequence and a CD30instracellular signaling sequence (SEQ ID NO: 95). CSR7 comprises CD30transmembrane and intracellular signaling sequences (SEQ ID NO: 96).CSR8 comprises a CD8 transmembrane sequence and a OX40 instracellularsignaling sequence (SEQ ID NO: 97). CSR9 comprises OX40 transmembraneand intracellular signaling sequences (SEQ ID NO: 98).

Primary T cells were transduced with an anti-CD19 CSR alone, or withanti-CD19 caTCR-1 in combination with an anti-CD19 CSR. Transductionefficiency was determined by cell surface staining and allcaTCR-transduced T-cells were matched at approximately 40% receptorpositive by mixing with mock T-cells.

T Cells Expressing Anti-CD19 CSR Alone In Vitro Killing

Raji or NALM6 cells were used as target cells for T-cell stimulation atan effector-to-target ratio of 2.5:1. Specific T-cell lysis was measuredafter 16 hr incubation using the Cytox 96 Non-radioactive CytotoxicityAssay (Promega). T cells expressing anti-CD19 CSR-6, CSR-7, CSR-8 orCSR-9 alone did not result in an elevated number of killed target cellscompared to untranduced mock T cells (data not shown).

Cytokine Secretion

The concentration of cytokines released into the supernatant of the invitro killing reactions was measured with a Bioplex200 (Luminex) usingthe Bio-plex Pro Human Cytokine 8-plex kit (BioRad). T cells expressinganti-CD19 CSR-6, CSR-7, CSR-8 or CSR-9 alone did not release significantamount of IFNγ when incubated with Raji or NALM6 (data not shown).

T Cells Expressing Anti-CD19 caTCR-1 and Anti-CD19 CSRs

In two different batches of experiments, respective T-cells expressingboth anti-CD19 caTCR-1 and an anti-CD19 CSR were serum starved overnightand labeled with CFSE using CellTrace CFSE (Thermo Fisher C34554).T-cells were incubated with NALM6 at an E:T ratio of 2:1 and flowcytometry was used to observe serial dilution of the CFSE dye as theT-cells divide at the indicated day. The total number of T-cells wascounted by FACs. These experiments were repeated using primary T cellsobtained from a second donor. Similar results were observed (data notshown).

CFSE dilution was observed in all T cells expressing both anti-CD19caTCR-1 and an anti-CD19 CSR, indicating high proliferation potential ofthese T cells (FIGS. 14-15). Additionally, T cells expressing bothanti-CD19 caTCR-1 and an anti-CD19 CSR showed significant persistenceover a period of 10 days (Table 9). In a control experiment, T cellsexpressing any one of anti-CD19 CSR-1 to anti-CD19 CSR-5 alone did notshow increased proliferation potential or persistence over time (datanot shown).

TABLE 9 # of T-Cells Persisting After Engagement with NALM6 caTCR-1 +caTCR-1 + caTCR-1 + caTCR-1 + caTCR-1 + CSR-1 CSR-2 CSR-3 CSR-4 CSR-5Day3 144622 171874 128353 158852 173153 Day5 307957 196842 126643 237138275630 Day7 187440 184933 75822 163892 168092 Day10 88562 114640 36480111527 118921 caTCR-1 + caTCR-1 + caTCR-1 + caTCR-1 + caTCR-1 + CSR-1CSR-6 CSR-7 CSR-8 CSR-9 Day3 206073 234073 202600 264248 240125 Day589685 243962 226587 264685 225515 Day7 111523 186479 187614 175982150052 Day10 141112 285946 278322 274536 228298

Example 6: In Vivo Efficacy Study of T Cells Transduced with Anti-CD19caTCR-1 and Anti-CD19 CSR

The in vivo anti-tumor activity of T cells expressing both anti-CD19caTCR-1 and anti-CD19 CSR-1 was tested in a human CD19+ NALM-6 pre-BAcute Lymphoblastic Leukemia (ALL) model. Luciferase-expressing NALM-6cells were implanted intravenously (i.v.) into NOD SCID gamma (NSG)immune-compromised mice and tumor burden was assessed by measuringtumor-derived bioluminescence. Six days post tumor implantation, micewere randomized based on total bioluminescent flux into treatmentgroups: (1) i.v. injection of 5×10⁶ un-transduced donor-matched (Mock) Tcells, (2) i.v. injection of 2×10⁶ T cells expressing anti-CD19 caTCR-1only (“caTCR-1 T cell”) and (3) i.v. injection of 2×10⁶ T cellsexpressing both anti-CD19 caTCR-1 and anti-CD19 CSR-1 (“caTCR-1 CSR-1 Tcell”; n=6 mice/group). Health effects resulting from T cell infusionsin mice were assessed by monitoring their general appearance, bodyweight, and other clinical signs of adverse response (includinghypothermia, labored respiration, and hind-limb paralysis/weakness).

As shown in FIG. 16, while both caTCR-1 T cell and caTCR-1 CSR-1 T celltreatment resulted in tumor growth inhibition, caTCR-1 CSR-1 T cellsshowed enhanced anti-tumor activity compared to caTCR-1 T cells. AllcaTCR-1 T cell-treated and caTCR-1 CSR-1 T cell-treated micedemonstrated normal gait, posture, and activity/responsiveness for theduration of the study. In addition, caTCR-1 T cell-treated and caTCR-1CSR-1 T cell-treated mice did not lose body weight during the study.Overall, the lack of observable abnormal parameters in treated micedemonstrates the safety of the caTCR-1 CSR-1 T cell therapy.

To determine the level of cytokine release in vivo, key cytokines,including those related to clinical cytokine release syndrome, wereanalyzed 24 hours after the NALM-6 tumor-bearing mice were administeredwith anti-CD19 CAR-T cells or caTCR-1 CSR-1 T cells. Cytokine levelswere quantified with Luminex Magpix technology using BioRad Bio-Plexkits. As shown in FIG. 17, caTCR-1 CSR-1 T cell-treated mice hadsignificantly lower level of cytokine release than CAR-T treated mice.

Example 7: In Vivo Efficacy Study of T Cells Transduced with Anti-AFPcaTCR-1 and Anti-GPC3 CSR

The in vivo anti-tumor activity of T cells expressing both anti-AFPcaTCR-1 and anti-GPC3 CSR-1 (see, Example 3 for construct information)was tested in an established human AFP⁺/HLA-A2⁺ Hep G2 liver cancerxenograft model. Hep G2 cells were implanted subcutaneously (s.c.) overthe right flank of SCID-Beige mice. When tumors reached ˜100 mm³, micewere intratumorally (i.t.) injected with either (1) 5×10⁶ un-transduceddonor-matched (Mock) T cells, (2) 2×10⁶ T cells expressing an anti-AFPCAR comprising the same anti-AFP binding moiety (SEQ ID NOs: 62 and 63),or (3) 2×10⁶ T cells expressing both anti-AFP caTCR-1 and anti-GPC3CSR-1 (n6 mice/group). Health effects resulting from the T cellinfusions in mice were assessed by monitoring their general appearance,body weight, and other clinical signs of adverse response (includinghypothermia, labored respiration, and hind-limb paralysis/weakness).

As shown in FIG. 18, both anti-AFP CAR T cell treatment and anti-AFPcaTCR-1/anti-GPC3 CSR-1 T cell treatment resulted in profound andsignificant (****P<0.0001; Dunnett's multiple comparison test) tumorgrowth inhibition. All anti-AFP CAR-T treated and anti-AFPcaTCR-1/anti-GPC3 CSR-1 T cell-treated mice demonstrated normal gait,posture, and activity/responsiveness for the duration of the study. Inaddition, anti-AFP CAR-T treated and anti-AFP caTCR-1/anti-GPC3 CSR-1 Tcell-treated mice did not lose body weight during the study. Overall,the lack of observable abnormal parameters in treated mice demonstratesthe safety of the anti-AFP caTCR-1/anti-GPC3 CSR-1 T cell therapy.

Sequence Listing SEQ ID NO Description Sequence   1 TCRα constantPNIQNPDPAVYQLRDSKSSDK domain SVCLFTDFDSQTNVSQSKDSD VYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIP EDTFFPSPESSCDVKLVEKSF ETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS   2 TCRβ constant EDLNKVFPPEVAVFEPSEAEI domainSHTQKATLVCLATGFFPDHVE LSWWVNGKEVHSGVSTDPQPL KEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSE NDEWTQDRAKPVTQIVSAEAW GRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVL MAMVKRKDF   3 TCRδ constant SQPHTKPSVFVMKNGTNVACLdomain VKEFYPKDIRINLVSSKKITE FDPAIVISPSGKYNAVKLGKY EDSNSVTCSVQHDNKTVHSTDFEVKTDSTDHVKPKETENTKQ PSKSCHKPKAIVHTEKVNMMS LTVLGLRMLFAKTVAVNFLLT AKLFFL  4 TCRγ constant DKQLDADVSPKPTIFLPSIAE domain TKLQKAGTYLCLLEKFFPDVIKIHWQEKKSNTILGSQEGNTM KTNDTYMKFSWLTVPEKSLDK EHRCIVRHENNKNGVDQEIIFPPIKTDVITMDPKDNCSKDAN DTLLLQLTNTSAYYMYLLLLL KSVVYFAIITCCLLRRTAFCC NGEKS  5 TCRα ILLLKVAGFNLLMTLRLWSS transmembrane domain   6 TCRβTILYEILLGKATLYAVLVSAL transmembrane VL domain   7 TCRδVLGLRMLFAKTVAVNFLLTAK transmembrane LFFL domain   8 TCRγYYMYLLLLLKSVVYFAIITCC transmembrane LL domain (same as uniprot)   9 TCRδVLGLRMLFAKTVAVNFLLTAK transmembrane LFSL domain F24S  10 TCRδVLGLRVLFAKTVAVNFLLTAK transmembrane LFFL domain M6V  11 TCRδVLGCRMLFAKTVAVNFLLTAK transmembrane LFFL domain L4C  12 TCRδVLGLRMLFAKTFAVSFLLTAK transmembrane LFFL domain V12F, N15S  13 TCRδVLGLRMLFAKTVAVNFLLTAK transmembrane LFF S domain L25S  14 TCRγYYMYLLLLLKSVYYFAIITCC transmembrane LLRRTAF domain V13Y  15 TCRγYYMYLLLLLKSVVYFAIITCG transmembrane LLRRTAF domain C21G  16 TCRγYLVYLLLLLKSVVYFVIVTCC transmembrane LLRRTAF domain Y2L, M3V, A16V, I18V 17 TCRγ YLMYLLLLLKSVVYFAIITCC transmembrane LLRRTAF domain Y2L  18 TCRγYYVYLLLLLKSVVYFAIITCC transmembrane LLRRTAF domain M3V  19 TCRγYYMYLLLLLKSVVYFVIITCC transmembrane LLRRTAF domain A16V  20 TCRγYYMYLLLLLKSVVYFAIVTCC transmembrane LLRRTAF domain I18V  21 TCRγYYIYLLLLLKSVVYFAIITCC transmembrane LLRRTAF domain M3I  22 TCRγYIIYLLLLLKSVVYFIILTCC transmembrane LLRRTAF domain Y2I, M3I, A16I, I18L 23 TCRγ YYMYCLLLLKSVVYFAIITCC transmembrane LLRRTAF domain L5C  24 TCRγYYMYLLLFLKSFVYSAIITCC transmembrane LLRRTAF domain L8F, V12F, F15S  25TCRγ YYMYLLLLLKSVVYFAIIT M C transmembrane LLRRTAF domain C19M  26 TCRγQ YMYLLLLLKSVVYFAIITCC transmembrane LLRRTAF domain Y1Q  27TCRα connecting ESSCDVKLVEKSFETDTNLNF peptide QNLSVIGFR  28TCRα connecting IPEDTFFPSPESSCDVKLVEK peptide MD SFETDTNLNFQNLSVIGFR  29TCRβ connecting ADCGFTSVSYQQGVLSA peptide  30 TCRβ connectingGRADCGFTSVSYQQGVLSA peptide MD  31 TCRδ connecting DHVKPKETENTKQPSKSCHKPpeptide KAIVHTEKVNMMSLTVLGLR  32 TCRδ connecting EVKTDSTDHVKPKETENTKQPpeptide MD SKSCHKPKAIVHTEKVNMMSL TVLGLR  33 TCRγ connectingMDPKDNCSKDANDTLLLQLTN peptide TSA  34 TCRγ connectingPIKTDVITMDPKDNCSKDAND peptide MD TLLLQLTNTSA  35 TCRβ intracellularMAMVKRKDF domain  36 TCRγ intracellular RRTAFCCNGEKS domain  37IgG1 C_(H)1 ASTKGPSVFPLAPSSKSTSGG TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICN VNHKPSNTKVDKRVEPKSC  38IgG2-0C C_(H)1 ASTKGPSVFPLAPCSRSTSES TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSNFGTQTYTCN VDHKPSNTKVDKTVERK  39IgG2-1C C_(H)1 ASTKGPSVFPLAPCSRSTSES TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSNFGTQTYTCN VDHKPSNTKVDKTVERKC  40IgG2-2C C_(H)1 ASTKGPSVFPLAPCSRSTSES TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSNFGTQTYTCN VDHKPSNTKVDKTVERKCC  41IgG3 C_(H)1 ASTKGPSVFPLAPCSRSTSGG TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYTCN VNHKPSNTKVDKRVELKTP  42IgG4 C_(H)1 ASTKGPSVFPLAPCSRSTSES TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTKTYTCN VDHKPSNTKVDKRVESKYG  43IgA1 C_(H)1 ASPTSPKVFPLSLCSTQPDGN VVIACLVQGFFPQEPLSVTWSESGQGVTARNFPPSQDASGDL YTTSSQLTLPATQCLAGKSVT CHVKHYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPS  44 IgA2 C_(H)1 ASPTSPKVFPLSLDSTPQDGNVVVACLVQGFFPQEPLSVTWS ESGQNVTARNFPPSQDASGDL YTTSSQLTLPATQCPDGKSVTCHVKHYTNPSQDVTVPCPVPP PPP  45 IgD C_(H)1 APTKAPDVFPIISGCRHPKDNSPVVLACLITGYHPTSVTVTW YMGTQSQPQRTFPEIQRRDSY YMTSSQLSTPLQQWRQGEYKCVVQHTASKSKKEIFRWPESPK AQASSVPTAQPQAEGSLAKAT TAPATTRNTGRGGEEKKKEKEKEEQEERETKTP  46 IgE C_(H)1 ASTQSPSVFPLTRCCKNIPSN ATSVTLGCLATGYFPEPVMVTWDTGSLNGTTMTLPATTLTLS GHYATISLLTVSGAWAKQMFT CRVAHTPSSTDWVDNKTFS  47IgM C_(H)1 GSASAPTLFPLVSCENSPSDT SSVAVGCLAQDFLPDSITLSWKYKNNSDISSTRGFPSVLRGG KYAATSQVLLPSKDVMQGTDE HVVCKVQHPNGNKEKNVPLP  48IgC_(L) domain GQPKANPTVTLFPPSSEELQA NKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSN NKYAASSYLSLTPEQWKSHRS YSCQVTHEGSTVEKTVAPTEC S  49fragment of CD28 IEVMYPPPYLDNEKSNGTIIH VKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFII FWVRSKRSRLLHSDYMNMTPR RPGPTRKHYQPYAPPRDFAAY RS  50fragment of CD3- RVKFSRSADAPAYQQGQNQLY zeta NELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQ KDKMAEAYSEIGMKGERRRGK GHDGLYQGLSTATKDTYDALHMQALPPR  51 CD28 co-stimulatory IEVMYPPPYLDNEKSNGTIIH fragment 1VKGKHLCPSPLFPGPSKPFWV LVVVGGVLACYSLLVTVAFII FWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAY RS  52 CD28 co-stimulatory RSKRSRLLHSDYMNMTPRRPGfragment 2 PTRKHYQPYAPPRDFAAYRS  53 4-1BB co- PADLSPGASSVTPPAPAREPGstimulatory fragment HSPQIISFFLALTSTALLFLL 1 FFLTLRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRF PEEEEGGCEL  54 4-1BB co- KRGRKKLLYIFKQPFMRPVQTstimulatory fragment TQEEDGCSCRFPEEEEGGCEL 2  55 OX40 co-DPPATQPQETQGPPARPITVQ stimulatory fragment PTEAWPRTSQGPSTRPVEVPG 1GRAVAAILGLGLVLGLLGPLA ILLALYLLRRDQRLPPDAHKP PGGGSFRTPIQEEQADAHSTL AKI 56 OX40 co- ALYLLRRDQRLPPDAHKPPGG stimulatory fragmentGSFRTPIQEEQADAHSTLAKI 2  57 CD8 TM fragment TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDF ACDIYIWAPLAGTCGVLLLSL VITLYC  58IgV_(H) domain of anti- EVQLVQSGAEVKKPGESLKIS CD19 antibodyCKGSGYSFTSYWIGWVRQMPG KGLEWMGIIYPGDSDTRYSPS FQGQVTISADKSISTAYLQWSSLKASDTAMYYCARQVWGWQG GMYPRSNWWYNLDSWGQGTLV TVSS  59IgV_(L) domain of anti- LPVLTQPPSVSVAPGKTARIT CD19 antibodyCGGNNIGSKSVHWYQQKPGQA PVLVVYDDSDRPSGIPERFSG SNSGNTATLTISRVEAGDEADYYCQVWDSSSDYVVFGGGTKL TVLG  60 IgV_(H) domain of anti-QVQLQQPGAELVKPGASVKMS CD20 antibody CKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQK FKGKATLTADKSSSTAYMQLS SLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSS  61 IgV_(L) domain of anti- QIVLSQSPAILSASPGEKVTMCD20 antibody TCRASSSVSYIHWFQQKPGSS PKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAAT YYCQQWTSNPPTFGGGTKLEI KR  62IgV_(H) domain of anti- EVQLVQSGAEVKKPGESLTIS AFP antibodyCKASGYSFPNYWITWVRQMSG GGLEWMGRIDPGDSYTTYNPS FQGHVTISIDKSTNTAYLHWNSLKASDTAMYYCARYYVSLVD IWGQGTLVTVSS  63 IgV_(L) domain of anti-QSVLTQPASVSGSPGQSITIS AFP antibody CTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVNNRPSEVSNR FSGSKSGNTASLTISGLQAED EADYYCSSYTTGSRAVFGGGT KLTVL 64 IgV_(H) domain of anti- QVQLVESGGGLVQPGGSLRLS GPC3 antibodyCAASGFTFSSYAMSWVRQAPG KGLEWVSVIYSGGSSTYYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTSYLNHG DYWGQGTLVTVSS  65 IgV_(L) domain of anti-QSVLTQPPSVSAAPGQRVTIS GPC3 antibody CSGTRSNIGSDYVSWYQHLPGTAPKLLVYGDNLRPSGIPDRF SASKSGTSATLGITGLQTGDE ADYYCGTWDYTLNGVVFGGGT KLTVLG 66 IgV_(H) domain of anti- QVQLQESGPGLVKPSQTLSLT CD47CTVSGYTFTNYYVFWVRQARG QRLEWIGDINPVNGDTNFNEK FKNRVTISADKSISTAYLQWSSLKASDTAMYYCARGGYTMDY WGQGTLVTVSS  67 IgV_(L) domain of anti-DIVMTQTPLSLPVTPGEPASI CD47 SCRSSQSLVHSNGNTYLHWYQ QKPGKAPKLLIYKVSYRFSGVPDRFSGSGSGTDFTLKISRVE AEDVGVYYCSQNTHVPRTFGQ GTKVEIKR  68anti-AFP158/HLA- EVQLVQSGAEVKKPGESLTIS A*02:01-caTCR-1-0CKASGYSFPNYWITWVRQMSG delta GGLEWMGRIDPGDSYTTYNPS FQGHVTISIDKSTNTAYLHWNSLKASDTAMYYCARYYVSLVD IWGQGTLVTVSSASTKGPSVF PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVP SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCEVKTDSTDHVK PKETENTKQPSKSCHKPKAIV HTEKVNMMSLTVLGLRMLFAKTVAVNFLLTAKLFFL  69 anti-AFP158/HLA- QSVLTQPASVSGSPGQSITISA*02:01-caTCR-1-0 CTGTSSDVGGYNYVSWYQQHP gamma GKAPKLMIYDVNNRPSEVSNRFSGSKSGNTASLTISGLQAED EADYYCSSYTTGSRAVFGGGT KLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGA VTVAWKADGSPVKAGVETTKP SKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV APTECSPIKTDVITMDPKDNC SKDANDTLLLQLTNTSAYYMYLLLLLKSVVYFAIITCCLLRR TAFCCNGEKS  70 anti-AFP158/HLA-EVQLVQSGAEVKKPGESLTIS A*02:01-caTCR-1- CKASGYSFPNYWITWVRQMSG TM5 deltaGGLEWMGRIDPGDSYTTYNPS FQGHVTISIDKSTNTAYLHWN SLKASDTAMYYCARYYVSLVDIWGQGTLVTVSSASTKGPSVF PLAPSSKSTSGGTAALGCLVK DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSSLGTQTYICNVNHKPSNTK VDKRVEPKSCEVKTDSTDHVKPKETENTKQPSKSCHKPKAIV HTEKVNMMSLTVLGLRVLFAK TVAVNFLLTAKLFFL  71anti-AFP158/HLA- QSVLTQPASVSGSPGQSITIS A*02:01-caTCR-1-CTGTSSDVGGYNYVSWYQQHP TM5 gamma GKAPKLMIYDVNNRPSEVSNRFSGSKSGNTASLTISGLQAED EADYYCSSYTTGSRAVFGGGT KLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGA VTVAWKADGSPVKAGVETTKP SKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV APTECSPIKTDVITMDPKDNC SKDANDTLLLQLTNTSAYLVYLLLLLKSVVYFVIVTCCLLRR TAFCCNGEKS  72 anti-CD19-caTCR-1-EVQLVQSGAEVKKPGESLKIS 0 delta CKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPS FQGQVTISADKSISTAYLQWS SLKASDTAMYYCARQVWGWQGGMYPRSNWWYNMDSWGQGTLV TVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCEVKTDSTDHVKPKETENTK QPSKSCHKPKAIVHTEKVNMM SLTVLGLRMLFAKTVAVNFLLTAKLFFL  73 anti-CD19-caTCR-1- LPVLTQPPSVSVAPGKTARIT 0 gammaCGGNNIGSKSVHWYQQKPGQA PVLVVYDDSNRPSGIPERFSG SNSGNTATLTISRVEAGDEADYYCQVWDSSSEYVVFGGGTKL TVLGQPKANPTVTLFPPSSEE LQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSK QSNNKYAASSYLSLTPEQWKS HRSYSCQVTHEGSTVEKTVAPTECSPIKTDVITMDPKDNCSK DANDTLLLQLTNTSAYYMYLL LLLKSVVYFAIITCCLLRRTAFCCNGEKS  74 anti-CD19-caTCR-1- EVQLVQSGAEVKKPGESLKIS TM5 deltaCKGSGYSFTSYWIGWVRQMPG KGLEWMGIIYPGDSDTRYSPS FQGQVTISADKSISTAYLQWSSLKASDTAMYYCARQVWGWQG GMYPRSNWWYNMDSWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPK SCEVKTDSTDHVKPKETENTK QPSKSCHKPKAIVHTEKVNMMSLTVLGLRVLFAKTVAVNFLL TAKLFFL  75 anti-CD19-caTCR-1-LPVLTQPPSVSVAPGKTARIT TM5 gamma CGGNNIGSKSVHWYQQKPGQAPVLVVYDDSNRPSGIPERFSG SNSGNTATLTISRVEAGDEAD YYCQVWDSSSEYVVFGGGTKLTVLGQPKANPTVTLFPPSSEE LQANKATLVCLISDFYPGAVT VAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKS HRSYSCQVTHEGSTVEKTVAP TECSPIKTDVITMDPKDNCSKDANDTLLLQLTNTSAYLVYLL LLLKSVVYFVIVTCCLLRRTA FCCNGEKS  76 scFv linkerSRGGGGSGGGGSGGGGSLEMA  77 anti-CD19 scFv LPVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQA PVLVVYDDSDRPSGIPERFSG SNSGNTATLTISRVEAGDEADYYCQVWDSSSDYVVFGGGTKL TVLGSRGGGGSGGGGSGGGGS LEMAEVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVR QMPGKGLEWMGIIYPGDSDTR YSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARQVW GWQGGMYPRSNWWYNLDSWGQ GTLVTVSS  78 anti-CD20 scFvQIVLSQSPAILSASPGEKVTM TCRASSSVSYIHWFQQKPGSS PKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAAT YYCQQWTSNPPTFGGGTKLEI KRSRGGGGSGGGGSGGGGSLEQVQLQQPGAELVKPGASVKMS CKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLS SLTSEDSAVYYCARSTYYGGD WYFNVWGAGTTVTVSS  79anti-GPC3 #37 scFv QSVLTQPPSVSAAPGQRVTIS CSGTRSNIGSDYVSWYQHLPGTAPKLLVYGDNLRPSGIPDRF SASKSGTSATLGITGLQTGDE ADYYCGTWDYTLNGVVFGGGTKLTVLGSRGGGGSGGGGSGGG GSLEMAQVQLVESGGGLVQPG GSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVIYSGGSS TYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYYCARTSYLNHGDYWGQGTLVTVSS  80 anti-CD19 CSR LPVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQA PVLVVYDDSDRPSGIPERFSG SNSGNTATLTISRVEAGDEADYYCQVWDSSSDYVVFGGGTKL TVLGSRGGGGSGGGGSGGGGS LEMAEVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVR QMPGKGLEWMGIIYPGDSDTR YSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARQVW GWQGGMYPRSNWWYNLDSWGQ GTLVTVSSAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSP LFPGPSKPFWVLVVVGGVLAC YSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQ PYAPPRDFAAYRS  81 anti-CD20 CSRQIVLSQSPAILSASPGEKVTM TCRASSSVSYIHWFQQKPGSS PKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAAT YYCQQWTSNPPTFGGGTKLEI KRSRGGGGSGGGGSGGGGSLEQVQLQQPGAELVKPGASVKMS CKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLS SLTSEDSAVYYCARSTYYGGD WYFNVWGAGTTVTVSSAAAIEVMYPPPYLDNEKSNGTIIHVK GKHLCPSPLFPGPSKPFWVLV VVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRP GPTRKHYQPYAPPRDFAAYRS  82 anti-GPC3 CSRQSVLTQPPSVSAAPGQRVTIS CSGTRSNIGSDYVSWYQHLPG TAPKLLVYGDNLRPSGIPDRFSASKSGTSATLGITGLQTGDE ADYYCGTWDYTLNGVVFGGGT KLTVLGSRGGGGSGGGGSGGGGSLEMAQVQLVESGGGLVQPG GSLRLSCAASGFTFSSYAMSW VRQAPGKGLEWVSVIYSGGSSTYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYYCART SYLNHGDYWGQGTLVTVSSAAAIEVMYPPPYLDNEKSNGTII HVKGKHLCPSPLFPGPSKPFW VLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTP RRPGPTRKHYQPYAPPRDFAA YRS  83 6NFAT responseGGAGGAAAAACTGTTTCATAC element AGAAGGCGTGGAGGAAAAACTGTTTCATACAGAAGGCGTGGA GGAAAAACTGTTTCATACAGA AGGCGTGGAGGAAAAACTGTTTCATACAGAAGGCGTGGAGGA AAAACTGTTTCATACAGAAGG CGTGGAGGAAAAACTGTTTCATACAGAAGGCGT  84 TA promoter GCCGCCCCGACTGCATCTGCG TGTTCCAATTCGCCAATGACAAGACGCTGGGCGGGGTTTGTG TCATCATAGAACTAAAGACAT GCAAATATATTTCTTCCGGGGACACCGCCAGCAAACGCGAGC AACGGGCCACGGGGATGAAGC AG  85 NFAT-derivedGGAGGAAAAACTGTTTCATAC promoter AGAAGGCGTGGAGGAAAAACTGTTTCATACAGAAGGCGTGGA GGAAAAACTGTTTCATACAGA AGGCGTGGAGGAAAAACTGTTTCATACAGAAGGCGTGGAGGA AAAACTGTTTCATACAGAAGG CGTGGAGGAAAAACTGTTTCATACAGAAGGCGTCTCGAGGCC GCCCCGACTGCATCTGCGTGT TCCAATTCGCCAATGACAAGACGCTGGGCGGGGTTTGTGTCA TCATAGAACTAAAGACATGCA AATATATTTCTTCCGGGGACACCGCCAGCAAACGCGAGCAAC GGGCCACGGGGATGAAGCAG  86 CD27 co-stimulatoryPTHLPYVSEMLEARTAGHMQT fragment 1 LADFRQLPARTLSTHWPPQRSLCSSDFIRILVIFSGMFLVFT LAGALFLHQRRKYRSNKGESP VEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP  87 CD27 co-stimulatory QRRKYRSNKGESPVEPAEPCR fragment 2YSCPREEEGSTIPIQEDYRKP EPACSP  88 CD30 co-stimulatoryAPPLGTQPDCNPTPENGEAPA fragment 1 STSPTQSLLVDSQASKTLPIPTSAPVALSSTGKPVLDAGPVL FWVILVLVVVVGSSAFLLCHR RACRKRIRQKLHLCYPVQTSQPKLELVDSRPRRSSTQLRSGA SVTEPVAEERGLMSQPLMETC HSVGAAYLESLPLQDASPAGGPSSPRDLPEPRVSTEHTNNKI EKIYIMKADTVIVGTVKAELP EGRGLAGPAEPELEEELEADHTPHYPEQETEPPLGSCSDVML SVEEEGKEDPLPTAASGK  89 CD30 co-stimulatoryHRRACRKRIRQKLHLCYPVQT fragment 2 SQPKLELVDSRPRRSSTQLRSGASVTEPVAEERGLMSQPLME TCHSVGAAYLESLPLQDASPA GGPSSPRDLPEPRVSTEHTNNKIEKIYIMKADTVIVGTVKAE LPEGRGLAGPAEPELEEELEA DHTPHYPEQETEPPLGSCSDVMLSVEEEGKEDPLPTAASGK  90 CSR1 AAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP FWVLVVVGGVLACYSLLVTVA FIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDF AAYRS  91 CSR2 AAATGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHT RGLDFACDIYIWAPLAGTCGV LLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCR FPEEEEGGCEL  92 CSR3 AAATGPADLSPGASSVTPPAPAREPGHSPQIISFFLALTSTA LLFLLFFLTLRFSVVKRGRKK LLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL  93 CSR4 AAATGTTTPAPRPPTPAPTIA SQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV LLLSLVITLYCQRRKYRSNKG ESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP  94 CSR5 AAATGPTHLPYVSEMLEARTA GHMQTLADFRQLPARTLSTHWPPQRSLCSSDFIRILVIFSGM FLVFTLAGALFLHQRRKYRSN KGESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP  95 CSR6 AAATGTTTPAPRPPTPAPTIA SQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV LLLSLVITLYCHRRACRKRIR QKLHLCYPVQTSQPKLELVDSRPRRSSTQLRSGASVTEPVAE ERGLMSQPLMETCHSVGAAYL ESLPLQDASPAGGPSSPRDLPEPRVSTEHTNNKIEKIYIMKA DTVIVGTVKAELPEGRGLAGP AEPELEEELEADHTPHYPEQETEPPLGSCSDVMLSVEEEGKE DPLPTAASGK  96 CSR7 AAATGAPPLGTQPDCNPTPENGEAPASTSPTQSLLVDSQASK TLPIPTSAPVALSSTGKPVLD AGPVLFWVILVLVVVVGSSAFLLCHRRACRKRIRQKLHLCYP VQTSQPKLELVDSRPRRSSTQ LRSGASVTEPVAEERGLMSQPLMETCHSVGAAYLESLPLQDA SPAGGPSSPRDLPEPRVSTEH TNNKIEKIYIMKADTVIVGTVKAELPEGRGLAGPAEPELEEE LEADHTPHYPEQETEPPLGSC SDVMLSVEEEGKEDPLPTAAS GK  97CSR8 AAATGTTTPAPRPPTPAPTIA SQPLSLRPEACRPAAGGAVHT RGLDFACDIYIWAPLAGTCGVLLLSLVITLYCALYLLRRDQR LPPDAHKPPGGGSFRTPIQEE QADAHSTLAKI  98 CSR9AAATGDRDPPATQPQETQGPP ARPITVQPTEAWPRTSQGPST RPVEVPGGRAVAAILGLGLVLGLLGPLAILLALYLLRRDQRL PPDAHKPPGGGSFRTPIQEEQ ADAHSTLAKI  99IgV_(H) domain of anti- EVQLVQSGAEVKKPGESLKIS CD19 antibodyCKGSGYSFTSYWIGWVRQMPG KGLEWMGIIYPGDSDTRYSPS FQGQVTIADKSISTAYLQWSSLKASDTAMYYCARQVWGWQGG MYPRSNWWYNLDSWGQGTLVT VSS 100IgV_(L) domain of anti- LPVLTQPPSVSVAPGKTARIT CD19 antibodyCGGNNIGSKSVHWYQQKPGQA PVLVVYDDSDRPSGIPERFSG SNSGNTATLTISRVEAGDEADYYCQVWDSSSDYVVFGGGTKL TVL 101 IgV_(H) domain of anti-QVQLVESGGGLVQPGGSLRLS CD22 antibody CAASGFTFSNYAMSWVRQAPGKGLEWVSSISGSGGSTYYADS VKGRFTISRDTSKNTLYLQMN SLRAEDTAVYYCARYGSAAWMDSWGQGTLVTVSS 102 IgV_(L) domain of anti- DIQLTQSPSSLSTSVGDRVTICD22 antibody TCQASHDIRNYLNWYQQKPGK APNLLIYAASNLQTGVPSRFSGRGSGTDFTLTISSLQPEDIA TYYCQQYDGLPLTFGQGTRLE IKR 103 Peptide linker AAA104 Peptide linker AAATG 105 GPC3-37/CD3 BsAb QSVLTQPPSVSAAPGQRVTISCSGTRSNIGSDYVSWYQHLPG TAPKLLVYGDNLRPSGIPDRF SASKSGTSATLGITGLQTGDEADYYCGTWDYTLNGVVFGGGT KLTVLGSRGGGGSGGGGSGGG GSLEMAQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSW VRQAPGKGLEWVSVIYSGGSS TYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCART SYLNHGDYWGQGTLVTVSSTS GGGGSDVQLVQSGAEVKKPGASVKVSCKASGYTFTRYTMHWV RQAPGQGLEWIGYINPSRGYT NYADSVKGRFTITTDKSTSTAYMELSSLRSEDTATYYCARYY DDHYCLDYWGQGTTVTVSSGE GTSTGSGGSGGSGGADDIVLTQSPATLSLSPGERATLSCRAS QSVSYMNWYQQKPGKAPKRWI YDTSKVASGVPARFSGSGSGTDYSLTINSLEAEDAATYYCQQ WSSNPLTFGGGTKVEIK

1. An immune cell comprising: a) a chimeric antibody-T cell receptor(TCR) construct (caTCR) comprising: i) an antigen binding module thatspecifically binds to a target antigen; and ii) a T cell receptor module(TCRM) comprising a first TCR domain (TCRD) comprising a first TCRtransmembrane domain (TCR-TM) and a second TCRD comprising a secondTCR-TM, wherein the TCRM facilitates recruitment of at least oneTCR-associated signaling molecule; and b) a chimeric signaling receptor(CSR) comprising: i) a ligand-binding module that is capable of bindingor interacting with a target ligand; ii) a transmembrane module; andiii) a co-stimulatory immune cell signaling module that is capable ofproviding a co-stimulatory signal to the immune cell, wherein theligand-binding module and the co-stimulatory immune cell signalingmodule are not derived from the same molecule, and wherein the CSR lacksa functional primary immune cell signaling domain.
 2. The immune cell ofclaim 1, wherein the CSR lacks any primary immune cell signalingsequences.
 3. The immune cell of claim 1, wherein the target antigen isa cell surface antigen, or a complex comprising a peptide and a majorhistocompatibility complex (MHC) protein.
 4. (canceled)
 5. The immunecell of claim 1, wherein the first TCR-TM is derived from one of thetransmembrane domains of a first T cell receptor and the second TCR-TMis derived from the other transmembrane domain of the first T cellreceptor.
 6. The immune cell of claim 5, wherein at least one of theTCR-TMs is non-naturally occurring.
 7. The immune cell of claim 5,wherein the first T cell receptor is a γ/δ T cell receptor. 8.(canceled)
 9. The immune cell of claim 1, wherein the caTCR furthercomprises a stabilization module comprising a first stabilization domainand a second stabilization domain, wherein the first and secondstabilization domains have a binding affinity for each other thatstabilizes the caTCR.
 10. The immune cell of claim 9, wherein thestabilization module is selected from the group consisting of a CH1-CLmodule, a CH2-CH2 module, a CH3-CH3 module, and a CH4-CH4 module. 11.The immune cell of claim 1, wherein the target antigen and the targetligand are the same.
 12. The immune cell of claim 1, wherein the targetantigen and the target ligand are different.
 13. The immune cell ofclaim 12, wherein the target ligand is a ligand expressed on the surfaceof a cell presenting the target antigen.
 14. The immune cell of claim 1,where the target ligand is a disease-associated ligand, avirus-associated ligand, an immunomodulatory molecule, or an apoptoticmolecule. 15-22. (canceled)
 23. The immune cell of claim 1, wherein theligand-binding module is an antibody moiety or derived from theextracellular domain of a receptor.
 24. (canceled)
 25. The immune cellof claim 1, wherein the transmembrane module of the CSR comprisestransmembrane domains derived from CD28, CD3ε, CD3ζ, CD45, CD4, CD5,CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, orCD154.
 26. The immune cell of claim 1, wherein the co-stimulatory immunecell signaling module is derived from the intracellular domain of aco-stimulatory receptor of a TCR. 27-32. (canceled)
 33. One or morenucleic acids encoding the caTCR and CSR of claim 1, wherein the caTCRand CSR each consist of one or more polypeptide chains encoded by theone or more nucleic acids.
 34. (canceled)
 35. An immune cell comprisingthe one or more nucleic acids of claim
 33. 36-37. (canceled)
 38. Amethod of killing a target cell presenting a target antigen, comprisingcontacting the target cell with the immune cell of claim
 1. 39. A methodof treating a target antigen-associated disease in an individual in needthereof, comprising administering to the individual an effective amountof a pharmaceutical composition, wherein the pharmaceutical compositioncomprises the immune cell of claim 1 and a pharmaceutically acceptablecarrier.
 40. A method of providing a co-stimulatory signal to an immunecell comprising a caTCR or transduced with a nucleic acid encoding acaTCR, comprising introducing into said cell the one or more nucleicacids of claim 33.